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ABSTRACT 
PART I. UNIFIED PHARMACOPHORE PROTEIN MODELS OF THE 
BENZODIAZEPINE RECEPTOR SUBTYPES 
PART II. SUBTYPE SELECTIVE LIGANDS FOR cc5 GABA(A) /BZ RECEPTORS 
by 
Terrill S. Clayton 
University of Wisconsin-Milwaukee, 2011 
Under the Supervision of Professor James M. Cook 
Part I. New models of unified pharmacophore/receptors have been constructed guided by 
the synthesis of subtype selective compounds in light of recent developments both in 
ligand synthesis and structural studies of the binding site itself. The evaluation of 
experimental data in combination with comparative models of the 
aip2y2, a2p2y2, a3p2y2 and a5p2y2 GABA(A) receptors has led to an orientation of 
the pharmacophore model within the benzodiazepine binding site (Bz BS). These results 
not only are important for the rational design of new selective ligands, but also for the 
identification and evaluation of possible roles which specific residues may have within 
the benzodiazepine binding pocket. More importantly, the process summarized here may 
be used as a general template to help scientists develop novel ligands for receptors for 
which the three dimensional structure has not yet been confirmed by X-ray 
crystallography or cryo-electron microscopy. Presented here are new models of the 
aip2y2, a2p2y2, a3P2y2 and a5p2y2 GABA(A) receptors which have incorporated 
iii 
homology models built based on the acetylcholine binding protein. These new models 
will further our ability to understand structural characteristics of ligands which act as 
agonists, antagonists, or inverse agonists to the Bz BS of the GABA(A) receptor. This 
approach will also serve as a powerful model for structure based approaches carried out 
using ligand-protein docking methods. 
Part II. An effective strategy to alleviate memory deficits would be to enhance memory 
and cognitive processes by augmenting the impact of acetylcholine released from 
cholinergic neurons of the hippocampus. Using the included volume pharmacophore 
presented in Part I, a number of a5 selective compounds were synthesized, notably PWZ-
029. PWZ-029 was examined in rats in the passive and active avoidance, spontaneous 
locomotor activity, elevated plus maze and grip strength tests which are indicative of the 
effects on memory acquisition, locomotor activity, anxiety, and muscle tone. 
Improvement of task learning was shown at a dose of 5mg/kg in passive avoidance test 
without effect on anxiety or muscle tone. Moderate negative modulation at GABA(A) 
receptors containing the a5 subunit using a moderate inverse agonist such as PWZ-029, 
is a sufficient condition for eliciting enhanced encoding/consolidation of declarative 
memory. Using low temperature NMR and X-ray analysis, it was shown that enhanced 
selectivity and potent in vitro affinity of a5 selective benzodiazepine dimers was possible 
with aliphatic linkers of 3 to 5 carbons in length. Although originally proposed to 
enhance solubility, oxygen-containing linkers caused the dimer to fold back on itself 
leading to the inability of dimers to enter the binding pocket. In addition, studies of a 
series of PWZ-029 analogs found that the electrostatic potential near the ligands' terminal 
substituent correlated with its binding selectivity toward the a5p2y2 versus alp2y2 BzR/ 
iv 
GABA(A) ergic isoform. Investigations further found that compound PWZ-029, which 
exhibits reasonable binding selectivity toward GABA(A) receptors containing the a5 
subunit and possesses a favorable electrophysiological profile, was able to attenuate 
scopolamine induced contextual memory impairment in mice. This compound appears to 
be useful (Harris, Delorey et al.) for the treatment of cognitive deficits in rodents as well 
as primates (Rowlett et al.) and may well be a compound for the treatment of patients 
with Alzheimers disease. 
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Introduction 
The GABA(A) receptor is the major inhibitory neurotransmitter receptor of the 
central nervous system (CNS) and the site of action of a variety of pharmacologically and 
clinically important drugs, such as benzodiazepines, barbiturates, neuroactive steroids, 
anesthetics and convulsants.1 It is now clear that these receptors regulate the excitability 
of the brain, anxiety, muscle tone, circadian rhythms, sleep, vigilance, memory, and 
learning.1 There are several disease states associated with the improper functioning of 
this ion channel, including anxiety, epilepsy,2 insomnia,3 depression, bipolar disorder,4'5 
and schizophrenia,6 as well as mild cognitive impairment and Alzheimer's disease.7 The 
role of GABA(A) receptors in drug and alcohol abuse has also been reported.8'9 
GABA(A) receptors are composed of 5 subunits that form a central chloride 
channel and can belong to different subunit classes. A total of 19 subunits 
(6a, 3(3, 3y, 15, le, lrc, 10, 3 p) of the GABA(A) receptor have been cloned and 
o 
sequenced from the mammalian nervous system. All these polypeptides possess an 
approximate molecular mass of ~ 50 kD and are structurally related. Each subunit 
consists of a large extracellular region, which contains several potential glycosylation 
sites and a characteristic "cys-loop" formed by a covalent bond between two conserved 
cysteines. This extracellular region is important in contributing to the agonist GABA(A) 
and modulatory benzodiazepine binding sites. The protein then traverses the lipid bilayer 
four times and has a large intracellular loop located between transmembrane regions 3 
and 4 (M3 and M4). This intracellular region contains possible phosphorylation sites 
necessary for regulation of the receptor. The homology within each subunit class is about 
60 - 80 %, while the homology between subunit classes is about 30 - 40 %. In Figure 1, 
2 
the proposed topology of a single GABA(A) receptor subunit is shown. The pentameric 
structure of a ligand-gated ion channel is shown in Figure 2? 
Extracellular 
CO2H 
Intracellular 
Figure 1. Proposed topology of a GABA(A) receptor subunit. The extracellular domain begins with 
the N-terminus and M1-M4 represents the four transmembrane domains.10 
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Figure 2. Longitudinal (A) and cross-sectional (B) schematic representations of the ligand-gated ion 
channel. The numbers 1-4 refer to the M1-M4 segments. The M2 segment contributes to the 
majority of the pore lining within the membrane lipid bilayer.10 
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Figure 3. Longitudinal homology model of the human alp2y2 ligand gated ion channel10 
Figure 4. Cross-sectional homology model of the human alf32y2 ligand gated ion channel11 
The GABA(A) ligand gated ion channel (Figures 3 and 4) was constructed in 
Deep View and rendered here using Tripos Benchware 3D Explorer. The al subunits are 
yellow and magenta, the 02 subunits are green and red, while the y2 subunit is blue.1 
The existence of multiple GABA(A) receptor subunits can give rise to a large 
number of different GABA(A) receptor subtypes.12"14 The majority of GABA(A) 
receptors, however, are composed of ly, 2a and 2p subunits. The presence of a y subunit 
within a GABA(A) receptor is necessary for the formation of a benzodiazepine binding 
6 
site that is located at the interface of an a and y subunit. Whereas the classical 
benzodiazepines, such as diazepam or flunitrazepam, exhibit a high affinity for receptors 
composed of alp2y2, a2p2y2, a3P2y2 or a5p2y2 subunits (the diazepam sensitive (DS) 
receptors), as well as for their less intensively investigated analogues containing the y3 
subunit, other benzodiazepine binding site ligands are also able to interact with a4p2y2 
or a6p2y2 receptors (diazepam insensitive (DI) receptors), or with receptors containing 
yl subunits.11'15-17 Receptors containing yl or y3 subunits exhibit quite a low abundance 
in the brain11' 18-25 and their contribution to the "in vivo" effects of Bz BS ligands 
currently is unclear. 
The concept of receptor multiplicity has been extremely valuable in that different 
receptor subtypes reside within anatomically distinct regions of the brain and are 
responsible for different physiological and pathological processes.26 For example, the 
aip2y2 receptor subtype has a prominent role in seizure susceptibility and sedation,27 the 
a2p2y2 and possibly the a3p2y2 subtypes are involved in anxiety, whereas the a5p2y2 
subtype has a prominent role in memory and learning (Table l).28'29 These distinctions 
have thus become a motivation for the design of subtype selective ligands in order to 
elicit a single specific response.30 Differences observed in the action of such drugs may 
be due to subtype-selective affinity and absolute and/or relative subtype-selective 
efficacy.31' 32 Herein lies the motivation for developing a unified pharmacophoric 
GABA(A) protein model for each of the GABA(A) benzodiazepine receptor subtypes. 
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Table 1. Action of benzodiazepines at GABA(A) al-6 f33y2 receptor subtypes.33,34 
Subtype Associated Effect 
al Sedation, anterograde amnesia, 
Some anticonvulsant action, ataxia, addiction presumably 
a2 Anxiolytic, hypnotic (EEG), some muscle relaxation 
a3 Some anxiolytic action, anticonvulsant action at higher dose 
Maybe some muscle relaxation 
a4 Diazepam-insensitive site 
a5 Cognition, temporal and spatial memory 
(Maybe memory component of anxiety) 
a6 Diazepam-insensitive site 
Agonist binding to the receptor opens an intrinsic chloride ion channel, typically 
hyperpolarizing the cell membrane or at least opposing depolarization, thereby inhibiting 
neuronal transmission (Figure 5). 
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Figure 5. Membrane potential over time during the transmission of a nerve signal. A 
hyperpolarized state represents a potential further away from the threshold potential. 
Benzodiazepine binding site ligands are allosteric modulators. They are unable 
to induce channel openings themselves, but instead function to vary the frequency, but 
if -\n 
not the channel opening, times. " Positive allosteric modulators at the benzodiazepine 
binding site (agonists) increase this frequency, while negative allosteric modulators 
(inverse agonists) decrease the frequency. Currently, it is not clear whether Bz BS 
ligands allosterically modulate GABA(A) affinity or channel gating. Recent studies38'39 
support the view that high-affinity classical benzodiazepines modulate alp2y2 GABA(A) 
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receptors via allosteric coupling to channel gating.40 Further studies are needed to 
determine whether the mechanism of modulation varies in different receptor subtypes. 
In recent years an initial unified pharmacophore/receptor model for agonists, 
antagonists and inverse agonists at the Bz BS was developed, using the techniques of 
chemical synthesis, radioligand binding and receptor mapping.41 This model did not 
include a perspective in regard to GABA(A) protein subunits. The overlap of these 
different modulators within the Bz BS has been supported by experimental data.42 Using 
this ligand-based pharmacophore/receptor model and our new 
aip2y2, a2p2y2, a3p2y2, and a5p2y2 GABA(A) receptor models,43 the experimental 
data of recent and past years have been evaluated and definite trends with regard to the 
orientation of the regions of the protein relative to the descriptors of the 
pharmacophore/receptor model have been identified and are presented here. The need to 
define such an orientation has already been established,44 since it permits inspection of 
ligand docking studies and the identification of possible roles specific residues may have 
within the Bz binding site. These roles may then be explored in future studies which 
involves covalent labeling, site-directed mutagenesis and structure-activity relationships, 
all of which contribute to the rational design of subtype-specific modulators of the Bz BS 
of GABA(A) receptors. 
Recent Alignment of Non-Classical Bz Binding Site Ligands Support the Unified 
Pharmacophore/Receptor Model 
Besides the major classes of Bz ligands used to define the model, several non-Bz 
ligands also fit within the pharmacophore/receptor model very well. Examples include 
zopiclone,!, and its active enantiomer, the flavonoid 2 and the 8-chloropyrazolo[5,l-
10 
c][l,2,4]-benzotriazine 5-oxide analog 38, as illustrated in Figures 6 and 7, as well as 
Figures 10 and 12. 
Zopiclone and its Active Enantiomer (Lunesta®) 
Since the sedative-hypnotic zopiclone 1 was first reviewed in Drugs in 1986,45 a 
much larger body of clinical data has become available to permit a more detailed 
comparison of the activity of non-benzodiazepine, zopiclone, with classical 
benzodiazepines.46 Results have shown that, regardless of the duration of action, 
zopiclone was generally at least as effective as benzodiazepines in the treatment of 
insomnia, although comparisons between zopiclone and flurazepam have produced 
inconsistent results. It was observed that zopiclone had a relatively low propensity to 
elicit residual clinical effects, such as difficulty in waking or reduced morning 
concentration. While tolerance to the effects of zopiclone was not noticed in short term 
clinical trials (> 4 weeks), the results from longer term studies were conflicting and, 
therefore, the potential for tolerance during long term administration of zopiclone was 
unclear. Rebound insomnia to a level above that at baseline can occur after withdrawal of 
zopiclone. However, on the basis of data from short term studies, this does not appear to 
be common. Evaluation of prescriptions filled has indicated that zopiclone does not have 
a high dependence potential, at least in those who are not regular drug abusers/addicts. 
Zopiclone was well-tolerated in both the elderly and younger patients with insomnia. A 
bitter after-taste was usually the most common adverse event, but was relatively 
infrequent at 3.6 % in the largest available post-marketing study. Thus, zopiclone has 
now been firmly established as an effective and well-tolerated sleep agent.46 
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The structure and alignment of zopiclone within the unified 
pharmacophore/receptor model is shown in Figure 6. The centroid of the pyridine moiety 
of zopiclone overlapped with region Li of the receptor, while the lone pair of electrons of 
the carbonyl oxygen (O) atom interacted with Hi of the receptor to form a hydrogen bond 
between the ligand and the receptor. A second hydrogen bond was formed between the 
amide carbonyl oxygen atom lone pair (LP) and H2 of the receptor protein (Figure 6). 
Figure 6. Structure of the sedative-hypnotic zopiclone 1, its alignment within the 
pharmacophore/receptor model and the model rotated 90°. 
However, a recent study by Sepracor47 indicated that one of the enantiomers of 
zopiclone was much more active than zopiclone itself. This may be the result of receptor 
subtype-selective efficacy or simply a pharmacokinetic effect, but the 
pharmacophore/receptor model developed here revealed that the active enantiomer fits 
better into the included volume of the al(32/3y2 subtype than zopiclone 1 itself (Figure 7). 
The a2 and a3 subunits are frequently co-expressed with the fi3 and y2 subunits, which 
12 
are particularly evident in hippocampal pyramidal neurons. This enantiomer (Lunesta) 
has just been approved by the FDA for treatment of insomnia. 
Figure 7. Alignment of zopiclone 1 (left) and its active enantiomer (right) in the included volume of 
the pharmacophore/receptor model for the aip3Y2 subtype. 
SH-053 Benzodiazepine Enantiomers 
Taking into consideration how enantiomers fit into pharmacophores within 
included volumes, the behavioral activity of three newly-synthesized active Bz 
enantiomers,49' 50 functionally selective for cc2, 013 and as-containing subtypes of 
GABA(A) receptors (SH-053-S-CH3 and SH-053-S-CH3-2'F), or one essentially 
selective for as subtypes (SH-053-R-CH3) were examined. Motor influence was tested in 
the elevated plus maze, spontaneous locomotor activity and rotarod test, which are 
considered primarily predictive of the anxiolytic, sedative and ataxic influence of BZs, 
respectively. There was substantially diminished ataxic potential of BZ site agonists 
devoid of al subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of 
SH-053-S-CH3 and SH-053-S-CH3-2'F. However, all three ligands, dosed at 30 mg/kg, 
decreased spontaneous locomotor activity, suggesting that sedation may be partly 
dependent on activity mediated by a5-containing GABA(A) receptors.51 Such an effect 
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could not have been observed previously, because to date, all apparently non-sedating BZ 
receptor ligands, which are devoid of activity at a 1-containing GABA(A) receptors, 
engendered essentially antagonist or only partial agonist efficacy at a5-containing 
GABA(A) receptors.49'50 Therefore, it cannot be ruled out that substantial efficacy at 
a5-containing GABA(A) receptors may contribute to sedative effects besides the effects 
on learning and memory processes.46 
Table 2. Binding affinity at ax$2y2 GABA(A) receptor subtypes (values are reported in nM) 
Compound al a2 a3 cx4 a5 a6 
SH-053-R-CH3 2026 2377 1183 >5000 949.1 >5000 
SH-053-S-CH3 1666 1263 1249 >5000 206.4 >5000 
SH-053-2 'F-R-CH3 759.1 948.2 768.8 >5000 95.17 >5000 
SH-053-2 T-S-CH3 350 141 1237 >5000 19.2 >5000 
This effect on locomotor activity is supported by two sets of data which indicate the 
possibility of substantial motor influence via a5-GABA(A) receptor modulation: In the 
spinal cord, somatic and preganglionic motoneurons (lamina IX and lateral cell column) 
exhibited a moderate to strong staining for the a5 subunit, suggesting a possible 
influence of receptors containing these subunits in motor behavior.53 In addition, the 
knock-in mice harboring the a5 subunit insensitive to diazepam are refractory to 
development of tolerance to the sedative effect of diazepam dosed subchronically. Such a 
14 
tolerance development might have been caused by a down regulation of receptors 
containing a5 subunits in the appropriate brain regions of wild-type mice.42 These two 
sets of evidence indicate that the motor influence of a5-GABA(A) receptor modulation 
is not necessarily an indirect consequence of the established effects on learning and 
memory processes.54 Hence, it has been hypothesized55' 56 that locomotor activity 
changes induced by ligands possessing a substantial a5-efficacy may be, at least in part, 
caused by modulation at GABA(A) receptors containing the a5 subunit. It therefore 
could be of importance to avoid substantial agonist potentiation of a5-subunits by 
candidate anxioselective anxiolytics, if clinical sedation is to be avoided. As a caveat to 
all studies examining sedation, it should be remembered that a decrease in automatically 
measured locomotor activity can be due to a variety of causes other than sedation, 
including the occurrence of stereotypical behavior, motor impairments, or pain 51 To 
dissect these overlaps in activity and uncertainties, much is expected from required 
screening of even more subtype selective BZ site ligands in the future. 
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Figure 8. Structures and conformations of SH-053-S-CH3 (A1-A3) and SH-053-R-CH3 (B1-B3) in the 
012P2/3Y2 subtype included volume. A3 and B3 are the pharmacophore model rotated 90° in a 
clockwise direction. 
The molecular modeling of ligands in the Milwaukee-based pharmacophore was 
{O 
carried out as described by Clayton et al. SH-053-S-CH3 fits to the pharmacophore 
within the included volume of the a2 subtype (A2). A3 is the A2 image rotated 90° 
(Figure 8). It can be clearly seen that this conformer fits within the included volume. 
Below, SH-053-R-CH3 (see Figure 8B2) is fitted to the pharmacophore in the included 
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volume of the a2 subtype (B2). B3 is the B2 image rotated 90°. The R-CH3-fiinction at 
the prochiral center C(4) changes the conformation of the molecule causing the pendant 
6-phenyl group to protrude outside the included volume, consequently this ligand is not 
efficacious at the a2 subtype (Figure 9). It simply does not interact strongly enough with 
aip3y2, a2p3y2 or a3p3y2 receptor subtypes. 
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Figure 9. Concentration-effect curves for SH-053-S-CH3 and SH-053-R-CH3 on 
alp3y2, ot2p3y2, a3p3y2, and a5p3y2 GABA(A) receptors. Data points represent means ± SEM from 
at least 4 oocytes from > 2 batches.8 
Flavonoids 
Flavonoids represent a class of non-Bz ligands that fit extremely well within the 
unified pharmacophore/receptor model. These compounds are a class of natural products 
isolated from a variety of herbal plants and have been employed as tranquilizers in folk 
medicine. They exhibit a wide range of biological activity, such as antiviral, anti­
inflammatory, antithrombotic, antioxidant and estrogenic effects.59 Flavonoids also 
display potent anxiolytic effects and appear devoid of myorelaxant, amnesic or sedative 
actions. Haberlein et al. has shown that the steric orientation of the substituents which lie 
coplanar to the aromatic ring are crucial for ligand affinity to the Bz BS.60 This was 
17 
especially true for the C(5) and C(6) positions. Furthermore, the recent work of Huang et 
al. indicated that 6,3'-dinitroflavone 2 exhibited a Kj value of 12 nM at the Bz BS (Table 
3) and was an extremely potent anxiolytic devoid of muscle relaxant effects. The 6-Br-
3'-nitroflavone 4 also demonstrated increased binding affinity, however, the anxiolytic 
effect was lower than the dinitroanalog 2.61 
Table 3. Affinities of a Series of Flavonoid Ligands for Benzodiazepine Receptors.61 
O 
Compound R* W Kj (nM) 
5 F N02 182 
6 CI N02 8.0 
7 Br CI 17.0 
8 CI Br 23.0 
9 Br Br 19.1 
2 N02 N02 12.0 
4 Br N02 1.0 
The flavonoids 2, 4 and 6 fit very well within the unified pharmacophore/receptor 
model. The alignment of 6,3'-dinitroflavone 2 within the a2p3y2 subtype is shown in 
Figure 10. The centroid of the phenyl moiety overlapped with the Li region and the 3'-
nitro group occupied region L2, while the lone pair of electrons of the carbonyl oxygen 
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(O) atom interacted with Hi to form a hydrogen bond between the ligand and the 
receptor. A second hydrogen bond was formed between the oxygen lone pair and H2 of 
the receptor protein. This alignment essentially agrees with what has been reported by 
Marder.62 
Figure 10. Alignment of 2 within the included volume of the a2p3y2 subtype. 
Recently, some flavone-related analogs were prepared (Figure ll)63'64 by Yu et 
al. in Milwaukee, however, these flexible ligands with additional lipophilic groups did 
not bind to any GABA(A) receptor subtype. It is believed that more planar ligands are 
required for affinity to these subtypes, as the twist chair of the dihydropyran unit 
prevented the fit required for high affinity binding at the Bz binding site. Together these 
data, combined with the work of others, indicate the phenyl ring, the carbonyl group and 
the double bond between C(2) and C(3) of the flavone are the key structural features that 
contribute to the binding affinity of flavonoids to the Bz binding site. This is in 
19 
agreement with the planar or near planar BzR binding site proposed by Hagen in 
Milwaukee in the 1980's. 
R = H, Et, COCH3 or acetylene 
Figure 11. A series of flavone-related analogs that were inactive at the Bz BS. 
Analogs of 8-Chloropyrazolo[5,l-c][l,2,4]-benzotriazine 5-oxide (3) 
It has been recognized that small structural modifications in the same chemical 
family can lead to ligands which display different intrinsic activity. Costanzo et al. 
reported that small structural modifications in analogs of 8-chloropyrazolo[5,l-c][1,2,4]-
benzotriazine 5-oxide (3) produced ligands that displayed different intrinsic activity 
(Table 4).65 When an aryl ester function occupied position-3, this class of ligands 
exhibited high affinity at the Bz BS (Table 4, Kj = 11 - 35 nM). It was proposed the 
methoxy group of ligand 3, which bound with an affinity of 1.0 nM, acted as an electron 
donor group to enhance the n-n stacking interactions between the phenyl ring of this 
ligand and the imidazole ring of the histidine side chain (HI02) in the receptor protein. 
However, it may also be that the methoxy group enhanced lipophilic interactions within 
the Li region. Costanzo et al. proposed that net inductive and resonance effects as well 
as the electron donating properties (a = - 0.27) and suitable lipophilic features of the 
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ligand facilitated this interaction. This has been supported by the current electrostatic 
maps created by the Milwaukee-based group (see QSAR section). 
Table 4. Affinities of a series of 8-chloropyrazolo|5,l-c]|l,2,4|benzotriazine 5-oxide ligands at the Bz 
BS of GABA(A) receptors.66 
o 
Ligand R K| (nM) 
10 Ph 47.5 
11 4-F-Ph 146.0 
12 2-F-Ph 14.0 
13 4-CL-Ph 49.2 
14 2-Cl-Ph 14.4 
15 4-Me-Ph 51.9 
16 2-Me-Ph 38.3 
17 4-N02-Ph 41.8 
18 2-NO2-PI1 106.0 
19 4-MeO-Ph 11.6 
20 3-MeO-Ph 41.1 
3 2-MeO-Ph 1.0 
Alignment of N-oxide 3 overlaid with diazepam is shown in Figure 12, wherein 
the N(l) and N(4) functions hydrogen bond to the H2 and Hi donor receptor sites, 
respectively. It was felt that the 3-ester function fits into a limited dimension lipophilic 
pocket in the Li/ L2 region. Moreover, the orientation of the lone pair of electrons of the 
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carbonyl oxygen atom of the ester function reinforced the receptor binding by means of a 
3-centered hydrogen bond (N(4)/ CO/ Hi). This hydrogen bond, which is similar to that 
described for the C(3) ester substituent in (3-carbolines, is also strengthened by the 
interaction between the 5-oxide group and the nitrogen atom with Hj.  
Figure 12. Alignment of N-oxide ligand 3 (black) overlayed with diazepam (cyan) within the unified 
pharmacophore/receptor model and rotated 90° (right side). 
Dimer Affinity for the Binding Site 
Some studies which involved monomeric imidazobenzodiazepines (/-BZDs) 
indicated that there may be a limit on the size of the 3'-imidazo substituents the receptor 
may accommodate.64' 66 However, studies that involved bivalent ligands suggested 
otherwise (Table 5).42 It is possible that the spacer for /-BZDs dimers threaded the 
second portion of the bivalent ligand through and/or around the LDi/A2 region that 
presented steric hindrance for the monomers. A proposed orientation is illustrated in 
Figure 13. 
22 
Table 5. Structures and Affinities at the axf33y2 Subtype. 
CO2R 
C02?-Bu 
Rol5-1788, 21 (R = Et) p-CCT, 22 (R - H) 
WY-S-8, 23 (R = -
WY-B-14, 24 (R= -
H) 
-TMS) 
CC^f-Bu f-BuC^C 
COs*-Bu f-BuO»C 
I 
J V-NH 
WY-S-2, 25 WY-S-6,26 
C £ 
/ 
\ 
XLi-093, 27 bis(7)-THA, 28 
Me Me 
Ph Ph 
XLi-210, 29 DMH-III-96, 30 
23 
Ligand 
Ki (nM)* 
al a2 a3 a4 a5 a6 Activity 
21, Rol5-1788 0.8 0.9 1.05 NR 0.6 148 ANT 
22, (3-CCT 0.72 15 18.9 NR 110.8 5000 IA 
23, WY-S-8 0.97 111 102 NR 208 1980 ND 
24, WY-B-14 6.8 30 36 2000 108 1000 ND 
25, WY-S-2 30 124 100 300 300 4000 ND 
26, WY-S-6 120 1059 3942 NR 5000 5000 ND 
27, XLi-093 1000 1000 858 1550 15 2000 ANT 
28, bis(7)-THA NR NR NR NR NR NR ANT 
29, XLi-210 231 661 2666 NR 5.4 54.2 ND 
30, DMH-III-96 460 5000 NR NR 5000 5000 ND 
"Affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for l^H] flunitrazepam or [3H] Rol5-4513 binding to HEK cell membranes 
expressing human receptors of composition alp3y2, <x2p3y2, a3P3y2, a4p3y2, and 
a5p3y2 and a6p3y2.66 Data represent the average of at least three determinations with a SEM 
of ±5%. 
Design of the bivalent ligand XLi-093 27 was based on the modeling of the 
a5-selective monomer RY-80 31 in the a5 pharmacophore model. The ability of XLi-
093 to bind (Table 5) and fit well within the pharmacophore (Figure 13) required the 3-
carbon linker to be in a linear (versus folded) conformation. This linear conformation of 
XLi-093 has been confirmed both in the solid phase (by X-ray) and in solution by NMR 
spectroscopy (Figure 14).64'66 The J values calculated from the dihedral angles (J - 5.38) 
were in excellent agreement with those determined from the solution NMR spectrum (J = 
24 
6.39). Because this bivalent ligand was the first dimeric a5-selective ligand reported, the 
enriched selectivity of this dimer and those similar to it might be entropic in nature since 
the loss of affinity at the other subtypes was profound.63 
Figure 13. Alignments of XLi-093 27 (white) and Rol5-1788 21 (cyan) within the included volume of 
the <x5p3y2 subtype/5 
It has been shown via crystallographic and solution NMR studies that 
modification of the aliphatic spacer to a -CH2OCH2- or a -(CH2)20(CH2)2- group, 
provided the bivalent ligand with a folded conformation (Figure 14).67 Modeling of this 
type of ligand (e.g. DMH-III-96 30, Figure 15) within the a5 pharmacophore model 
illustrated the inability of bivalent ligands in the folded conformation to bind, 
presumably, because they are either too hindered to access the Bz BS or its inability to fit 
in the included volume binding site space. Current data displaying these trends is shown 
25 
in Table 6, while further studies are underway to evaluate the length the lipophilic 
spacers may contribute toward the selectivity of both the benzodiazepine and p-carboline 
bivalent ligands (e.g. XLi-210, 29 and WY-S-6,26). It is clear that the second imidazole 
unit is protruding into the extracellular domain of the BzR/GABA(A) a5 binding site. 
This has a profound effect on the ligand design. For it means other homodimers or even 
heterodimers may bind o BzR/GABA(A)ergic sites. 
Figure 14. Crystal structures of the linear XLi-093 (27, above) and the folded DMH-III-96 (30, 
below).33'68'69 
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Table 6. The Molecular Composition and Stable Conformation of Various Bz BS Bivalent Ligands. 
ND = not determined yet. 
A 
Ligand Monounit 1 Monounit 2 Spacer Conformation 
in solution 
Crystal 
structure 
27, XLi-093 A A (CH2)3 linear linear 
29, XLi -210 A A (CH2)5 linear ND 
46, XLi -347 A A (CH2)20(CH2)2 folded ND 
47, XLi-374 A A CH2OCH2 folded ND 
30, DMH-III-96 - - (CH2)20(CH2)2 folded folded 
27 
Figure 15. Alignment of DMH-III-96 (30) within the included volume of the a5P3y2 subtype. It was 
apparent that the folded conformation prevented it from binding to this GABA(A) subtype. 
It is apparent that a folded conformation prevents these types of dimers from binding to 
this GABA(A) subtype and others as well. This will be discussed further in Part II. 
Success of XLi-093 and earlier in vitro data on WY-S-8 23 and WY-B-14 24 
(Table 5) indicated the C(6)-substituent of p-carbolines lies in the Loi region of the 
pharmacophore model or in the extracellular domain of Bz BS. For this reason, the P-
CCT dimer, WY-S-2 25 was designed and synthesized. Although the ai subtype 
selectivity was not amplified with this particular P-carboline dimer, the ligand does bind. 
It was proposed that the two-carbon linker was not long enough and that crowding 
between the second P-CCT unit and the receptor protein decreased the binding affinity at 
the al subtype, thereby negating potential selectivity.70"72 Further evaluation of the p-
CCT bivalent ligand with a bis-acetylene linker (WY-S-6 26) was done. Binding data 
revealed the bis-acetylene linker led to enhanced selectivity but was not as potent as WY-
28 
S-2. It was believed that by increasing the length of the linker, the ligand would have 
been able to thread itself into the binding site more efficiently (Figure 16). 
Figure 16. Alignment of WY-S-2 (25, left) and WY-S-6 (26, right) within the included volume of the 
alp3y? subtype. 
Similar to XLi-093, the dimer bis-(7)-THA 28 of Wang et al. was found to be a 
competitive antagonist at the Bz BS in both electrophysiological experiments and 
receptor binding assays (Table 4). 60 Although additional experimental data is needed, 
inspection of the alignment of XLi-093 (Figure 13) and our receptor model (Figure 17) 
indicated the aliphatic linker of these bivalent ligands would thread the second half of the 
dimer through the Ld,/A2 regions and toward the solvent accessible space outside of the 
pocket. 
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Beta-Carbolines 
The crystal structures and molecular mechanics simulations of several p-
carbolines has recently been reported. ' In general, substitution at C(3) and C(6) had 
the greatest effect on affinity. Consistent with the interaction with the Hi descriptor, high 
affinity ligands were always associated with groups able to interact as hydrogen bond 
acceptors at C(3). Furthermore, affinity was much lower for constrained P-carbolines 
which contained the carbonyl group in the anti conformation, in agreement with the 
proposed 3-centered hydrogen bond74'75 afforded by many p-carbolines in the stable syn 
conformation with the Hi descriptor proposed in Milwaukee years ago. 65 
•s f m 
Figure 17. Flexidocking of PCCT to the unified pharmacophore receptor model of the aly2 model of 
the protein subunits 
30 
As previously stated, the C(6)-substituent of (3-carbolines lies in the Ld, region of 
the unified pharmacophore/ receptor model for inverse agonists and antagonists. 
However, based on the CoMFA studies of Huang et al.,lb p-carboline agonists have been 
proposed to take on a vertical alignment with respect to the horizontal alignment of 
inverse agonists and antagonists. While only four P-carbolines have been reported to 
display agonistic activity, each of these compounds had a 4-methylmethoxy group that 
permitted interaction with the H2 descriptor and partial interaction with the region near 
the entrance to the L3 pocket (Table 6). It was postulated that 6-PBC 32 should display 
agonistic activity, and indeed, since partial occupation of a lipophilic region near the 
C(6)-substituent is probable (relative to ZK-93423 33), 6-PBC was a partial agonist.42 
However, it is likely that the type of activity displayed by 6-PBC may be receptor 
subtype-dependent, because when evaluated in vivo, it inhibited PTZ-induced seizures in 
a dose-dependent fashion and exhibited anxiolytic activity when evaluated in the elevated 
plus-maze paradigm. Yet, unlike typical 1,4-benzodiazepines, 6-PBC 32 was devoid of 
muscle relaxant activity and even antagonized the muscle relaxant/ataxic activity of 
77 70 
diazepam. " This is an interesting and unique molecule. 
Table 7. Affinities (Ki=nM) of 3,6-disubstituted p-carbolines at axp3y2 (x=l-3,5,6) receptor 
subtypes.* 
H 
31 
Ligands R* R3 <*L A-, <x4 «5 A 6 
22(PCCt) H COjtBu 0.72 15 18.9 1000 111 >5,000 
48(PCCE) H C02Et 1.2 4.9 5.7 ND 26.8 2,700 
37(3-PBC) H OnPr 5.3 52.3 68.8 1000 591 >1.000 
49(WYB14) TMS—^ C02tBu 6.8 30 36 2000 108 1000 
50(WY-B-25) TMS-== CO2CH2CF3 17 59 88 200 1444 >3000 
51(WY-B-99-l) TMS—^ C02Et 4.4 4.5 5.58 2000 47 2000 
23(WYS8) H—= C02tBu 0.972 111 102 2000 1473 1980 
52(WY-B-26-2) H~= CO2CH2CF3 4.5 44.6 42.7 2000 124 2000 
53(iodo-pCCt) 1 C02tBu 14.4 44.9 123 >4000 65.3 >4000 
54(WY-B-20) I CO2CH2CF3 12 39 47 2000 122 3000 
55(iodo-pCCE) I C02Et 4.8 31 34 1000 286 1000 
56(WY-B-08) I C02CH(CF3)2 78 301 131 3000 681 3000 
57(WYS13) Q C02tBu 2.4 13 27.5 NA 163 5000 
58(WYB27-1) Q CO2CH2CF3 26 143 117 3000 127 2000 
59(WYS12) Q C02tBu 37 166 314 NA 2861 5000 
60(WYB27-2) Q CO2CH2CF3 9.2 13 72 2000 449 2000 
61(WYS15) 0 C02tBu 3.63 2.02 44.3 NA 76.5 5000 
62(WYB29-2) 0 C02CH2CF3 25 137 125 2000 299 2000 
CMA57 F COC3H7 3.7 27 40 NA 254 >2500 
CM-A-82a C(CH3)3 C02tBu 2.78 8.93 24.5 1000 7.49 1000 
CM-A-87 F C02tBu 1.62 4.54 14.7 1000 4.61 1000 
25(WYS2) Beet — Beet 30 124 100 >300 >300 >4000 
26(WYS6) Beet—=—= — Beet 120 1059 3942 5000 5000 5000 
^Affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [3H]flunitrazepam or [3H] Ro-15-4513 binding to HEK cell membranes 
expressing human receptors of composition 
aip3y3, a2f33y2, ot3p3y2, a4p3y2, a5P3y2 and a6p3y2.80 Data represent the average of at least 
three determinations with a SEM of ±5%. 
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A series of 3,6-disubstituted P-carbolines was synthesized and evaluated 
for their in vitro affinities at 0^372 GABA(A) /benzodiazepine receptor subtypes by 
radioligand binding assays in search of a, subtype selective ligands. A potential 
therapeutic application of such analogs is to treat alcohol abuse. Analogues of P-
carboline-3-carboxylate-/-butyl ester (pCCt, 22) were synthesized via a CDI-mediated 
process by Yin et al.81 and the related 6-substituted P-carboline-3-carboxylates 36 
including WYS8 (23) were synthesized via a Sonogashira or Stille coupling process from 
6-iodo PCCt (35). The bivalent ligands of PCCt (25 and 26) were also designed and 
prepared via a palladium-catalyzed homocoupling process to expand the structure-
activity relationships (SAR) to larger ligands. Based on the pharmacophore/receptor 
model, a preliminary SAR study on 34 analogues illustrated that large substituents at 
position -6 of the p-carbolines were well tolerated.82"85 As expected, these groups are 
proposed to project into the extracellular domain (LD, region) of GABA(A) / Bz receptors 
(see 25 and 26). Moreover, substituents located at position -3 of the p-carboline nucleus 
exhibited a conserved stereo interaction in lipophilic pocket Li, while N(2) presumably 
underwent a hydrogen bonding interaction with Hi. Three novel P-carboline ligands 
(PCCt, 3PBC and WYS8), which preferentially bound to al BzR subtypes, permitted a 
comparison of the pharmacological efficacies with a range of classical BzR antagonists 
(flumazenil, ZK93426) from several different structural groups and indicated these p-
carbolines were "near GABA neutral antagonists". Based on the SAR, the most potent 
(in vitro) (Xi selective ligand was the 6-substituted acetylenyl pCCt (WYS8, 23). Earlier 
both PCCt and 3PBC had been shown to reduce alcohol self-administration in alcohol 
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preferring (P) and high alcohol drinking (HAD) rats but had little or no effect on sucrose 
IJ£ OO 
self-administration. " 3PBC was also active in baboons (Weerts et al. unpublished 
results in a poster at a CPDD meeting, manuscript in preparation).84,89 
Application of P-Carbolines to Treat Alcohol Addiction 
Alcohol addiction and dependence remain significant public health concerns, 
impacting physical and mental well-being, family structure and occupational stability.90"95 
While advances have been made in the development of novel therapies to treat 
alcoholism,96'97 alcohol-dependent individuals represent a heterogeneous group,79- 98"101 
and it is unlikely that a single pharmacological treatment will be effective for all 
alcoholics. Hence, a better understanding of the neuromechanisms which regulate alcohol 
seeking behaviors and the design of clinically safe and effective drugs that reduce alcohol 
addiction and dependence remain a high priority.102"104 While the precise 
neuromechanisms regulating alcohol-seeking behaviors remain unknown, there is now 
compelling evidence that the GABA(A) receptors within the striatopallidal and extended 
amygdala system are involved in the "acute" reinforcing actions of alcohol.105"107 Among 
the potential GABA(A) receptor isoforms within the VP regulating alcohol-seeking 
behaviors, GABA receptors containing the ai receptor subtype (GABA al) appear 
preeminent. Thus, Criswell and colleagues observed that acute alcohol administration 
selectively enhanced the effects of ionotophoretically applied GABA in the ventral 
pallidum (VP).90 However, no effects were seen in the septum, ventral tegmental area 
(VTA), and CA1 hippocampus. These data suggest the al Bz/Gaba(A)ergic receptor 
plays an important role in alcohol-motivated behaviors. Research on the neuroanatomical 
basis of alcohol reward has shown that the NACC, VTA, VP, central amygdala (CeA), 
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and hippocampus are all involved in GABAergic regulation of ethanol (EtOH) 
reinforcement.108- 109 Other investigators have identified a dense reciprocal projection 
from the VP to the NACC,110"112 and many of these have been found to be GABAergic 
neurons.105, I,3"n6 The NACC is now well established as a substrate that regulates the 
reinforcing properties of abused drugs.86, 92' 117, 118 Finally, immunohistochemical108"112 
and in situ hybridization studies79 have demonstrated that the VP contains one of the 
highest concentrations of mRNA encoding the al subunit in the CNS. These findings, 
together with pharmacological studies suggest the VP plays a major role in reward-
mediated behaviors of psychostimulants and opiates.99'100'119,120 This suggests a possible 
role of the VP-al receptors in the euphoric properties of alcohol. Findings of previous 
studies concluded that inhibition of VP-al receptors by the al preferring antagonist 3-
PBC produced marked reductions on alcohol-maintained responding.1 0 8 ,  1 1 1  The al-
mediated suppression at the VP level by 3-PBC showed a high degree of neuroanatomical 
specificity. Specifically, the a 1-mediated suppression was not observed with the more 
dorsal placements in the NACC or caudate putamen. The failure of 3-PBC to alter 
alcohol self-administration in the NACC/striatum is in agreement with previous research 
which has consistently reported a lack of expression of the al transcript in the NACC 
and caudate.109"112 
An understanding of the neuromechanisms that regulate alcohol drinking is key in 
the development of drugs to treat alcohol addiction and dependence in humans.96' 97 In 
recent years, much evidence has accumulated in favor of the GABA system;79 however, 
much remains unknown about the role of specific GABA(A) receptor subtypes in 
regulating ethanol reinforcement. This is due to both a lack of high-affinity and selective 
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ligands capable of discriminating among the GABA(A) receptor subunits and the 
heterogeneity of various subunits within the known alcohol reward circuitry.73,121 Of the 
potential GABA(A) receptors involved in the reinforcing properties of alcohol, evidence 
suggests the al subtype within the VP may play an important role in regulating alcohol-
seeking behaviors, as mentioned above. The VP contains one of the highest distributions 
7-5 1 J 
of al subunits in the mesolimbic system. ' ' Acute ethanol administration has been 
reported to selectively enhance the effects of iontophoretically applied GABA in the VP. 
These effects correlate highly with [3H] Zolpidem binding (an ai-subtype selective 
agonist).123"126 
To evaluate the role of the al receptor in regulating alcohol reinforcement, 3-
propoxy-P-carboline hydrochloride (3-PBC), a mixed benzodiazepine (BDZ) agonist-
antagonist with binding selectivity at the al receptor was developed. 108' 109' m' 127 
Compared with the prototypical BDZ agonist Zolpidem, 3-PBC exhibited a slightly higher 
binding selectivity for the al receptor.79'124,128 Preliminary behavioral studies in several 
species (e.g., rats, mice, and primates) show that 3-PBC is a BDZ antagonist, exhibiting 
competitive binding-site interactions with BDZ agonists at low to moderate doses (2.5-15 
mg/kg).73'124'129-133 At higher doses (15-60 mg/kg), 3-PBC produces anxiolytic effects in 
the plus maze that are comparable with those of chlordiazepoxide in alcohol preferring 
(P) rats.124 Thus given the proposed subunit composition of the GABA(A) receptors 
11 
within the CeA, pharmacological compounds capable of exploiting the al, a2.and a3 
subunit-containing GABA(A) receptors represent optimal tools to evaluate the role of 
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GABA(A) receptors in alcohol reinforcement and better understand neurobehavior and 
ethanol responding. 
The P-carboline-3-carboxylate-t-butyl ester (PCCt) is a mixed benzodiazepine 
agonist- antagonist ligand with binding selectivity at al receptors;79, 134 PCCt also 
exhibits some affinity (albeit weaker) for both a2 and a3 receptors. Behavioural studies 
in several species (eg, rats, mice, primates) has shown that PCCt is a BDZ antagonist 
exhibiting competitive binding site interactions with BDZ agonists over a broad range of 
doses.79'134 Other studies show that PCCt produced anxiolytic effects in P rodents19'M' 
198 1 ^ 
and potentiates the anticonflict response induced by al subtype agonists in 
primates.68'136"142 Thus, pCCt displays a weak agonist-antagonist profile depending on 
the behavioral task, species, and dose employed. 
In studies involving the al subtype, pCCT and 3-PBC were observed to 
Aft 71 i *3*5 i "in i IQ 
selectively reduce alcohol-motivated behaviors in a variety of experiments. ' ' 
143-147 f|owever? unlike the a5 selective inverse agonist RY-23, both the p-carboline 
antagonists PCCT and 3-PBC displayed mixed weak agonist-antagonist profiles in vivo in 
alcohol P and HAD rats. Therefore, in addition to being able to study the molecular basis 
of alcohol reinforcement, al Bz P-carboline ligands which display mixed agonist-
antagonist pharmacology in alcohol P and HAD rats may be capable of reducing alcohol 
intake while eliminating or greatly reducing the anxiety associated with habitual alcohol, 
abstinence or detoxification. Thus, these types of ligands may be ideal clinical agents 
for the treatment of alcohol dependent individuals.148"153 
37 
Consequently, several series of structurally different compounds have been 
synthesized which possess some ai subtype selectivity. The discovery of high affinity, 
saturable, and stereospecific ligands for the BzR has been coupled with the demonstration 
that P-carbolines exhibited an affinity for the BzR.148'154 Some of these agents act on the 
BzR to induce effects that are functionally opposite (inverse agonists/antagonists) to 
those of classical BDZs. Consequently, the affinities of a wide variety of P-carbolines 
have been reported on synaptosomal membranes from this laboratory,78- 79 as well as the 
laboratories of others,78'79 and this prompted a study of the binding affinities of a series 
of P-carbolines48' 73' 155 at 5 recombinant GABA(A) /BzR subtypes (aip3y2, a2p3y2, 
a3p3y2, a5p3y2 and a6p3y2) expressed from recombinant human cell lines.129 In 
general, this series of p-carboline ligands exhibited some selectivity at cti receptor 
subtypes including pCCt (22) and 3-PBC (70).78 These two ligands displayed a 20-fold 
and 10-fold selectivity, respectively, for the a.] subtype over the a2 and a3 receptors, as 
well as over 150-fold selectivity for the al site over the a5 subtype.78'79'96'97,112 PCCt 
(22) was more selective at the ai subtype in vitro than the classical al selective agonists 
Zolpidem (77) and CL 218872 (78).156' 157 A number of in vitro and in vivo studies 
employing ai (e.g., Zolpidem ,CL 218872,121 PCCt, and 3-PBC71) selective ligands 
suggest the ai-containing GABA(A) /Bz receptors of the ventral pallidum (VP) play an 
important role in regulating alcohol's neurobehavioral effects; particularly alcohol's 
reinforcing properties as mentioned above.121 
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Structure Activity Relationships of (3-Carbolines 
A predictive 3-D QSAR pharmacophore/receptor model for inverse 
agonist/antagonist P-carbolines was initially developed via Comparative Molecular Field 
Analysis (CoMFA) and later refined.158"161 Affinities of ligands from 15 different 
structural classes have been evaluated.158 Based on this CoMFA study of a series of p-
carbolines, Huang et al. reported that P-carbolines bind to all diazepam sensitive (DS) 
sites of the BzR with some selectivity at the al containing receptor isoform and this was 
confirmed by in vitro binding affinity of these ligands.158 A lipophilic region (LDj) of the 
pharmacophore receptor model appears to be larger in the al, a2 and a3-containing 
i 
receptor isoforms and important for al subtype selectivity. More recently, during the 
design and synthesis of pCCt-related bivalent ligands,135 it was found that a series of 3,6-
disubstituted P-carbolines (see Figure 18), including 6-iodo-pCCt (53) and 6-
trimethylsilanyl-ethynyl-pCCt (49) possessed al subtype selectivity.78'79 
22 pCCt 
ai a2 a3 a5 at 
0.72 15 18.9 110.8 >5,000 
78 CL 218872 
ai a2 a3 as 
57 1964 1161 561 >10,000 
h 
23 WYS8 (6-ethynyl-PCCt) 
ai a2 a3 a5 a6 
0.972 111 102 1473 1980 
.OCH2CH2CH3 
7 Zolpidem 
53 6- iodo-|3CCt 49 6-trimethylsilanylethynyl-pCCt 
ai a2 as a5 a6 ai a2 a3 a5 a6 
14.4 44.9 ,23 65.3 >4000 6.8 30 36 108 1000 
25 PCCt bivalent ligand 
ai a2 a3 a5 a6 
30 124 100 >300 >4000 
Figure 18. In vitro binding affinities of a series of cti selective BzR ligands (Kj in nM). 
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The rigidly linked linear bivalent ligands of PCCt at position "6" did bind to BzR 
receptors with some ai subtype selectivity and may provide the desired ai selectivity 
through specific occupation of the LD, region of the pharmacophore/receptor model.79'126 
Although the two 3,6-disubstituted-fi-carbolines 35 and 36 are less potent than pCCt (22), 
the potent binding affinities observed for 35 and 36 at the ai subtype has stimulated the 
synthesis of the PCCt analogs: 3-substituted-P-carbolines as well as 3,6-disubstituted-P-
carbolines. 
On the other hand, these studies also indicated that the selectivity of GABA(A) 
/BzR site ligands could be described in relation to binding and pharmacological efficacy 
in vitro. This efficacy was based on the capacity of a ligand to modulate GABAergic 
function.163 BzR ligands act to modulate chloride flux over a continuum ranging from 
positive to negative modulation, with neutral antagonists acting theoretically, at a point 
on the continuum, with zero intrinsic efficacy (e.g. they bind to the receptor but exhibit 
no activity).163 Consequently, the pharmacological profiles of PCCt and 3-PBC at recombinant 
aip3y2, a2p3y2, a3p3y2,a4p3y2, a5p3y2 and a6p3y2 receptor subtypes expressed in 
Xenopus oocytes were investigated.78'128'163 
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Flumazenil 
ZK93426 
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Figure 19. Efficacy of PCCt in modulating GABA at recombinant GABA al-a5 receptors164 in 
Xenopus oocytes: comparison with other BzR antagonists. 
Illustrated in Figure 19 is the modulation of GABA(A) aip3y2,a2p3y2, a3p3y2, a4p3y2 and 
0t5p3y2 receptor subunit combinations expressed in Xenopus oocytes by pCCt (open bars), 
flumazenil (shaded bars), and ZK 93426 (black bars). A saturating concentration (1-10 (jM) was 
coapplied over voltage-clamped oocytes along with an EC50 of GABA. 
The results of this study illustrated that PCCt was a near "neutral" antagonist (i.e., 
little or no efficacy) at all receptor subtypes. In fact, the level of intrinsic efficacy of pCCt 
in oocytes was less at some receptor subtypes than the classical nonselective antagonist 
flumazenil (Ro 15-1788, for which intrinsic efficacy at all BZ-sensitive GABA(A) 
subtypes was relatively low, but not zero). To date, no compound has been characterized 
that exhibits zero efficacy at all BzR subtypes, raising the possibility that a compound 
labeled as an "antagonist" may indeed exhibit functional activity given the right 
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circumstances. For example, more recently, the efficacies of both PCCt and 3-PBC in the 
selective reduction of alcohol responding and production of anxiolytic effects were 
demonstrated in P and HAD rats following oral administration.165 When compared with 
naltrexone treatment, these reductions in alcohol responding were more selective and 
longer in duration.42'121 The antagonist pCCt exhibited either a neutral or low-efficacy 
agonist response at GABA receptors in oocytes. Although there has been some debate in 
the literature at present as to whether a ligand's binding or efficacy selectivity was "the 
more salient factor" in determining a ligand's capacity to function as an alcohol 
antagonist,38'42"166'167 the knowledge of the efficacy of an individual putative anti-alcohol 
reward ligand across all GABA(A) receptors was indeed critical to the knowledge of 
their mode of action in the CNS. 
Based on the limited availability of data on the series of al "binding" and 
"efficacy" selective P-carbolines (PCCt, 3PBC) as anti-alcohol agents,6S'168 a study was 
designed to expand the SAR and search for better al subtype selective ligands. These 
compounds may be promising modulators of alcohol-related co-morbid behaviors in 
alcohol dependence via the GABA(A) /BzR system. Although recent evidence suggests a 
salient role for GABAergic mechanisms in the regulation of excessive alcohol drinking 
and the negative affective states associated with abstinence, decreased GABAergic tone 
stemming from chronic alcohol use and withdrawal may serve to generate anxiety.121'169 
Thus, compounds that enhance GABAergic tone may be effective and safe treatments for 
both excessive alcohol drinking and the negative affective states associated with 
abstinence and may represent novel pharmacotherapies to treat alcoholism. 
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In this regard, the established pharmacophore/receptor models42, 170 of BDZ 
binding sites was employed to design ligands with respect to the Ld, region at position-6, 
as well as characterize the binding pocket L) at position-3. Protein-ligand docking of the 
al subtype GABA(A) receptor protein and WYS8 illustrated the agreement between the 
pharmacophore/receptor model and BzR site prediction based on homology modeling.73 
The chemistry and pharmacological evaluation of a series of structurally modified 
analogues of pCCt (22) as selective and potent a\ subtype-preferring ligands is described. 
The synthesis of the al selective compound 23 (WYS8) and the structure-activity 
relationships (SAR) of 3,6-disubstituted P-carbolines were also studied. 
The PCCt Bivalent Ligands 
The in vitro biological protocols employed follow the published procedure.76 
Although the aip3y2 BzR/GABAergic subtype is very similar in structure to the a2 and 
a3 subtypes, there are slight differences.42 One major difference is in region LDi, which 
appears larger in the al subtype than in either the a2, or a3 or a5 subtypes. This is 
located near position -6 of pCCt and can be seen in the model of the Comparative 
Molecular Field Analysis (CoMFA) study for the al subtype (Figure 20).71'158 
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Figure 20. Orthogonal views of CoMFA contour maps for the affinity of 6-benzyl-substitute(l 0-
carbolines at the alp3y2 BzR. Orthogonal view of CoMFA contour maps for thea 1 P3y2 receptor 
subtype with 6-benzyl-substituted P-carbolines modeled by Huang.71'158 Green contours represent 
areas of positive steric interaction at a contribution level of 85%, which would result in reduced 
binding affinity. Blue contours represent areas of positive charge interaction at a level of 85%, 
which would increase the affinity of a ligand. 
Blue contours in the western region of the pharmacophore/receptor model imply positive 
lipophilic interactions in this area that corresponds to region Loi (a region in the 
pharmacophore adjacent to the extracellular domain of the receptor) of the unified 
pharmacophore/receptor model. In this region bulky substituents are tolerated and 
occupation of this area with substituents appears to enhance affinity or selectivity at al 
subtypes. This knowledge provided an opportunity to introduce a linker between two 
pharmacophoric P-carboline-3-carboxylate residues in order to design selective and rigid 
bivalent ligands. Initial efforts to find a novel series of a 1-preferring ligands focused on 
design and synthesis of pCCt bivalent ligands by Yin71'121 based on molecular modeling. 
Although the al subtype selectivity was not amplified with the particular acetylenyl 
linked bivalent ligand 25, the ligand does bind preferentially at al subtypes (Table 7). It 
was proposed the two-carbon linker was not long enough and that crowding between the 
second pCCt unit and the receptor protein decreased the binding affinity at the al 
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subtype, thereby negating some of the potential selectivity. However, these rigidly linked 
linear bivalent ligands 25 and 26 fit the GABA(A) /BzR pharmacophore/receptor model 
very well (Figure 16).171 The unit at C-6, presumably, protrudes into the extracellular 
domain of the BzR, as previously expected,172 and bound to BzR with some ai subtype 
selectivity.173"177 To our knowledge these are the first two rigid bivalent ligands in the p-
carboline series, which bind to BzR. Further pharmacological evaluation in vivo of the 
pCCt bivalent ligand with the longer rigid linker should shed light on the above 
hypothesis and this would also provide some tools to determine the size and exact 
location of the Loi region. 
WYS8 
A series of 6-substituted-P-carboline-3-carboxylates have been synthesized and 
bound in vitro to the aip3y2 BzR subtype preferentially as compared to other subtypes 
(see Tables 1-3) by Yin et al.65 These ligands have also been modeled in the GABA(A) 
/BzR pharmacophore model, and the 6-substitutents align well in the LDj region.141,152'178' 
179 Occupation of this region should lead to enhanced selectivity of a ligand at the ai 
containing isoform. Among the new 3,6-disubstituted-P-carbolines, 6-
trimethylsilanylethnyl-pCCt 22 has been recently synthesized and found in vitro to prefer 
the al subtype. However, the most selective ligand for the ai subtype was WYS8 (23). 
This al subtype selective ligand was 100 fold more selective over the other subtypes. 
This is the most al subtype selective ligand reported, to date, to these authors' 
knowledge. This 6-substituted acetylenyl PCCt 23 was 214 fold more selective for al 
isoforms over a5 isoforms. Studies of SAR in Table 7 confirmed the occupation of 
region Loi of the receptor pharmacophore model did enhance al selectivity in 
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comparison to the affinity of the non-selective ligand diazepam or the a5 selective 
ligand, RY080. As illustrated in the two dimensional Figure 21, full occupation of the LD, 
lipophilic region by P-carbolines may account for the potency/selectivity of this class of 
ligands at the al subunit. Analysis of the in vitro binding data for this series of bulky 6-
substituted P-carbolines (Table 7) has shown some selectivity for the al receptor 
subtype. In addition, it is important to note that binding affinity in this series of ligands of 
greater than 400nM usually results in zero efficacy at the subtype at pharmacologically 
relevant concentrations. 
Figure 21. Overlap of diazepam and pCCt in the previous two dimensional pharmacophore/receptor 
model. 
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The structure of WYS8 and diazepam is illustrated in a simple representation of the 
pharmacophore model (Figure 21). WYS8 (blue line) and diazepam (black line) fitted to 
the inclusive pharmacophore model for the BzR. Sites Hi and H2 represent hydrogen 
bond donor sites on the receptor protein complex, while A2 represents a hydrogen bond 
acceptor site necessary for potent inverse activity in vivo. Li, L2, L3 and Loi are four 
lipophilic regions in the binding pharmacophore. Descriptors Sj, S2, and S3 are regions of 
negative steric repulsion. 
The homology model employed here of the GABA(A) receptor included a 
number of alternative models for loop C, which was two residues shorter than the 
template and hence built from a loop database. The final model (Figure 17) was selected 
based on assessment of model quality138, 145' 146 and consistency with published 
mutational data,68' ,45'146 particularly with the T206 side-chain appropriately positioned 
facing the benzodiazepine-binding pocket. In this illustration, positioning of WYS8 in 
the BzR was executed using a genetic algorithm in FlexiDock®. 
Table 8. Affinities (Kj=nM) of 3,6-disubstituted (5-carbolines at ax|33y2 (x=1-3,5,6) receptor 
subtypes." 
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Ligands R6 R3 ai AI a3 a4 «5 a<, 
22((5CCt) H C02tBu 0.72 15 18.9 1000 111 >5,000 
48(PCCE) H C02Et 1.2 4.9 5.7 ND 26.8 2,700 
37(3-PBC) H OnPr 5.3 52.3 68.8 1000 591 >1,000 
49(WYB14) TMS-= C02tBu 6.8 30 36 2000 108 1000 
50(WY-B-25) TMS^S CO2CH2CF3 17 59 88 200 1444 >3000 
51(WY-B-99-l) TMS—= COjEt 4.4 4.5 5.58 2000 47 2000 
23(WYS8) H-= C02tBu 0.972 111 102 2000 1473 1980 
52(WY-B-26-2) H-= CO2CH2CF3 4.5 44.6 42.7 2000 124 2000 
53(iodo-(3CCt) I C02tBu 14.4 44.9 123 >4000 65.3 >4000 
54(WY-B-20) I CO2CH2CF3 12 39 47 2000 122 3000 
55(iodo-pCCE) I C02Et 4.8 31 34 1000 286 1000 
56(WY-B-08) I C02CH(CF3)2 78 301 131 3000 681 3000 
57(WYS13) Q C02tBu 2.4 13 27.5 NA 163 5000 
58(WYB27-1) Q CO2CH2CF3 26 143 117 3000 127 2000 
59(WYS12) Q C02tBu 37 166 314 NA 2861 5000 
60(WYB27-2) Q CO2CH2CF3 9.2 13 72 2000 449 2000 
61(WYS15) 0 
C02tBu 3.63 2.02 44.3 NA 76.5 5000 
62(WYB29-2) 0 CO2CH2CF3 25 137 125 2000 299 2000 
CMA57 F COC3H7 3.7 27 40 NA 254 >2500 
CM-A-82a C(CH3)3 C02tBu 2.78 8.93 24.5 1000 7.49 1000 
CM-A-87 F C02tBu 1.62 4.54 14.7 1000 4.61 1000 
25(WYS2) Beet — Beet 30 124 100 >300 >300 >4000 
26(WYS6) Beet — -— Beet 120 1059 3942 5000 5000 5000 
aThe affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^H] or [3H] Ro-15-4513 binding to HEK cell membranes expressing human 
receptors of composition aip3'y2,a2p3y2,a3p372,a4p372,a5p3'y2 and a6P3y2.71-73'136171 Data 
represent the average of at least three determinations with a SEM of ±5%. 
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3-Substituted p-CarboIines 
It was initially believed by Braestrup, Loew, and others that an ester moiety at 
position-3 of P-carbolines was required for a ligand to exhibit high affinity binding at Bz 
i sn 1511 
binding sites. However, high affinity binding of p-carbolines including the 
antagonist 3-propoxy P-carboline (3-PpC, Table 8) demonstrated this was not the case.65 
Examination of data from additional studies65 have suggested that at least two factors 
affected high affinity binding at BzR with respect to 3-alkoxy substituted P-carbolines,182 
one of which was the lipophilicity of the substituent which interacted at Li. The Li pocket 
tolerates linear groups up to 4 carbons in length via molecular modeling and receptor 
binding. Comparison of the in vitro receptor binding affinity of the ligands depicted in 
Table 8 indicated the alkyl ethers 37 and 38 bind potently to ai subtypes while the larger 
branched analog 41 does not; binding affinity is lost, illustrating that the substituent at the 
3-position is to large to allow the ligand to bind. Likewise, the 3-benzyloxy P-carboline 
42 is also too bulky to fit the LI pocket despite its lipophilic nature. The second factor 
was the ability of the substituent at position-3 to release electron density to the pyridine 
ring. This enhanced the basicity of the nitrogen atom at N(2) which resulted in a greater 
ligand-receptor interaction at H]. Analysis of the binding affinities of the novel 
trifluoroalkyl esters of P-carboline-3-carboxylic acid further supported this hypothesis 
(Table 7). The trifluoroalkyl esters exhibited reduced binding affinity at all receptor 
subtypes when compared to their corresponding alkyl esters (43 vs. 44, 45 vs. PCCE). 
Since the trifluoromethyl group was a strong electron-withdrawing group, when 
compared to the corresponding alkoxycarbonyl moiety, the 3-trifluoroalkoxycarbonyl 
substituent would decrease electron density to the pyridine (N2) ring reducing the 
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basicity of the nitrogen atom. This would result in a weaker ligand-receptor interaction at 
Hi. In addition, the trifluoroalkyl group was less lipophilic than the corresponding alkyl 
moiety, which may result in a weaker interaction at Li. Ramachandran and Hanzawa 
have reported that trifluoromethyl groups are nearly as large as isopropyl or t-butyl 
functions. ' It was possible, the trifluoromethyl substituted ligands are simply too 
large to exert high affinity binding; however, (3CCT (22), WY-B-24 (68) and CM-A-77 
(69) all bound with good potency to al BzR subtypes, and these ester functions occupy a 
large molecular volume. 
Table 9. Afflnities (Kj=nM) of 3-substituted P-carbolines at axP3y2 (x=l-3,5,6) receptor subtypes 
H 
51 
Ligands R* al Oil «3 a4 a* as 
48BCCE H COjEt 1.2 4.9 5.7 1000 26.8 2700 
45 H CO2CH2CF3 3.0 24.5 41.7 >500 125.7 >2000 
63(WYB09-I) H C02CH(CF3)2 3.99 8 32 1000 461 2000 
64(WYB23-1) H CC^CHJCCIJ 10 33 43 1000 189 2000 
65(WYB17) H C02CH(CH3)CC13 2000 2000 2000 3000 2000 5000 
66(CMA64) H C02CH(CH3)C2H5 18 60 116 NA 216 >2000 
67(CMA69) H C02CH(CF3)C2H5 
F 
1000 1000 1000 NA 1000 >2000 
22.0 177 44.8 3000 422 3000 
68(WY-B-24) FR ° T F 
H 
0 1 
69(CM-A-77) Or fVWS 33.5 1000 1000 1000 1000 3000 
H 
The affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by competition for 
pH]flunitrazepam or [3H] Ro-15-4513 binding to HEK cell membranes expressing human receptors 
of composition aip3y2, CC2P3Y2, a3p3y2, a4p3y2, a5p3y2 and a6f}3y2.171 Data represent the average of 
at least three determinations with a SEM of ±5%. 
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Table 10. Affinities (Ki=nM) of Ether-substituted P-earbolines at axp3y2 (x=l-3,5,6) Receptor 
Subtypes 
Ligands 
3000 3000 3000 350.2 10000 
3000 3000 10000 830 10000 
42 
194 245 1000 1000 36.9 
123.6 139.2 1000 10000 24.9 
859 245 818 10000 10000 
523 68.8 591 53 1000 
25.1 28.2 826 1000 6.43 
The affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by competition for 
pH|flunitrazepam or [3H] Ro-15-4513 binding to HEK cell membranes expressing human receptors 
of composition aip3y2, a2(J3y2, a3P3y2, a4p3y2, a5P3y2 and a6P3?2.71'170 Data represent the average 
of at least three determinations with a SEM of ±5%. 
Chiral 3-Substituted P-Carbolines. 
Examination of the binding data for the enantiomeric pair of P-carboline sec-butyl 
esters 73 and 74 (Table 11) indicated that the (R)-enantiomer 74 bound tighter to the 
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receptor subtypes than the (S) isomer 73. Although both enantiomers exhibited 
approximately a 4-fold selectivity for the a 1^372 subtype, the (R) isomer remained more 
potent in vitro at all 5 BzR subtypes. Because the receptor subtype selectivity remained 
about the same for the (R) and (S) isomers, this indicated the stereoenvironment in 
lipophilic pocket Li was highly conserved across the entire series of BzR subtypes in 
agreement with earlier work on the binding affinities of the enantiomers of the 
framework-constrained 4,5-substituted pyrroloimidazobenzodiazepines.65 It is possible 
that lipophilc pocket Li is simply a large area in the pharmacophore/receptor model with 
only small steric differences between receptor subtypes. More work will be required to 
determine if this is the case. A similar result was observed in the case of (R) and (S) 
isomers of CMD-30. The (R)-enantiomer CMD-30 R (72) bound slightly tighter to the 
receptor subtype than the (S) isomer (71) with almost 70 fold more selectivity for the al 
subtype over the a5 isoform. In addition, previously it was reported that a hydrogen 
bond between the N (9) H atom of a P-carboline and the secondary site A2 in the receptor 
pharmacophore was required for potent inverse agonist activity in vivo.79 Therefore, a 
series of ligands with the Boc group at position-9 such as 75 and 76 were evaluated and 
were not ai subtype selective ligands. In fact, they did not bind to BzR at all in 
agreement with previous work (Table 12).79'126 73'l26'133 
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Table 11. Affinities (Kj=nM) of chiral 3-substituted (5-carbolines at axP3y2 (x=l-3,5,6) receptor 
subtypes 
Ligands «i «2 «3 0(4 as a$ 
71 
72 
O^CF3 
CMD-30(S) 
CMD-30(R) 
90 931 172 >3000 1847 >2000 
27.0 343.3 453 >3000 1847 >2000 
73 
74 
17 59 NA 1444 >3000 
7.7 32.5 43 NA 69 >2000 
The affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by competition 
for pHjflunitrazepam or [3H] Ro-15-4513 binding to HEK cell membranes expressing human 
receptors of composition a2p3y2, o3P3t2, a4p3y2, a5p3y2 and a6(J3y2.135 Data represent the 
average of at least three determinations with a SEM of ±5%. 
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Table 12. Affinities (Ki=nM) of Boc-protected 3-substituted {5-carbolines at axP3y2 (x=l-3,5,6) 
receptor subtypes 
Ligands ct) cti a 3 04 a.5 ag 
75 
450 5000 ND ND 5000 5000 
N ' ^ N  W Y S 2 0  
Boc 
O 
* 'xxc °̂k 
ND ND ND ND 1847 ND 
£ WYS21 
Boc 
ND = not determined yet (see previous tables for details of receptor binding). Data represent the 
average of at least three determinations with a SEM of ±5%. 
Efficacy of al Preferring Ligands in Oocytes at GABA(A) Receptor Channels 
The physiological efficacy of (3CCt, as compared to other Bz antagonists was 
investigated across all diazepam sensitive (DS) receptor subunits at recombinant al, a2, 
a3, and a5 receptor subunits in the Xenopus oocytes assay and is depicted in Figure 22 
by Harvey et al.163 
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Figure 22. Efficacy of pCCt in modulating GABA at recombinant GABA al-a5 receptors 
Xenopus oocytes: comparison with other BzR antagonists. 
135, 183, 184 in 
In comparison to other BzR antagonists such as flumazenil and ZK 93426, as 
mentioned, PCCt exhibited either a neutral or low-efficacy agonist response at GABA a\ 
(96±7%), a2 (99±10%), a3 (108±6%), and a4 (107±5%) receptors. However, a low-
efficacy partial inverse agonist response was observed at the a5 receptor (88±7% of the 
GABA response) compared to the control diazepam. Flumazenil exhibited an efficacy 
profile that was qualitatively similar to PCCt at the a 1 (99±5%), a3 (118±7%), and a5 
(96±6%) subtypes. At the 012 receptor, flumazenil produced a low-efficacy agonist 
response (115±4%), while PCCt was GABA neutral (99±10%). Flumazenil also produced 
a qualitatively similar response to PCCt at the a4 receptor, albeit the magnitude of 
GABA potentiation by flumazenil far exceeded that of PCCt (132±6 vs. 108±6%, 
respectively). However, it is important to note, with regard to a4/a6p3y2 subtypes, the 
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agonist effect was observed at 10 (iM, far above that required for agonist efficacy at the 
DS subtypes. In contrast, ZK 93426 produced a clear weak agonist profile, potentiating 
GABAergic activity by 137±8%and 148±11% across the al-a4 subtypes, but was 
GABA neutral at the a5 receptor (96±6%). These findings suggested that PCCt had no 
appreciable intrinsic efficacy. The rationale for referring to this agent as a "mixed 
agonist-antagonist" was based on the fact that, despite the ability to potentiate GABA at 
certain receptor subtypes, it was "GABA neutral" at select doses. In addition, at select 
doses, PCCt and 3-PpC were capable of competitive antagonism of classical 
benzodiazepine agonists, therefore, the development of subtype-selective antagonists 
for GABA(A) receptors, such as pCCt, which targeted the GABA(A) al receptor as a 
weak agonist-like antagonist,185 should facilitate efforts to understand the antialcohol 
actions of P-carbolines in nonhuman primates and humans as well. In the NIMH 
supported PDSP screen neither PCCT, 3PBC, nor WYS8 exhibited significant 
interactions at other receptors (See Appendix for PDSP screen or http://pdsp.med.unc.edu 
for details). 
Innate elevations of the a i and az subunits of the HAD rat may contribute to the 
capacity of novel P-carboline ligands to function as both anxiolytic agents and alcohol 
antagonists in this genetic rat line.111 These differences may explain the capacity of 
novel P-carboline ligands to block alcohol drinking and still exhibit anxiolytic actions in 
the P and HAD alcoholic rats. WYS8 may be a suitable ligand to evaluate as a 
preclinical agent to reduce alcohol dependence. Its reduced efficacy at the al - al 
subunits in potentiating GABA may render it a safe BDZ receptor ligand devoid of 
synergistic interactions with alcohol and with much less abuse potential.16 
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Table 13. Structures and affinities at axf32y2 recombinant receptor; and modulation by p-
carbolines. pAg = weak partial agonist; Ag = agonist19'186 
K, (nM) 
Ligand R* Rs R., R3 al a2 a3 a4 a5 a6 Activity 
32.6-PBC On-Pr H MOM C02Et 
33, ZK-93423 OCH2Ph H MOM C02Et 
81, ZK-91296 H OCH2Ph MOM COjEt 
82, Abecarnil OCH2Ph H MOM C02-/-Pr 
0.49 1.21 2.2 NR 2.39 1343 pAg 
4.1 4.2 6 NR 4.5 1000 Ag 
NR NR NR NR NR NR pAg 
12.4 15.3 7.5 NR 6 1000 pAg 
Ligands that Occupy the L2 Region and are Selective for a5 Containing Receptors; 
RY-24 and Related Analogs 
Continued interest in the development of a5 selective ligands goes forward in the 
CNS area for many reasons. One of these involves the localization of these receptors and 
their presumed importance in developmental biology. Over 30 % of GABA(A) receptors 
in neonatal rat pups are comprised of a5p3y2 subtypes, whereas they only comprise 
about 5 % in adult rats.19'21 In addition, these a5 subtypes are primarily found in the 
hippocampus,16, 187 which prompted interest in memory and learning.188 From the 
evaluation of Kj values, it was found that many 8-substituted z'-BZDs, such as RY-80 31 
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and RY-24 83 and their trimethylsilyl precursors 5 and 84 (Table 14) exhibited a 
significant degree of binding selectivity at the a5 subtype in vitro. This observation was 
in agreement with the previous hypothesis that correct occupation of the L2 region can 
promote a5 selectivity of a ligand.21 Therefore, the efficacy of the a5-subtype selective 
ligand RY-24 83 was evaluated in vitro. Recently, it was determined that this ligand was 
a potent inverse agonist at the a.5 subtype with a much weaker efficacy at the other 
subtypes (Figure 24). These results confirmed previous binding data, which indicated that 
this ligand was a5-selective due to the lipophilic C(8)-substituent which fully occupied 
the L2 pocket.189 The data were also in agreement with previous studies in vivo, which 
indicated that some of these ligands enhanced cognition while other Bz BS ligands were 
not as effective.111'190 Furthermore, ligands devoid of a lipophilic substituent at the C(8) 
position showed no selectivity for the a5 subtype (Table 14). 
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Table 14. Structures and affinities of some a5p3y2 subtype selective ligands. 
Me 
DM-I-81,87 88 
Kj (nM) 
Ligand Rs Rs al a2 a3 a5 a6 
83, RY-24 -H f-Bu 26.9 26.3 18.7 0.4 5.1 
84, RY-23 —TMS r-Bu 197 143 255 2.61 58.6 
31, RY-80 -H Et 28.4 21.4 25.8 0.49 28.8 
85, RY-79 —TMS Et 121 142 198 5.0 114 
86 H Et 1.2 2.0 1.1 0.4 >300 
87, DM-I-81 Ph NA >2000 >2000 >2000 176 >2000 
88, PWZ-02921'191 CI NA >300 >300 >300 38.8 >300 
Inspection of the data in Table 14 revealed some observations worth noting. 
While the lipophilic substituent at Rg of RY-24 83 and RY-80 31 decreased the affinity 
for al, a2 and a3 subtypes, it retained affinity for a5 and actually increased affinity for 
the a6 subtype. Furthermore, selective affinity of /-BZDs at the a5 subtype was 
independent of the occupation of the L3 pocket, as illustrated by the in vitro data of DM-
1-81 87 (Table 14). This data again supports the importance of the occupation of the 
lipophilic pocket L2 for potent selectivity at the a5 subtype. 
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Figure 23. Subtype efficacy of RY-24 (83), Dose response curves for RY-24 in oocytes expressing 
different subunit combinations of GABA(A) receptors. Subtype combinations are indicated in 
legends. cRNA-injected Xenopus oocytes were held at -60 mV under two-electrode voltage clamp. 
Increasing concentrations of RY-24 were superfused together with a GABA concentration eliciting ~ 
20% of the maximal current amplitude. RY-24 was pre-applied for 30 sec before the addition of 
GABA, which was co-applied with the drugs until a peak response was observed. Data were 
normalized for each curve assuming 100% for the response in the absence of RY-24. RY-24 was 
made up and diluted as stock solution in DMSO. Final DMSO concentrations perfusing the oocyte 
were 0.1%. Values are presented as mean ± SD of at least 4 oocytes from at least 2 batches. 
June et al. recently reported the neurobehavioral results of RY-23 and RY-24 in 
70 181 
rats. In agreement with previous studies, ' these a5 selective ligands were highly 
selective in suppressing ethanol-maintained responding (Figure 25).79' 183 As previously 
stated, the hippocampus contains the greatest concentration of a5-containing receptors in 
the CNS,16 and it is possible that these hippocampal a5 receptors may regulate alcohol-
motivated responding following systemic administration of an a5-selective agent. 
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Furthermore, RY-24 also antagonized the motor-impairing and sedative effects of ethanol 
in Long-Evans rats. Combined with additional studies within the ventral pallidum (VP), it 
has been proposed that the GABAergic systems within the VP and hippocampal 
pathways may represent new extensions of the mesolimbic ethanol reward circuitry. 
Although these data do not strongly support a direct role for the modulatory influences of 
intrinsic efficacy in the behaviors examined, the synthesis of a5 subtype selective ligands 
provides researchers a unique opportunity to explore the role of this subtype in the 
neurobehavioral effects of alcohol.19'192 However, the efficacy (inverse agonist, negative 
modulation) of RY-23 and RY-24 at al and a2 subtypes precludes potential clinical uses 
of such agents for both agents are proconvulsant and RY-24 is also convulsant. The 
efficacy of PWZ-029 (see below) is more promising in this respect. 
In studies involving the ai subtype, P-CCT and 3-PBC were observed to 
selectively reduce alcohol-motivated behaviors in a variety of experiments, as mentioned 
10^ previously. However, unlike the a5 selective inverse agonist RY-23, both the p-
carboline antagonists P-CCT and 3-PBC displayed mixed weak agonist-antagonist 
profiles in vivo in alcohol P and HAD rats. Therefore, in addition to being able to study 
the molecular basis of alcohol reinforcement, ai Bz BS ligands which display mixed 
agonist-antagonist pharmacology in alcohol P and HAD rats may be capable of reducing 
alcohol intake while eliminating or greatly reducing the anxiety associated with habitual 
alcohol, abstinence or detoxification. Thus, these types of ligands may be ideal clinical 
agents for the treatment of alcohol-dependent individuals, as mentioned before.194 
Additional behavioral studies of RY-24 were performed by Helmstetter et al. and 
provided further support for the role of the hippocampus in anxiety and learning.191' 192 
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Moreover, the data suggested that Bz BSs within the hippocampus are important for the 
acquisition of fear conditioning. Although this subtype selective ligand has been shown 
to be an inverse agonist at the a5 subtype,191"192 this study suggested that RY-24 may act 
as an agonist at other alpha subtypes because larger doses of RY-24 were not as 
anxiogenic as the smaller doses and resulted in decreased learning. Consistent with the 
studies of Stephens et al. using a5 knock-out mice18 and the efficacy studies of Liiddens, 
June and Cook et al.,195' 196 these findings support the concept that the pharmacology 
observed depends upon the dose, behavioral paradigm employed and subunit composition 
activated. Ligands such as RY-24 have proven to be valuable in the study of the 
biochemical and pharmacological properties of GABA(A) receptors and have permitted 
insight into the role this protein plays in anxiety and learning. 
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Figure 24. Suppression of alcohol-motivated responding by RY-24 (83) and RY-23 (84)18 
On the left is a dose-response of ip administration of RY-24 (0.0-3.5 mg/ kg) and 
vehicle on responding maintained by ethanol (10 % v/v) (top panel) and water (white 
bottom panel) in male Long-Evans rats. On the right is the dose-response of unilateral 
infusions of RY-23 (0.0-40 |ag) in the hippocampus on a concurrent fixed-ratio (FR4) 
schedule for ethanol (10 % v/v) (top panel) and saccharin-maintained (0.025 % v/v) {grey 
bottom panel) responding. For both studies, *p < 0.05 versus control condition values 
was determined using ANOVA and post hoc Newman-Keuls test. Each bar represents 
the mean (± SEM) (n = 15 for RY-24 and n = 7 for RY-23).18 
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QH-II-066 
Due to the pharmacological profile that the negative modulator RY-24 exhibited 
in vivo (enhanced cognition via a5 subtypes), the development of additional a5 subtype 
selective ligands was pursued. Thus, the 7-acetyleno analog of diazepam, QH-ii-066 89, 
was synthesized and was determined to also exhibit a binding and functional selectivity at 
the a5 subtype over the al subtype (Table 15).197 This was due to full occupation of the 
L2 pocket, relative to diazepam (Figure 25). To our knowledge, this was the first agonist 
ligand to display some a5 selectivity from the 1,4-benzodiazepine family. Importantly, 
the 7-cyano congener 90 (Table 15) did not potently bind to recombinant receptors of the 
a5 subtype, which is in agreement with earlier work of Haefely and Fryer et al. on the 
SAR of 1,4-benzodiazepines.198'204 This cyano ligand also did not exhibit any subtype 
selectivity, re-emphasizing that occupation of the L2 region with lipophilic groups is 
important for a5 selectivity as well as for high affinity. 
66 
H, 
Figure 25. Comparison of non-selective diazepam (black) with the a5-selective QH-ii-066 (cyan) 
when aligned within the unified pharmacophore/ receptor model. 
The acetylenic moiety of QH-ii-066 increased the occupation of the L2 region relative to 
that of diazepam. Furthermore, Lelas and Cook et al. have determined that although 
QH-ii-066 had similar affinity for the DS subtypes in rats, it displayed functional 
selectivity in vivo, with diazepam-like efficacy at the a5 subtype and partial efficacy at 
the al subtype.198"204 The study also indicated that this 7-acetyleno substituted diazepam 
analog exhibited less potency in protection against MES-induced seizures (maximal 
electroshock) relative to diazepam than against PTZ-induced (pentylenetetrazol) seizures. 
Hence, the ai subtype may play a more prominent role in MES-induced seizures than in 
PTZ-induced seizures.203 
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Table 15. Structures and affinities of 1,4-benzodiazepines. 
Kj (nM) 
Ligand R7 ql q2 <x3 a5 a6 
34, diazepam CI 14 20 15 11 >3000 
89, QH-ii-066 =—H 76.3 42.1 47.4 6.8 >3000 
90 c^N 320 310 350 265 >3000 
The Interactive Compound Table 
The Milwaukee-based database of compounds has grown to 600-700 compounds. 
The database designed by Clayton has been entered into a Microsoft Excel with 
ChemDraw Ultra 12.0 creating an interactive database. The database allows a user to 
search by Kj value or create mathematical expressions to identify most subtype specific 
ligands. Additional features of the table are the presence of chemical properties and 
physical properties (log P), and volume. The program also allows one to search the 
complete database by substructure, perform similarity searches and R-group analysis. 
Data can be both imported or exported into other software programs for QSAR and 
modeling (See complete compound table in Appendix). 
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Evidence from Covalently Reactive Ligands Allows One to Position the L2 
Lipophilic Pocket 
Covalent labeling studies contributed significantly to the determination of 
1 QQ 
residues that are located within the Bz BS. 
Table 16. Ligands used for affinity labeling studies.202 
Ligand Activity Site of Interaction 
[ HJflunitrazepam agonist 
91,[3H]RO 15-4513 inverse agonist cuY210 
cuH102 
93 
92 agonist aiHlOlC (rat) 
partial agonist aiHlOlC, aiG157C 
aiV202, aiV211C (rat) 
O 
92 93 
7-isothiocyano-1,4-benzodiazepine 8-isothiocyano imidazolebenzodiazepine 
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Photoincorporation studies with the agonist [ H] flunitrazepam identified alH102 
of the human sequence as the primary site of incorporation. McKernan et al. has 
proposed that flunitrazepam is coupling via the nitro group at the 7-position.204" 206 
Studies with the inverse agonist [3H]Ro 15-4513 indicated alY210 as the primary site of 
incorporation.35, 173'204'207 Thus, the azido group at the 7-position of Ro 15-4513 should 
be in close apposition to alY210, assuming no rearrangement of the photo-activated 
intermediate. Further information comes from recent studies reporting the covalent 
coupling of the 7-isothiocyano- derivatives (Rice et al.) of a 1,4-benzodiazepine, 
(isothiocyanate 92)204 and of Ro 15-1788 (isothiocyanate 93)204' 206 to GABA(A) 
receptors in which individual amino acid residues had been mutated to cysteines. The 
primary site of reaction of both substances was the rat alHlOlC mutant that is 
homologous to a 1 HI02 of the human subunit. Thus, the 7-substituent both of 1,4-
benzodiazepines and of imidazodiazepines appears to be in apposition to alH102. The 
imidazobenzodiazepine 93 reacted with additional cysteines in positions corresponding in 
the human sequence to positions alV203C and alV212C in the loop C stem, and with 
alG158C in loop B (see alignment in Figure 64). Thus, the 7-substituent of this 
compound, in agreement with the data from photolabeling HI02 with flunitrazepam and 
Y210 with Ro 15-4513, is in apposition to loop A, the loop C base, and additionally loop 
B. 
Thus, all the findings from covalently incorporated ligands given above can be 
reconciled by placing the 7-substituent, and thus the L2 descriptor of the unified 
pharmacophore model, between the loop C base near aiV203/aiV212/otiY210 and loop 
A aiH102. The homology models reveal that this is not only topologically possible, but 
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also provides the additional apposition to loop B that is suggested by the reaction of 
isothiocyanate 93 with rat alG157C. Thus, the L2 lipophilic pocket is most likely formed 
by the base of loop C, together with parts of loop A. 
The A2 Descriptor and the LDI Region 
Experimental data yields some very convincing evidence for assignment of the A2 
descriptor and the LDI region of lipophilic interaction next to A2 to protein segments close 
to residues y2A79 and y2T81 at loop D. Certain imidazobenzodiazepines, which occupy 
the pharmacophore volume close to A2 (see Figure 71), are more sensitive to y2A79 
mutations than classical benzodiazepines or benzodiazepines that lack a 3'-imidazo 
substituent. This was shown in a study where mutations of y2A79 and y2T81 had little 
effect on the binding of the agonists diazepam and flunitrazepam, but in a roughly size 
dependent fashion decreased the affinities of antagonist Rol5-1788 and inverse agonists 
Ro 15-4513.42 In agreement with other studies, midazolam, which lacks a 3' substituent, 
behaved more closely to classical benzodiazepines than /-BZDs.1'208'209 This trend is 
enhanced by rigid and bulky 3'-imidazo substituents, altogether suggesting that y2A79 
and y2T81 are located close to the region of the Bz BS surrounding the 3' substituent of /-
1 -j 1 
BZDs. The localization of the 3'-imidazo substituents in the unified pharmacophore 
model, thus positions the A2 and LDI descriptors near residues y2A79 and y2T81 (Figure 
71). Further support for this localization comes from the observation that DMCM also 
looses affinity upon mutagenesis in positions y2A79 and y2T81,121'210 consistent with the 
alignment of this substance in the pharmacophore. Figure 67 shows that changes to the 
protein near the A2 descriptor would in all likelihood not be tolerated by DMCM but 
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should not impact the efficacy of diazepam (Figure 26). The affect of mutations on 
positions y2A79 and y2T81 is in agreement with the proposed unified pharmacophore 
protein model of Milwaukee.170'211,212 
Figure 26. Diazepam in the pharmacophore receptor model and the key residues y2A79 and y2T81 
Included Volume Analysis of Ligands Binding to Receptors Containing Different 
Alpha Subunits 
The benzodiazepine binding site of aPy2 GABA(A) receptors is strongly 
influenced by the type of a subunit present in these receptors as indicated by the 
existence of ligands exhibiting certain selectivity for receptors containing the respective 
170 • a subunits. If subtype selective ligands are then aligned within the pharmacophore 
model according to the resulting alignment rules33' 213 their included volumes can be 
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constructed and used to compare the topologies of benzodiazepine binding pockets of 
different receptor subtypes.214 Ligands employed in the included volume for each 
receptor subtype exhibited potent affinity (Kj < 20 nM) at the respective receptor subtype. 
CL-218,872 (Kj = 57 nM at ai) and Zolpidem (Kj = 26.7 nM at ai) were added to the 
included volume of the aip3y2 subtype since they are both ai-subtype selective ligands. 
The major differences with regard to volume and affinity are shown below and are 
important for interpreting experimental data. 
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The Previous Benzodiazepine Subtype Selective Receptor Pharmacophore Models 
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Figure 27. Overlap between pairs of previous included volumes derived from receptor subtype selective ligands: 
a) al and a2, b) a2 and a3, c) a4 and a6, d) al and a6, e) al and a5. Yellow color indicates 
overlapping regions and each grid measures 4 A in width and height. In order to provide the 
connection between this figure and other figures, f) shows diazepam and the descriptors of the 
unified pharmacophore model depicted in the included volume requirement of the subtype 
(aip3y2). 
The included volume requirements show some trends that are useful to explain 
subtype preferences of ligands and that have already guided substance development: 
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1. The included volumes of the al, a2 and a3 subtypes are similar both in size and 
topology. This is consistent with the similar affinity profiles these subtypes displayed for 
classical benzodiazepine agonists, pyrazoloquinolinones and imidazobenzodiazepines (/-
BZDs).33 34-213 The included volume of the al subtype is slightly different from that of 
al and a3 subtype as indicated by the selective affinities of Zolpidem, CL-218,872, 6-
substituted p-carbolines (e.g. 6-methylbenzyl amino betacarboline) and pyridodiindoles 
for this subtype and the space needed for accommodating these structures (Figure 27 
a,b).54,71 Results from both the SAR studies and the included volume analysis imply that 
the a2 and a3 subtypes are very similar in shape, polarity and lipophilicity. 
2. The included volumes of the al and a4 or a6 subtypes are very different. From 
examination of Figure 27d, it is evident that the included volume of the a6 subtype is 
significantly smaller than that of the al subtype. Especially the Lo, region is much larger 
in al receptors. Contributions to the Loi region are derived in a large measure from 6-
substituted p-carbolines and ring-A substituted pyrazoloquinolines, thus implying that 
occupation of the LDI region may be critical for ligand selectivity at the al subtype. This 
is supported by the finding that the LD| region was also larger for the alp3y2 subtype 
when compared with the a5p3y2 subtype (Figure 27e). 
3. L$ region is very small or non-existent for the a4 and a6 DI subtypes. Based on 
the inability to bind 1,4-benzodiazepines, the lack of region L3 was believed to be 
responsible for the diazepam-insensitivity of these receptor subtypes (Figure 27c, d).42 
With a few exceptions, P-carbolines also do not bind to the a6p3y2 receptor subtype. 
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while the smaller /-BZDs and pyrazoloquinolinones (CGS series) represent the primary 
ligands that bind to this subtype. 
4. The Li and LD, regions are slightly smaller for the a6 versus the a4 subtype. The 
sequence of the a4 subunit is most homologous to the a6 subunit and it was determined 
that the pharmacological profiles of these DI sites toward classical benzodiazepines are 
very similar.195 Differences in the included volume of these DI sites are shown in 
Figure 27c. The L2 region contributes to a2 and a5 selectivity. It has been observed 
that ligands with o2 and/or a5 selectivity are generally /-BZDs and have a lipophilic 
C(8)-substituent that occupies the L2 pocket. Based on ligands from various studies, 
examination of data in Figure 27 illustrates that the Lj region is deeper and larger for the 
a2 and a5 subtypes, respectively, than for the corresponding al or a6 subtypes.196,215'216 
5. This L2 region seems to account for the selective affinity of ligands at the a5 
subtype, as clearly illustrated in Figure 27e, whereas the same region may account for the 
selective efficacy observed at the a2 subtype. The Lj region in the a5 subtype is larger 
than the al subtypes. This is a key result. It is the principle difference between a5 
subtypes compared to al and a3 subtypes, but especially in regard to al subtypes (L2 
smaller in al) .  
6. The L3 region is larger in the a5 subtype as compared to the al, a2, a3, a4 and 
a6 BzR sites. R analogs of benzodiazepines with pendant phenyls had increased affinity 
to a5 supporting the larger L3 pocket in this receptor subtype, while S isomers bound to 
a2, a3, and a5 subtypes because of different conformational constraints. 
76 
Recent Discovery of Alpha 5 Volume Differences 
In regard to molecular modeling, depicted in Figure 29 is the included volume 
and ligand occupation of the SH-053-2T-S-CH3 and SH-053-2T-R-CH3 enantiomers in 
the a5 subtype as well as the a2 subtype. It is clear a new pocket (L4), has been located 
in the a5 subtype permitting the 2'F(R)-isomer (94R) as well as the 2'F(S)-isomer (94S) 
to bind to the a5 subtype. Examination of both ligands in the a2 subtype clearly 
illustrates the analogous region in the a2 subtype is not present and thus does not 
accommodate the 2'F(R)-isomer(94R) for the pendant phenyl lies outside of the included 
volume in the space allocated for the receptor protein itself. 
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SH-053-2'F-S-CH3 fits to the pharmacophore in the 
included volume of the alpha 2 subtype 
SH-053-2'F-R-CH3 does not fit the pharmacophore in 
the included volume of the alpha 2 subtype 
SH-053-2 F-S-CH3 fits the pharmacophore in the 
included volume of the alpha 5 subtype 
SH-053-2'F-R-CH3 fits the pharmacophore in the 
included volume of the alpha 5 subtype 
The same image of figure rotated 90°. It can be 
clearly seen that the molecule fits within the included volume 
The same image of figure rotated 90°. It can be 
clearly seen that the conformation of the molecule is such 
that the pendant 6-phenyl sticks outside the included volume 
The same image of figure rotated 90°. It can be 
clearly seen that the molecule fits within the included volume 
The same image of figure rotated 90°. It can be 
clearly seen that the molecule fits within the included 
volume 
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Figure 28. Included volume and ligand occupation of the SH-053-2T-S-CH3 and SH-053-2'F-R-CH3 
enantiomers in the a5 and a2 BzR subtypes 
Table 17. Binding affinity at axp2y2 GABA(A) receptor subtypes (values are reported in nM) 
SH-053-2 'F-R-CH3 SH-053-2 'F-S-CH3 
Compound al a2 a3 a4 a5 a6 
SH-053-R-CH3 2026 2377 1183 >5000 949.1 >5000 
SH-053-S-CH3 1666 1263 1249 >5000 206.4 >5000 
SH-053-2 F-R-CH3 759.1 948.2 768.8 >5000 95.17 >5000 
SH-053-2'F-S-CH3 350 141 1237 >5000 19.2 >5000 
Based on this analysis a series of (S) and (R) isomers have been synthesized. 
The functional selectivity of these ligands was determined by Sieghart et al.46 and will be 
79 
discussed in Part II. From examination of Figure 28 and Table 17, it is clear the (R)-
isomers bound to the a5 subtype while the (S)-isomers were selective for a2/a3/a5 
subtypes. Work is in progress to determine the in vitro potency and in vivo 
pharmacology of the functionally selective (S) and (R) enantiomeric ligands. It is clear, 
as postulated earlier,217 that the major difference in GABA(A) /Bz receptors subtypes 
stems from differences in asymmetry in the lipophilic pockets Li, L2, L3, L4, and Loi in 
the pharmacophore/receptor model and indicates even better functional selectivity is 
possible with asymmetric BzR ligands. 
The synthetic switching of chirality at the C-4 position of imidazo 
benzodiazepines to induce subtype selectivity was successful. Moreover, increase of the 
potency of imidazobenzodiazepines can be achieved by substitution of the 2'-position 
hydrogen atom with an electron rich atom (fluorine) on the pendant phenyl ring in 
agreement with Haefly, " Fryer, and our own work. The biological data on the 
two enantiomer pairs of benzodiazepine ligands confirm the ataxic activity of BZ site 
agonists is mediated by aip2/3y2 subtypes, as reported. The anti-anxiety activity 
of the S isomers was preserved, whereas the confounding sedation was observed in both 
S isomers (functionally selective for a2, a3 and a5 receptor subtypes) and R isomers 
(essentially selective for a5 subtype), and appears to involve at least in part agonist 
activity at a5 BzR subtypes. There are some a5 BzR located in the spinal cord which 
might be the source of the decrease in locomotion with SH-053-2'F-R-CH3 and SH-053-
2T-S-CH3. Hence, in agreement, with many laboratories including our own224, 225 that 
the best potential nonsedative, nonamnesic, antianxiety agents stem from ligands with 
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agonist efficacy at a2 and a3 subtypes essentially silent at al and a5 subtypes (to avoid 
sedation).72,226 
Structure-activity relationship (SAR) studies have been carried out by a number 
of research groups on structurally diverse classes of ligands, and have resulted in the 
formulation of several different pharmacophore/receptor models for the benzodiazepine 
receptor.196 Models which attempt to explain ligand efficacy as a function of ligand-
receptor interaction at the molecular level have been put forth by Loew,227 Crippen,228 
Codding,229 Fryer,33'34'68-70-74'75",46' 23°-235 Gilli and Borea,33"34 Wermuth,33'34"68-70-74'75' 
146,230-235 ancj <3artjneiVw 34 as wcn as from our own laboratory.73- 236 
A comprehensive pharmacophore/receptor model for the BzR was developed 
using the techniques of chemical synthesis, radioligand binding and receptor mapping.19, 
71 73 169 170 237 238 ' ' The model unified the previous models for inverse agonist/antagonist 
and agonist activity as well as included the recent model for the "diazepam-insensitive" 
(DI) sites.239 This unified pharmacophore/receptor model was employed to include 
agonist, antagonist, and inverse agonist ligands, which encompassed 12 families of 
structurally diverse ligands (Figure 70).75 Four basic anchor points, Hi, H2, A2, and L], 
were assigned, and 3 additional lipophilic regions were defined as L2, L3, and LQ, (see 
captions in Figure 70 for details); regions Si, S2 and S3 represent negative areas of steric 
repulsion. As previously reported, the synthesis of both partial agonists and partial 
inverse agonists has been achieved by using parts of this model.62'12'170-226'240-244 
The cloning, expression and anatomical localization of multiple GABA(A) 
subunits has facilitated both the identification and design of subtype selective 
compounds. With the availability of binding data from different recombinant receptor 
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subtypes, affinities of ligands from a number of different structural classes of ligands 
have been evaluated. 
H102) LP 
Y210 T142 
Figure 29. The Milwaukee-based unified pharmacophore 
Illustrated in Figure 29 is the pyrazolo[J,4-c]quinolin-3-one CGS-9896 (96) 
(dotted line), a diazadiindole (95) (thin line), and diazepam (thick line) fitted to the 
inclusive pharmacophore model for the BzR. Sites H| (Y210) and H2 (HI02) represent 
hydrogen bond donor sites on the receptor protein complex while A2 (T142) represents a 
hydrogen bond acceptor site necessary for potent inverse activity in vivo. Li, L2, L3 and 
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Ld, are four lipophilic regions in the binding pharmacophore. Descriptors S|, S2, and S3 
are regions of negative steric repulsion. 
Based on SAR data obtained for these ligands at 6 recombinant BzR subtypes,245" 
249 an effort has been made to establish different pharmacophore/receptor models for 
BzR subtypes. The alignment of the twelve different structural classes of benzodiazepine 
receptor ligands was based on the least squares fitting of at least three points. The 
coordinates of the four anchor points (A2, Hi, H2 and LI) employed in the alignment are 
outlined in Figure 30. Herein are described the results from ligand-mapping experiments 
at recombinant BzR subtypes of 1,4-benzodiazepines, imidazobenzodiazepines, P-
carbolines, diindoles, pyrazoloquinolinones, and others.250 Some of the differences and 
similarities among these subtypes can be gleaned from this study and serve as a guide for 
future drug design. 
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H2 is 0.1 A below the plar 
of the pyrazoloquinoline 
ring system 
e 
I_1 is 0.5 A above the plane 
!_! of the pyrazoloquinoline 
| ring system. 
d 
is on the plane of the 
pyrazoloquinoline ring 
system 
A2 is on the plane of A2' 
the pyrazoloquinoline 
ring system 
a = 6.735A; b = 9.980A; c = 5.860A 
d = 5.734A; e = 5.218A; f = 7.317A 
Figure 30. The schematic representation of the descriptors for the inclusive BzR pharmacophore.251 
Computer Modeling Methods 
The core structures of the ligands used to build the pharmacophore and included 
volume were taken from available x-ray crystallographic coordinates or generated using 
the SYBYL fragment library.252 The structures which resulted were energy minimized 
using MM2 (molecular mechanics program 2) or MMFF (Merck molecular force field) 
force fields.253"256 The subsequent Monte Carlo conformational searches were carried out 
on MacroModel 4.5 or MacroModel 6.025 257 on a Silicon Graphics Personal Iris 4D/35 
workstation or a Silicon Graphics Octane SI 2P 175 R10000 workstation, respectively. 
MM2 is a force field developed for hydrocarbons and is the force field of choice for 
determination of the energies and structures of hydrocarbons. 
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Recently, the laboratory upgraded to the Linux version of Sybyl 8.1 and ran on 
RedHat 4.0 Enterprise. On the newer platform, structures were minimized using Tripos 
force fields. The low energy conformations were then fully optimized via molecular 
orbital calculations at the 3-21G basis set with torsional angles fixed. The structures 
which resulted were further calibrated with 6-31G* single point calculations at an 
"SCF=TIGHT" convergence criteria via Gaussian 92 ' on a Silicon Graphics Indigo 
R4400 workstation, or Gaussian 9465 on a Silicon Graphics Octane SI2P175R10000 
workstation. With ligands containing heavy atoms (bromine or iodine), the necessary 6-
31G* basis sets were not included in the commercially available Gaussian 92 and 
Gaussian 94 programs. These basis sets were taken from splitting the MP4 basis set 
reported by Andzelm et al. and then addition of d functions.46 
The available ab initio 6-31G* geometries of the ligands were used for the 
included volume analysis. Ligands which possessed BzR affinities of < 20 nM at one 
recombinant receptor subtype were considered as "active" and used for the included 
volume analysis for that subtype. Zolpidem, CL 218872 and ligands reported to be more 
selective for one subtype65 were included even though the binding affinities were 
somewhat higher than 20 nM. Currently the molecular graphics, root-mean-squares 
(RMS) fit, calculations of centroids of substructures and included volume analyses were 
carried out by means of SYBYL 6.565 on a Silicon Graphics Octane SI 2P 175 R10000 
workstation or Sybyl 8.1 operating on a Dell Vostro 1720. The lengths of hydrogen bond 
extension vectors (HBV) were set to 1.84 A, while the C-N-HBV and C=0-HBV valence 
angles used were chosen to mimic the geometry of an ideal hydrogen bond. 
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The Updated Included Volume Analysis Models 
Illustrated in Figure 32 is the included volume of the updated pharmacophore 
receptor model of the al(33y2 subtype of Clayton et al. The current model for the 
al (33y2 subtype has new features. The cyclopropyl group of CD-214 extended 2 A past 
the A2 descriptor slightly increasing its volume. The trimethylsilyl group of QH-II-82 
and WYS7 illustrate how bulky groups are tolerated near the entrance of the binding 
pocket. Although not as potent, dimers of beta carbolines, WYS2 and WYS6 bound at 
30 nm and 120 nm respectively. Their ability to bind, albeit weakly, supports the 
location of the binding site entrance. The included volume of the aip3y2 was previously 
1085.7 cubic Angstroms. The volume has now been measured as 1219.2 cubic 
angstroms. Volume measurements should be used carefully as the binding site is not 
enclosed and the theoretical opening near LDI is not clearly demarcated. Dimers were 
excluded from the included volume exercise because although they bound to the receptor, 
they represented compounds which were felt to extend outside the receptor binding 
pocket when docked to the protein. Where appropriate, their monomers were included in 
the included volume analysis. Ligands considered for the inlcluded volume in Table 18 
exhibited potent binding at al subtypes (Kj < 20 nM) but were not necessarily subtype 
selective. 
The aip3y2 Receptor Subtype 
Table 18. Ligands with potent affinity for al; ligands bound with Kj values <20 nm at this subtype 
COOK CODE" al a2 aJ a4 a5 a6 
WY-TSC-4(WYS8) 0.007 0.99 1.63 51.04 
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COOK CODE" al a2 a3 a4 a.5 a6 
SH-TSC-2(BCCT) 0.03 0.0419 0.035 69.32 
QH-II-090(CGS-
8216) 
0.05 0.08 0.12 0.25 17 
XLI-286 0.051 0.064 0.118 0.684 
QH-II-077 0.06 0.08 0.05 0.12 4 
QH-II-092 0.07 0.03 0.04 ND 0.17 ND 
JYI-57 0.076 0.076 0.131 ND 0.036 ND 
QH-II-085 0.08 0.06 0.02 ND 0.08 ND 
XHE-II-024 0.09 0.18 0.32 14 0.24 11 
PWZ-007A 0.11 0.1 0.09 ND 0.2 10 
CGS8216 0.13 ND ND ND ND 46 
SPH-121 0.14 1.19 1.72 ND 4 479 
QH-II-075 0.18 0.21 0.25 ND 1.3 40 
PZII-028 0.2 ND 0.2 ND 0.32 1.9 
CGS9895 0.21 ND ND ND ND 9.3 
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31 
XHE-III-24 0.25 ND 8 222 10 328 
JYI-42 0.257 0.146 0.278 ND 0.256 ND 
CGS9896 0.28 ND ND ND ND 181 
JYI-64 
(C17H12N4FBr) 
0.305 1.111 0.62 ND 0.87 5000 
PZII-029 0.34 ND 0.79 ND 0.52 10 
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7 
FG8205 0.4 2.08 1.16 ND 1.54 227 
YT-5 0.421 0.6034 36.06 ND 1.695 ND 
6-PBC 0.49 1.21 2.2 ND 2.39 1343 
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COOK CODE0 al oc2 a3 a4 a5 a6 
QH-146 0.49 ND 0.76 ND 1.1 10000 
DM-II-90 
(C17H12N4BrCl) 
0.505 1 0.63 ND 0.37 5000 
SPH-165 0.63 2.79 4.85 ND 10.4 1150 
BCCt 0.72 15 18.9 ND 110.8 5000 
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND 
alprazolam 0.8 0.59 1.43 ND 1.54 10000 
Rol5-1788 0.8 0.9 1.05 ND 0.6 148 
WYS10 
C14H9F3N202 
0.88 36 25.6 ND 548.7 15.3 
WY-B-15 0.92 0.83 0.58 2080 4.42 646 
WY-A-99-2(WYS8) 0.972 111 102 2000 208 1980 
XHE-IIl-06a 1 2 1 5 1.8 37 
XU366 
C22H21N302 
1 ND ND ND ND ND 
JYI-59 
(C22H13N302F4) 
1.08 2.6 11.82 ND 11.5 5000 
WYSC1 
C16H16N202 
1.094 5.44 12.3 ND 69.8 21.2 
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000 
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15 
BCCE 1.2 4.9 5.7 ND 26.8 2700 
XHE-III-04 1.2 2 1.1 219 0.4 500 
XLi350 
C17H11C1N20 
1.224 1.188 ND ND 2.9 ND 
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1 
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03 
DM-239 1.5 ND 0.53 ND 0.14 6.89 
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COOK CODE1 al a2 aJ a4 a5 a.6 
XLi351 
C21H21ClN20Si 
1.507 0.967 ND ND 1.985 ND 
XLi352 
C18H13C1N20 
1.56 0.991 ND ND 1.957 ND 
TG-4-39 1.6 34 24 5.6 1.4 23 
TG-II-82 1.6 2.9 2.8 ND 1 1000 
CM-A87 1.62 4.54 14.73 1000 4.61 1000 
QH-II-082 1.7 1.8 1.6 ND 6.1 100 
JYI-49 
(C20H12N302F4Br) 
1.87 2.38 ND ND 6.7 3390 
LJD-III-15E 1.93 14 19 ND 70.8 1000 
SPH-38 2 5.4 10.8 ND 18.5 3000 
XHE-I-093 2 7.1 8.9 1107 20 1162 
MSA-IV-35 2.1 16 21 ND 995 3000 
JYI-19 
(C23H23N303S) 
2.176 205 ND ND 34 12.7 
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000 
YCT-5 2.2 11.46 16.3 ND 200 10000 
TJH-IV-51 2.39 17.4 14.5 ND 316 10000 
WYS13 
C20H18N203 
2.442 13 27.5 ND 163 5000 
YT-III-25 2.531 5.786 5.691 ND 0.095 ND 
XHE-III-14 2.6 10 13 2 7 
WYS9 
C16H15IN202 
2.72 22.2 23.1 ND 562 122 
JYI-47 2.759 2.282 0.511 ND 0.427 ND 
CM-A82a 2.78 8.93 24.51 1000 7.49 1000 
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9 
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COOK CODE0 al a2 aJ a4 a.5 a6 
XU268 
C17H13BrN4 
2.8145 0.6862 ND ND 0.6243 ND 
JYI-54 
(C24H15N303F4) 
2.89 172 6.7 ND 57 1890 
MMB-II-74 3 24.5 41.7 500 125.7 1000 
MMB-III-016 3 1.97 2 1074 0.26 211 
MMB-III-16 3 1.97 2 1074 0.26 211 
QH-II-080b 3 3.7 4.7 ND 24 1000 
YCT-7A 3 23.8 30.5 ND 240 10000 
JYI-32 
(C20H15N302BrF) 
3.07 4.96 ND ND 2.92 52.24 
Ro 15-4513 3.3 2.6 2.5 ND 0.26 3.8 
XHE-II-017 3.3 10 7 258 17 294 
XLi-JY-DMH 
ANX3 
3.3 0.58 1.9 ND 4.4 5000 
MLT-II-18 3.4 11.7 11 ND 225 10000 
TJH-V-88 3.41 30 ND 140.9 10000 
XLI-2TC 3.442 1.673 44.08 ND 1.121 
WYS15 
C22H20N202 
3.63 2.02 44.3 ND 76.5 5000 
CM-A57 3.7 27 40 ND 254 1000 
XHE-II-006b 3.7 15 12 1897 144 1000 
JYI-60 
(C17H11N20F) 
3.73 1.635 4.3 ND 1.7 5000 
RY-008 3.75 7.2 4.14 ND 1.11 44.3 
MLT-II-18 3.9 12.2 24.4 ND 210 10000 
OMB-18 3.9 1.2 3.4 1733 0.8 5 
WY-B-09-1 3.99 8 32 1000 461 2000 
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COOK CODE" al a2 aJ a4 a5 a6 
SHU-1-19 4 12 1 48 14 84 
ZK 93423 4.1 4.2 6 ND 4.5 1000 
WY-B-23-
2(WYS11) 
4.2 37.7 39 2000 176 69.4 
WY-B-23-
2(WYS11) 
4.2 37.7 73 ND 176 69.4 
WY-B-99-1 4.4 4.5 5.58 2000 47 2000 
WY-B-26-2 4.45 44.57 42.66 2000 124 2000 
XHE-II-006a 4.7 4.4 20 1876 89 3531 
CM-B01 4.8 31 34 1000 286 1000 
PWZ-085 4.86 13 8.5 ND 0.55 40 
MLT-II-16 5.05 10.41 18.4 ND 260 10000 
3 PBC 5.3 52.3 68.8 ND 591 1000 
MA-3-PR0P0XYL 5.3 52.3 68.8 ND 591 1000 
TJH-IV-43 5.42 30.19 48.9 ND 475 10000 
DMCM 5.69 8.29 4 ND 1.04 134 
DM-139 5.8 ND 169 ND 9.25 325 
XHE-II-073A (R 
ENRICHED) 
5.9 11 10 15 1.18 140 
MSR-I-032 6.2 18.7 4 ND 3.3 74.9 
JYI-70 
(C19H13N4F) 
6.3 2.1 ND ND 0.56 5000 
XLi343 
C20H19ClN20Si 
6.375 17.71 ND ND 150.5 ND 
3 EBC 6.43 25.1 28.2 ND 826 1000 
DM-146 6.44 ND 148 ND 4.23 247 
DM-215 6.74 ND 7.42 ND 0.293 8.28 
ZG69A 6.8 16.3 9.2 ND 0.85 54.6 
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COOK CODE2 al a2 aJ a4 a.5 a6 
ZG-69a(Ro 15-1310) 6.8 16.3 9.2 ND 0.85 54.6 
WY-B-14(WYS7) 6.84 30 36 2000 108 1000 
YT-II 6.932 0.8712 3.518 ND 5.119 ND 
SVO-8-67 7 41 26 15 2.3 191 
MLT-II-34 7.04 15.95 22.3 ND 158 1000 
SPH-195 7.2 168.5 283.5 ND 271 10000 
XHE-I-065 7.2 17 18 500 57 500 
ZG-234 7.25 22.14 9.84 ND 0.3 5.25 
SH-I-04 7.3 6.136 5.1 ND 7.664 ND 
XHE-I-038 7.3 5 34 ND 132 1000 
XHE-III-13 7.3 ND 7.1 880 1.6 311 
WY-B-25 7.6 40 66 2000 263 2000 
CM-A49(R) 7.7 32.5 43 ND 69 1000 
SVO-8-14 8 25 8 6.9 0.9 14 
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61 
XHE-II-002 8.3 18 13 3.9 1.5 11 
WY-B-14(WYS7) 8.5 165 245 ND 1786 5000 
XHE-II-011 9 60 39 3233 90 1000 
WY-B-27-2 9.19 111 72 2000 449 2000 
QH-II-063 9.4 9.3 31 ND 7.7 3000 
JC184 
C13H9BrN20S 
9.606 10.5 ND ND 6.709 ND 
ZG-208 9.7 11.2 10.9 ND 0.38 4.6 
RY-I-31 10 45 19 ND 6 1000 
WY-B-23-1 10 33 43 1000 189 2000 
RY-098 10.1 22.2 16.5 ND 1.68 100 
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COOK CODE" aJ a2 a3 a4 aS a.6 
Hzl48 C18H15N3 10.98 5000 ND ND 256 5000 
SVO-8-20 11 40 28 19 8.6 138 
XHE-II-073B (S-
ENRICHED) 
11 17 12 33 2.1 269 
SH-I-085 11.08 4.866 13.75 ND 0.24 ND 
PWZ-096 11.1 36 16.9 ND 1.07 51.5 
ZG-168 11.2 10.7 9.2 ND 0.47 9.4 
CM-A77 11.51 51.9 105.16 1000 42.62 1000 
WY-B-20 12 39 47 2000 122 3000 
ABECARNIL 12.4 15.3 7.5 ND 6 1000 
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND 
ZG-213 12.8 49.8 30.2 ND 3.5 22.5 
EDC-I-071 12.9 83.1 ND ND 314 5000 
MMB-III-14 13 13 6.9 333 1.1 333 
DM-173 13.1 ND 38.1 ND 0.78 118 
XLI-348 13.56 11.17 1.578 ND 82.05 ND 
EDC-I-093 13.6 423 ND ND 2912 5000 
diazepam 14 20 15 ND 11 ND 
XLi223 
C22H20BrN302 
14 8.7 18 1000 10 2000 
WYSC2 
C15H11F3N202 
14.14 113 170 ND 518 61.2 
SH-I-030 14.42 11.04 19.09 ND 1.89 ND 
CM-A100 14.49 44.91 123.8 1000 65.31 1000 
RY-033 14.8 56 25.3 ND 1.72 22.9 
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND 
YT-6 15.31 87.8 60.49 ND 1.039 ND 
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COOK CODE" al a.2 a3 a4 aS a6 
EDC-II-044 15.4 ND 293 ND 323 1000 
CM-A58 16 120 184 ND 1000 1012 
QH-II-067a 16 31 52 ND 199 3000 
CD-214 16.4 48.2 42.5 ND 9.8 168 
JYI-06 
(C23H23N304) 
16.5 5.48 5000 ND 12.6 5000 
CM-A50(S) 17 59 88 ND 144 1000 
RY-061 17 13 6.7 ND 0.3 31 
ZG-224 17.1 33.7 50 ND 2.5 30.7 
ZG-63A 17.3 21.6 29.1 ND 0.65 4 
DM-II-30 
C20H13N302BrF3) 
17.6 13.4 28.51 ND 7.8 5000 
CM-A64 18 60 116 ND 216 1000 
RY-071 19 56 91 ND 7.2 266 
WZ-113 19.2 13.2 13.4 ND 11.5 300 
YT-III-23 19.83 23.65 19.87 ND 1.105 ND 
CM-E09b 20 22 19 55 0.45 69 
MMB-II-90 20 24 5.7 9 0.25 36 
aAffinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^HJflunitrazepam or [3H] Rol5-4513 binding to HEK cell membranes 
expressing human receptors of composition 
alp3y2, <x2p3y2, a3p3y2, a4p3y2, a5p3y2 and a6P3y2.M Data represent the average of at least 
three determinations with a SEM of ±5%. 
As the focus of our research was aimed at diazepam sensitive receptors, additional 
features to the a4(Dy2 and a6p3y2 receptors were not identified. The major new feature 
94 
identified for the a5p3y2 receptor was a new L4 pocket. This new lipophilic pocket was 
identified with R and S chiral analogs of SH-053.65 
Figure 31. Overlay of selected compounds for al03y2 subtype from Table 8 
95 
Figure 32. Updated alp3y2 subtype (solid) overlayed with the previous model (line). 
The a2p3y2 Receptor Subtype 
Table 19. Ligands with potent affinity for a2; ligands bound with Kj values <20 nm at this subtype 
COOK CODE1 al a2 a3 a4 a5 a6 
QH-II-092 0.07 0.03 0.04 ND 0.17 ND 
SH-TSC-2(BCCT) 0.03 0.0419 0.035 ND 69.32 ND 
QH-II-085 0.08 0.06 0.02 ND 0.08 ND 
XLI-286 0.051 0.064 0.118 ND 0.684 ND 
JYI-57 0.076 0.076 0.131 ND 0.036 ND 
QH-II-090(CGS-
8216) 
0.05 0.08 0.12 ND 0.25 17 
QH-II-077 0.06 0.08 0.05 ND 0.12 4 
PWZ-007A 0.11 0.1 0.09 ND 0.2 10 
JYI-42 0.257 0.146 0.278 ND 0.256 ND 
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COOK CODE" al a.2 a3 a4 a.5 a.6 
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31 
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND 
XHE-II-024 0.09 0.18 0.32 14 0.24 11 
QH-II-075 0.18 0.21 0.25 ND 1.3 40 
XLi-JY-DMH 
ANX3 
3.3 0.58 1.9 ND 4.4 5000 
alprazolam 0.8 0.59 1.43 ND 1.54 10000 
YT-5 0.421 0.6034 36.06 ND 1.695 ND 
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7 
XLi268 
C17H13BrN4 
2.8145 0.6862 ND ND 0.6243 ND 
WY-B-15 0.92 0.83 0.58 2080 4.42 646 
YT-II 6.932 0.8712 3.518 ND 5.119 
Rol5-1788 0.8 0.9 1.05 ND 0.6 148 
XLi351 
C21H21ClN20Si 
1.507 0.967 ND ND 1.985 ND 
WY-TSC-4(WYS8) 0.007 0.99 1.63 ND 51.04 ND 
XLi352 
C18H13C1N20 
1.56 0.991 ND ND 1.957 ND 
DM-II-90 
(C17H12N4BrCl) 
0.505 1 0.63 ND 0.37 5000 
JYI-64 
(C17H12N4FBr) 
0.305 1.111 0.62 ND 0.87 5000 
XLi350 
C17H11C1N20 
1.224 1.188 ND ND 2.9 ND 
SPH-121 0.14 1.19 1.72 ND 4 479 
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000 
OMB-18 3.9 1.2 3.4 1733 0.8 5 
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COOK CODE" al a2 a3 a4 a5 a.6 
6-PBC 0.49 1.21 2.2 ND 2.39 1343 
YT-III-271 32.54 1.26 2.35 ND 103 ND 
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03 
DM-II-72 
(C15H10N20BrCl) 
5000 1.37 ND ND 2.02 5000 
JYI-60 
(C17H11N20F) 
3.73 1.635 4.3 ND 1.7 5000 
XLI-2TC 3.442 1.673 44.08 ND 1.121 ND 
QH-II-082 1.7 1.8 1.6 ND 6.1 100 
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND 
MMB-III-016 3 1.97 2 1074 0.26 211 
MMB-III-16 3 1.97 2 1074 0.26 211 
XHE-III-06a 1 2 1 5 1.8 37 
XHE-III-04 1.2 2 1.1 219 0.4 500 
WYS15 
C22H20N202 
3.63 2.02 44.3 ND 76.5 5000 
FG8205 0.4 2.08 1.16 ND 1.54 227 
JYI-70 
(C19H13N4F) 
6.3 2.1 ND ND 0.56 5000 
JYI-47 2.759 2.282 0.511 ND 0.427 ND 
JYI-49 
(C20H12N302F4Br) 
1.87 2.38 ND ND 6.7 3390 
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000 
JYI-59 
(C22H13N302F4) 
1.08 2.6 11.82 ND 11.5 5000 
Rol5-4513 3.3 2.6 2.5 ND 0.26 3.8 
SPH-165 0.63 2.79 4.85 ND 10.4 1150 
YT-II-76 95.34 2.797 0.056 ND 0.04 ND 
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COOK CODE" al a2 a3 a4 a5 a.6 
TG-II-82 1.6 2.9 2.8 ND 1 1000 
QH-II-080b 3 3.7 4.7 ND 24 1000 
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9 
PS-1-34B 
C20H17N4BrO 
ND 4.198 3.928 ND ND ND 
ZK 93423 4.1 4.2 6 ND 4.5 1000 
XHE-II-006a 4.7 4.4 20 1876 89 3531 
WY-B-99-1 4.4 4.5 5.58 2000 47 2000 
CM-A87 1.62 4.54 14.73 1000 4.61 1000 
OMB-19 22 4.6 20 3333 3.5 40 
SH-I-085 11.08 4.866 13.75 ND 0.24 ND 
BCCE 1.2 4.9 5.7 ND 26.8 2700 
JYI-32 
(C20H15N302BrF) 
3.07 4.96 ND ND 2.92 52.24 
XHE-I-038 7.3 5 34 ND 132 1000 
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15 
SPH-38 2 5.4 10.8 ND 18.5 3000 
WYSC1 
C16H16N202 
1.094 5.44 12.3 ND 69.8 21.2 
JYI-06 
(C23H23N304) 
16.5 5.48 5000 ND 12.6 5000 
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1 
YT-III-25 2.531 5.786 5.691 ND 0.095 ND 
SH-I-04 7.3 6.136 5.1 ND 7.664 ND 
XHE-I-093 2 7.1 8.9 1107 20 1162 
RY-008 3.75 7.2 4.14 ND 1.11 44.3 
DMH-D-053 
(C43H30N604) 
236 7.4 272 5000 194.2 5000 
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COOK CODE" al a2 aJ a4 cx5 a.6 
WY-B-09-1 3.99 8 32 1000 461 2000 
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND 
DMCM 5.69 8.29 4 ND 1.04 134 
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND 
XLi223 
C22H20BrN302 
14 8.7 18 1000 10 2000 
CM-A82a 2.78 8.93 24.51 1000 7.49 1000 
QH-II-063 9.4 9.3 31 ND 7.7 3000 
9.4 9.3 31 ND 7.7 3000 
XHE-II-017 3.3 10 7 258 17 294 
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61 
MLT-II-16 5.05 10.41 18.4 ND 260 10000 
JC184 
C13H9BrN20S 
9.606 10.5 ND ND 6.709 ND 
ZG-168 11.2 10.7 9.2 ND 0.47 9.4 
XHE-II-073A (R 
ENRICHED) 
5.9 11 10 15 1.18 140 
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND 
SH-I-030 14.42 11.04 19.09 ND 1.89 ND 
XLI-348 13.56 11.17 1.578 ND 82.05 ND 
ZG-208 9.7 11.2 10.9 ND 0.38 4.6 
YT-TC-3 141.4 11.43 118.1 ND 29.22 ND 
YCT-5 2.2 11.46 16.3 ND 200 10000 
MLT-II-18 3.4 11.7 11 ND 225 10000 
XHE-II-053-ACID 50.35 11.8 44 ND 5.9 5000 
SHU-1-19 4 12 7 48 14 84 
RY-067 21 12 10 ND 0.37 42 
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COOK CODE0 al a2 a3 a.4 a5 a6 
DM-III-01 
(C18H12N302Br) 
5000 12 ND ND 4.73 5000 
MLT-II-18 3.9 12.2 24.4 ND 210 10000 
SH-053-2'F 21.99 12.34 34.9 ND 0.671 ND 
WYS13 
C20H18N203 
2.442 13 27.5 ND 163 5000 
PWZ-085 4.86 13 8.5 ND 0.55 40 
MMB-III-14 13 13 6.9 333 1.1 333 
RY-061 17 13 6.7 ND 0.3 31 
WZ-113 19.2 13.2 13.4 ND 11.5 300 
YT-II-83 32.74 13.22 24.1 ND 3.548 ND 
DM-II-30 
C20H13N302BrF3) 
17.6 13.4 28.51 ND 7.8 5000 
LJD-III-15E 1.93 14 19 ND 70.8 1000 
YT-III-272 295.9 14.98 10.77 ND 103.3 ND 
BCCt 0.72 15 18.9 ND 110.8 5000 
XHE-II-006b 3.7 15 12 1897 144 1000 
ABECARNIL 12.4 15.3 7.5 ND 6 1000 
MLT-II-34 7.04 15.95 22.3 ND 158 1000 
MSA-IV-35 2.1 16 21 ND 995 3000 
JYI-04 
(C21H23N303) 
28.3 16 ND ND 0.51 1.57 
PS-1-35 
C23H22N50Br 
ND 16.03 24.41 ND ND ND 
ZG69A 6.8 16.3 9.2 ND 0.85 54.6 
ZG-69a(Ro 15-1310) 6.8 16.3 9.2 ND 0.85 54.6 
YT-III-42 382.9 16.83 44.04 ND 9.77 ND 
XHE-I-065 7.2 17 18 500 57 500 
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COOK CODE? al a2 a3 a4 a5 a6 
XHE-II-073B (S-
ENRICHED) 
11 17 12 33 2.1 269 
TJH-IV-51 2.39 17.4 14.5 ND 316 10000 
SH-I-047 1710 17.52 1222 ND 1519 ND 
XLi343 
C20H19ClN20Si 
6.375 17.71 ND ND 150.5 ND 
XHE-II-002 8.3 18 13 3.9 1.5 11 
YT-III-38 1461 18.21 14.63 ND 3999 
JY1-72 
(C22H21N4SiF) 
48.5 18.5 ND ND 11.5 5000 
MSR-I-032 6.2 18.7 4 ND 3.3 74.9 
JC208 
C15H10N20S 
22.42 18.89 ND ND 5.039 ND 
diazepam 14 20 15 ND 11 ND 
aAffinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^HJflunitrazepam or [3H] Rol5-4513binding to HEK cell membranes 
expressing human receptors of composition 
alp3y2, a2p3y2, a3P3y2, a4P3y2, a5P3y2 and a6p3y2.46 Data represent the average of at least 
three determinations with a SEM of ±5%. 
Ligands in this table have been selected because they have Kj values <20 nm at a 
subtypes. 
Figure 33. Overlay of compounds selective for a2p3y2 subtype 
Figure 34. Updated <X2(33Y2 subtype (solid) overlayed with the previous model (line). 
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The a3p3y2 Receptor Subtype 
Table 20. Ligands with potent affinity for a3; ligands bound with K; values <20 nm at this subtype 
COOK CODE0 al a2 a3 a4 aS a6 
QH-II-085 0.08 0.06 0.02 ND 0.08 ND 
SH-TSC-2(BCCT) 0.03 0.0419 0.035 ND 69.32 ND 
QH-II-092 0.07 0.03 0.04 ND 0.17 ND 
QH-II-077 0.06 0.08 0.05 ND 0.12 4 
YT-II-76 95.34 2.797 0.056 ND 0.04 ND 
PWZ-007A 0.11 0.1 0.09 ND 0.2 10 
XLI-286 0.051 0.064 0.118 ND 0.684 ND 
QH-II-090(CGS-
8216) 
0.05 0.08 0.12 ND 0.25 17 
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31 
JYI-57 0.076 0.076 0.131 ND 0.036 ND 
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7 
PZII-028 0.2 ND 0.2 ND 0.32 1.9 
QH-II-075 0.18 0.21 0.25 ND 1.3 40 
JYI-42 0.257 0.146 0.278 ND 0.256 ND 
XHE-II-024 0.09 0.18 0.32 14 0.24 11 
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND 
JYI-55 41.39 ND 0.504 ND 24.75 ND 
JYI-47 2.759 2.282 0.511 ND 0.427 ND 
DM-239 1.5 ND 0.53 ND 0.14 6.89 
WY-B-15 0.92 0.83 0.58 2080 4.42 646 
JYI-64 
(C17H12N4FBr) 
0.305 1.111 0.62 ND 0.87 5000 
DM-II-90 
(C17H12N4BrCl) 
0.505 1 0.63 ND 0.37 5000 
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COOK CODE1 al a2 a3 a4 a5 a6 
QH-146 0.49 ND 0.76 ND 1.1 10000 
PZII-029 0.34 ND 0.79 ND 0.52 10 
WYS19 
C26H32N204Si 
ND ND 0.89 ND ND ND 
XHE-III-06a 1 2 1 5 1.8 37 
Rol5-1788 0.8 0.9 1.05 ND 0.6 148 
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000 
XHE-III-04 1.2 2 1.1 219 0.4 500 
FG8205 0.4 2.08 1.16 ND 1.54 227 
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03 
alprazolam 0.8 0.59 1.43 ND 1.54 10000 
XLI-348 13.56 11.17 1.578 ND 82.05 ND 
QH-II-082 1.7 1.8 1.6 ND 6.1 100 
WY-TSC-4(WYS8) 0.007 0.99 1.63 ND 51.04 ND 
SPH-121 0.14 1.19 1.72 ND 4 479 
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000 
MMB-III-016 3 1.97 2 1074 0.26 211 
MMB-III-16 3 1.97 2 1074 0.26 211 
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND 
6-PBC 0.49 1.21 2.2 ND 2.39 1343 
YT-III-271 32.54 1.26 2.35 ND 103 ND 
Ro 15-4513 3.3 2.6 2.5 ND 0.26 3.8 
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9 
TG-II-82 1.6 2.9 2.8 ND 1 1000 
OMB-18 3.9 1.2 3.4 1733 0.8 5 
YT-II 6.932 0.8712 3.518 ND 5.119 ND 
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COOK CODE" al a2 aJ a4 aS a.6 
PS-1-34B 
C20H17N4BrO 
ND 4.198 3.928 ND ND ND 
DMCM 5.69 8.29 4 ND 1.04 134 
MSR-I-032 6.2 18.7 4 ND 3.3 74.9 
RY-008 3.75 7.2 4.14 ND 1.11 44.3 
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1 
JYI-60 
(C17H11N20F) 
3.73 1.635 4.3 ND 1.7 5000 
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000 
XLI-317 60.24 24.05 4.562 ND 0.295 ND 
QH-II-080b 3 3.7 4.7 ND 24 1000 
SPH-165 0.63 2.79 4.85 ND 10.4 1150 
SH-I-04 7.3 6.136 5.1 ND 7.664 ND 
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15 
WY-B-99-1 4.4 4.5 5.58 2000 47 2000 
YT-III-25 2.531 5.786 5.691 ND 0.095 ND 
BCCE 1.2 4.9 5.7 ND 26.8 2700 
MMB-II-90 20 24 5.7 9 0.25 36 
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND 
ZK 93423 4.1 4.2 6 ND 4.5 1000 
RY-061 17 13 6.7 ND 0.3 31 
JYI-54 
(C24H15N303F4) 
2.89 172 6.7 ND 57 1890 
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61 
MMB-III-14 13 13 6.9 333 1.1 333 
XHE-II-017 3.3 10 7 258 17 294 
SHU-1-19 4 12 7 48 14 84 
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COOK CODE? al a2 a3 a4 aS a6 
XHE-III-13 7.3 ND 7.1 880 1.6 311 
DM-215 6.74 ND 7.42 ND 0.293 8.28 
ABECARNIL 12.4 15.3 7.5 ND 6 1000 
SVO-8-14 8 25 8 6.9 0.9 14 
XHE-III-24 0.25 ND 8 222 10 328 
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND 
PWZ-085 4.86 13 8.5 ND 0.55 40 
XHE-I-093 2 7.1 8.9 1107 20 1162 
ZG-168 11.2 10.7 9.2 ND 0.47 9.4 
ZG69A 6.8 16.3 9.2 ND 0.85 54.6 
ZG-69a(Ro 15-1310) 6.8 16.3 9.2 ND 0.85 54.6 
ZG-234 7.25 22.14 9.84 ND 0.3 5.25 
XHE-II-073A (R 
ENRICHED) 
5.9 11 10 15 1.18 140 
RY-067 21 12 10 ND 0.37 42 
XHE-III-14 2.6 ND 10 13 2 7 
YT-III-272 295.9 14.98 10.77 ND 103.3 ND 
SPH-38 2 5.4 10.8 ND 18.5 3000 
ZG-208 9.7 11.2 10.9 ND 0.38 4.6 
MLT-II-18 3.4 11.7 11 ND 225 10000 
DM-II-33 
(C20H13N302BrC13) 
88.6 85 11.6 ND 26.2 5000 
JYI-59 
(C22H13N302F4) 
1.08 2.6 11.82 ND 11.5 5000 
XHE-II-006b 3.7 15 12 1897 144 1000 
XHE-II-073B (S-
ENRICHED) 
11 17 12 33 2.1 269 
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COOK CODE1 al a2 a3 a4 a5 a6 
CM-B44(ss) 32 43 12 379 4.3 485 
WYSC1 
C16H16N202 
1.094 5.44 12.3 ND 69.8 21.2 
JYI-48 75.59 90.68 12.78 ND 31.28 ND 
XHE-II-002 8.3 18 13 3.9 1.5 11 
RY-076 26 27 13 ND 0.7 22 
WZ-113 19.2 13.2 13.4 ND 11.5 300 
SH-I-085 11.08 4.866 13.75 ND 0.24 ND 
CM-E10 23 26 14 215 0.51 96 
TJH-IV-51 2.39 17.4 14.5 ND 316 10000 
YT-III-38 1461 18.21 14.63 ND 3999 ND 
CM-A87 1.62 4.54 14.73 1000 4.61 1000 
diazepam 14 20 15 ND 11 ND 
RY-053 49 29 15 ND 1 46 
YCT-5 2.2 11.46 16.3 ND 200 10000 
RY-098 10.1 22.2 16.5 ND 1.68 100 
PWZ-096 11.1 36 16.9 ND 1.07 51.5 
XLi223 
C22H20BrN302 
14 8.7 18 1000 10 2000 
XHE-I-065 7.2 17 18 500 57 500 
SH-I-02B 29.82 1315 18 ND 74.05 ND 
MLT-II-16 5.05 10.41 18.4 ND 260 10000 
RY-024 
C19H19N303 
26.9 26.3 18.7 ND 0.4 5.1 
BCCt 0.72 15 18.9 ND 110.8 5000 
LJD-III-15E 1.93 14 19 ND 70.8 1000 
CM-E09b 20 22 19 55 0.45 69 
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COOK CODE" al a2 a3 a4 a5 a.6 
RY-I-31 10 45 19 ND 6 1000 
SH-I-030 14.42 11.04 19.09 ND 1.89 ND 
YT-III-23 19.83 23.65 19.87 ND 1.105 ND 
XHE-II-006a 4.7 4.4 20 1876 89 3531 
OMB-19 22 4.6 20 3333 3.5 40 
XHE-III-06b 32 33 20 299 28.6 740 
aAffinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^H]flunitrazepam or [3H] Rol5-4513binding to HEK cell membranes 
expressing human receptors of composition 
aip3y2, cc2p3y2, a3(33y2, a4p3y2, a5p3y2 and a6p3y2.65 Data represent the average of at least 
three determinations with a SEM of ±5%. 
Figure 35. Overlay of compounds selective for a3p3y2 subtype 
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Figure 36. Updated a3p3y2 subtype (solid) overlayed with the previous model (line). 
The <x4p3y2 Receptor Subtype 
Table 21. Ligands with potent affinity for a4; ligands bound with K; values <20 nm at this subtype 
COOK CODE" al a2 aJ a4 aS a.6 
CM-D45 
C19H21N304 
90.5 65.5 30.3 0.15 1.65 0.23 
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92 
XHE-III-74 77 105 38 0.42 2.2 5.8 
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9 
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15 
XHE-II-002 8.3 18 13 3.9 1.5 11 
XHE-III-06a 1 2 1 5 1.8 37 
RY-080 
C17H15N303 
28.4 21.4 25.8 5.3 0.49 28.8 
TG-4-39 1.6 34 24 5.6 1.4 23 
SVO-8-14 8 25 8 6.9 0.9 14 
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COOK CODE1 al a2 a3 a4 a5 a6 
RY-023 
C22H27N303Si 
197 142.6 255 7.8 2.61 58.6 
MMB-II-90 20 24 5.7 9 0.25 36 
XHE-III-14 2.6 10 13 2 7 
XHE-II-024 0.09 0.18 0.32 14 0.24 11 
XHE-II-073A 
(R ENRICHED) 
5.9 11 10 15 1.18 140 
SVO-8-67 7 41 26 15 2.3 191 
CM-B31i(ss) 90 184 78 18 4.9 121 
SVO-8-20 11 40 28 19 8.6 138 
aAffinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^H]flunitrazepam or [3H] Rol5-4513binding to HEK cell membranes 
expressing human receptors of composition 
aip3y2, a2p3y2, a3p3y2, a4p3y2, a5p3y2 and a6P3y2.170 Data represent the average of at least 
three determinations with a SEM of ±5%. 
Figure 37. Overlay of selected compounds selective for a4p3y2 subtype 
Figure 38. Updated a4p3y2 subtype (solid) overlayed with the previous model (line). 
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The a5P3y2 Receptor Subtype 
Table 22. Ligands with potent affinity for a5; ligands bound with Ki values <20 nm at this subtype 
COOK CODE1 al a2 a3 a4 a.5 
JYI-57 0.076 0.076 0.131 ND 0.036 
YT-II-76 95.34 2.797 0.056 ND 0.04 
QH-II-085 0.08 0.06 0.02 ND 0.08 
YT-III-25 2.531 5.786 5.691 ND 0.095 
SH-I-048A 0.774 0.1723 0.383 ND 0.11 
QH-II-077 0.06 0.08 0.05 ND 0.12 
DM-239 1.5 ND 0.53 ND 0.14 
QH-II-092 0.07 0.03 0.04 ND 0.17 
TG-4-29 2.8 3.9 2.7 2.1 0.18 
SH-I-75 1487 989.9 773 ND 0.1825 
PWZ-007A 0.11 0.1 0.09 ND 0.2 
XHE-II-024 0.09 0.18 0.32 14 0.24 
SH-I-085 11.08 4.866 13.75 ND 0.24 
MMB-II-90 20 24 5.7 9 0.25 
QH-II-090(CGS-
8216) 
0.05 0.08 0.12 ND 0.25 
JYI-42 0.257 0.146 0.278 ND 0.256 
MMB-III-016 3 1.97 2 1074 0.26 
MMB-III-16 3 1.97 n 1074 0.26 
Ro 15-4513 3.3 2.6 2.5 ND 0.26 
DM-215 6.74 ND 7.42 ND 0.293 
XLI-317 60.24 24.05 4.562 ND 0.295 
RY-061 17 13 6.7 ND 0.3 
ZG-234 7.25 22.14 9.84 ND 0.3 
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COOK CODE0 al a2 a3 a4 aS 
PZII-028 0.2 ND 0.2 ND 0.32 
RY-067 21 12 10 ND 0.37 
DM-II-90 
(C17H12N4BrCl) 
0.505 1 0.63 ND 0.37 
ZG-208 9.7 11.2 10.9 ND 0.38 
XHE-III-04 1.2 2 1.1 219 0.4 
TG-4-29 8.3 10.2 6.9 ND 0.4 
RY-024 
C19H19N303 
26.9 26.3 18.7 ND 0.4 
JYI-47 2.759 2.282 0.511 ND 0.427 
PWZ-0071 0.23 0.17 0.12 ND 0.44 
CM-E09b 20 22 19 55 0.45 
ZG-168 11.2 10.7 9.2 ND 0.47 
RY-080 
C17H15N303 
28.4 21.4 25.8 5.3 0.49 
BRETAZENIL 0.35 0.64 0.2 ND 0.5 
CM-E10 23 26 14 215 0.51 
JYI-04 
(C21H23N303) 
28.3 16 ND ND 0.51 
PZII-029 0.34 ND 0.79 ND 0.52 
PWZ-085 4.86 13 8.5 ND 0.55 
JYI-70 
(C19H13N4F) 
6.3 2.1 ND ND 0.56 
CM-D44 34.3 56.3 20.7 0.33 0.57 
SVO-8-30 1.1 5.3 5.3 2.8 0.6 
Ro15-1788 0.8 0.9 1.05 ND 0.6 
XLi268 
C17H13BrN4 
2.8145 0.6862 ND ND 0.6243 
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COOK CODE1 al a2 aJ a4 a5 
ZG-63A 17.3 21.6 29.1 ND 0.65 
SH-053-2T 21.99 12.34 34.9 ND 0.671 
XLI-286 0.051 0.064 0.118 ND 0.684 
SH-I-S66 22.93 30.36 55.26 ND 0.69 
RY-076 26 27 13 ND 0.7 
DM-173 13.1 ND 38.1 ND 0.78 
OMB-18 3.9 1.2 3.4 1733 0.8 
HJ-I-037 15.07 8.127 28.29 ND 0.818 
PWZ-009A1 1.34 1.31 1.26 ND 0.84 
ZG69A 6.8 16.3 9.2 ND 0.85 
ZG-69a(Ro 15-1310) 6.8 16.3 9.2 ND 0.85 
JYI-64 
(C17H12N4FBr) 
0.305 1.111 0.62 ND 0.87 
SVO-8-14 8 25 8 6.9 0.9 
JYI-03 
(C21H21N303) 
185.4 107 ND ND 0.954 
TG-II-82 1.6 2.9 2.8 ND 1 
RY-053 49 29 15 ND 1 
YT-6 15.31 87.8 60.49 ND 1.039 
DMCM 5.69 8.29 4 ND 1.04 
PWZ-096 11.1 36 16.9 ND 1.07 
MMB-III-14 13 13 6.9 333 1.1 
YT-III-23 19.83 23.65 19.87 ND 1.105 
RY-008 3.75 7.2 4.14 ND 1.11 
XLI-2TC 3.442 1.673 44.08 ND 1.121 
XHE-II-073A (R 
ENRICHED) 
5.9 11 10 15 1.18 
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COOK CODE1 al a2 aJ a4 aS 
QH-II-075 0.18 0.21 0.25 ND 1.3 
RY-054 59 44 27 ND 1.3 
TG-4-39 1.6 34 24 5.6 1.4 
XHE-II-002 8.3 18 13 3.9 1.5 
RY-031 (RY-10) 20.4 27 26.1 ND 1.5 
FG8205 0.4 2.08 1.16 ND 1.54 
alprazolam 0.8 0.59 1.43 ND 1.54 
XHE-III-13 7.3 ND 7.1 880 1.6 
CM-D45 
C19H21N304 
90.5 65.5 30.3 0.15 1.65 
RY-098 10.1 22.2 16.5 ND 1.68 
YT-5 0.421 0.6034 36.06 ND 1.695 
JYI-60 
(C17H11N20F) 
3.73 1.635 4.3 ND 1.7 
RY-033 14.8 56 25.3 ND 1.72 
XHE-III-06a 1 2 1 5 1.8 
SH-I-030 14.42 11.04 19.09 ND 1.89 
XLi352 
C18H13C1N20 
1.56 0.991 ND ND 1.957 
XLi351 
C21H21ClN20Si 
1.507 0.967 ND ND 1.985 
XHE-III-14 2.6 ND 10 13 2 
DM-II-72 
(C15H10N20BrCl) 
5000 1.37 ND ND 2.02 
XHE-II-073B (S-
ENRICHED) 
11 17 12 33 2.1 
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 
XHE-III-74 77 105 38 0.42 2.2 
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COOK CODE? al a.2 a3 a4 a.5 
SVO-8-67 1 41 26 15 2.3 
6-PBC 0.49 1.21 2.2 ND 2.39 
RY-058 86 40 85 ND 2.4 
ZG-224 17.1 33.7 50 ND 2.5 
RY-066 83 60 48 ND 2.6 
RY-023 
C22H27N303SJ 
197 142.6 255 7.8 2.61 
XLi350 
C17H11C1N20 
1.224 1.188 ND ND 2.9 
JYI-32 
(C20H15N302BrF) 
3.07 4.96 ND ND 2.92 
SH-I-89S 12.78 8.562 8.145 ND 3.23 
MSR-I-032 6.2 18.7 4 ND 3.3 
OMB-19 22 4.6 20 3333 3.5 
ZG-213 12.8 49.8 30.2 ND 3.5 
YT-II-83 32.74 13.22 24.1 ND 3.548 
RY-059 89 70 91 ND 3.7 
SPH-121 0.14 1.19 1.72 ND 4 
RY-047 200 124 79 ND 4 
XLI-8TC 21.52 11.01 2.155 ND 4.059 
YT-I-38 945.9 326.8 245.9 ND 4.07 
DM-146 6.44 ND 148 ND 4.23 
CM-B44(ss) 32 43 12 379 4.3 
CM-B47 32 63 34 2007 4.4 
XLi-JY-DMH 
ANX3 
3.3 0.58 1.9 ND 4.4 
WY-B-15 0.92 0.83 0.58 2080 4.42 
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COOK CODE? al a2 a3 a4 a5 
ZK 93423 4.1 4.2 6 ND 4.5 
JYI-12 
(C19H16N303F3) 
91 39 ND ND 4.5 
CM-A87 1.62 4.54 14.73 1000 4.61 
DM-III-01 
(C18H12N302Br) 
5000 12 ND ND 4.73 
RY-057 73 85 97 ND 4.8 
JYI-15 
(C19H14N303F3) 
205 812 ND ND 4.8 
CM-B31i(ss) 90 184 78 18 4.9 
RY-079 121.1 141.9 198.4 159 5 
JC208 
C15H10N20S 
22.42 18.89 ND ND 5.039 
YT-II 6.932 0.8712 3.518 ND 5.119 
XLi270 
C19H14N4 
36.39 25.81 ND ND 5.291 
XHE-I-051 35 39 42 ND 5.3 
MMB-II-87 200 333 107 109 5.4 
XLI-210 231 661 2666 ND 5.4 
XHE-II-053-ACID 50.35 11.8 44 ND 5.9 
ABECARNIL 12.4 15.3 7.5 ND 6 
RY-I-31 10 45 19 ND 6 
QH-II-082 1.7 1.8 1.6 ND 6.1 
SH-TSC-1(PWZ-
029) 
362.4 180.3 328.2 ND 6.185 
XHE-II-065 1000 409 216 37 6.4 
JYI-49 
(C20H12N302F4Br) 
1.87 2.38 ND ND 6.7 
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COOK CODE" al a2 aJ a4 a5 
JC184 
C13H9BrN20S 
9.606 10.5 ND ND 6.709 
QH-II-066 76.3 42.1 47.4 2000 6.8 
76.3 42.1 47.4 ND 6.8 
XLI-381 619.9 285.6 3639 ND 7.051 
RY-071 19 56 91 ND 7.2 
RY-I-28 283 318 102 ND 7.2 
CM-A82a 2.78 8.93 24.51 1000 7.49 
YT-III-31 36.39 67.85 129.7 ND 7.59 
SH-I-04 7.3 6.136 5.1 ND 7.664 
QH-146 0.49 ND 0.76 ND 7.7 
QH-II-063 9.4 9.3 31 ND 7.7 
9.4 9.3 31 ND 7.7 
JC221 ANXl 106.175 49.405 182 ND 7.7495 
DM-II-30 
C20H13N302BrF3) 
17.6 13.4 28.51 ND 7.8 
SH-TS-CH3 107.2 50.09 20.95 ND 8.068 
RY-073 156 88 122 ND 8.5 
SVO-8-20 11 40 28 19 8.6 
SHU-221-1 66 41 43 3000 9 
YT-III-231 51.09 61.46 26.34 ND 9.124 
CM-E09a 176 192 122 490 9.2 
DM-139 5.8 ND 169 ND 9.25 
YT-III-42 382.9 16.83 44.04 ND 9.77 
CD-214 16.4 48.2 42.5 ND 9.8 
XHE-III-24 0.25 ND 8 222 10 
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COOK CODE" al a2 a3 a4 a5 
XLi223 
C22H20BrN302 
14 8.7 18 1000 10 
SPH-165 0.63 2.79 4.85 ND 10.4 
JYI-
01 (C19H20N303Br) 
59.2 159 96 ND 10.6 
diazepam 14 20 15 ND 11 
XHE-III-49 1.3 5.5 4.2 38.7 11.3 
WZ-113 19.2 13.2 13.4 ND 11.5 
JYI-59 
(C22H13N302F4) 
1.08 2.6 11.82 ND 11.5 
JYI-72 
(C22H21N4SiF) 
48.5 18.5 ND ND 11.5 
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 
JYI-10 
(C17H13N303F3Br) 
5000 368 ND ND 12.3 
WZ-069 40 30.5 38.5 ND 12.6 
JYI-06 
(C23H23N304) 
16.5 5.48 5000 ND 12.6 
RY-072 220 150 184 ND 12.7 
JYI-14 
(C17H14N303F3 ) 
32 25 ND ND 13 
XHE-II-053 287 45 96 1504 13.8 
Xli-347 
C34H28N607 
828.05 690.2 ND ND 13.87 
SHU-1-19 4 12 7 48 14 
CM-C28(SR) 176 752 244 290 14 
CM-E11 333 308 161 394 14 
XHE-II-012 49 24 31 1042 14 
MMB-III-018 117 140 78 3500 14 
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COOK CODE2 al a.2 a3 a4 a5 
MMB-III-18 117 140 78 3500 14 
CM-B31c(ss) 118 319 173 37 15 
CM-B45 230 557 336 265 15 
XLI-093 1000 1000 858 1550 15 
DM-II-20 
(C22H14N302F3) 
54.3 27.14 35.68 ND 15.35 
XU269 
C22H22N4Si 
221.8 154.2 ND ND 15.51 
SH-053-S-CH3-2T 350 141 1237 ND 16 
JYI-13 
(C21H16N304F3) 
5000 63.7 ND ND 16 
CM-B34 All 451 223 114 17 
XHE-II-017 3.3 10 7 258 17 
JC222 
C16H12N20S 
86.7 45.11 ND ND 17.63 
SPH-38 2 5.4 10.8 ND 18.5 
WZ-070 72.7 30.7 53.2 ND 18.6 
73 31 53 ND 19 
RY-069 692 622 506 ND 19 
SH-053-2T-S-CH3 468.2 33.27 291.5 ND 19.2 
XHE-I-093 2 7.1 8.9 1107 20 
"Affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^H]flunitrazepam or [3H] Rol5-4513 binding to HEK cell membranes 
expressing human receptors of composition 
al|33y2, a2p3y2, a3p3y2, a4P3y2, a5P3y2 and a6p3y2.25<' Data represent the average of at least 
three determinations with a SEM of ±5%. 
Figure 39. Overlay of selected compounds selective for a5(J3y2 subtype 
Figure 40. Updated a503y2 subtype (solid) overlayed with the previous model (line). 
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Figure 41. Overlay of the <x5p3y2 receptor (yellow) subtype with the aip3y2 receptor (magenta) 
subtype. Orange surfaces indicate overlapping regions. 
123 
Figure 42. Overlay of the a5p3y2 receptor (yellow) subtype with the aip3y2 receptor (magenta) 
subtype (Figure 42 rotated 90°). Orange surfaces indicate overlapping regions. 
The multiple volume contours displayed in Figure 33-42 were created using the 
mvolume function (multiple volume contour function in Sybyl and compounds with 
binding affinity at the receptor less than or equal to 20 nm. To create the overlays, first, 
the display (dsp) and contour (cnt) files were created for the oc5P3y2 receptor subtype and 
the aip3y2 receptor subtype by overlaying the compounds for each of these receptors 
(given above). Using the mvolume function, a logical expression was entered to create 
the surfaces making up the union as well as the included volume for each receptor 
subtype itself. It is clear from the included volume overlay that the L2 pocket is deeper 
for the a5 subtype as determined previously. The new L4 pocket can be distinguished as 
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the new yellow region of the a5p3y2 subtype which is due to recently designed R-
isomers by Huang.260 
The <x6p3y2 Receptor Subtype 
Table 23. Ligands with potent affinity for a6; ligands bound with K; values <20 nm at this subtype 
COOK CODE1 al a.2 aJ a4 a.5 a.6 
CM-D45 
C19H21N304 
90.5 65.5 30.3 0.15 1.65 0.23 
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92 
JYI-04 
(C21H23N303) 
28.3 16 ND ND 0.51 1.57 
PZII-028 0.2 ND 0.2 ND 0.32 1.9 
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03 
JYI-
01 (C19H20N303Br) 
59.2 159 96 ND 10.6 2.88 
JYI-03 
(C21H21N303) 
185.4 107 ND ND 0.954 3.34 
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8 
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9 
JYI-11 
(C22H22N303F3Si) 
5000 5000 ND ND 648 3.97 
QH-II-077 0.06 0.08 0.05 ND 0.12 4 
ZG-63A 17.3 21.6 29.1 ND 0.65 4 
ZG-208 9.7 11.2 10.9 ND 0.38 4.6 
OMB-18 3.9 1.2 3.4 1733 0.8 5 
RY-024 
C19H19N303 
26.9 26.3 18.7 ND 0.4 5.1 
ZG-234 7.25 22.14 9.84 ND 0.3 5.25 
XHE-III-74 77 105 38 0.42 2.2 5.8 
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COOK CODE0 al a2 aJ a4 a.5 a6 
JYI-12 
(C19H16N303F3) 
91 39 ND ND 4.5 6.8 
DM-239 1.5 ND 0.53 ND 0.14 6.89 
XHE-III-14 2.6 ND 10 13 2 7 
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61 
DM-215 6.74 ND 7.42 ND 0.293 8.28 
JYI-13 
(C21H16N304F3) 
5000 63.7 ND ND 16 8.38 
CGS9895 0.21 ND ND ND ND 9.3 
ZG-168 11.2 10.7 9.2 ND 0.47 9.4 
PWZ-007A 0.11 0.1 0.09 ND 0.2 10 
PZII-029 0.34 ND 0.79 ND 0.52 10 
XHE-II-024 0.09 0.18 0.32 14 0.24 11 
XHE-II-002 8.3 18 13 3.9 1.5 11 
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7 
JYI-19 
(C23H23N303S) 
2.176 205 ND ND 34 12.7 
SVO-8-14 8 25 8 6.9 0.9 14 
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15 
WYS10 
C14H9F3N202 
0.88 36 25.6 ND 548.7 15.3 
QH-II-090(CGS-
8216) 
0.05 0.08 0.12 ND 0.25 17 
PWZ-0071 0.23 0.17 0.12 0.44 17.31 
aThe affinity of compounds at GABA(A) /BzR recombinant subtypes was measured by 
competition for [^H]flunitrazepam binding to HEK cell membranes expressing human 
receptors of composition aip3y2, o2J}3y2, a3p3y2, a4p3y2, a5|J3y2 and a6p3y2.260 Data represent 
the average of at least three determinations with a SEM of ±5%. 
Figure 43. Overlay of selected compounds selective for a6fJ3y2 subtype 
Figure 44. Updated <x6p3y2 subtype (solid) overlayed with the previous model (line). 
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QSAR 
A non-traditional quantitative structure activity relationship (QSAR) project was 
executed to observe steric and electrostatic preferences for each receptor subtype. A 
subset of the compounds used in each subtype pharmacophore model were chosen with a 
good cross-section of scaffold variety. The compounds used in the COMFA maps are the 
imidazobenzodiazines published previously39 and additionally, alternative scaffolds 
which bound with <20nm at the respective subtype (see compound table in Appendix V). 
The interest here was in creation of steric and electrostatic maps of the 
comparative molecular field analyses (COMFA) created from molecular spreadsheets. A 
variety of compounds selective for each subtype were selected and placed into a dataset 
used to build the CoMFA models. Activities (K, values) were converted to logarithmic 
units for this study. A CoMFA descriptor set was created based on the -log (K,) of over 
70 structures. The goal was to derive an alternative three dimensional shape of the 
receptor using biological activity of the most selective compounds. Structures were 
determined by crystal structure where available or by calculation. Charges were provided 
based on the Gasteiger-Huckel model. Conformations were kept consistent based on 
previous studies of low energy conformations.38 40 It should be noted that this was not a 
traditional QSAR study as nonselective compounds were excluded. Therefore, Kj values 
did not cross 3 log units. This was acceptable since the goal was not to create a 
predictive QSAR predictive algorithm, rather a map of the receptor based on sterics and 
electrostatics. Hydrogen acceptor radii were set to 3.0 and the hydrogen donor radii 
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were set to 2.6 based on recommendations from Certara (Tripos). Analyses were 
executed using PLS (partial least squares). 
For each of the following QSAR models, green areas represent desirable steric 
bulk and yellow represents undesirable steric bulk. Positive electrostatic contributions 
are represented by blue and negative electrostatic contributions are represented by red. 
The al(33y2 Receptor Subtype 
Figure 45. Steric (left) and electrostatic maps of alp3y2 receptor subtype shown in transparent mode 
as seen from the classic perspective. 
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Figure 46. Steric (left) and electrostatic maps of a 1 f}3y2 receptor subtype shown in transparent mode 
as seen from the classic perspective rotated 90°. 
Figure 47. Steric (left) and electrostatic maps of aip3y2 receptor subtype shown in line mode as seen 
from the classic perspective. 
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Figure 48. Steric (left) and electrostatic maps of alf33y2 receptor subtype shown in line mode as seen 
from the classic perspective rotated 90°. 
The <x2p3y2 Receptor Subtype 
Figure 49. Steric (left) and electrostatic maps of a2|J3y2 receptor subtype shown in transparent mode 
as seen from the classic perspective. 
131 
Figure 50. Steric (left) and electrostatic maps of oc2P3y2 receptor subtype shown in transparent 
mode as seen from the classic perspective rotated 90°. 
Figure 51. Steric (left) and electrostatic maps of a2p3y2 receptor subtype shown in line mode as seen 
from the classic perspective. 
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Figure 52. Steric (left) and electrostatic maps of a2p3y2 receptor subtype shown in line mode as seen 
from the classic perspective rotated 90°. 
The a3p3y2 Receptor Subtype 
Figure 53. Steric (left) and electrostatic maps of <x3p3y2 receptor subtype shown in transparent mode 
as seen from the classic perspective. 
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Figure 54. Steric (left) and electrostatic maps of a3(33y2 receptor subtype shown in transparent mode 
as seen from the classic perspective rotated 90°. 
Figure 55. Steric (left) and electrostatic maps of a3P3y2 receptor subtype shown in line mode as seen 
from the classic perspective. 
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Figure 56. Steric (left) and electrostatic maps of a3p3y2 receptor subtype shown in line mode as seen 
from the classic perspective rotated 90°. 
The a5p3y2 Receptor Subtype 
Figure 57. Steric (left) and electrostatic maps of a5p3y2 receptor subtype shown in transparent 
mode as seen from the classic perspective. 
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Figure 58, Steric (left) and electrostatic maps of <x5p3y2 receptor subtype shown in transparent mode 
as seen from the classic perspective rotated 90°. 
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Figure 59. Steric (left) and electrostatic maps of a5P3y? receptor subtype shown in line mode as 
seen from the classic perspective. 
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Figure 60. Steric (left) and electrostatic maps of a5p3y2 receptor subtype shown in line mode as seen 
from the classic perspective rotated 90°. 
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Figure 61. Clockwise from the top left, line maps of the aip3y2,a2p3y3,a3p3y2, and a5p3y2 
CoMFA. 
From the CoMFA maps several observations (Figure 61) can be made. The 
yellow steric regions near L3 in the a5P3y2 map are unique. This illustrates that, in 
general, benzodiazepines lacking a pendant phenyl are more suited to targeting the alpha 
5 subtype. The LD, region of the alpha 1 subtype is most tolerable for compounds with 
steric interactions in this location with the alpha 3 subtype receptor preferring compounds 
which have no steric interaction in this location. Negative electrostatics are most 
preferred by the L3 pocket of the alpha 2 and alpha 5 receptors. In general, the alpha 1 
subtype receptor prefers molecules without a dipole. It should be noted that none of our 
analogs are ionic in nature and the charges for this model were provided by the 
Gasteiger-Huckel model. For this reason more emphasis is placed on the steric 
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relationships which exclude interactions in the pharmacophores. In the future a QSAR 
study which includes non-binding benzodiazepines in the data set along with activity data 
will permit the creation of a predictive logarithm which will be very useful in lead 
targeting. 
Comparative Model of the Benzodiazepine Binding Site 
Crystallization of GABA(A) receptors thus far has not been accomplished, but 
the successful structure determination of the water-soluble acetylcholine binding protein 
(AChBP)261 has generated much interest in the GABA(A) receptor community. Although 
this protein shares only - 18 % sequence homology with the extracellular domain of the 
GABA(A) receptor, the structural resemblance has been estimated to be relatively 
high (60 - 75 %). " Several comparative modeling studies have used the AChBP 
structure to derive models of the extracellular domain of GABA(A) receptors.40"263, 264 
Following electron cryomicroscopy (cryo-EM) determination of the extracellular and 
transmembrane domain structure of the nACh receptor, this structure was used as 
templates for modeling GABA(A) receptors.39" 265-267 Sequence homology is so low 
however, that detailed features of the models are highly uncertain, and the proposed 
dockings of Bz BS ligands104"106 have a qualitative character and as of this writing do not 
sufficiently explain the observed differential effects of ligands interacting with different 
receptor subtypes. The experimental structure of the nAChR268,269 has provided initial 
90S 010 
data on how much the fold can vary between members of a family. ' " From this 
data the extent to which GABA(A) receptor subunits differ from each other in structure 
can be qualitatively extrapolated, but not predicted in detail. 
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As mentioned before, the majority of GABA(A) receptors are composed of ly, 
2a and 2p subunits. Each subunit has per convention a "plus" and a "minus" side (Figure 
62). The subunit interfaces consequently consist of the plus and minus sides of 
neighboring subunits. The modulatory Bz BS is located at the a+y subunit interface and is 
larger than, but homologous to the two agonist (GABA) binding sites, which are 
- > / o  ' y  s  q  
located at the p+a subunit interfaces. The absolute subunit configuration for the 
al(32y2 GABA(A) receptor appears to be ypapa, when viewed counter clockwise (from 
+ to -, Figure 62).260 
Figure 62. Absolute subunit arrangement of the alp2y2 GABA(A) receptor when viewed from the 
synaptic cleft. 
The GABA(A) binding sites are located at the p+a subunit interfaces and the modulatory 
benzodiazepine binding site is located at the a+y subunit interface. The part of the 
schematically drawn subunits marked by the + indicates loop C of the respective subunits 
(Figure 62). 
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While the y2 subunit is required for recognition and binding of benzodiazepines 
as well as many other substance classes that act via the Bz BS,262 it is now clear that 
sequence variations between different a subunits determine subtype selectivity and 
efficacy of Bz BS ligands.271 The Bz BS has been proposed to consist of three segments 
provided by the a+ side, the so-called "loops A, B and C" and by three segments of the 
y , the so-called "loops D, E and F".272 These segments were then confirmed by X-ray 
crystallographic and EM-structures of AChBP272 and the nAChR174 to form a groove-like 
pocket at the interface boundary between subunits that appears to be conserved in the 
entire superfamily. The group at Milwaukee proposed a near planar cleft to represent the 
BzR binding sites as long ago as the 1980's by Trudell and Hagen.18'22 26 
ai_human 
a2 human ^ 
a3_human 
&5_human 
a4_human 
Y58JHH ••••••• ••••_-_ 
gl human 
g2_human 
93-human 
Figure 63. Alignment and homology model depiction of the so called "loops A-F" and flanking 
regions of the human sequences of the Bz recognition site in different subunits. 
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The homology model (Figure 64) is as seen from "outside" of the channel mouth, 
the membrane would be parallel to the top edge of the image. Key residues are shown in 
stick representation: Loop A Hisl02, loop B Tyr 160 and loop D Phe77. 
Even later than the nAChR structure, a series of AChBP crystal structures with 
co-crystallized ligands appeared.273 These structures revealed how ligand binding can 
alter the local conformation of the binding site. Particularly loop C has been found to be a 
highly mobile sub-domain, with additional and more subtle changes seen along the entire 
subunit boundary.274 These findings are consistent with the hypothesis that many receptor 
conformations exist, that are separated by low energy barriers, and can be stabilized by 
different ligands. Unfortunately, it cannot be decided conclusively at this time a priori 
which of the experimental structures is the "best" template to model a particular 
receptor/ligand complex. Depending on template and alignment choice, model Bz 
pockets differ in total volume by as much as 40% and can vary by several angstroms in 
the distances between key residues in the binding site loops. 
Although changes in protein conformation may be minor, it has been 
demonstrated that they can profoundly affect the efficacy of Bz BS ligands.275 
Furthermore, efficacy can vary for the same ligand at different GABA(A) receptor 
l o  
subtypes. Since proteins are inherently dynamic and able to sample many 
conformations, the stabilization of the active state relative to the inactive state has been 
calculated to be less than 1 kcal/mol.261 It is not possible at present to provide absolute 
assignments of specific side chains to specific descriptors for any particular 
conformation. This conformational flexibility may imply that residues which satisfy 
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certain pharmacophoric descriptors can vary, resulting in a "soft" orientation of the 
pharmacophore in the receptor. Thus, a unified view of a pharmacophore model and a 
homology derived receptor model will assign large areas of lipophilic interaction to 
specific regions in the protein, but allow a flexible assignment of specific interactions 
such as H-bridges or n- n stacking. Further complicating matters is the possibility of 
waters participating in the binding pocket. This is the reason for the Milwaukee-based 
pharmacophore/receptor models for drug design have been based on the rigid planar 
ligands (Kj = 5nM-20nM) of Trudell et al.42 
Relative Orientation of the Pharmacophore within the Comparative Model 
Prior to structure determination of the AChBP, a review was published from 
Milwaukee, which evaluated results of site-directed mutagenesis and provided insights as 
to where certain side chains in the Bz BS might be located relative to the pharmacophoric 
descriptors.260"262"272 However, with the knowledge gained from recent experimental 
data and with the aid of our GABA(A) receptor models, built by homology to lymnea 
AChBP,195 aplysia AChBP and the nAChR204 an update of the orientation is provided 
here. An orientation is now proposed which is favored by experimental evidence and 
allows some degree of conformational flexibility. It can lead to variable assignments for 
H-bridge interactions, but is based on specific areas of lipophilic interactions that are 
determined by binding site geometry and hydrogen bonding to certain residues which 
align "softly" with docked ligands (Figure 67). 
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T142 
T207 
M130 
Synaptic cleft 
Figure 64. Ribbon illustration of the GABA(A) BzR binding pocket conceived by Clayton et al.198' 276, 
277 
Combining Homology Model and Experimental Evidence 
If the two assignments discussed above are correct, they should be reflected in 
results of computational ligand docking to homology models of the binding site. Thus, 
computational docking of diazepam and flumazenil was performed in multiple different 
models based on different templates274 and the best 100 docking poses per model were 
collected in a database. A database query was then formulated to search among the 
(unrefined) docking poses for those with the following properties: The seven membered 
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ring of diazepam or flumazenil is in the conformation that is assumed to be the active 
one;33, 62' 69, 213 the 7-substituents are near residues alH102/alV203/ and 
alY210/alV212 in order to be consistent with the covalent labeling data; the 3' ester 
group of flumazenil is near residues y2A79 and y2T81. Such a query yields docking 
poses that are consistent with all covalent labeling studies on the one hand, and with the 
"yfjc 
steric requirements that were found for 3' substituted imidazobenzodiazepines on the 
Figure 65. Flumazenil 
Such poses were indeed present in the database, and one representative diazepam 
pose is shown in Figure 66. 
other hand. 
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Figure 66. Diazepam docking pose in aly2. The beta subunit is not in the binding pocket. 
In Figure 67, diazepam was rendered space filling, (turquoise: carbon, white: hydrogen, 
green: halogen, red: oxygen, and blue: nitrogen), the protein as a ribbon, and the key 
amino acids in stick representation. The insert figure shows the empty pocket in the 
"upright" position to facilitate orientation in the main figure, where the model has been 
turned and tilted to bring diazepam approximately into the orientation depicted in the 
unified pharmacophore model. In this particular docking pose, Hisl02 and Thr207 
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satisfy H2 and Hi, respectively, and His 102, Val 212 and Tyr 210 would be part of the L2 
hydrophobic pocket. This positions 7-substituted reactive analogues such as 
isothiocyanate 92 into a position where the reactive groups find free access to His 102, 
Tyr 210, Val 212, and Val 203. 
T142 
V212 
Y210 T207 
Figure 67. High resolution image of diazepam docking pose in aly2 binding pocket 
The docking pose in Figure 67 and similar docking poses not only satisfy the two 
assignments for L2 and A2 that are discussed in the sections above, but at the same time 
position the remaining descriptors as follows: Hi can be satisfied by appropriate side 
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chains near the tip of loop C, the LDI region is near the subunit interface, essentially 
between al loop B (Y160) and the y2 region spanned by the interface forming the sheet 
involving Ml30, T142 and F77; A2 can be satisfied by H-bridge accepting sites near 
al Y160, y2A79, y2T81, y2M130 and y2T142. If these proximity relations that are found 
in the docking poses are transferred to the unified pharmacophore model, the following 
residue orientation emerges: 
HIS102 
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Figure 68. Orthogonal views of the location of residues with respect to pharmacophore in the aip3y2 
BzR binding pocket 
The location of important Bz BS residues relative to the pharmacophore 
descriptors in two views that correspond to a 90° rotation about L|, with A2 in front, as 
determined by evaluation of experimental data and the comparative model of the al P2y2 
GABA(A) receptor are illustrated in Figure 67 and 68. The ligand shown is diazepam. 
Since inverse agonists stabilize protein conformations that vary from the conformations 
preferred by agonists, it is plausible that more than one side chain could satisfy the same 
descriptor. 
Within the different poses that exhibit this orientation, there is still some degree of 
variation in structural details. There are several sources for this variability in the 
computationally derived structures: template and alignment choice, model construction 
and refinement, as well as docking algorithms contribute to the variability of the poses 
that are found. 
This orientation is also strongly supported by the observation that XLi-093, as 
aligned in Figure 13 with the docked Rol5-1788 shown above, will be able to thread the 
portion of the molecule not inside the included volume towards the solvent accessible 
space through the subunit boundary, but into the extracellular domain. 
Agreement between this orientation of the pharmacophore model inside the 
structural model of the protein with single ligand dockings that have been proposed in the 
978 • ... 
past will have to be examined in detail. The overall picture appears to be pointing 
towards a satisfactory orientation of the pharmacophore model in the pocket, and for 
those instances where there could be a discrepancy, further experiments will clarify. 
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Refinement of the predicted protein-ligand complexes with the aid of the unified 
pharmacophore model is a very promising approach to arrive at 3D structures that are of 
sufficient accuracy to be used for structure guided drug design. Studies that combine 
advanced protein modeling techniques with the classical pharmacophore approach are 
currently underway. 
fi 
Figure 69. Unified model of the aly2 subtype benzodiazepine receptor with diazepam docked in the 
binding site. 
Construction of the Unified Pharmacophore/Receptor Model 
More than 150 agonists, antagonists and inverse agonists at the Bz binding 
site43-44 which encompassed 15 structural families were used for generating the unified 
pharmacophore/receptor model. Although the relative affinities, efficacies and functional 
effects displayed by various ligands from the same structural class at the diazepam-
sensitive and diazepam-insensitive benzodiazepine binding sites were taken into account, 
the approximate locations of descriptors (hydrogen bond donor sites, hydrogen bond 
151 
acceptor sites, lipophilic regions, and regions of steric repulsion) were based primarily on 
in vitro binding affinities. Ligands from different structural classes were then 
superimposed on each other to satisfy the same descriptors, resulting in the unified 
pharmacophore model. The rigid planar templates (Ki = 5nM-20nM) of Trudell were 
9 Afi 
employed to begin this effort. 
The pharmacophore/receptor model consists of two hydrogen bond donating 
descriptors (Hi and H2), one hydrogen bond accepting descriptor (A2) and one lipophilic 
descriptor (Li). In addition to these descriptors, there are lipophilic regions of interaction 
(L2, L3, L4, and LDj) as well as regions of negative steric repulsion (Si, S2 and S3). While 
occupation of L2 and/or L3, and L4 as well as interactions at Hi, H2. and Li are important 
for positive allosteric modulation, inverse agonists only require interactions with the Hi, 
Li and A2 descriptors of the pharmacophore/receptor model for potent activity in vivo. 
The L3 descriptor is a region of lipophilic interaction, for which the difference between 
the diazepam sensitive (DS) and the diazepam insensitive (DI) sub-pharmacophore 
models is most pronounced. Depicted in Figure 30 are the relative locations of the 
different descriptors and regions of the model. Several classes of ligands for GABA(A) 
are shown in Table 24. 
Table 24. Structures of ligands and their modulation at the al subtype 
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diazepam 
agonist 
flunitrazepam 
agonist 
midazolam 
agonist 
_N 
V 11 
triazolam 
agonist 
Me Me 
Rol5-1788 
antagonist 
Ro 15-4513 
inverse agonist 
NMe2 
Zolpidem 
agonist 
CF3 
CL-218,872 
partial agonist 
C02Me 
p-CCM 
inverse agonist 
MeO 
MeO 
,C02Me 
DMCM 
inverse agonist 
BnO, 
MOM 
,C02Et 
ZK-93423 
agonist 
Pr-n 
MOM 
C02Et 
6-PBC 
partial agonist 
C02(-Bu 
p-CCT 
antagonist 
,0-nPr 
3-PBC 
antagonist 
,C02Et 
p-CCE 
inverse agonist 
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O 0 
XLi-093 
antagonist at a5 
The alignments of several Bz BS ligands within this model are shown in Figure 
70. 
Ro 15-1788 Ro 15-1788 rotated 90° 
>7. 
V 
A, 
diazepam diazepam rotated 90° 
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DMCM DMCM rotated 90° 
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Zolpidem Zolpidem rotated 90° 
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CL-218,872 CL-218, 872 rotated 90° 
Figure 70. Alignments of several Bz BS ligands within the pharmacophore model. 
A unified pharmacophore model incorporating many substance classes that act at 
the DS and DI benzodiazepine binding sites of GABA(A) receptors has been updated to 
include new substance classes. Compound development guided by this pharmacophore 
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model has led to new agents with interesting pharmacological profiles, particularly 
enhanced preference for a.2 or a5 containing GABA(A) receptor subtypes. Based on the 
evaluation of experimental data and comparative models of the al P2y2 GABA(A) 
receptor, the location of several residues relative to the descriptors of the 
pharmacophore/receptor model has been proposed. Although no absolute assignments 
were made regarding which amino acids satisfy the pharmacophoric descriptors, 
experimental data strongly indicated definite trends with regard to how ligands of varying 
pharmacological activity are oriented within the receptor. Because the unified 
pharmacophore/receptor model accounts for the binding and activity profiles at the six 
GABA(A) receptor subtypes containing any one of the different alpha subunits, the 
proposed orientation should also be similar within the different models260 of the various 
receptor subtypes. Information to be immediately gained from these proposed 
orientations can have far reaching benefits, not only for the rational design of selective 
ligands and the interpretation of ligand docking results, but also for the identification and 
evaluation of possible roles certain residues may have within the pocket. As structure 
determination of the GABA(A) receptor is eagerly awaited, it is hoped that these 
proposed orientations may be used by others to gain additional insight into the potential 
mechanisms underlying binding and modulation at the Bz site, all of which will lead to a 
better understanding of the structure and function of GABA(A) receptors. In the next 
section the methods used to build the protein model will be explained. 
Homology Models of the Benzodiazepine Receptor 
The y-aminobutyric-acid (GABA(A) and GABAc) pentameric ligand gated ion 
channels are members of a superfamily of allosteric transmembrane proteins which 
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includes the nicotinic acetylcholine (nAChR), serotonin 5-HT3, and glycine receptors. 
Electrophysiological data on GABA(A) is available but attempts at atomic resolution to 
acquire structural data have so far been unsuccessful. However, in 2001 Smit260 
discovered a homologue of the nACh receptor ligand-binding domain from the snail 
Lymnaea stagnalis. Acetylcholine-binding protein (AChBP) is produced in the glial cells 
of Lymnaea stagnalis. In the synaptic cleft, AChBP modulates synaptic transmission. 
Subunits of the snail glial cells form a stable homopentamer with conserved N terminal 
domains. Known agonists and antagonists of nAChRs bind to the homologue. For this 
reason, it is a valuable template for modeling the N-terminus domains of pentameric 
ligand gated ion channels.263 
Brejc et al. successfully solved the crystal structure of AChBP by X-ray 
crystallography using weak Pb multiple wavelength anomalous diffraction (MAD) data in 
two crystal forms.38 The crystals were grown at room temperature using the hanging-
drop vapour diffusion technique. The crystal structure revealed a radially symmetric 
homopentamer with extracellular dimensions of the nicotinic acetylcholine receptor 
97Q 
(nAChR) which correlated with measurements taken using electron microscopy. 
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Subunits are homologous and have been colored by chain to distinguish them. In 
space filling models, HEPES (N-2-hydroxyethylpeperazine-N'-2-ethanesulphonic acid 
(present during the crystallization process) can be seen bound in the ligand binding site 
between each subunit interface. 
The N terminus is located at the "mouth" of the ion channel in the synaptic cleft. 
A molecule of HEPES was present in the acetylcholine binding pocket. This was verified 
as the residues implicated with agonist binding in nAChR and AChBP were conserved in 
the receptor. The residues lie in four regions identified as loops A, B, C, and D. Loops 
A, B, and C are located on what is referred to as the 'plus' face while loops D, E, and F 
lie on the 'minus' face (see Figures 72 and 73). In the heteromeric nAChR, agonist 
binding takes place between the 'plus' face of a subunit and the 'minus' face of an a or 8 
subunit. Site directed mutagenesis and radioligand binding assays have established that 
residues of the GABA(A) receptor involved in ligand binding align with residues in 
loops A, B, and C of the a subunit and loops D and E of the y subunit. 
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Extracellular 
Intracellular 
Figure 72. Single subunit of acetychoiine binding protein crystallized from Lymnaea stagnalis (side 
view) 
Figure 73. Single subunit of acetycholine binding protein crystallized from Lymnaea stagnalis (top 
view) 
Since the AChBP is a member of the Cys-loop LGIC superfamily, it offers a 
template for building models of the the ligand binding domains of the Cys-loop 
superfamily. The AChBP was used to build homology models of the subtypes of the 
GABA(A) receptors. The ligand binding domains of human GABA(A) receptors 
(al, a2, a3, a5, P2 and y2) were obtained from the Research Collaboratory for Structural 
Bioinformatics (RCSB). Originated in 1971 at Brookhaven National Laboratories, this is 
the home of the Protein Data Bank. The PDB archive is the repository of information 
about the 3D structures of large biological molecules such as proteins and nucleic acids. 
With the protein sequences in hand, a critical first step in building a homology model is 
to align the raw protein sequence with the protein sequence of a target protein or template 
structure. Alignments are prepared using multiple sequence alignment software for DNA 
T O  
and proteins. 
After calculating the best match for the selected sequences, they are lined up so 
identities, similarities, and differences can be seen. Programs which perform this include 
MAFFT, Muscle, Multalin, ClustalW, and BlastAlign (http://pbil.univ-
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lyonl.fr/alignment.html). Templates can also be found by performing a query of the raw-
protein sequence against the Protein databank. This is performed using the protein 
T O  #  (  
database search program, Gapped Blast. The report will contain a list of sequences 
producing significant alignments, PDB code, protein description, a normalized alignment 
score and an Expect (E) value. In general, a lower E score describes the background 
noise that exists between sequences. A lower E value correlates to a more significant 
score. Once a proper alignment of protein sequences was performed, the raw protein 
sequence was threaded onto the AChBP using Deep View. The crystal structure of the 
AChBP was downloaded from the Swiss Protein Databank Viewer. Deep View is a 
Swiss Protein Databank Viewer (http://ca.expasv.org/spdbv). Threading is performed 
after the alignment is complete. Amino acids which have been identified as equivalent 
between the proteins are "fit". This is similar, but more precise than the "3 
corresponding atoms" technique. Deep View includes a tool, Magic Fit,10 which 
performs the threading procedure for all residues across a raw sequence and a reference 
protein. Once the preliminary model has been built, a manual inspection can be 
performed. Considerations during manual inspection include, identifying areas of low 
•jo I  
homology, and manually aligning gap regions with loops in the reference protein. 
Loop regions which correspond to gaps were in the alignment can be modeled by fitting 
structures from a loop database. In the current model, loop regions were mapped to a 
loop database by Cromer et al.42'263 
Upon completion of the preliminary model, the following properties can be studied using 
Deep View and Sybyl38: 
1. Surface hydrophobicity 
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2. Solvent accessibility of N-glycosylation sites after pentamer assembly 
3. Acidic,basic, and non polar maps 
4. Sybyl X minimizations 
5. Steric clashes 
6. RMSD of alpha carbons 
7. Location of disulfide bonds 
In order to improve the prediction of areas of low homology PHD was utilized by 
-jo-j "JQA 
Cromer et al. " PHD or more commonly referred to as PredictProtein is a sequence 
analysis tool and the prediction of protein structure and function. Protein sequences or 
alignments are submitted to Columbia University; PredictProtein returns multiple 
sequence alignments, PROSITE sequence motifs, low-complexity regions (SEG), nuclear 
localisation signals, regions lacking regular structure (NORS) and predictions of 
secondary structure, solvent accessibility, globular regions, transmembrane helices, 
coiled-coil regions, structural switch regions, disulfide-bonds, sub-cellular localization, 
and functional annotations. Upon request the Rost group will perform fold recognition 
by prediction-based threading, CHOP domain assignments, predictions of transmembrane 
strands and inter-residue contacts are also available. PredictProtein is run by Burkhard 
Rost at Columbia University in New York (www.rostlab.org).285 As an alternative, 
Swiss Model can be used to model subunit loop regions by searching structures from loop 
databases. 
Once subunits were completed, a pentamer was constructed taking into 
consideration residues determined experimentally to be present in the allosteric and 
GABA binding site. On the a subunit, this includes aTyrl60, aTyr210, yPhe77, and 
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aSer205.286'287 After manually assembling the subunits and comparing an overlay with 
AChBP, the structure was energy minimized. 
With protein receptor models for al p3y2, a2p3y2, a3p3y2.and oc5p3y2 
completed a truly unified pharmacophore model was assembled for each receptor 
subtype. Using the Tripos Biopolymer software, the pharmacophore was manually 
aligned into each protein. With mutagenesis data on residue interaction on key ligands, 
the pharmacophore was carefully adjusted so as to recreate the protein-ligand interactions 
discussed previously. The protein models below represent the cumulative results of over 
20 years of research. The proteins are oriented with the y2 on the left and the a subunit on 
the right with loop C reaching over the middle to y2. Diazepam has been docked in each receptor 
and the pharmacophore is visible. 
Protein Models of the aip3y2, a2P3y2, a3P3y2 and a5P3y2 Subtypes 
Presented here are the complete unified protein-pharmacophore models. The 
Milwaukee-based pharmacophore has been inserted into each of the homology models 
for the receptor subtypes of the benzodiazepine receptor. The models show the 
similarities we expected. The two oxygens of serine 206 represent the hydrogen bond 
acceptor A2. The hydrogen bond donor, Hi, is due to the hydroxyl group oxygens of 
Threonine 231 and Tyrosine 234. Threonine 193 is responsible for the H2 hydrogen bond 
donor as its hydroxyl group coordinates with lone pairs of ligands. The imidazole ring 
of histidine 102 coordinates with phenyl rings of ligands through 7t—Tt stacking 
interactions. 
Figure 74. The al(33y2 subtype receptor with key residues shown 
Figure 75. The benzodiazepine binding site of the aip3y2 receptor 
Figure 76. The benzodiazepine binding site of the aip3y2 receptor rotated 90° 
Figure 77. The a2p3y2 subtype receptor with key residues shown 
.HIS102 
Figure 78. The benzodiazepine binding site of the a2p3y2 receptor 
Figure 79. The benzodiazepine binding site of the a2p3y2 receptor rotated 90° 
Figure 80. The a3p3y2 subtype receptor with key residues shown 
Figure 81. The benzodiazepine binding site of the a3p3y£ receptor within the active site 
Figure 82. The benzodiazepine binding site of the a3p3y2 receptor rotated 90° 
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Figure 83. The benzodiazepine binding site of the aip3y2 receptor with diazepam in the binding 
pocket. 
HIS 102 VAL212 
YR210 
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THR207 
Figure 84. The benzodiazepine binding site of the alp3y2 receptor rotated 90° with diazepam in the 
binding site 
HIS102 
VAL212 
TYR160 
\ \  
THR207 
Figure 85. The benzodiazepine binding site of the a 1 p3y2 receptor rotated 90° (reverse direction) 
with diazepam in the binding site 
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Figure 86. The a5p3y2 subtype receptor with key residues shown with diazepam in the binding site 
Figure 87. The benzodiazepine binding site of the a5P3y2 receptor with diazepam in the binding site 
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Figure 88. The benzodiazepine binding site of the <x5P3y2 receptor rotated 90° with diazepam in the 
binding site 
From this unified model which was constructed on binding data from hundreds of 
compounds, included volume analysis, site directed mutagenesis, manual as well as Sybyl 
Flexidock and AutoDock algorithms, one can now see how any compound will dock in 
the benzodiazepine binding site of GABA(A). Presented below is a compound for 
further research on drug abuse, WYS8. 
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Figure 89. Flexidock fit of WYS8 
Refinement of WYS8 in the unified pharmacophore receptor was completed using 
FlexiDock. The protein with the pharmacophore set inside the benzodiazepine receptor is 
displayed with a ligand docked to the pharmacophore. From the compute function, 
Flexidock is executed. The pocket needs to be defined for Sybyl if it has not already. 
Pick atoms which are located near the binding site. All atoms within 4 Angstroms will be 
automatically selected by Sybyl to assist. For Flexidock to work with rigid proteins the 
following steps must be taken: 
1. Water must be removed 
2. Select atoms around the binding pocket 
3. Add hydrogens 
4. Pick 4A radius to display around binding pocket 
5. Have Sybyl add charges if necessary 
6. Set rotatable bonds 
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From these models, the individual pharmacophores, and the compound database 
the medicinal chemist has a powerful set of tools to determine future ligands to 
synthesize in order to deliver subtype selective drugs with reduced side effects. New 
ligands based on this work have been proposed in Part II. For example, knowing how to 
dock ligands into the pharmacophore, one can begin taking measurements of ligands and 
residues and analyzing interactions. In the a2(32y2 Bz receptor His 102 and the phenyl 
ring of diazepam have a n stacking distance of 4.1 Angstroms. Next we will discuss how 
one can properly dock ligands into the binding site. 
Docking Studies Using AutoDock 4.2 
Docking of ligands into the new binding sites of the homology models was also 
executed using the suite of Autodock Tools developed at Scripps Institute.289' 290 The 
general procedure entails preparing pdb file formats of the receptor (protein) as well as 
the ligand. Once these docking grids and docking parameters are set, the docking run 
will produce multiple potential docking reports. Prior knowledge from SAR studies and 
mutagenesis studies is then used to select those for a parallel run (clusters) and a final 
docking prediction is developed. 
Preparing the Ligand for Autodock 
The ligand is loaded into Autodock as a pdb file. Once in Autodock, Gasteiger 
partial charges are determined along with aromatic carbons, rotatable bonds and torsional 
degrees of freedom. A new "pdgqt" file is created which has this information attached to 
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it. Preparation of the receptor begins with loading it too as a pdb file into Autodock. 
Water molecules must be removed from the protein if present for Autodock processing. 
If any residues are flexible, these need to be identified in the receptor. Once identified, 
torsion angles can be assigned. Bonds in side chains can be manually or automatically 
selected as rotatable, unrotatable, or non-rotatable. Autodock needs two files when 
docking ligands in proteins with flexible residues, a flexible PDBQT file and a Rigid 
PDBQT file. Before docking can begin the receptor is checked for Gasteiger charges. A 
map is created which identifies possible hydrogen bonding interactions. Next, a grid box 
(Figure 90) is constructed around the general vicinity of the receptor if this is known. 
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Figure 90. Setting the autogrid in Autodock for the Bz BS protein 
With all the appropriate information stored in a parameter file, the docking 
program will know which map file to use, details about the ligand rules, the potential 
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presence of flexible residues and which docking algorithm to use. Four different docking 
algorithms are currently available in AutoDock. Monte Carlo simulated annealing (SA) 
was used. Briefly, the ligand makes random moves in the receptor and the energy of the 
new position is compared to the old one. Moves in which the energy is lowered are 
accepted. 
Figure 91. WYS8 
Docking WYS8 
WYS8 was drawn in ChemDraw Ultra 8.0 (Figure 91). Lone pairs were added 
and the molecule was minimized in ChemDraw 3D using MM2 to a minimum RMS 
gradient of 0.100. This was converted to a PDB file to be loaded into AutoDock 4. Upon 
loading into Autodock, Gasteiger charges were added, 14 non-polar hydrogens were 
merged, 10 aromatic carbons were identified, 3 rotatable bonds were detected, and 
TORSDOF was set to 3. 
N 
H 
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Figure 92. Rotatable bonds are identified along with root atom in ligand WYS8 
The root atom with the smallest largest sub-tree (in this case an acetylenic hydrogen) is 
marked with a green sphere and the root portion (red) is identified. The rotatable bonds 
are colored green. The receptor was rigid for this analysis. 
Figure 93. AutoDock result rendering was performed using Tripos Benchware. 
Using Tripos Benchware 3D Explorer 2.6, one of the results was modeled (Figure 
93). Key residues were identified and the protein surface five angstroms from the ligand 
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was mapped showing its lipophilic potential. The results using AutoDock and a rigid 
protein will be much improved when flexible residues are allowed in the binding pocket 
along with rotatable bonds. The docking in Figure 89 is preferred when considering the 
orientation in the Milwaukee-based pharmacophore. 
Homology models which have the pharmacophore aligned in the binding pocket 
have been presented for the al P2y2, a2p2y2, a3p2y2, and a5p2y2 GABA(A) receptors. 
The binding site was constructed in light of years of work including structure-activity-
relationships (SAR), site directed mutagenesis, and docking studies of monomer and 
dimers alike. The a4p2y2 and a6p2y2 receptors have not been made as these "diazepam-
insensitive" binding sites are not a focus of our research to date. An updated included 
volume analysis has been presented using ligands from 15 different structural families. 
The new included volume analyses and the unified pharmacophore protein models will 
continue to drive the design of novel and selective benzodiazepine receptor ligands. 
From these new ligands, scientists will increase their understanding of the physiological 
responses of the specific receptors, the design of pharmaceuticals with reduced side 
effects, and treatments for schizophrenia, drug addiction and Alzheimer's disease. The 
a5P2y2 receptors are of particular interest because of their concentration in the 
hippocampus. The discovery of a larger L3 pocket in the a5p2y2 receptor versus the 
other subtypes will provide medicinal chemists with a structural advantage in designing 
more subtype selective ligands. From the unified pharmacophore protein models 
presented here, the design of new compounds for the GABA(A) will be more productive 
than ever. 
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Future Work 
Screening and modeling of more subtype selective ligands will further our current 
understanding of the benzodiazepine receptor and its function. Continued work on the 
molecular spreadsheet which will include all the compounds designed in the Milwaukee 
laboratory as well as other organizations will create a powerful QSAR algorithm for 
answering the age old question, "What compound should we make next?" This study 
will need to include all binding and non-binding compounds in order to create a 
-j •} 
predictive program with a high degree of accuracy (r , q ) in predicting activity. 
Site directed mutagenesis needs to be continued in which receptors of all subtypes 
are tested to determine how a residues substitution affects each of the subtypes. Such 
experimentation will shed further light on how ligands are positioned in the binding 
pocket and what residues they are interacting with. Adding to the new pharmacophore 
protein alignments which can now be executed, docking runs using Autodock in which 
the residues in the receptor are set to flexible may give further information as to docking 
preferences of ligands helping to better understand key interactions in each of the 
different subtypes. 
All of these activities have allowed us to develop the current ligands as well as 
propose next generation ligands, which will be discussed in Part II. The new 
pharmacophores will aid in furthering our understanding of GABA and in designing 
better drugs for the CNS until a complete GABA(A) protein receptor ion channel is 
captured in high resolution. 
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Part II. Subtype Selective Ligands for a5 GABA(A) /Bz Receptors 
Introduction 
Senile dementia of the Alzheimer's type (SDAT) accounts for the major portion of 
-)OQ 
all neurodegenerative diseases. Within the U.S. alone, about 4 million individuals are 
•>QA 1 
afflicted with SDAT, with about 130,000 new cases occurring per year. ' Annual 
")fiO OQfi 'IQ'I 
costs associated with AD are estimated to exceed $100 billion. ' Epidemiologists 
expect that by the year 2050 in the more developed world, life expectancies at birth will 
surpass 80 years of age.293' 294 Inevitably, this development will lead to increased 
numbers of elderly people, from 414 million people over 65 years of age in 2000 to 
7OC 
probably 1.4 billion in the year 2050. Many of them will be afflicted by dementia, the 
prevalence of which rises rapidly with very old age. According to a Canadian study, the 
prevalence of dementia is about 23% in people of the age group, 85-89 years, about 40% 
in people of the age group, 90-94 years, whereas in people older than 95 years the 
prevalence of dementia rises to about 58%. ' In 2002, the number of individuals 
suffering from dementia in the more developed world was about 13.5 million cases. This 
figure is expected to rise to 37 million by the year 2030 and to 105 million worldwide by 
2050.289 
SDAT and age-related memory decline arises from progressive failure of the 
cholinergic system, leading to impaired memory and deterioration of other cognitive 
functions.16 17 Pharmacological treatment for this cognitive decline has primarily focused 
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on cholinomimetrics and cholinesterase inhibitors to mitigate the cholinergic 
hypofunction. These strategies tend to elicit direct postsynaptic stimulation. The 
constant tonic neuronal activity which results is unfavorable to normal cognitive 
processing and seriously undercuts the usefulness of this standard approach.16-17~2%'297 
A more effective strategy to alleviate memory deficits, attributed to cholinergic 
hypofunction, would be to enhance cognitive processing by augmenting the impact of 
acetylcholine (ACh) released from surviving cholinergic neurons on hippocampal 
pyramidal cells, without disrupting the highly complex transmission patterns inherent to 
these cortical cholinergic pathways. An exciting yet largely underdeveloped 
therapeutic approach with excellent potential to achieve this outcome is one that would 
reduce postsynaptic inhibition of cholinergic excitation in the hippocampus via 
aoc 7QC 
pharmacology. A rational means to achieve this aim is to influence the functional 
regulation pathways involved in cognition by manipulating the inhibitory nature of the 
neurotransmitter GABA.299'300 As mentioned, when GABA binds to the GABA(A) / 
benzodiazepine receptor, it induces chloride ion ( CI") passage into the neuron, causing 
hyperpolarization of the surrounding membrane preventing synaptic excitation. GABA's 
inhibitory effects can be fine-tuned by a variety of substances, including those that 
specifically bind to the benzodiazepine binding site (BzR) on the GABA(A) receptor.299 
300 Appropriate BzR ligands modulate GABA's inhibitory influence on numerous 
neuronal pathways, including the cholinergic pathways of the basal forebrain that project 
to the hippocampus.301 These cholinergic pathways are important to cognition and are 
prone to degeneration in SDAT. Although BzR ligands are relatively safe drugs, their 
downside is due to their broad spectrum of activity and lack of behavioral specificity. 
Consequently, insight into how BzR ligands elicit their specific physiological effect is 
183 
crucial to development of the next generation of behaviorally-specific BzR ligands with 
reduced side effects. 
BzR ligands alone do not activate GABA(A) receptors, but instead act as 
modulators of GABA's ability to activate this receptor. For example, when cognitive 
events activate cholinergic excitation in the hippocampus, the GABAergic system is 
likewise activated to modulate the level of this excitation. In situations where the 
cholinergic excitation is decreased due to the loss of cholinergic neurons, as in the case of 
SDAT, the precise reduction in GABAergic inhibition in brain regions where the 
weakened cholinergic neurons project would selectively augment the functional impact of 
the ACh released. ' It is important to point out that GABAergic neurons remain 
intact and functional until the very last stages of Alzheimer's disease while cholinergic 
deficits become more pronounced as the disease progresses.303'304 Consequently, a5 
BzR/GABAergic neurons have now become pharmacological targets because these are 
located almost exclusively in the hippocampus305 and are still functional throughout most 
stages of the disease. It is well documented that the BzR ligands flunitrazepam and 
midazolam impair cognition in animal models and humans306 by augmenting GABA-
mediated CI" flux through the GABA(A) receptor which prevents the induction of Long 
Term Potentiation (LTP) in rodent hippocampal neurons.50'307 Conversely, BzR ligands 
that retard GABA-mediated CI" passage into the neuron (negative allosteric modulation) 
potentiates LTP in rodent hippocampal neurons,16' 17 which results in improved learning 
•}Qzr 7Q7 . 
and memory. ' Earlier, the therapeutic potential for memory augmentation by BzR 
ligands has been considered to be limited due to the side effects such as convulsant or 
proconvulsant activity that occur at slightly higher doses.308 However, new findings 
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suggest that particular combinations of GABA(A) receptor subunits are intimately 
associated with cognitive influence.64 Although a5 selective inverse agonists from our 
laboratory64"309 310 and from the laboratories of others50 307 have been shown to enhance 
cognition, recently we have developed an a5 subtype selective antagonist which clearly 
enhances cognition.311"314 It has no efficacy at al-a6 subtypes; however, binds to the a5 
subtype at 15nM and antagonized potently the percent modulation of GABA by diazepam 
in oocytes.17 315 It was then shown to enhance cognition on the mean delay achieved by 
C57BL/6J mice under the titrating delayed matching-to-position schedule.316 An 
antagonist at BzR sites would be expected to exhibit no sedative effect, no convulsive, 
-)OC 
nor any proconvulsive side effects. " 
Support for this approach was also derived from the following lines of reasoning: 
1) While most neurotransmitter systems are degenerating in the SDAT brain, the 
GABAergic infrastructure is relatively well preserved.314- 315 2) Numerous cognitive 
deficit models of cholinergic hypofunction, both human and animal, benefit cognitively 
when GABA activity is reduced.30 3) Beneficial effects of BzR inverse agonists can also 
be generalized to the aged nervous system, as indicated by their ability to improve 
working memory performance in memory impaired aged rats.50 4) Lesion studies 
demonstrate that animals with 50-70% loss of cortical cholinergic fibers exhibit improved 
19 21 18S 237 cognitive performance from BzR treatment. " As the loss of cholinergic 
neurons in age associated memory impairment and SDAT is commonly in the 40-70% 
9Qf\ "7Q7 1 7 
range until the very last stage, the effects of BzR inverse agonists on restoring 
neural transmission in animals with a partial loss of cortical cholinergic inputs suggests 
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development of specific BzR inverse agonists for the treatment of cognitive decline 
associated with aging and SDAT. 
a5 Selective Ligands 
Interest in BzR/GABA(A) a5 subtypes has been stimulated recently by the report 
of Mohler et. al.16' 17 296' 297' 317 3,8 on a5 "knockin mice." In brief, this group has 
provided strong evidence that hippocampal extrasynaptic a5 GABA(A) receptors play a 
critical role in associative learning as mentioned above.16 
Previously, a series of a5 subtype selective ligands [(RY-023), (RY-024), (RY-
079) and (RY-080)] based on the structure of (Ro 15-4513) have been reported from this 
laboratory,16 as well as several ligands by McKernan, Atack et. al,17 These ligands are 
BzR inverse agonists in vivo and a number have been shown to enhance cognition.64 One 
of these ligands was shown by Bailey, Helmstetter et. al.64 to be important in the 
acquisition of fear conditioning and has provided further evidence for the involvement of 
hippocampal GABA(A)/BzR in learning and anxiety.64 This is in agreement with the 
work of DeLorey et. al.64 in a memory model with a ligand closely related to a5 subtype 
selective inverse agonists RY-024 and RY-079. 
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a5 Selective Antagonist (1) 
RY -80 
DM H-III-96 
(no affinity) 
Ligand al a2 a3 a4 a5 a6 
RY-80 28.4 21 4 25.8 5 3 0.49 28 8 
XLi-093 >1000 >1000 858 1550 15 >2000 
Figure 94. Alpha 5 selective compounds 
To enhance the subtype selectivity, the bivalent form of RY-080 was synthesized 
to provide XLi-093.64 The binding affinity of XLi093 in vitro was determined on 
ai-6P3y2 LTK cells and is illustrated in Figure 94. This bivalent ligand bound to a5p3y2 
subtypes with a Kj of l5nM, but exhibited little or no affinity at other BzR/GABA(A) 
subtypes.309 Since receptor binding studies indicated bivalent ligand XLi-093 bound almost 
exclusively to the a5 subtype, the effect of this ligand on various GABA(A) receptors expressed 
in Xenopus oocytes was investigated by Sieghart, Furtmueller, Li and Cook.309 Analysis of the 
data indicated that XLi093 up to a concentration of l pM did not trigger chloride currents in any 
one of the GABA(A) subtypes tested. At l |j.M XU093 did not modulate GABA induced 
chloride flux in aip3y2, a2p3y2, or a3p3y2 receptors, but very slightly inhibited currents in 
a5p3y2. At luM, (1) only marginally influenced diazepam stimulation of GABA-induced current 
in aip3y2, a2p3y2 and a3p3y2 BzR but shifted the diazepam dose response curve to the right in 
a5P3y2 receptors in a significant fashion.308 Importantly, bivalent ligand (1) was able to dose 
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dependently and completely inhibit diazepam-stimulated currents in a5p3y2 receptors. This was 
the first subtype selective benzodiazepine receptor site antagonist at a.5 receptors. This bivalent 
ligand (1) provided a lead compound for all of the bivalent ligands in this research.308 
Depicted in Figure 95 is Xli093 aligned in the pharmacophore-receptor model of the 
a5p3y2 subtype. The fit is excellent.66'308 310 The fit to the pharmacophore-receptor and the 
binding data indicate that bivalent ligands will bind to BzR subtypes.309 310 As discussed in Part 
I, it is believed that the dimer enters the binding pocket with one monomeric unit docking while 
the other monomer tethered by a linker extends out of the protein into the extracellular domain. 
In an even more exciting development, Wenger, Li, Cook et. al.19' u 121 have reported 
preliminary data that the a5 subtype selective antagonist XH093 does indeed enhance 
performance under a titrating delayed matching to position schedule of cognition in C57BL/6J 
mice, as illustrated in Figure 96.66-308 310 This agent does cross the blood brain barrier. 
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Figure 95. XH093 aligned in the included volume of the 
pharmacophore receptor model for the a5f}3y2 subtype 
Cognition Enhancement by XLi-093 (1) 
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Figure 96. Xli093 in cognition enhancement (Wenger 
unpublished) 
To date, in regard to bivalent ligands, the preferred linkers between the two 
pharmacophores (see XH093) have been established as 3 methylene units, 4 methylene 
units or 5 methylene units. This was established by low temperature NMR experiments, 
molecular modeling and X-ray crystallography of the ligands in question and will be 
discussed. 
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Recently a number of more selective ligands for a5p3y2 subtypes have been 
synthesized (See Table 25). Although the basic imidazobenzodiazepine scaffold has been 
maintained,17 substituents were varied in regions around the scaffold based on molecular 
modeling.16 These are now the most a5 subtype selective ligands ever reported.307- 319 
Moreover, one can now mix and match the substituents on these ligands to obtain a5 
subtype selective agents with 400-1000 fold selectivity for a5 subtypes over the other 5 
subtypes. This is the key to unlocking the true, unequivocal physiological responses 
mediated by a.5 subtypes in regard to cognition, (amnesia), anxiety and convulsions, all 
of which to some degree, may be influenced by a.5 subtypes. It is clear, in most cases, in 
the ligands in Table 25 and Table 26, affinity has occurred only at a5(33y2 subtypes. In 
addition, since bivalent ligand XH093 bound very tightly only to a5 BzR subtypes, the 
functionality present can be incorporated into other bivalent ligands. 
From the data in Figure 96 it is clear the a5 antagonist Xli093 has enhanced 
cognition, moreover, the two acetylenic groups of XLi093 have been reduced to provide 
ethyl functions.309 This provided a new bivalent ligand (XLi-356) which shows (in 
oocytes) no activity at al subtypes but is a clear inverse agonist at a5 subtypes (Table 
21).30 DeLorey has recently shown that Xli-356 does potently reverse scoploamine 
induced memory deficiencies. This bivalent a5 inverse agonist enhances cognition in 
agreement with work reported from our laboratory on monovalent inverse agonists 
RY1016 and RY 023.17 In addition Roth et. al. has recently determined Kj values for Xli-
356 in HEK-T cells [al (no affinity); a5(107 nM)]. 
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DM-l-81 aligned in the included volume of the pharmacophore/receptor 
model for the a1p3y2 (light grey) and u5p3y2 (dark grey) subtypes 
Figure 97. The a5 selective agonist DM-I-8I 
Mohler has proposed that a5 selective inverse agonists or a5 selective agonists 
might enhance cognition.64' 66' 308' 320 This is because of the extrasynaptic pyramidal 
nature of a5p3y2 subtypes, located almost exclusively in the hippocampus. Because of 
this, a new "potential agonist" which binds solely to a5[33y2 subtypes was designed by 
computer modeling (See Figure 97). This ligand (DM-I-81) has an agonist framework 
and binds only to a5P3y2 subtypes.64' 66'320 The binding potency at a5 subtypes is 174 
nM. Additional work on this scaffold was discontinued as it was felt that the bulk of the 
8-phenyl moiety was too large to fit into the L2 pocket potently. 
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Table 25. Binding data of selected imidazobenzodiazepines 
DM-I-81 
Kj(nM) 
Ligand Ri al a.2 a3 a4 aS a6 
3a CH2OCH3 >300 >300 >300 ND 38.8 >300 
3b CH2CI >300 >300 >300 ND 28.5 >300 
3c CH2OEt >300 >300 >300 ND 82.7 >300 
4 CH3 >89 >70 >91 ND 3.7 >301 
5 C02Et >1000 >1000 >1000 >1000 64 >1000 
2 C02Et >2000 >2000 >2000 >2000 176 >2000 
3 Data shown here are the means of two determinations which difFered by less than 10% 
ND = Not Determined (presumably similar to a6). 
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Table 26. Binding data of selected imidazobenzodiazepines 
XLi356 
Br 
RY-062 
O 
RY-069 
RY-068 
N N-y 
\ /' » 
-O 
O 
RY-I-29 
K,(nM)a 
Ligand al a.2 <x3 a4 aS a.6 
XU356 ND ND ND ND ND ND 
RY068 >500 877 496 ND 37 >1000 
RY062 >1000 >1000 >500 ND 172 >2000 
RY069 692 622 506 ND 19 >1000 
RY-I-29 >1000 >1000 >1000 ND 157 >1000 
a Data shown here are the means of two determinations which differed by less than 10% 
ND = Not Determined (presumably similar to a6). 
In regard to a5 receptor subtype selective ligands, Bailey, Helmstetter et.al. have 
used RY024 to enhance cognition and provide further evidence for the involvement of 
hippocampal GABA(A) /benzodiazepine receptors in learning and anxiety.309'310 This 
has been supported by DeLorey et. al, who demonstrated that the closely related a5 
inverse agonist RY10 potently reversed scopolamine-induced memory impairment. 
These a5 inverse agonists provide tools to be used to decipher how GABA(A) receptors 
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influence contextual memory, an aspect of memory affected in age associated memory 
(A 
impairment and especially in Alzheimer's disease. In this regard, Savic et.al,. have 
recently employed the al preferring ligand BCCt in studies on passive avoidance, which 
clearly indicated the amnesic effects of midazolam are due to interaction of agonist 
ligands at a5 in addition to al BzR subtypes. 
The preferred 3 carbon linkers for BzR/GABA(A) bivalent ligands have been 
determined19'1221 °'297 by low temperature NMR studies and X-ray analysis and will be 
described.66121-3,73,8 
Molecular modeling was used to generate new lead compounds aimed at the 
preparation of subtype selective agonists, and inverse agonists of a5 subtypes to study 
memory and learning as well as amnesia mediated by the hippocampus. All of these 
compounds have been designed based on the structures of a5 subtype selective ligands 
prepared in our laboratory321 (see Table 25-26), as well as the binding affinity 
(15nM)/selectivity of bivalent a5 antagonist XLi093.322 
Pharmacology 
The affinity of all ligands at the 6 major recombinant GABA(A) /BzR subtypes 
was measured by competition for [3H]Rol5-1788 binding to HEK-T cells expressing 
both human and rat GABA(A) /Bz receptors of composition al(32y2 (al), a2p2y2 (a2), 
a3p2y2 (a3), and a5(32y2 (a5). It is well known that the 02 and P3 subunits can be 
interchanged with no effect on Bz ligand affinity or efficacy.323 The a4 and a6 subtypes 
(diazepam insensitive) were assayed using [3H]-Ro 15-4513.324 This work was done in 
the laboratory of Bryan Roth64 who has already expressed the receptors employing the 
work of Kucken et. al.325 and Gray et. al64 Roth has currently obtained Kj values on 
more than 125 ligands. In brief, for membrane preparations, the cells were scraped on ice 
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into 5mL of phosphate buffered saline (pH=7.40) and cells pelleted by centrifugation for 
5 min. at 4°C. The pellets were resuspended in lmL of 50mM Tris-acetate buffer (pH 
7.4) and centrifuged at 18,000g for 20 min. Radioligand binding assays were performed 
in 50mM Tris-acetate buffer (pH 7.4) using 10"3M diazepam for non-specific binding; 
typically specific binding will represent 90% of total binding. Each pellet was diluted to 
6mL and then 100 |iL of membranes was incubated with approximately InM final 
concentration of [3H]Ro 15-1788 in a total volume of 250|aL together with serial dilutions 
of test compound for 90 min. on ice. The membranes were harvested in 
polyethyleneimine-pretreated Whatman GF/C filters and after drying and addition of 
scintillation cocktail, counted in a scintillation counter. The counts per minute (cpm) 
retained on the filters was plotted against log concentration (M) and fitted to one site 
competition equation to obtain the Kj using Graphpad Prizm (V4.0) using the Cheng-
Prusoff approximation.64 
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Xli356 and RYIO were screened in stably expressed HEK cells. 
nil. III ill HI 
cort 3 3C con: 3 30 cool 3 30 com 3 30 
[XLi-356] (uM) [RY-10] 
oAfiA •«**> CiABA •ftYW ^ASA 
|3.|U: ;X*M; !«*#• JJW r.aw 
r '[ r V r 
<150272 
GABA -ftric &ABA -»RY 13 SABA 
u\h.W' 1304/1 i-*»v j,A*. i*Mr 
I 
uip:?; 
Figure 98. Xli356 and RYIO were screened in stably expressed HEK cells. 
Efficacy at the 6 major receptor subtypes was determined by our collaborators, 
Sieghart64 and Halliwell121'326 in Xenopus oocytes and correlated to the in vivo activity 
determined below. Since evaluation of the efficacy of ligands in vitro on Xenopus 
oocytes is time consuming, only subtype specific ligands with a selectivity of 40 fold or 
more were evaluated in this measure. In brief, adult female Xenopus laevis were 
anesthetized in a bath of ice-cold 0.17% Tricain326 before decapitation and removal of the 
frog's ovary. Ovary tissue was removed via a small abdominal incision and stage 5 to 6 
oocytes were isolated with fine forceps. After mild colagenase treatment to remove 
follicle cells, the oocyte nuclei were directly injected with 10-20|j.L of injection buffer 
containing different combinations of human GABA(A) subunit cDNAs engineered into 
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the expression vector pCDM8 or pcDNAI/Amp. After incubation for 24 hr, oocytes were 
placed in a 50|xL bath and perfused with modified Barth's medium. From Figure 98, it 
can be seen that Xli-356 is an inverse agonist selective for the a.5 receptor over al. 
Cells were impaled with two 2-3 MQ electrodes which contain 2MKC1 and voltage 
clamped at a holding potential of-60mV.326"330 GABA modulators were preapplied for 30 seconds 
before the addition of GABA, which was coapplied with ligands until a peak response was 
observed. The highest concentration of DMSO employed in this study perfusing the oocyte was 
0.1% which had no effect when applied alone at this concentration.16'331"333 
In regard to cognition, the effect of systemic administration of subtype selective 
agents on short term memory was determined in white Carneau pigeons by Wenger et. 
al.16' 17 Administration of drug was intramuscularly and the titrating matching-to-sample 
schedule of reinforcement was used.334 Matching-to-sample is widely used as a measure 
of short-term memory, and has been shown to be sensitive to the effects of agents to 
actions at the GABA(A) chloride complex in laboratory animals and humans. Xli-093, 
the first a5 selective antagonist was shown to enhance cognition in Wenger's laboratory 
(Figure 96). 
Because the hippocampus is involved in the regulation of events underlying 
learning and memory, a5 subtype selective agents were evaluated for their ability to 
modulate hippocampal-dependent and hippocampal-independent forms of memory using 
Pavlovian fear conditioning paradigms307' 336-339 with DeLorey.307' 336"339 Savic et. al. 
studied selected ligands in the active avoidance acquisition and retention paradigm339 and 
passive avoidance task.340 
Since the GABAergic system is the major inhibitory neurotransmitter system in 
the CNS,341 it has tremendous therapeutic potential. Alterations in GABA(A) function 
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from controls are known to occur in anxiety disorders,342 including panic disorder,343 
epilepsy,344 hypersensitive behavior,345 phobias,346 schizophrenia,347 alcoholism,310 
Angelmans Syndrome310 and Rhetts syndrome307' 336"m 342 as well as other diseases.348 
Since BzR ligands modulate this system, the design of subtype selective ligands is one 
way to generate better, safer therapeutic agents. 
Synthesis and pharmacological evaluation of these subtype selective agents 
permitted the assignment of the correct physiological functions to a5 subtypes. This is of 
special importance here in regard to cognition/amnesia mediated by the hippocampus. It 
is felt a potential therapeutic agent to improve memory and learning will result from this 
continued research. 
The ligand XLi356 is an inverse agonist in a5p3y2 oocytes and a weak agonist at 
al(53y2 sites (Figure 98). RY10 behaved as a weak agonist at both al and a5 subtypes in 
oocytes. Therefore, the dimerization of RY10 switches the effect from agonist towards 
inverse agonist at a5p3y2 subtypes with a lesser influence (other binding) on aip3y2 
subtypes.349 The methods used to prepare Xli-356, Xli-093, and RY-10 were reported by 
Li.350 
Correlation of a specific BzR subtype to a specific pharmacological response is 
crucial for understanding the mechanisms which underlie cognitive deficits but also 
anxiety disorders,351 sleep disorders, convulsions, and will help design selective agents to 
treat these disease states while being devoid of abuse potential. 
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History of GABA(A) / Benzodiazepine Receptors 
In 1950, Eugene Roberts and Jorge Awapara found large amounts (lmg per gram) of 
y-amino butyric acid (GABA) in the mammalian central nervous system.352 Ernst Florey 
discovered that this GABA acted as an inhibitory neurotransmitter from inhibition studies 
of the stretch receptor in crayfish.353 Later, in 1963, Del Castillo demonstrated, through 
electrophysiological recordings, the application of GABA opens chloride channels in the 
nerve cells of Ascaris.354 This GABA-gated chloride channel is now known as the 
GABA(A) receptor. Activation of GABA(A) receptors allows chloride ions to enter the 
nerve cell. The influx of chloride results in hyperpolarization of the cell membrane 
decreasing the excitability of the cell and is referred to as "hyperpolarizing inhibition."355 
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Figure 99. GABA function in C. elegans. 
GABA released from presynaptic neurons activates the inhibitory GABA(A) 
receptor; the influx of chloride ions causes the relaxation of the body muscles. GABA is 
cleared from the cleft by the plasma membrane transporter, SNF-11 (Figure 99).330'356 
Although benzodiazepines have been approved for use since 1963, it was not until 
the late seventies that evidence correlated the GABA(A) receptors and benzodiazepines. 
In 1977, Mohler and Okada,357' 358 as well as Squires and Braestrup,358 identified high-
affinity binding sites for tritiated diazepam, an early benzodiazepine prescribed primarily 
to counteract anxiety symptoms. In 1978, Bertilsson, an NIMH (National Institute of 
Mental Health) researcher, found direct evidence of an interaction of diazepam with the 
GABA(A) receptor. Using l3C labeled GABA, a decrease in GABA turnover was seen 
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in rat brain nuclei treated with diazepam (Valium).359 The pharmacological effects of 
these benzodiazepines include sedation, anxiolytic, anticonvulsant, muscle relaxation, 
and amnesic properties, as well as some addiction.'•208,209 
As discussed previously, the lead compounds synthesized in our lab as well as 
other laboratories resulted in high affinity ligands that have been been pooled in a 
database. The database is an interactive version of Chemdraw/Excel. This interactive 
database allows one to generate reports based on queries designed by the user and has 
proven a valuable research tool for querying structural and activity data. Substructure as 
well as activity searches allow for quick data analysis of our laboratories' library. 
Primarily, SAR studies quickly help to guide future drug design. This rational approach 
has led to several compounds with subtype selectivity. The synthesis of key scaffolds 
will be summarized now. 
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Synthesis of 8-Substituted imidazobenzodiazepines 
,NH2 
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Briefly, bromoacetyl bromide is added to 2-aminobenzophenone 4, followed by 
treatment with methanol saturated with ammonia under the cooling of an ice-water bath. 
The benzodiazepine, 5, is brominated to provide 6, and reacted with ethyl 
isocyanoacetate to generate the imidazobenzodiazepine, 7. The bromide 7 was subjected 
to a Stille-type coupling to give DM-I-81.210 This route can be executed on several 
hundred gram scale. 
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Figure 100. Synthesis of 8-substituted imidazobenzodiazepine bivalent ligands 
The benzodiazepine monomers were prepared by the method of Fryer and Gu.121, 
"M0 * * 1 • The isatoic anhydride was heated with sarcosine in dimethyl sulfoxide to provide 
amide 9. Bromination of 9 in a mixture of acetic acid, bromine, and sodium acetate 
afforded the corresponding monosubstituted bromide, 10 in good yield. Deprotonation of 
10 with lithium diisopropyl amide (LDA) in THF was followed by treatment with diethyl 
chlorophosphate to provide the intermediate enol phosphate. The enol phosphate was 
stirred with a solution of ethyl isocyanoacetate and LDA to yield the imidazo congener. 
A Heck type coupling reaction was employed with the bromide, 11 with 
bis(acetate)bis(triphenylphosphine)palladium(II) to provide the acetylene 12. Treatment 
of 12 with BU4NF removed the trimethyl silyl group. Hydrolysis of the ester function of 
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13 provided the acid 14 in excellent yield and this material was dried scrupulously and 
subjected to a standard CDI-mediated coupling reaction to furnish bivalent ligand 
XLi093. The imidazobenzodiazepine diethyl diester XLi356 (3) was obtained from 
XLi093 in high yield via catalytic hydrogenation (Pd/C, H2). 
The dimers XH093 and XH356 were sent to Case Western Reserve ( NIMH 
supported PDSP program, Roth et al.) for full panel receptor binding and they do not 
bind to other receptors at levels of concern (Table 27). 
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Data ("Secondary Binding") are K, values. K, values are reported in nanomolar 
concentration, Case Western Reserve University. Green indicates "Primary Missed" ) 
<50% affinity). (See Appendix for full PDSP screen data) 
Table 27. Full panel receptor binding reported for XH093 and Xli356. 
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Although XU093, 27 was found to be an antagonist at the a.5 subtype, XH356, 3 was 
found to be a weak agonist. XH356 was found to reverse scopolamine induced memory 
deficits in mice. When XH356 was looked at in audio cued fear conditioning, the results 
show no activity. This suggests that the effect of XH356 is selective through a5 receptors 
which are abundant in the hippocampus which is highly associated with contextual 
memory. Audio cued memory instead is amygdala-based, and should not be affected by 
an a5 subtype selective compound.33'34-71-213 
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As illustrated in Figure 101, scopolamine (1 mg/kg) reduced freezing (ie. impairs 
memory) typically caused by pairing the context (the cage) with a shock. The drug 
XH356 when given at lOmg/kg attenuates the impairment of memory returning the 
freezing to the level that one typically sees the mouse freeze at (ie veh). In audio cued, 
memory the response was triggered by sound not the context. XU356 was not able to 
reverse this type of memory effect which is amygdala driven. 
Contextual Memory Audio Cued Memory 
p>0.05 
XLI356 Scop XLi35610mg 
+ + 
Scop Scop 
Figure 101. Visual and audio qued data for XH356 
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Included Volume Analysis of Ligands Binding to Receptors Containing a5 Subunits 
As discussed previously, the benzodiazepine binding site of aPy2 GABA(A) 
receptors is strongly influenced by the type of a subunit present in these receptors as 
indicated by the existence of ligands exhibiting certain selectivity for receptors 
containing the respective a subunits.46 If subtype selective ligands are then aligned 
within the pharmacophore model according to the resulting alignment rules,47 their 
included volumes can be constructed and used to compare the topologies of 
benzodiazepine binding pockets of different receptor subtypes. 48. 
For enhanced selectivity at a5, it has been observed that ligands are generally i-
BZDs and have a lipophilic C(8)-substituent that occupies the Li pocket. Based on 
ligands from various studies, examination of data in Figure 27 and 102 illustrated that the 
L2 region was deeper and larger for the a2 and a5 subtypes, respectively, than for the 
corresponding al or a6 subtypes.49'50 
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Figure 102. Updates of the a5f32y2 subtype (solid) overlayed with the previous model (line). 
SH-053 Analogs 
In extension of this approach using BZ enantiomers, the behavioral activity of 
three newly-synthesized compounds,51 functionally selective for 012, CC3 and a5-containing 
subtypes of GABA(A) receptors (SH-053-S-CH3 and SH-053-S-CH3-2'F), or essentially 
selective for as subtypes (SH-053-R-CH3) were examined. Motor influence was tested 
in the elevated plus maze, spontaneous locomotor activity and rotarod test, which are 
considered primarily predictive of the anxiolytic, sedative and ataxic influence of BZs, 
respectively. There was substantially diminished ataxic potential of BZ site agonists 
devoid of al subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of 
SH-053-S-CH3 and SH-053-S-CH3-2'F. However, all three ligands, dosed at 30 mg/kg, 
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decreased spontaneous locomotor activity, suggesting that sedation may be partly 
dependent on activity mediated by a5-containing GABA(A) receptors. Such an effect 
could not have been observed previously, because to date, all apparently non-sedating BZ 
receptor ligands, which are devoid of activity at a i -containing GABA(A) receptors, 
S2 • * engendered essentially antagonist" or only partial agonist efficacy at as-containing 
GABA(A) receptors.49'50 Therefore, it cannot be ruled out that substantial efficacy at a5-
containing GABA(A) receptors may contribute to sedative effects besides the effects on 
learning and memory processes.46 This is supported by two sets of data which indicate 
the possibility of substantial motor influence via a5-GABA(A) receptor modulation: In 
the spinal cord, somatic and preganglionic motoneurons (lamina IX and lateral cell 
column) exhibited a moderate to strong staining for the a5 subunit, suggesting a possible 
influence of receptors containing these subunits in motor behavior. In addition, the 
knock-in mice harboring the a5 subunit insensitive to diazepam are refractory to 
development of tolerance to the sedative effect of diazepam dosed subchronically. Such a 
tolerance development might have been caused by a downregulation of receptors 
containing a5 subunits in the appropriate brain regions of wild-type mice.42 These two 
sets of evidence indicate that the motor influence of a5-GABA(A) receptor modulation 
is not necessarily an indirect consequence of the established effects on learning and 
memory processes. It has been hypothesized that locomotor activity changes induced 
by ligands possessing a substantial a5-efficacy may be, at least partly, contributed to by 
modulation at GABA(A) receptors containing the a5 subunit. It, therefore, could be of 
importance to avoid substantial agonist potentiation of as-subunits by candidate 
anxioselective anxiolytics, if clinical sedation is to be avoided. Nevertheless, as a caveat 
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to all studies examining sedation, it should be remembered that a decrease in 
automatically measured locomotor activity can be due to a variety of causes other than 
sedation, including the occurrence of stereotypical behavior, motor impairments or 
pain.64' 66 To dissect these overlaps in activity und uncertainties, much is expected from 
screening of even more selective BZ site ligands in the future. 
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Figure 103. SH053 compounds in the a2 pharmacophore/receptor model 
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Structures and conformations of SH-053-S-CH3 (A1-A3) and SH-053-R-CH3 (B1-B3) 
are presented in Figure 103. The molecular modeling was carried out as described in 
Clayton et al, 2007.66 SH-053-S-CH3 fits in the pharmacophore within the included 
volume of the a2 subtype (A2). A3 is the same image as A2 rotated 90°. It can be 
clearly seen that this conformer fits within the included volume. SH-053-R-CH3 fit to the 
pharmacophore in the included volume of the a2 subtype (B2). B3 is the same image 
rotated 90°. The R-CH3 at the prochiral center C4 changes the conformation of the 
molecule causing the pendant 6-phenyl to stick outside the included volume, 
consequently this ligand is not efficacious at the a2 subtype. It simply does not interact 
strongly with al, a2 or a3 subtypes. However, note that the R-isomer does bind to a5 
selectively. It is believed that further enhancement of potency can be achieved using this 
as a lead compound, by addition of a 2-F' or 2-N' substituent in the pendant phenyl ring at 
C-6, following the observations of Haefly et al. 
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Figure 104. Concentration-effect curves for SH-053-S-CH3 and SH-053-R-CH3 on 
alp3y2, a2p3y2, a3p3y2, and a5p3y2 GABA(A) receptors. Data points represent means ± SEM from 
at least 4 oocytes from > 2 batches. 
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Dimeric Benzodiazepines 
XLi-210,18 DMH-III-96,19 
Table 28. Structures and affinities at the axP3y2 subtype.I9'213 NR = not reported; ANT = 
antagonist; IA = inverse agonist; ND = not determined yet. Activity is defined for receptor subtype 
listed in bold. 
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Kj (pM) 
Ligand ql a2 a3 a4 a5 a6 Activity 
20, Rol5-1788 0.8 0.9 1.05 NR 0.6 148 ANT 
1, XLi-093 1000 1000 858 1550 15 2000 ANT 
18, XLi-210 231 661 2666 NR 5.4 54.2 ND 
19. DMH-III-96 460 5000 NR NR 5000 5000 ND 
Design of the bivalent ligand XLi-093 1 was based on the modeling of the 
a5 selective monomer RY-80 21 in the a5 pharmacophore model. The ability of this 
ligand to bind (Table 23) and fit well within the pharmacophore (Figure 105) required the 
3-carbon linker to be in a linear (versus folded) conformation. This linear conformation 
of XLi-093 has been confirmed both in the solid phase and in solution (Table 29).19,21 
The J values calculated from the dihedral angles (J = 5.38) were in excellent agreement 
with those determined from the solution NMR spectrum (J = 6.39), as previously 
mentioned. Because this bivalent ligand is a5-selective, the enriched selectivity of this 
dimer and those similar to it, was presumably entropic in nature, as the loss of affinity at 
the other subtypes was profound.16' 187 Future work should include the synthesis of 
monomeric imidazobenzodiazepine with model (longer) aliphatic alcohol groups in the 3-
position to confirm the enriched selectivity is indeed due to an entropic effect, rather than 
enthalpic. 
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Figure 105. Alignment of XLi-093 1 (white) and Rol5-1788 20 (cyan) within the included volume of 
the a5P3y2 subtype. 
It has been shown via crystallographic and solution NMR studies that 
modification of the aliphatic spacer to a -CH2OCH2- or a -(CH2)20(CH2)2~ group, 
1 88 provided a bivalent ligand with a folded conformation (Figure 106). Modeling of this 
type of ligand (e.g. DMH-III-96 19, Figure 107) within the a5 pharmacophore model 
illustrated the inability of bivalent ligands in the folded conformation to bind, 
presumably, because they are too hindered to access the Bz BS. Current data displaying 
these trends is shown in Table 29. 
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Figure 106. Crystal structures of the linear XLi-093 1 (left) and the folded DMH-III-96 19 (right). 
A 
Table 29. The molecular composition and stable conformation of various Bz BS bivalent ligands. 
ND = not determined yet. 
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Ligand Monounit 1 Monounit 2 Spacer Conformation Crystal 
in solution structure 
1, XLi-093 A 
18, XLi -210 A 
22, XLi -347 A 
23, XLi-374 A 
19, DMH-III-96 
A (CH2)3 linear linear 
A (CH2)5 linear ND 
A (CH2)20(CH2)2 folded ND 
A CH2OCH2 folded ND 
(CH2)20(CH2)2 folded folded 
Figure 107. Alignment of DMH-III-96 within the included volume of the a5^3y2 subtype. It is 
apparent that the folded conformation prevented it from binding to this GABA(A) subtype. 
Although additional experimental data is needed, inspection of the alignment of XLi-093 
(Figure 105) and our receptor model indicated the aliphatic linker of these bivalent 
ligands would thread the second half of the dimer through the Loi/A2 regions and toward 
the solvent accessible space outside (extracellular domain) of the receptor. 
RY-24 and related analogs 
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Continued interest in the development of a5 selective ligands goes forward in the 
CNS area for many reasons. From the evaluation of K; values, it was found that many 8-
substituted /-BZDs, such as RY-24 24 and RY-80 31 and their trimethylsilyl precursors 
25 and 26 (Table 30), exhibited a significant degree of binding selectivity at the a5 
subtype in vitro. This observation was in agreement with the previous hypothesis that 
1/A 
correct occupation of the L2 region can promote a5 selectivity of a ligand. Therefore, 
the efficacy of the a5-subtype selective ligand RY-24 24 was evaluated in vitro. 
Recently, it was determined that this ligand was a potent inverse agonist at the a5 
subtype with a much weaker efficacy at the other subtypes (Figure 108). These results 
confirmed previous binding data, which indicated that this ligand was a5-selective due to 
the lipophilic C(8)-substituent which fully occupied the L2 pocket.21 The data were also 
in agreement with previous studies in vivo, which indicated that some of these ligands 
189 enhanced cognition while other Bz BS ligands were not as effective. Furthermore, 
ligands devoid of a lipophilic substituent at the C(8) position showed no selectivity for 
the a5 subtype (Table 30, 28). 
Table 30. Structures and affinities of some a5P3y2-subtype selective ligands. 
CO2R3 
56 DM-I-81, 55 
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Ligand Rs R3 
Kj (nM) 
al a2 a3 a5 a6 
24. RY-24 — -H t-Bu 26.9 26.3 18.7 0.4 5.1 
25, RY-23 —TMS /-Bu 197 143 255 2.61 58.6 
13, RY-80 — -H Et 28.4 21.4 25.8 0.49 28.8 
26, RY-79 —TMS Et 121 142 198 5.0 114 
28 H Et 1.2 2.0 1.1 0.4 >300 
2, DM-I-81 Ph NA >2000 > 2000 >2000 176 >2000 
56, PWZ-029111,190 CI >300 >300 >300 >300 38.8 >300 
PWZ-029 CI 920 ND ND ND 30 ND 
PWZ-029 CI 362.4 180.3 328.2 ND 6.185 ND 
Inspection of the data inTable 30 revealed some observations worth noting. 
While the lipophilic substituent at Rg of RY-24 24 and RY-80 31 decreased the affinity 
for al, a2 and a3 subtypes, it retained affinity for a5 and actually increased affinity for 
the a6 subtype. Furthermore, selective affinity of z'-BZDs at the a5 subtype was 
independent of the occupation of the L3 pocket, as illustrated by the in vitro data of DM-
1-81 2 (Table 25). This data again supports the importance of the occupation of the 
lipophilic pocket L2 for potent selectivity at a5 subtype. However, although 8-pendant 
phenyl of DM-I-81 was lipophilic and bound to the L2 pocket, it was abandoned as a lead 
since its bulk was detrimental to activity and potency was only 176 nm at a5 (weak). 
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Figure 108. Subtype efficacy of RY-24 
As illustrated in Figure 108, dose response curves for RY-24 in oocytes expressed 
different subunit combinations of GABA(A) receptors. Subtype combinations are 
indicated in legends. cRNA-injected Xenopus oocytes were held at -60 mV under two-
electrode voltage clamp. Increasing concentrations of RY-24 were superfused together 
with a GABA concentration eliciting ~ 20% of the maximal current amplitude. RY-24 
was pre-applied for 30 sec before the addition of GABA, which was co-applied with the 
drugs until a peak response was observed. Data were normalized for each curve assuming 
100% for the response in the absence of RY-24. RY-24 was made up and diluted as a 
stock solution in DMSO. Final DMSO concentrations perfusing the oocyte were 0.1%. 
Values are presented as mean ± SD of at least 4 oocytes from at least 2 batches. From 
examination of these data (Figure 108) it was clear RY-24 was a potent inverse agonist at 
a5 subtypes. It was also an inverse agonist at al and a2 subtypes, albeit less potent. 
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This al and a2 inverse agonist efficacy is the reason RY-24 also exhibits proconvulsant 
and convulsant effects in rodents.21-191 
Importantly, however, June et al. recently reported the neurobehavioral results of 
RY-23 and RY-24 in rats. In agreement with previous studies,16 these a5 selective 
ligands were highly selective in suppressing ethanol-maintained responding (Figure 
109).19 192 As previously stated, the hippocampus contains the greatest concentration of 
a5-containing receptors in the CNS,193 and it is possible that these hippocampal a5 
receptors may regulate alcohol-motivated responding following systemic administration 
of an a5-selective agent. Furthermore, RY-24 also antagonized the motor-impairing and 
sedative effects of ethanol in Long-Evans rats. Combined with additional studies within 
the ventral pallidum (VP), it has been proposed that the GABAergic systems within the 
VP and hippocampal pathways may represent new extensions of the mesolimbic ethanol 
reward circuitry. Although these data do not strongly support a direct role for the 
modulatory influences of intrinsic efficacy in the behaviors examined, the synthesis of a5 
subtype selective ligands provides researchers a unique opportunity to explore the role of 
this subtype in the neurobehavioral effects of alcohol which is now in progress by Donna 
Piatt at NERPC with PWZ-029.194 It is clear PWZ-029 reduces alcohol self-
administration in monkeys (Piatt et al., unpublished results). 
Additional behavioral studies of RY-24 were performed by Helmstetter et al. and 
provided further support for the role of the hippocampus in anxiety and learning.191' 192 
Moreover, the data suggested that Bz binding sites within the hippocampus are important 
for the acquisition of fear conditioning. Although this subtype selective ligand has been 
shown to be an inverse agonist at the a5 subtype,191'192 the study suggested that RY-24 
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may act as an agonist at other alpha subtypes because larger doses of RY-24 were not as 
anxiogenic as the smaller doses and resulted in decreased learning. Consistent with the 
studies of Stephens et al. using a5 knock-out mice18 and the efficacy studies of Luddens, 
June and Cook et al.,195' 196 these findings support the concept that the pharmacology 
observed depends upon the dose, behavioral paradigm employed and subunit composition 
activated. Ligands such as RY-24 have proven to be valuable in the study of the 
biochemical and pharmacological properties of GABA(A) receptors and have permitted 
insight into the role this protein plays in anxiety and learning. 
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Figure 109. Suppression of alcohol-motivated responding by RY-24 and RY-23.185 
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On the left panel of Figure 109, the dose-response of ip administration of RY-24 (0.0-
3.5 mg/ kg) and vehicle on responding maintained by ethanol (10 % v/v) (top panel) and 
water (bottom panel) in male Long-Evans rats. On the right, the dose-response of 
unilateral infusions of RY-23 (0.0-40 fxg) into the hippocampus on a concurrent fixed-
ratio (FR4) schedule for ethanol (10 % v/v) (top panel) and saccharin-maintained (0.025 
% v/v) (bottom panel). For both studies, *p < 0.05 versus control condition values was 
determined using ANOVA and post hoc Newman-Keuls test. Each bar represents the 
mean (± SEM) (n = 15 for RY-24 and n- 7 for RY-23).18 It is clear both RY-23 and 
RY-24 reduce alcohol self-administration in rats with very little effect on the saccharin 
control. This has prompted the work on PWZ-029 by Piatt et al. at NERPC since PWZ-
029 is a much more selective and safer a5 ligand (neither proconvulsant nor convulsant). 
QH-II-066 
Due to the pharmacological profile which RY-24 exhibited in vivo, the 
development of additional a5 subtype selective ligands was pursued. Thus, the 7-
acetyleno analog of diazepam, QH-ii-066 29, was synthesized and was determined also to 
exhibit a binding and functional selectivity at the a5 subtype over the al subtype (Table 
26).18 This was due, presumably, to the full occupation of the L2 pocket, relative to 
diazepam (Figure 110). To our knowledge, this was the first agonist ligand to display 
some a5 selectivity from the 1,4-benzodiazepine family. Importantly, the 7-cyano 
congener 30 (Table 31) did not potently bind to recombinant receptors of the a5 subtype, 
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which is in agreement with earlier work of Haefely and Fryer et al. on the SAR of 1,4-
benzodiazepines.361'362 This cyano ligand also did not exhibit any subtype selectivity, re-
emphasizing that occupation of the L2 region with lipophilic groups is important for a5 
selectivity as well as for high affinity. The selective efficacy of this QH-ii-066 ligand 
over the al subtype was demonstrated by reversing the convulsant actions of RY-24 24, 
an a5-selective inverse agonist, in NIH mice.363' 364 This ability was not observed at 
comparable doses for the al-selective agonist Zolpidem 31. The acetyleno group of QH-
ii-066 increased the occupation of the L2 region relative to that of diazepam. 
Figure 110. Comparison of non-selective diazepam (black) with the a5-selective QH-ii-066 (cyan) 
when aligned within the unified pharmacophore/ receptor model. 
Furthermore, Lelas and Cook et al. have recently determined that although QH-ii-
066 had similar affinity for the DS subtypes in rats, it displayed functional selectivity in 
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vivo, with diazepam-like efficacy at the a5 subtype and partial efficacy at the al 
subtype.363 The study also indicated that this 7-acetyleno substituted diazepam analog 
exhibited less potency in protection against ECS-induced seizures relative to diazepam 
than against PTZ-induced seizures. Hence, the al subtype may play a more prominent 
role in ECS-induced seizures than in PTZ-induced seizures.13,365 
Table 31. Structures and affinities of 1,4-benzodiazepines. 
V 
Ligand Rt 
Kj (nM) 
al a2 a3 a5 a6 
32, diazepam CI 14 20 15 11 >3000 
29, QH-ii-066 -H 76.3 42.1 47.4 6.8 >3000 
30 C=N 320 310 350 265 >3000 
224 
Compound development guided by pharmacophore models has led to new agents 
with interesting pharmacological profiles, particularly with enhanced preference for a2 or 
a5 containing Bz GABA(A) receptor subtypes. Based on the evaluation of experimental 
data and comparative models of the aip2y2 GABA(A) receptor, the location of several 
residues relative to the descriptors of the pharmacophore/receptor model has been 
proposed. Absolute assignments were made in part I regarding which amino acids satisfy 
the pharmacophoric descriptors, experimental data strongly indicated definite trends with 
regard to how ligands of varying pharmacological activity are oriented within the 
receptor. Future site directed mutagenesis work needs to confirm these assignments and 
will help improve the a5 model. Information to be immediately gained from this 
proposed orientation can have far reaching benefits, not only for the rational design of 
selective ligands and the interpretation of ligand docking results, but also for the 
identification and evaluation of possible roles certain residues may have within the 
pocket. Structural determination of the a5 GABA(A) receptor is eagerly awaited. It is 
hoped that the proposed orientation may be used by others to gain additional insight into 
the potential mechanisms underlying binding and modulation at the a5 Bz site, all of 
which will lead to a better understanding of the structure and function of this receptor. 
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Affect on Passive Avoidance Learning in Rats of a Modest Inverse Agonist (PWZ-
029) with Functional Selectivity at GABA(A) Receptors Containing a5 Subunits 
It is known that benzodiazepine (BZ) site ligands affect vigilance, anxiety, 
memory processes, muscle tone somnolence and epileptogenic propensity through 
modulation of neurotransmission at GABA(A) receptors containing oti, 0C2, (X3 or as 
subunits, and may have numerous experimental and clinical applications. The ability of 
nonselective BZ site inverse agonists to enhance cognition, documented in animal models 
and human studies, is clinically not feasible due to potentially unacceptable psychomotor 
effects. Most investigations to date have proposed the a] and/or as subunit-containing 
GABA(A) receptors as comprising the memory-modulating population of these 
receptors. The novel ligand PWZ-029, which was synthesized on large scale and 
characterized electrophysiologically, possesses in vitro binding selectivity and moderate 
inverse agonist functional selectivity at cc5-containing GABA(A) receptors. This ligand 
has also been examined in rats in the passive and active avoidance, spontaneous 
locomotor activity, elevated plus maze and grip strength tests, primarily predictive of the 
effects on the memory acquisition, basal locomotor activity, anxiety level and muscle 
tone, respectively. The improvement of task learning was detected at the dose of 5 mg/kg 
in the passive, but not active avoidance test. The inverse agonist PWZ-029 had no effect 
on anxiety or muscle tone, whereas at higher doses (10 and 20 mg/kg) it decreased 
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locomotor activity. This effect was antagonized by flumazenil and also by the lower (but 
not the higher) dose of an agonist (SH-053-R-CH3-2'F) selective for GABA(A) 
receptors containing the as subunit. The hypolocomotor effect of PWZ-029 was not 
antagonized by the antagonist 6-CCt exhibiting a preferential affinity for a i-subunit 
containing receptors. These data suggest that moderate negative modulation at GABA(A) 
receptors containing the a5 subunit is a sufficient condition for eliciting enhanced 
encoding/consolidation of declarative memory, while the influence of higher doses of 
modulators at these receptors on motor activity shows an intricate pattern whose 
relevance and mechanism wait to be defined. 
One desirable property in this regard is the pro-mnesic activity of BZ site inverse 
agonists, repeatedly reported in animal models,13 as well as in human volunteers.49,50- 366 
However, this desirable effect is confounded by different concomitant psychomotor 
effects (increased vigilance, anxiogenic and/or proconvulsant state), some of which have 
been described in memory studies with non-selective inverse agonists in humans, urging 
their early termination of the studies." 367 Point mutated mice could not be used to 
identify the receptor subtypes mediating the promnesic activity of inverse agonists 
because an unexplained switch to the agonist mode of action occurs when an inverse 
agonist at wild type diazepam-sensitive recombinant GABA(A) receptors is tested at the 
respective point-mutated receptors.368 Thus, inverse agonists exerted agonistic-like 
sedative and anticonvulsant effects in mice with the point-mutated al subunits,369 while 
corresponding experiments in models of learning and memory were not performed. 
Nevertheless, behavioral examination of genetically modified animals conducted to date 
has indicated the ai and as subunit-containing GABA(A) receptors comprise the 
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'memory-modulating' population of these receptors.29, 370 371 It is notable that 
GABA(A) receptors containing the a5 subunit are abundantly expressed in the 
hippocampus. the structure substantially involved in memory formation.' Recent 
evidence from animal studies with affinity-selective37"' or efficacy-selective ligands46 has 
confirmed that the a$ subunit was significantly involved in cognition enhancement 
mediated by the negative modulation of GABA(A) receptor functions. Moreover, it was 
shown in humans that pre-treatment with an a5 efficacy-selective inverse agonist 
significantly reduces the amnesic effect of alcohol on learning a word list.334 However, 
the affinity- or efficacy-selectivity of the ligands, as well as the diversity of the 
behavioral tasks used in their characterization to date, were of limited extent, which 
necessitates screening of newer BZ site negative modulatory ligands, to determine the 
putative therapeutic role of such compounds in various disorders with diminished 
cognitive capabilities in humans.374'375 
In this regard, the BZ site ligand PWZ-029 was synthesized (Figure 111) as 
mentioned. Its efficacy profile was examined by two-electrode voltage clamp 
experiments in Xenopus oocytes expressing recombinant GABA(A) receptor subtypes. 
The behavioral effects on adult male Wistar rats were evaluated in the passive and active 
avoidance, spontaneous locomotor activity, elevated plus maze and grip strength tests, 
primarily predictive of detecting the changes in the memory acquisition, basal locomotor 
activity, anxiety level and muscle tone, respectively. 
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Figure 111 . I n  v i t r o  efficacy of PWZ-029 in Xenopus oocytes 
Concentration-effects curve for modulation of GABA elicited currents by PWZ-
029 on Xenopus oocytes expressing GABA(A) receptor subtypes 011P3Y2, (X2P3Y2, 0C3P3Y2, 
and (X5P3Y2 is illustrated in Figure 111. Concentrations of GABA that elicit 3% of the 
maximum GABA-triggered current (EC3) of the respective cells were applied alone and 
with various concentrations of PWZ-029. Control currents represent responses in the 
absence of PWZ-029. Data points represented means ± SEM from 4 oocytes from > 2 
batches. As you can see, l(j.M PWZ-029 resulted in 114±4%, 105±8%, 118±5% and 
80±4% of control current (at GABA EC3) in (X1P3Y2, OC2P3Y2, OC3P3Y2, and (X5P3Y2 receptors, 
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respectively. All these values except the one for (X2P3Y2 receptors were significantly 
different from that of the respective control currents (P<0.01, student's t-test). 
Electrophysiological Experiments 
In vitro data for PWZ-029 (Figure 111b) demonstrated that at concentrations up to 
1 |^M this ligand engendered a significant partial inverse agonist efficacy at the a5-
containing GABA(A) receptors (reduction of control current by 20%), whereas its 
activity at the other three types of receptors tended to be weakly and for al- and a3-
containing receptors significantly in the agonistic direction. Similarly, at 10 }j.M 
concentrations PWZ-029 exhibited a weak but significant partial agonistic effect at al­
and a3-containing receptors. The lower potencies of PWZ-029 for al-, a2- and a3-
subtypes, relative to the a5-containing GABA(A) receptors, deduced from the respective 
efficacy curves, conform with the explicit binding affinity data (Table 27). Hence, PWZ-
029 shows a distinct affinity-, potency-, as well as efficacy- selectivity for the a5-
containing GABA(A) receptors. PWZ-029 exerted negligible activity in 42 other 
receptor and enzyme assays (See Appendix B. Roth et al., NIMH Psychoactive Drug 
Screening Program, UNC, unpublished results, available at 
https://kidbdev.med.unc.edu/pdsp). The in vitro concentration-effect curves for SH-053-
R-CH3-2'F, the ligand used for interaction studies in the locomotor activity test, showed 
it is a high-efficacy agonist at the a5-containing GABA(A) receptors, with very low 
efficacies at al, a2 and a3-containing subtypes;334,375 the profile was comparable with 
that published for its close congener SH-053-R-CH3,368 except for greater potencies and 
a5-efficacy for SH-053-R-CH3-2T than SH-053-R-CH3. 
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Figure 112. The effects of DMCM (0.2 mg/kg) and PWZ-029 (2, 5 and 10 mg/kg) on retention 
performance in a passive-avoidance task (*P<0.05 compared to solvent (SOL) group). Number of 
animals per treatment group: 10. 
Table 32. Table 1. PWZ-029 binding affinity (Ki, nM) at human recombinant GABA(A) receptors 
containing 33, y2 and named a subunit, stably expressed in mouse fibroblast L(tk-) cells* 
al a2 a3 a4 a5 a6 
>300 >300 >300 ND 38.8 >300 
920° ND ND ND 30.0° ND 
362.4 180.3 328.2 ND 6.1 ND 
a Affinity was measured using |3H|flumazenil (for al-, a2-, a3-, and a5-containing recombinant 
receptors), and |3H|Ro 15-4513 (for a6-containing recombinant receptors) as radioligands, according 
to the method described in Huang et al., 1996. ND - not determined. 
Recent binding affinity, based on the radioligand binding assay described in Lameh et al., 2001, 
obtained using the transiently transfected Sf9 insect cell line; data by DeLorey et al., unpublished 
results. 
Passive Avoidance 
The acquisition session latencies did not differ significantly irrespective of the 
treatment administered 15 min before the session (data not shown). The influence of the 
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pre-acquisition treatment on the retention trial latency was significant [H(4) =11.45, 
p=0.022]. Subsequent Dunn's test indicated that DMCM (0.2 mg/kg) and PWZ-029 at 5 
mg/kg, administered before the acquisition session, significantly increased retention 
session latency relative to the control group. 
Active Avoidance 
Figure 120a shows that DMCM (0.1 mg/kg) and PWZ-029 (2-10 mg/kg) did not 
affect acquisition of avoidance responses on the training day [F(4, 35) = 0.19, p=0.98]. 
Retention AA performance on the second day was significantly altered by the treatment 
before the acquisition session [F(4, 35) = 2.82, p=0.039]; however, DMCM (0.1 mg/kg), 
but not the PWZ-029, was effective (Dunnett's test) (Figure 113b). Neither of the motor 
parameters measured (habituation crossings, intertrial crossings) differed significantly on 
the training or testing day (data not shown). 
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Figure 113. The effects of DMCM (0.2 mg/kg) and PWZ-029 (2,5 and 10 mg/kg) on acquisition (a) 
and retention (b) performance in an active-avoidance task (*P<0.05 compared to solvent (SOL) 
group). Number of animals per treatment group: 8. 
Locomotor Activity Assay 
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Whole Chamber-Activity 
An ANOVA showed a significant effect of treatment on total distance travelled 
during 30 min of monitoring (F(4,43) = 4.06, p = 0.007) (Figure 114, whole bars). 
According to Dunnett's test, the two higher doses of PWZ-029 (10 and 20 mg/kg) exerted 
the activity-decreasing effect related to solvent. When the ANOVA with post hoc 
analysis was applied on the 5-min intervals of travelled distance (Figure 115), it turned 
out that locomotor activity was significantly depressed in the time periods 0-10 min 
(DMCM, 2 mg/kg and PWZ-029, 10 and 20 mg/kg), 10-15 min and 20-25 (PWZ-029, 20 
mg/kg). It is notable that in the periods 15-20 min, 20-25 min and 25-30 min the rats 
treated with DMCM (2 mg/kg) travelled on average for 23%, 21% and 96% greater 
distance, respectively, than control animals; the difference did not reach statistical 
significance at either of the periods tested (student's t-test). 
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Figure 114. DMCM (2 mg/kg) and PWZ-029 (5,10 and 20 mg/kg) 
The effects of DMCM (2 mg/kg) and PWZ-029 (5,10 and 20 mg/kg) on distance 
travelled in the central (hatched bars) and peripheral (open bars) zone of the activity 
chamber during 30 min of recording (total activity corresponds to the height of the whole 
bar). *P<0.05 compared to solvent (SOL) group. Number of animals per treatment group 
(Figures 114-115) was 10, except for PWZ-029 (8 rats). 
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Figure 115. The effects of DMCM (2 mg/kg) and PWZ-020 (5,10 and 20 mg/kg) on the distance 
travelled in 5-min intervals in the activity assay. *P<0.05 compared to solvent (SOL) group. 
Central/Peripheral Distance 
An ANOVA showed a significant effect of treatment on distance travelled in the 
arbitrarily set central parts of the chamber during 30 min of monitoring (F(4,43) = 4.35, 
p=0.005) (Figure 114, hatched bars); the effects of PWZ-029 10 and 20 mg/kg were 
statistically significant. According to ANOVA, the influence of treatment on activity in 
peripheral parts of the chamber (Figure 114, open bars) was similar: F(4,43) = 2.91, 
p-0.033; PWZ-029 20 mg/kg significantly decreased activity (Dunnett's test). 
Antagonism of the Effect of PWZ-029 (Figure 116) 
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Both B-CCt (30 mg/kg) and flumazenil (10 mg/kg), the a 1-affinity selective and 
non-selective antagonist of BZ subtypes, respectively, failed to affect on their own the 
total distance travelled in the whole chamber, whereas only flumazenil reversed the 
suppression of locomotion induced by PWZ-029. The a5-selective agonist SH-053-R-
CH3-2T showed a dose-dependent hypolocomotor influence on rats in the spontaneous 
locomotor activity assay, with the effective dose of 30 mg/kg (Savic, Furtmiiller, Cook, 
unpublished data). When combined with PWZ-029 20 mg/kg, the dose of 10 mg/kg, but 
not 20 mg/kg, of SH-053-R-CH3-2T antagonized the effect of the inverse agonist. There 
were no significant differences among groups in distances travelled in the central zone of 
the activity chamber. 
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Figure 116. Antagonism of selected ligands (SH = SH-053-) 
The influence of addition of the antagonists (flumazenil - FLU and fl-CCt -
bCCt) and the agonist SH-053-R-CH3-2T (SH-2'F-R) on the effect of PWZ-029, 
administered with solvent (SOL+PWZ-029), on distance travelled in the central (hatched 
bars) and peripheral (open bars) zone of the activity chamber during 30 minutes of 
recording (total activity corresponds to the height of the whole bar). *p<0.05 compared to 
solvent (SOL+SOL) group. +p<0.05 compared to SOL+PWZ-029 group, student's t-test. 
Number of animals per treatment groups, for SOL+SOL through SH-053-R-CH3-2'F, 
respectively, was: 7, 7, 7, 6, 7, 8, 8. 8. 
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Elevated Plus Maze 
Activity-Related Parameters 
The influence of treatment on closed arm entries (F(4,35) = 0.23, p=0.922), total 
arm entries (F(4,35) = 1.54, p=0.213) and total distance travelled (F(4,35) = 1.44, 
p=0.241) did not reach statistical significance (data not shown). 
Anxiety-Related Parameters (Figure 117) 
The overall influence of treatment on distance travelled in open arms (Figure 
117a) was not significant (F(4,35) = 2.04, p=0.11). There were significant effects of 
treatment on the percentage of open arm entries (F(4,35) = 4.21, p=0.007) (Figure 117b) 
and percentage of time spent on open arms (F(4,35) = 3.13, p=0.026) (Figure 117c). In 
both cases, the effective treatment was DMCM 1.25 mg/kg. 
Figure 117. DMCM and PWZ-029 in open arm experiments 
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The effects of DMCM (1.25 mg/kg) and PWZ-029 (5,10 and 20 mg/kg) on the a) 
distance travelled on open arms, b) percentage of entries in open arms and c) percentage 
of time spent on open arms of the EPM. Number of animals per treatment group was 8 
*P<0.05 compared to solvent (SOL) group. 
Grip Strength Test 
According to ANOVA, the overall influence of treatment on grip strength was not 
significant (F(4,35) = 2.31, p=0.077). The grip strength (mean ± SEM) of rats treated 
with solvent, DMCM 1.25 mg/kg, PWZ-029 5 mg/kg, PWZ-029 10 mg/kg and PWZ-029 
20 mg/kg was 505.0 ± 11.4 g, 561.1 ± 29.3 g, 546.5 ± 42.7 g, 468.0 ± 23.3 g, and 467.2 ± 
27.1 g, respectively. 
The present results demonstrated that PWZ-029, a novel BZ site negative 
modulator possesses in vitro binding selectivity as well as moderate inverse agonist 
functional selectivity for the a5-containing GABA(A) receptors, which has translated 
into the promnesic effect detected in the PA (10 mg/kg), but not AA, learning task in rats. 
It has been shown that the non-selective inverse agonist DMCM enhances retention 
performance when administered at a small dose before the acquisition session of the 
active,376 or passive377 avoidance test, and these findings were replicated as a positive 
control in the present study. The interactions between DMCM and the antagonists 
flumazenil and B-CCt have suggested that the ai-subunit is substantially involved in 
processing of both of these memory tasks, whereas the interactions between agonists 
(midazolam and Zolpidem) and antagonists pointed to the importance of some other a-
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subunit(s), in addition to the ai-subunit, in the passive, but not active avoidance task.49 
378 The latter agrees well with the memory-enhancing effect of the a5-selective 
inverse agonist PWZ-029, a ligand largely inactive at al-containing GABA(A) 
receptors, in the PA task. 
Although seemingly similar, these two tests differ in some important 
characteristics, including the type of memory assessed and the brain regions involved in 
memory processing. Namely, the one-trial step-through PA test assesses declarative 
memory (to the point that terms such as 'declarative' or 'explicit' can be applied to 
rodent experiments),379 and for the retention of the task requires the preserved 
hippocampus.367, 380 On the other hand, the two-way AA test is an implicit, i.e. 
procedural,14 334' 375 hippocampal-independent memory task14. However, as aversively 
motivated tests, both 'measure' memory of emotionally arousing experiences, and 
critically involve activity of the amygdala, especially the basolateral amygdala" 367 in 
which the al subunit is the most abundant of the six a subunits.50'381 It is felt that this 
fact at least in part explains the uniform involvement of the al subunit-containing 
GABA(A) receptors in modulation of memory acquisition, found for the present49 with 
DMCM as well as similar, aversively motivated, memory tasks, such as the water-lick 
37!  suppression test. 
Receptors containing the a5 subunit constitute a modest fraction of BZ-sensitive 
GABA(A) receptors (approximately 5%), but are substantially expressed in several brain 
regions, most notably the hippocampus, the olfactory bulb and layers V and VI of the 
neocortex.382 Studies with untreated mice with the point mutation at the a5 subunit, 
which unexpectedly displayed a partial loss, restricted to the hippocampus, of the 
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expression of this subunit, have indicated the significance of the a5 subunit for learning 
of certain aversively- as well as appetitively- motivated memory tasks which require 
T Q7 
temporal integration. On the other hand, in line with the present findings, mice with 
the deleted a5 subunit did not differ in comparison to the wild-type controls in 
acquisition of the two-way AA task. The results with PWZ-029 in the present memory 
tests suggest that moderate negative modulation of GABA-ergic transmission mediated 
by GABA(A) receptors containing the a5 subunit is a sufficient, but possibly not 
prerequisite condition for eliciting enhanced encoding/consolidation of declarative 
memory assessed by the PA test. 
PWZ-029 had no effect on anxiety-related parameters in the EPM, in agreement 
with results with the other a5-selective inverse agonist tested in this model;385 the a5 
affinity- selective inverse agonist L-655,708 exerted an unusual U-shaped anxiogenic 
effect in the murine EPM. but with the use of a non-standard statistical analysis .385 The 
effect of PWZ-029 on muscle tension measured by the grip strength test also was absent. 
Hence, its hypolocomotor effect seen in the locomotor activity assay could not be 
ascribed to any muscle relaxation. Further, there was no hint of convulsive activity in any 
of the rats treated with PWZ-029 throughout the behavioral studies. This was in 
agreement with Stables et al. (NINDS) that showed PWZ-029 exhibited weak 
anticonvulsant activity as well as Rowlett et al. who showed it was a weak anxiolytic in 
rhesus monkeys (Rowlett, unpublished results). Decreases of locomotor activity may 
also reflect an increase in emotional reactivity, i.e. anxiety. ' However, such an 
activity was not seen with PWZ-029 in the EPM test, nor was its hypolocomotor effect 
disproportionately more pronounced in the central, more exposed, and hence 'emotional', 
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zone of the chamber, but was notably different from standard patterns of activity of a 
nonselective inverse agonist (i.e. DMCM). Namely, as a rule, when rodents explore a 
novel environment under the influence of a negative modulator of GABA(A) receptors, 
locomotor activity is depressed, but usually in a relatively short period of habituation;128 
afterwards, a type of rebound hyperlocomotion may ensue.386- 387 However, as we have 
concluded from the experiment with DMCM and the ai-subunit selective antagonist B-
CCt, hyperlocomotion in habituated animals may depend primarily on the negative 
"7Q"7 "?71 
modulation at al subunit-containing GABA(A) receptors ' " and this was not 
observed with PWZ-029. Instead, the temporal pattern of the extended motor depression 
with PWZ-029 (20 mg/kg) was more similar to activity of an agonist, rather than an 
inverse agonist, and the most parsimonious explanation would be that, at the higher 
doses, PWZ-029 binds to enough al, a2, and a3-containing GABA(A) receptors to 
manifest its slight partial agonistic activity. Nevertheless, the effect of PWZ-029 was 
mediated by BZ site(s) (antagonism of the effect by flumazenil) other than those at the 
a 1-containing GABA(A) receptors (lack of antagonism by B-CCt). Comparative analysis 
of in vitro affinity and efficacy data of flumazenil and B-CCt46 suggests that the principal 
difference between them lies in activity at a5 subunit-containing GABA(A) receptors. 
Namely, flumazenil and B-CCt show qualitatively similar mixed antagonist/agonist 
efficacy profiles, with the main distinction being at a5 subunit-containing GABA(A) 
receptors at which B-CCt is a weak inverse agonist, and flumazenil an antagonist/weak 
agonist. Moreover, a 150-fold lower affinity of B-CCt for the a5 over the al Bz subtype 
of GABA(A) receptors49 should plausibly preclude its in vivo binding at a5 subunit-
containing GABA(A) receptors and influencing any effect mediated by them. Hence, it 
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is hardly conceivable that B-CCt may antagonize the effects of PWZ-029 at these 
receptors. Similarly, the slight positive modulation at a2 or a3 subunit-containing 
GABA(A) receptors, also observed at high doses of PWZ-029, could hardly have 
contributed to its hypolocomotor activity.30'388 
Standard tests of locomotor activity were not usually employed in reported studies 
1QO 
with a5 subunit-selective agents by Merck. Based on the results with three novel BZ 
site agonists functionally silent at the al subunit, we recently set out the hypothesis that 
positive modulation at the GABA(A) receptors containing a5 subunits may also 
contribute to the sedative properties of BZ site agonists.13 The finding that SH-053-R-
CH3-2'F at the lower (10 mg/kg), but not higher dose (20 mg/kg), antagonized the 
hypolocomotor effect of PWZ-029 adds to the notion that there may exist certain 
discontinuous 'effective windows' of the modulation of locomotion exerted by neurons 
expressing the a5-subunit containing GABA(A) receptors. Namely, the maximal level of 
receptor inhibition obtained with PWZ (80% of the basal GABA effects sustained by the 
a5-subunit containing receptors) is clearly different from that present in mice lacking this 
subunit at all (0% of the basal GABA effects at the affected receptors388) or in mice 
harboring a point mutation at the a5 subunits (approximately 70% of the basal GABA 
effects in the hippocampus related to the a5-subunit containing receptors).389 
Nevertheless, the respective locomotor outputs (a decrease with higher doses of PWZ-
029, no changes in knockout mice, stimulation/no changes in mice with a point mutation 
at the a5 subunits) were apparently random in relation to the level of receptor 
modulation, but certainly dependent on the stress level and experimental settings (cf. an 
increase of spontaneous locomotor activity in the mice with point-mutated a5 GABA(A) 
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receptor subunits390 vs. lack of changes391' 392). The present hypothesis of the protean 
influences of the a5-subunit containing receptors on locomotion, possibly related to the 
intricacy of the different processes which are concomitantly modulated by these receptors 
(such as sensorimotor gating334 and firing of the layer V pyramidal neurons of the 
neocortex334), should be checked through various locomotor tests employing a range of 
doses of different a5 subunit-selective ligands, both as single treatments and in 
combination. It is well known that a5 BzR/GABAergic subtypes are located in the 
dorsal horn of the spinal cord and may be the neurons responsible for any hypolocomotor 
activity of PWZ-029. 
Examination of the present results suggests that the negative modulation 
engendered by the novel BZ site ligand PWZ-029, which demonstrates binding and 
functional selectivity for the a5-containing GABA(A) receptors, may be sufficient to 
effect enhanced formation of declarative memory. The sedative-like effects, seen at doses 
higher than those affecting memory formation, reduce the probability of generation of 
anxiogenic or proconvulsant states. This is important and greatly enhances the clinical 
potential of these a5 subtype selective negative modulators (inverse agonists). The 
molecular and neuronal substrates in regard to the role of a5-subunit containing 
GABA(A) receptors in control of vigilance, including the proposed phenomenon of the 
'on/off switch', may be numerous and wait to be further elucidated. In regard to PWZ-
029 it is important to note that neither Stables (NINDS, anticonvulsant activity) nor 
Rowlett (Rhesus monkeys, anxiolytic) reported any loss of locomotor activity in their 
strains/species of animals. 
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Experimental Procedure 
Drugs 
PWZ-029 (methyl (8-chloro~5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a] 
[1,4] benzodiazepin-3-yl)methyl ether), SH-053-R-CH3-2T (the (R) stereoisomer of 8-
ethynyl-6-(2-fluorophenyl)-4-methyl-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic 
acid ethyl ester) and the preferential ai-subunit selective antagonist B-carboline-3-
carboxylate-t-butyl ester (B-CCt) were synthesized in Milwaukee. The non-selective 
antagonist flumazenil was donated from F. Hoffman-La Roche (Basel, Switzerland) and 
the non-selective inverse agonist DMCM was purchased from Research Biochemicals 
Incorporated (Natick, MA, USA). 
Electrophysiological Experiments (with Sieghart et al.) 
The cloning of GABA(A) receptor subunits al, p3 and y2 into pCDM8 
expression vectors (Invitrogen, CA) has been described elsewhere.393 The cDNAs for 
subunits a2, a3 and a5 were gifts from P. Malherbe and were subcloned into pCI-vector. 
After linearizing the cDNA vectors with appropriate restriction endonucleases, capped 
transcripts were produced using the mMessage mMachine T7 transcription kit (Ambion, 
TX). The capped transcripts were polyadenylated using yeast poly(A) polymerase (USB, 
OH) and were diluted and stored in diethylpyrocarbonate-treated water at -70°C. 
The methods used for isolating, culturing, injecting and defolliculating of the oocytes 
were identical as described previously. 11 Briefly, mature female Xenopus laevis (Nasco, 
WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-aminobenzoate, 
Sigma, MO) before decapitation and removal of the frogs ovary. Stage 5 to 6 oocytes 
with the follicle cell layer around them were singled out of the ovary using a platinum 
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wire loop. Oocytes were stored and incubated at 18°C in modified Barths' Medium (MB. 
containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM NaHC03, 1 mM KC1, 
0.82 mM MgSC>4, 0.41 mM CaCh, 0.34 mM Ca(N03)2) that was supplemented with 100 
U/mL penicillin and 100 ng/mL streptomycin. Oocytes with follicle cell layers still 
around them were injected with a total of 2.25 ng of cRNA. cRNA ratio used was 1:1:5 
for the a subunits, p3 and y2, respectively. After injection of cRNA, oocytes were 
incubated for at least 36 hours before the enveloping follicle cell layers were removed. 
To this end, oocytes were incubated for 20 minutes at 37°C in MB that contained 1 
mg/mL collagenase type IA and 0.1 mg/mL trypsin inhibitor I-S (both Sigma). This was 
followed by osmotic shrinkage of the oocytes in doubly concentrated MB medium 
supplied with 4 mM Na-EGTA and manually removing of the follicle cell layer. After 
peeling off the follicle cell layer, the cells were allowed to recover overnight before being 
used in the electrophysiological experiments. 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath 
of Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 
7.4), 1 mM MgCh, 1 mM KC1 and 1 mM CaCh) The oocytes were constantly washed by 
a flow of 6 mL/min XR which could be switched to XR containing GABA and/or drugs. 
Drugs were diluted into XR from DMSO-solutions resulting in a final concentration of 
0.1 % DMSO perfusing the oocytes. Drugs were preapplied for 30 seconds before the 
addition of GABA, which was coapplied with the drugs until a peak response was 
observed. Between two applications, oocytes were washed in XR for up to 15 minutes to 
ensure full recovery from desensitization. For current measurements the oocytes were 
impaled with two microelectrodes (2-3 mQ) which were filled with 2 mM KC1. All 
recordings were performed at room temperature at a holding potential of -60 mV using a 
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Warner OC-725C two-electrode voltage clamp (Warner Instruments, Hamden, CT). Data 
were digitised, recorded and measured using a Digidata 1322A data acquisition system 
(Axon Instruments, Union City, CA). Results of concentration response experiments 
were graphed using GraphPad Prism 4.00 (GraphPad Software, San Diego. CA). Data 
were graphed as mean ± SEM of at least four oocytes from at least two batches. 
Behavioral Experiments (with Savic et al.) 
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, 
Serbia), weighing 220-250 g. All procedures in the study conformed to EEC Directive 
86/609 and were approved by the Ethical Committee on Animal Experimentation of the 
Medical Faculty in Belgrade. The rats were housed in transparent plastic cages, six 
animals per cage, and had free access to pelleted food and tap water. The temperature of 
the animal room was 22±1°C, the relative humidity 40-70%, the illumination 120 lux, and 
the 12/12 h light/dark period (light on at 6:00 h). All handling and testing took place 
during the light phase of the diurnal cycle. Throughout the study the animals were used 
only once, with the exception of the grip strength measurement, which was done 
immediately after the tracking of behavior on the elevated plus maze. Spontaneous 
locomotor activity and elevated plus maze behavior were analyzed by the ANY-maze 
Video Tracking System software (Stoelting Co., Wood Dale, IL, USA). All drugs were 
dissolved/suspended with the aid of sonication in a solvent containing 85% distilled 
water, 14% propylene glycol, and 1% Tween 80, and were administered intraperitoneally 
in a volume of 1 mL/kg, 15 min before behavioral testing (for active and passive 
avoidance test, before the acquisition session). Time of administration, as well as the 
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doses of DMCM in various tests were chosen based on our previous studies (Savic et al., 
2005a; 2005b; 2006). For interaction studies in the locomotor activity assay, the first 
treatment indicated in combination was administered into the lower left quadrant of the 
peritoneum 20 minutes before testing, and the second treatment 5 minutes later into the 
lower right quadrant of the peritoneum. 
Passive Avoidance (PA) Paradigm 
The experiments were performed in an adapted Automatic reflex conditioner 
(Ugo Basile, Milan, Italy, Model 7051), as described earlier.394 In short, the apparatus 
consisted of a shuttle-box, equipped with a grid floor and divided with a sliding door into 
a lit and a dark compartment, and a programming unit. The animals were submitted to 
two, 24 hour - separated sessions. The acquisition session started by placing individual 
subjects in the illuminated compartment. After 30 seconds, the entrance to the dark 
compartment was opened, and as soon as the rat had entered it with all four paws, the 
footshock (2 s, 0.3 mA) was delivered. Immediately afterwards, the rat was returned to its 
home cage. The same procedure was repeated 24 hours later (retention session), without 
footshock. A cut-off time of 180 seconds was used on the training day, whereas, on the 
retention trial, a ceiling of 300 seconds was imposed. 
Two-Way Active Avoidance (AA) Paradigm (with Savic et al.) 
The AA test was performed in automated two-way shuttle-boxes (Campden 
Instruments, Sileby, UK), as described earlier.395 In short, the animals were submitted to 
two, 24-hour separated sessions. Training and test sessions were procedurally identical. 
Animals were placed singly into the shuttle box and left to freely explore for 15 minutes, 
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and habituation crossings were automatically counted. Afterward, they received 30 tone 
foot shock trials. During the first 5 seconds of each trial, a sound signal was presented 
(broadband noise of 69 dB), allowing the animal to avoid shocks by moving to the other 
compartment (avoidance response). If the animal did not respond within this period, a 
foot shock of 0.5 mA (7-s duration) was applied. Crossing to the adjacent compartment 
during the shock discontinued its delivery. The animal could move freely in the apparatus 
between trials (18-s intertrial intervals), and the intertrial crossings were automatically 
counted. 
Measurement of Locomotor Activity (with Savic et al.) 
Activity of single rats in a clear Plexiglas chamber (40 x 25 x 35 cm) under dim 
red light (20 lux) was recorded for a total of 30 minutes, without any habituation period, 
using ANY-maze software (as described above). For purposes of improving data 
analysis, the central 20% of the chamber (200 cm ) was virtually set as a central zone. 
The minimum percentage of animal that must have been in the zone for an entry to occur 
was set at 70%, and 50% of the animal must have remained in the zone for an exit not to 
occur. 
Behavior on the Elevated Plus Maze (EPM) (with Savic et al.) 
The apparatus consisted of two open (50 x 10 cm, with a ledge of 0.3 cm) and two 
enclosed arms (50 x 10 x 40 cm), connected by a junction area (10 x 10 cm). The 
illumination in the experimental room was 10 lux on the surface of the arms. At the 
beginning of the experiment, single rats were placed in the center of the maze, facing one 
of the enclosed arms, and their behavior was recorded for 5 min. An entry into an open or 
closed arm was scored when 90% of the animal crossed the virtual line separating the 
central square of the maze from the arm, whereas an exit occurred when more than 90 % 
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of the animal left the respective arm. After each trial, the maze was cleaned with dry and 
wet towels. 
Grip Strength Test (with Savic et al.) 
Muscle strength was assessed by the grip strength meter (Ugo Basile, Milan, Italy, 
model 47105). When pulled by the tail, the rat grasps the trapeze connected to a force 
transducer, and the apparatus measures the peak force of experimenter's pull (in g) 
necessary to overcome the strength of the animal's forelimbs grip. Each animal was given 
three consecutive trials, and the median value was used for further statistics. 
Statistical Analysis 
All numerical data presented in the figures were given as the mean ± SEM, except 
for results from the PA test (median latency with 25th, 75th interquartile range; data were 
non-parametric because the procedure involved a cut-off). For electrophysiological data 
Student's t-test was used for statistical analysis. Data from PA test were assessed by a 
Kruskal-Wallis non-parametric ANOVA, with post-hoc comparison relative to solvent 
control by a Dunn's test (a=0.05). Data from the AA, EPM, grip strength and activity 
assay were assessed by a one-way ANOVA. If the ANOVA was significant, each 
treatment condition was compared with control by a Dunnett's test (a=0.05). Where 
appropriate, the assessment of the antagonist influence on the inverse agonist effect was 
conducted by a student's t-test. Statistical analyses were performed with ANY-maze 
Video Tracking System software (Stoelting Co., Wood Dale, IL, USA) and SigmaStat 2.0 
(SPSS, Inc., Chicago, IL, USA). 
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Sedative Influence of a5 Benzodiazepine Site Agonists or Stereotypical Behavior? 
Genetic studies suggest that modulation at the oi| subunit contributes to much of 
the adverse effects of BZs, most notably sedation, ataxia and amnesia. Hence, BZ site 
ligands functionally inactive at GABA(A) receptors containing the ai subunit are 
considered to be promising leads for novel, anxioselective anxiolytics, devoid of sedative 
properties. In pursuing this approach, three compounds were examined 
electrophysiologically to determine the behavioral properties. They were shown to be 
functionally selective for 0C2, 0C3 and as-containing subtypes of GABA(A) receptors (SH-
053-S-CH3 and SH-053-S-CH3-2T), or essentially selective for as subtypes (SH-053-R-
CH3). Possible influences on motor function were tested in the elevated plus maze, 
spontaneous locomotor activity and rotarod test, which are considered primarily 
predictive of the anxiolytic, sedative and ataxic influence of BZs, respectively. The 
results confirmed the substantially diminished ataxic potential of BZ site agonists devoid 
of ai subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of SH-
053-S-CH3 and SH-053-S-CH3-2T. However, all three ligands, dosed at 30 mg/kg, 
decreased spontaneous locomotor activity, suggesting that sedation may be partly 
dependent on activity mediated by as-containing GABA(A) receptors. As mentioned 
previously, a small amount of a5 subtypes are found in the spinal cord consistent with 
this hypothesis. Hence, it could be of importance to avoid substantial agonist 
potentiation of as-subunits by candidate anxioselective anxiolytics, if clinical sedation is 
to be avoided. 
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The basic characterization of the diverse pharmacological effects of BZs: 
anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsive and amnesic, has been 
considered to represent one of the major successes of behavioural pharmacology.14- 48~386 
3%. 397 jn recent years much effort has been expended to improve the understanding of the 
molecular and neuronal substrates of these effects, with the final goal to clinically 
separate desired from unwanted side effects.48 Among the latter effects, psychomotor and 
cognitive impairment is common, and more serious neuropsychiatric reactions such as 
amnesic and aggressive episodes may occur.135 BZs act as allosteric modulators of fast 
inhibitory neurotransmission in the mammalian brain mediated through GABA(A) 
receptors, which are involved in the regulation of vigilance, anxiety, sleep, muscle 
tension, epileptogenic activity, and memory functions.47" m 387' 398 It has been 
postulated that the four BZ site-building a-subunits, with their distinct patterns of 
anatomical distribution in the brain, differently participate in the various effects of BZs. 
Indeed, recent genetic and pharmacological studies pointed to the specific contribution of 
individual receptor subtypes to the spectrum of behavioral actions of BZ site ligands. 
Specifically, sedative effects of BZs were principally attributed to ai-containing 
GABA(A) receptor subtypes, anxiolytic actions to the a2/a3-containing receptors, 
anterograde amnesic effects to the ai/015-subtypes, anticonvulsant activity partially to the 
a 1-containing receptors, and muscle relaxant effects largely due to effects through o.t 
containing receptors, as previously mentioned.338, 399 Moreover, it appears that L-
838,417, a ligand with zero efficacy at the ai-subtype, is unable to engender sedation in 
rodents47, 387 or monkeys,20' 48 and similar conclusions were drawn from behavioral 
experiments with other compounds functionally selective for receptors other than ar 
254 
containing receptors such as XHe-II-053 and Hz-166 sythesized in Milwaukee and 
characterized in rhesus monkeys by Rowlett et al.51 Since the ai-subunit is critically 
involved in much of the unwanted psychomotor activity of nonselective BZs, "ai-
neutral" agonists at BZ site are being pursued in the quest for anxioselective 
anxiolytics.52 
To date, all apparently non-sedating BZ site ligands, which are devoid of activity 
at a i-containing GABA(A) receptors, engendered essentially antagonist49, 50 or only 
7 7 "2 
partial agonist efficacy at as-containing GABA(A) receptors. Therefore, it cannot be 
ruled out that substantial efficacy at as-containing GABA(A) receptors may contribute 
to sedative effects. This is supported by data which indicate the possibility of substantial 
motor influence by modulation of a5 subunit-containing GABA(A) receptors. In the 
spinal cord, somatic and preganglionic motoneurons (lamina IX and lateral cell column) 
exhibited a moderate to strong staining for the a5 subunit.14 48 Knock-in mice with the 
GABA(A) receptor a5 subunit rendered insensitive to diazepam were refractory to 
development of tolerance to the sedative effects of diazepam dosed subchronically.48 400 
These two sets of evidence indicate that the motor influence of a5-GABA(A) receptor 
modulation, if present, is not necessarily an indirect consequence of the established 
effects on learning and memory processes.401 Hence, any activity changes seen with 
ligands possessing a substantial agonistic efficacy for a5 subunit-containing GABA(A) 
receptors may be, at least partly, mediated by such receptors. 
To test this hypothesis, we have performed the in vitro efficacy measurements and 
also compared behavioral profiles of three BZ site ligands, functionally selective for a2, 
a3 and a$ subtypes of GABA(A) receptors (SH-053-S-CH3 and SH-053-S-CH3-2T), or 
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essentially selective for the a5 subtypes (SH-053-R-CH3). with that of the classical 
nonselective agonist diazepam. Possible influences on motor function were tested in the 
elevated plus maze (EPM), spontaneous locomotor activity (SLA) and rotarod test, that 
are considered primarily predictive of the anxiolytic, sedative and ataxic influence of 
BZs, respectively. 
Drugs 
SH-053-S-CH3 and SH-053-R-CH3 (the (S) and (R) stereoisomer, respectively, 
of 8-ethynyl-4-methyl-6-phenyl-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid 
ethyl ester; structures given in Figure 125), as well as SH-053-S-CH3-2T (the (S) 
stereoisomer of 8-ethynyl-6- (2-fluorophenyl)-4-methyl- 4H-2,5,10b- triaza-benzo [e] 
azulene-3-carboxylic acid ethyl ester) were synthesized in Milwaukee. Diazepam for 
behavioral studies was obtained from Galenika (Belgrade, Serbia). 
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Figure 118. Structures and conformations of SH-053-S-CH3 (A1-A3) and SH-053-R-CH3 (B1-B3) in 
the included volume of the pharmacophore receptor model for the a.2 subtype. 
The molecular modeling was carried out as described in Part I. 
Rotarod Performance 
Rotarod test (Ugo Basile, Comerio, Italy) measured the capacity of the animal to 
maintain itself on the rod revolving 10 rpm. During two consecutive days, the rats were 
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trained to walk on the revolving rod until they could complete three 180 s sessions (each 
day) without falling off. In the morning of the third day, the final selection was made. 
Only animals capable of remaining 180 s on the rod, without any fall, were chosen for 
further testing. Those animals without capability to meet the same criterion when tested 
20 minutes after treatment were considered incapacitated. 
Statistical Analysis 
All numerical data presented in the figures were given as the mean ± SEM. Data 
from the EPM and activity assay were assessed by a one-way ANOVA. If the ANOVA 
was significant, each treatment condition was compared with control by a Dunnett's test 
(a=0.05). ED50 value for rotarod incapacitation was calculated by probit analysis 
according to the method of Litchfield and Wilcoxon. Statistical analyses were performed 
with ANY-maze Video Tracking System software (Stoelting Co., Wood Dale, IL, USA). 
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Results 
In vitro data for SH-053-S-CH3 (Figure 119A) and SH-053-R-CH3 (Figure 119B) 
demonstrated that at concentrations up to 1 (iM both ligands are high-efficacy agonists at 
the a5-containing GABA(A) receptors, with very low efficacies at al containing 
subtypes. However, while SH-053-S-CH3 exerted substantial potentiation of an EC3 
GAB A response at a2 and a3-containing GABA(A) receptors, the influence of SH-053-
R-CH3 at these receptors was comparable to its minor effect at the al subtype (cf. 
molecular modeling in Figure 118). The in vitro concentration-effects curves for SH-053-
S-CH3-2'F393 were similar to those for SH-053-S-CH3, but with the higher magnitude of 
efficacies at the respective a2, a3 and a5 GABA(A) receptor subtypes in the 
concentration range 0.1-10 |iM as expected from earlier work from Haefley, Fryer and 
Milwaukee. 
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Figure 119. Illustrated here are the concentration-effects curves for SH-053-S-
CH3 (A) and SH-053-R-CH3 (B) on aip3y2, a2P3y2, a3p3y2, and a5p3y2 
GABA(A) receptors, using an EC3 CABA concentration. Data points represent 
means ± SEM from at least 4 oocytes from > 2 batches. 
Elevated Plus Maze 
SH-053-S-CH3 
Activity-related parameters (Figure 120) 
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The influence of treatment on closed arm entries did not reach statistical 
significance (F(4,27) = 1.19, p=0.337) (Figure 120a), neither statistical analysis by 
ANOVA showed a significant effect of treatment on total arm entries (F(4,27) = 1.72, 
p=0.175) (Figure 120b) or total distance travelled (F(4,27) = 1.80, p=0.157) (Figure 
120c). 
Distance travelled (m) Total entries 
Closed entries 
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Illustrated in Figure 120, the effects of diazepam (1.25 mg/kg) and SH-053-S-CH3 (10, 
20 and 30 mg/kg) on the a) closed arm entries, b) total arm entries and c) total distance 
travelled in the EPM. *P<0.05 compared to solvent (SOL) group. Number of animals per 
treatment (Figures 127- 128), for SOL through SH-053- S-CH3 30 mg/kg, respectively): 
6, 6, 5, 6, 6. 
Anxiety-Related Parameters (Figure 121) 
There was a close to significant effect of treatment on distance travelled in the 
open arms (F(4,27) = 2.37, p=0.078) (Fig. 121a). The overall influence of treatment on 
the percentage of open arm entries has reached statistical significance (F(4,27) = 3.13, 
p=0.031) (Fig. 121b), Dunnett's test pointed to the anxiolytic influence of diazepam 
(p=0.038) and SH-053-S-CH3 dosed at 30 mg/kg (p=0.049). The influence on the 
percentage of time on open arms also was significant (F(4,27) = 2.75, p=0.049) (Figure 
121c), but post hoc testing did not detect significant effect of any single treatment. 
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Figure 121. Illustrated here are the effects of diazepam (1.25 mg/kg) and SH-053-S-CH3 (10, 20 and 
30 mg/kg) on the a) distance travelled on open arms, b) percentage of entries in open arms and c) 
percentage of time spent on open arms of the EPM. *P<0.05 compared to solvent (SOL) group. 
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SH-053-S-CH3-2T 
Activity-related parameters (Figure 122) 
Statistical evaluation by ANOVA did not show significant influences of treatment 
on closed arm entries (Figure 122a), total arm entries (Figure 122b) or total distance 
travelled (Figure 122c) [(F(4,45) = 1.29, p=0.290), (F(4,45) = 0.13, p=0.969) and 
(F(4,45) = 0.25, p=0.911), respectively]. 
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Figure 122. Illustrated here are the effects of diazepam (1.25 mg/kg) and SH-053-S-CH3-2'F (10,20 
and 30 mg/kg, designated as S-CH3-2'F) on the a) closed arm entries, b) total arm entries and c) total 
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distance travelled in the EPM. Number of animals per treatment (Figure 120-121, for SOL through 
SH-053-S-CH3-2T 30 mg/kg) was 10 
Anxiety-related parameters (Figure 123) 
While the influence of treatment on distance travelled in open arms was 
not significant (F(4,45) = 1.92, p=0.124) (Figure 123a), the overall effect on the 
percentage of open arm entries (Figure 123b) and the percentage of time on open arms 
(Figure 123c) has reached statistical significance [(F(4,45) = 2.94, p=0.031) and (F(4,45) 
= 2.92, p=0.031), respectively]. For both of these parameters, post hoc testing revealed 
the equivalent influence of diazepam and SH-053-S-CH3 dosed at 30 mg/kg (p values 
0.018 for the percentage of open arm entries and 0.017 for the percentage of time on open 
arms). 
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Figure 123. Illustrated here are the effects of diazepam (1.25 mg/kg) and SH-053-S-CH3-2'F (10, 20 
and 30 mg/kg, designated as S-CH3-2'F) on the a) distance travelled on open arms, b) percentage of 
entries in open arms and c) percentage of time spent on open arms of the EPM 
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SH-053-R-CH3 
When tested at doses up to 30 mg/kg, SH-053-R-CH3 failed to induce any significant 
change of the measured EPM parameters (data not shown). It was not anxiolytic. 
Motor Activity Assay 
An ANOVA in whole chamber-activity showed a significant effect of treatment 
on total distance travelled during 45 min of monitoring (F(4,31) = 3.86, p=0.000) (Figure 
131, whole bars). According to Dunnett's test, the activity-decreasing effect of all four 
tested compounds (diazepam 1.25 mg/kg, SH-053-S-CH3, SH-053-S-CH3-2T and SH-
053-R-CH3 at 30 mg/kg each) appeared to be significant related to solvent. When the 
ANOVA of travelled distance was developed into 5-min intervals (Figure 132), it turned 
out that a significant depression of locomotion was effective in the time period 5-20 min 
(SH-053-S-CH3 (30 mg/kg), SH-053-S-CH3-2T (30 mg/kg) and SH-053-R-CH3 (30 
mg/kg)), whereas diazepam 1.25 mg/kg decreased locomotion in the period 5-15 minutes. 
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Figure 124. Whole chamber activity 
The effects of diazepam (1.25 mg/kg), SH-053-S-CH3 (30 mg/kg), SH-053-S-CH3-2T 
(30 mg/kg, designated as SH-053-S-2T) and SH-053-R-CH3 (30 mg/kg) on distance 
travelled in the central (hatched bars) and peripheral (open bars) zone of the activity 
chamber during 45 minutes of recording (total activity corresponds to the height of the 
whole bar). *P<0.05 compared to solvent (SOL) group. Number of animals per treatment 
group (Figures 124-125) for SOL through SH-053-S-CH3-2'F 30 mg/kg was 8, and 4 for 
SH-053-R-CH3. Since the P-value was less than 0.05, the null hypothesis can be rejected 
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and the results are statistically significant. 
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Figure 125. Distance travelled in activity 
In Figure 125, the effects of diazepam (1.25 mg/kg), SH-053-S-CH3 (30 mg/kg), SH-
053-S-CH3-2'F (30 mg/kg) and SH-053-R-CH3 (30 mg/kg) on the distance travelled in 
5-min intervals in the activity assay. *P<0.05 compared to solvent (SOL) group; 
Central/Peripheral Distance 
An ANOVA showed a significant effect of treatment on distance travelled in the 
arbitrarily set central parts of the chamber during 45 min of monitoring (F(4,31) = 2.73, 
p=0.047) (Figure 124, hatched bars). The respective p values for diazepam 1.25 mg/kg, 
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SH-053-S-CH3 30 mg/kg, SH-053-S-CH3-2T 30 mg/kg and SH-053-R-CH3 30 mg/kg 
were 0.491, 0.029, 0.067 and 0.207, related to solvent. According to ANOVA, the 
influence of treatment on activity in peripheral parts of the chamber (Figure 124, open 
bars) was more distinct: F(4,31) = 3.59, p=0.016; all the four treatments significantly 
decreased activity when related to control by Dunnett's test. 
Rotarod Test 
When one monitors the influence on rotarod performance as a quantal 
phenomenon (i.e. all or none effect), the minimal incapacitating doses of SH-053-S-CH3 
and SH-053-S-CH3-2'F were 200 mg/kg for both substances. The median incapacitating 
doses of diazepam, SH-053-S-CH3 and SH-053-S-CH3-2T were 2.99 mg/kg, 213.67 
mg/kg and 218.80 mg/kg, respectively. Due to the shortage of substance, the median 
incapacitating dose of SH-053-R-CH3 was not found; at doses up to 100 mg/kg it did not 
induce any manifest incapacitation in this test. 
Discussion 
The present experiments demonstrated the anxiolytic potential of two newly-
synthesized compounds functionally selective for a2, a3 and a5-containing GABA(A) 
receptors, SH-053-S-CH3 and SH-053-S-CH3-2T, which are mainly devoid of ataxic, 
but not of sedative actions characteristic of nonselective BZs. Furthermore, a 
stereoisomer of SH-053-S-CH3 functionally selective for GABA(A) receptors 
containing the a5-subunit, SH-053-R-CH3, exerted in the locomotor activity paradigm a 
significant hypolocomotor effect comparable to diazepam, without observable anti­
anxiety or ataxic activity in the EPM and rotarod test, respectively. 
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These findings were somewhat unexpected, since both, motor incoordination and 
sedation have been ascribed to the al-subunit - mediated action of diazepam.402 Hence, 
either these three compounds were not silent at the a 1-subtype when dosed at 30 mg/kg, 
or some non-al subunits contribute to the hypolocomotor action of BZ site agonists. 
Although the absence of occupancy data for distinct receptor subtypes precludes drawing 
firm conclusions, high minimal incapacitating doses of the present functionally selective 
ligands in the rotarod test could be seen as indirect evidence for lack of involvement of 
GABA(A) receptors containing the ai-subunit in behavioral actions of 30 mg/kg doses. 
Namely, diazepam-induced loss of motor coordination in the rotarod test was linked to 
the al-subunit,403 and the sevenfold differences in effective doses of SH-053-S-CH3 and 
SH-053-S-CH3-2T in rotarod vs. SLA test could hardly exist if substantial modulation at 
al-subunit containing GABA(A) receptors were attained already at 30 mg/kg. However, 
there may exist marked differences in fractional occupancy of GABA(A) receptors 
containing the ai-subunit needed for producing behavioral effects of a BZ site agonist in 
these two tests, meaning that low to moderate modulation at such receptors is sufficient 
for eliciting sedative, but not rotarod incapacitating action.404 Nevertheless, the latter 
explanation is not highly probable for the ligands tested had very low efficacies at al 
containing subtypes. Namely, even the preferential al subunit-selective agonist, 
Zolpidem, does not possess more than 4.3 and 2.5 times greater potency to decrease 
locomotor activity compared to rotarod impairment in rats and mice, respectively,399 
whereas non-subtype-selective agonists, such as diazepam, may be even more potent in 
exerting rotarod impairment than locomotor hypoactivity 405 
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In its broadest sense, sedation involves decreased psychomotor and cognitive 
performance, and in most instances it is considered an adverse effect of psychotropic 
drugs, which should be avoided. In animals, the psychomotor component is most 
frequently studied, and measurement of motor activity in rodents represents a standard 
behavioral assay for testing the sedative potential of drugs.403" 404 In fact, sensitivity of 
preclinical tests for discerning the sedative potential of a drug is of paramount 
importance; several BZ site partial agonists developed as putative low-sedating 
anxiolytics have nevertheless appeared to be incapacitating when subsequently tested in 
humans.407 In support of the sensitivity of the standard SLA test used in the present 
study, Dailly20'387" 408'409 observed a sedative effect of diazepam (1 mg/kg i.p.) in the 
actimeter, but not in the light-dark test of anxiety, which also measured locomotor 
activity of mice. In accordance, SH-053-S-CH3, SH-053-2T-S-CH3 and SH-053-R-CH3, 
all dosed at 30 mg/kg, exerted a statistically significant depression of locomotion in the 
SLA test in our study, while the influence on the standard activity parameters in the EPM 
(closed arm entries and total distance travelled), if any, was far from significant. It should 
be emphasized that the hypolocomotor influence in the SLA test is also evident when 
separately analyzing activity in the peripheral zone of the chamber. Hence, the observed 
motor depressant effects of the ligands tested were not dependent on central zone activity, 
which is confounded by influences on emotional reactivity, i.e. anxiety, and could be 
seen as a pure measure of sedation 409 These results further support the routine use of the 
•507 
SLA test in efforts to predict clinical sedation. 
On the other hand, it is noticeable that standard studies of motor activity, which 
form the very basis of knowledge of drug effects on behavior,410 were not employed for 
characterization of recently reported putative anxioselective agents.410 Jennings reported 
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on an a2/a3 BZ site selective ligand from the class of imidazo[l,2-b][l,2,4]triazines with 
anxiolytic activity in the rat EPM test at the dose of 1 mg/kg, which showed no motor 
incapacitation in the mouse rotarod test at doses up to 30 mg/kg. A close congener of that 
compound was anxiolytic in the rat EPM test at 3 mg/kg, whereas it showed no 
significant activity in a surrogate assay of sedation (chain-pulling test in rats) and in the 
mouse rotarod test when tested in doses up to 10 mg/kg; reportedly, this compound was 
chosen as a clinical candidate.49'50 Similarly, a l,2,4-triazolo[4,3-b]pyridazine, TPA023, 
exerted anxiolytic-like activity in the rat EPM and fear potentiated startle tests at the dose 
of 1 mg/kg as well as in the assay of conditioned suppression of drinking at 3 mg/kg, 
whereas, at doses up to 30 mg/kg, it did not significantly affect behavior of rats in the 
chain pulling test nor rotarod performance of mice.51 However, the same experimental 
group, when testing pagoclone, detected sedative action of this BZ site agonist dosed at 1 
mg/kg in the chain-pulling test, while already at 0.3 mg/kg in the SLA test.52 The very 
high dose (10 mg/kg) of diazepam used as the active control in the chain-pulling test53 
additionally supports the view of superior sensitivity of the standard SLA test. 
From these reasons, it was difficult to compare behavioral profiles of the 
compounds described in the present dissertation with findings from the above cited 
studies. Evidently, all three newly-synthesized BZ site ligands could have acted through 
the as subtype-containing GABA(A) receptors, one of them (SH-053-R-CH3) as an 
essentially subtype-selective ligand. There exist data that support the possibility of 
substantial motor manifestations of a5-containing GABA(A) receptor modulation, 
besides the indirect consequences brought on by the effects on learning and memory 
processes, where pertinent.396 Somatic and preganglionic motoneurons in the spinal cord 
exhibit a moderate to strong staining for the a5 subunit,21 whereas the knock-in mice 
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harboring the a5 subunit insensitive to diazepam are refractory to development of 
tolerance to the sedative effect of diazepam dosed subchronically, presumably due to a 
down regulation of a5 subunits in the dentate gyrus.396 Hence, we hypothesize that any 
locomotor activity changes induced by ligands possessing a substantial a5-efficacy may 
be. at least partly, contributed by modulation at GABA(A) receptors containing this 
subunit. Nevertheless, as a caveat to all studies examining sedation, it should be 
remembered that a decrease in automatically measured locomotor activity can be due to a 
variety of causes other than sedation, including the occurrence of stereotyped behavior, 
•27-5 
motor impairments or pain. In addition, particular caution is needed when transposing 
in vitro data to the in vivo conditions. Atack reported on a substantial decrease of the 
TQ7 
a5 subtype-binding selectivity of the BZ site inverse agonist RY-080 when binding 
was t e s t e d  i n  v i v o ;  s i n c e  R Y - 0 8 0  e x e r t e d  a p p r e c i a b l e  i n v e r s e  a g o n i s t  e f f i c a c y  a t  t h e  a l -
containing GABA(A) receptors,399 interpretation of behavioral actions of such 
functionally-nonselective ligands is especially hindered. To dissect these overlaps in 
activity und uncertainties, much is expected from screening of newer BZ site ligands in 
the future, which will be still more functionally selective than those presented in this 
work. 
The present results confirm the highly diminished ataxic potential of BZ site 
agonists devoid of ai subunit-mediated effects. Anti-anxiety activity of such ligands 
remains preserved, whereas the confounding sedation stays observable, and may be partly 
dependent on the as-containing GABA(A) receptors. Hence, it could be of importance to 
avoid substantial potentiation through the as-subunits by the candidate anxioselective 
anxiolytics, if the clinical sedation is to be prevented. However, it is important to note 
that Fisher, Rowlett et al.4li have recently shown that SH-053-2T-S-CH3 is a 
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nonsedating anxiolytic in rhesus monkeys even dosed to 10 mg/kg while SH-053-2T-R-
CH3 exerted anxiolytic activity only at much higher doses.412 In fact Rowlett et al. have 
shown that in the light-dark box paradigm that SH-053-S-CH3 is a weak but nonsedating 
anxiolytic while the R-enantiomer (SH-053-R-CH3) is devoid of activity at the doses 
tested (Rowlett et al, unpublished results). 
Behavioral Effects Due to Differences in Activity at al Plus a5 Versus a2 Plus a3 
Subunits 
The affinity and efficacy of four recently-synthesized BZ site ligands: SH-053-
2'N, SH-053-S-CH3-2T, SH-053-R-CH3-2T and JY-XHe-053 were assessed. They 
were also studied in behavioral tests of spontaneous locomotor activity, elevated plus 
maze, and water maze in rats, which are considered predictive of, respectively, the 
sedative, anxiolytic, and amnesic influence of BZs. The novel ligands had moderately 
low to low affinity and mild to partial agonistic efficacy at GABA(A) receptors 
containing the ai subunit, with variable, but more pronounced efficacy at other BZ-
sensitive binding sites. While presumably ai receptor-mediated sedative effects of 
GABA(A) modulation were not fully eliminated with any of the ligands tested, only SH-
053-2TM and SH-053-S-CH3-2T, both dosed at 30 mg/kg, exerted anxiolytic effects. The 
lack of clear anxiolytic-like activity of JY-XHe-053, despite its efficacy at 012- and (X3-
GABA(A) receptors, may have been partly connected with its preferential affinity at a5-
GABA(A) receptors coupled with weak agonist activity at ai-containing subtypes. Any 
sedative activity in JY-XHe-053 would have covered up the anxiolytic activity. The 
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memory impairment in the water-maze experiments, generally reported with BZ site 
agonists, was completely circumvented with all four ligands. The results suggest that a 
substantial amount of activity at ai GABA(A) receptors is required for effecting spatial 
learning and memory impairments, while much weaker activity at aj- and a5-GABA(A) 
receptors is sufficient for eliciting sedation. 
As stated previously, the sedative and ataxic effects of BZs have been attributed 
to a i-containing GABA(A) receptor subtypes, anxiolytic actions to the a2/a3-containing 
receptors, anterograde amnesic effects to the a|/a5-subtypes, anticonvulsant activity, in 
part, to all the containing receptors, muscle relaxant effects largely to a2-
subtypes, and tolerance to sedative effects to the coupling of al receptors to as-
containing receptors.413 If the concept holds true, an ideal anxioselective anxiolytic, 
selectively acting through a2/a3-containing receptors, would be devoid of sedative, 
ataxic, amnesic and tolerance adverse effects. However, despite the notable successes of 
the studies of several research groups published to date,414 including the encouraging 
safety records for an a2/(X3-subtype selective partial modulator in healthy volunteers,415 it 
appears the ultimate goal of translating breakthroughs in preclinical research into new 
clinical therapies is still far from realization. An exception to this may be HZ-166. The 
awareness that a similar conclusion may apply to the whole field of pharmacological 
modulation of central nervous system disorders46'221416 calls for rethinking the clear-cut 
hypotheses on receptor subtypes and their roles. In this vein, it is interesting to note that 
some newer BZ binding-site agonists, such as ocinaplon417,418 and DOV 5 1 892,397 were 
reportedly devoid of overt sedative effects, despite the fact that they did not display 
compelling subtype selectivity for any of the GABA(A) receptor subtypes.419 
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In pursuit of the approach of pharmacological testing of four subtypes of BZ-
sensitive GABA(A) receptors to further elucidate their native role, a series of BZ site 
ligands, presumably inactive/low-activity at a\-containing GABA(A) receptors was 
recently synthesized. Specific portions of the characterization of six of them, with code 
names SH-053-S-CH3, SH-053-R-CH3, SH-053-2TS1, JY-XHe-053, SH-053-S-CH3-2T 
and SH-053-R-CH3-2T, have been already published.420 The affinity and efficacy data 
of four of these ligands: SH-053-2'N, SH-053-S-CH3-2T, SH-053-R-CH3-2T and JY-
XHe-053, as well as their behavioral actions in the tests of spontaneous locomotor 
activity, elevated plus maze and water maze, which are considered primarily predictive of 
the sedative, anxiolytic, and amnesic influence of BZs, respectively, will be described. 
Diazepam, a standard non-selective positive allosteric modulator, and Zolpidem, a 
moderately ai-subtype selective positive modulator,390 were used as reference ligands, 
where applicable. The aim of the study was to elucidate whether the expected subtle 
affinity and efficacy differences at four BZ-sensitive GABA(A) receptor subtypes 
among the tested BZ-site modulators reflect themselves in dissimilarities in behavioral 
responses of Wistar rats, with possible implications for further research. Concurrently, 
the data were to be compared with findings from the knock-in approach269- 391 as well as 
with results from classical studies in the same behavioral tests, investigating antagonism 
of the effects of non-selective positive modulators (diazepam or midazolam) with the 
preferential ai-subunit affinity-selective antagonist, B-CCt.46,335 419 
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Drugs 
The SH-053-2(8-ethynyl-6-(2'-pyrydine)-4H-2,5,10b-triaza-benzo[e]azulene-
3-carboxylic acid ethyl ester), SH-053-S-CH3-2T and SH-053-R-CH3-2T (the (S) and 
(R) stereoisomer, respectively, of 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-2,5,10b-
triaza-benzo[e]azulene-3-carboxylic acid ethyl ester), as well as JY-XHe-053 (8-ethynyl-
6-(2-fluorophenyl)-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester) 
were synthesized. Zolpidem for behavioral studies was purchased from Toronto 
Research Chemicals (North York, Canada), and diazepam was obtained from Galenika 
(Belgrade, Serbia). 
Competition Binding Assays 
Competition binding assays were performed in a total volume of 0.5 mL at 4 °C 
"2 
for 1 hour using [ H] flunitrazepam as the radiolabeled ligand. A total of 6|ig of cloned 
human GABA(A) receptor DNA containing the desired a subtype along with 02 and y2 
subunits were used for transfecting the HEK 293T cell line using Fugene 6 (Roche 
Diagnostic) transfecting reagent. Cells were harvested 48 hrs after transfection, washed 
with Tris-HCl buffer (pH 7.0) and Tris Acetate buffer (pH 7.4) and the pellets which 
resulted were stored at -80°C until assayed. On the day of the assay, pellets containing 
20-50 f-ig of GABA(A) receptor protein were resuspended in (50 mM Tris-acetate buffer, 
pH 7.4 at 4°C) and incubated with the radiolabel as previously described.46, 221' 335 
Nonspecific binding was defined as radioactivity bound in the presence of 100 JJ.M 
diazepam and represented less than 20% of total binding. Membranes were harvested 
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with a Brandel cell harvester followed by three ice-cold washes onto polyethyleneimine-
pretreated (0.3%) Whatman GF/C filters. Filters were dried overnight and then soaked in 
Ecoscint A liquid scintillation cocktail (National Diagnostics; Atlanta, GA). Bound 
radioactivity was quantified by liquid scintillation counting. Membrane protein 
concentrations were determined using an assay kit from Bio-Rad (Hercules, CA) with 
bovine serum albumin as the standard. 
Electrophysiological Experiments (with Sieghart et al.) 
The cloning of rat GABA(A) receptor subunits al, P3 and y2 into pCDM8 
expression vectors (Invitrogen, CA) has been described elsewhere.46 The rat cDNAs for 
subunits al, a3 and a5 were gifts from P. Malherbe and were subcloned into pCI-vector. 
After linearizing the cDNA vectors with appropriate restriction endonucleases, capped 
transcripts were produced using the mMachine T7 transcription kit (Ambion, TX). The 
capped transcripts were polyadenylated using yeast poly(A) polymerase (USB, OH) and 
were diluted and stored in diethylpyrocarbonate-treated water at -70°C. 
The methods used for isolating, culturing, injecting and defolliculating of the oocytes 
were identical as described previously.46 Briefly, mature female Xenopus laevis (Nasco, 
WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-aminobenzoate, 
Sigma, MO) before decapitation and removal of the frogs ovary. Stage 5 to 6 oocytes 
with the follicle cell layer around them were singled out of the ovary using a platinum 
wire loop. Oocytes were stored and incubated at 18°C in modified Barths' Medium (MB, 
containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM NaHC03, 1 mM KC1. 
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0.82 mM MgSC>4, 0.41 mM CaCb. 0.34 mM Ca(N03)2) with 100 U/mL penicillin and 
100 [ig/mL streptomycin. Oocytes with follicle cell layers still around them were injected 
with a total of 2.25 ng of cRNA. The cRNA ratio used was 1:1:5 for the a, P3 and y2 
subunits, respectively. After injection of cRNA, oocytes were incubated for at least 36 
hours before the enveloping follicle cell layers were removed. To this end, oocytes were 
incubated for 20 minutes at 37°C in MB that contained 1 mg/mL collagenase type IA and 
0.1 mg/mL trypsin inhibitor I-S (both Sigma). This was followed by osmotic shrinkage of 
the oocytes in doubly concentrated MB medium supplied with 4 mM Na-EGTA and 
manually removing of the follicle cell layer. After peeling off the follicle cell layer, the 
cells were allowed to recover overnight before being used in electrophysiological 
experiments. 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath 
of Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 
7.4), 1 mM MgCb, 1 mM KC1 and 1 mM CaC^). The oocytes were constantly washed by 
a flow of 6 mL/min XR which could be switched to XR containing GABA and/or drugs. 
Drugs were diluted into XR from DMSO solutions which resulted in a final concentration 
of 0.1 % DMSO perfusing the oocytes. Drugs were preapplied for 30 seconds before the 
addition of GABA, which was coapplied with the drugs until a peak response was 
observed. Between two applications, oocytes were washed in XR for up to 15 min to 
ensure full recovery from desensitization. For current measurements the oocytes were 
impaled with two microelectrodes (2-3 mQ) which were filled with 2 mM KC1. All 
recordings were performed at room temperature at a holding potential of -60 mV using a 
Warner OC-725C two-electrode voltage clamp (Warner Instruments, Hamden, CT). Data 
were digitised, recorded and measured using a Digidata 1322A data acquisition system 
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(Axon Instruments, Union City. CA). Results of concentration response experiments 
were graphed using GraphPad Prism 4.00 (GraphPad Software, San Diego, CA). Data 
were graphed as mean ± SEM of at least four oocytes from at least two batches. 
Behavioral Experiments (with Savic et al.) 
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, 
Serbia), weighing 220-250 g. All procedures in the study conformed to EEC Directive 
86/609 and were approved by the Ethical Committee on Animal Experimentation of the 
Faculty of Pharmacy in Belgrade. The rats were housed in transparent plastic cages, six 
animals per cage, and had free access to food pellets and tap water. The temperature of 
the animal room was 22±1°C, the relative humidity 40-70%, the illumination 120 lux, and 
the 12/12 h light/dark period (light on at 6:00 h). All handling and testing took place 
during the light phase of the diurnal cycle. Separate groups of animals were used for three 
behavioral paradigms. Care was taken to counterbalance the test order across treatment 
conditions. The differences in treatments in individual paradigms (vide infra) are related 
to the fact that some pertinent parts of experiments have been done previously.421 The 
behavior was recorded by a ceiling-mounted camera and analyzed by the ANY-maze 
Video Tracking System software (Stoelting Co.. Wood Dale, IL, USA). The drugs were 
dissolved/suspended with the aid of sonication in a solvent containing 85% distilled 
water, 14% propylene glycol, and 1% Tween 80, and were administered intraperitoneally 
in a volume of 2 ml/kg, 20 min before behavioral testing. The selection of dose ranges 
and the injection-test interval was based on previous experiments,422 as well as on 
284 
observations in preliminary experiments, avoiding, where applicable, testing of lower 
doses in case of lack of the expected behavioral effect at a higher dose. 
Measurement of Locomotor Activity 
Twenty minutes after receiving the appropriate treatment, single rats were placed 
in a clear Plexiglas chamber (40 x 25 x 35 cm). Activity under dim red light (20 lux) was 
recorded for a total of 30 or 45 minutes, without any habituation period, using ANY-
maze software. Besides the total distance traveled, behavior was analyzed by dividing the 
locomotor activity data into 5-minute bins. For purposes of improving data analysis, the 
central 20% of the chamber (200 cm2) was virtually set as a central zone. An entry into a 
zone was counted when 70% of the animal's body had crossed the zone border. An exit 
from the zone was counted when more than 50% of the animal's body had left the zone. 
Three experiments were performed. In the first study, locomotor influences of SH-053-
2'N, dosed at 30 mg/kg, were assessed in comparison with diazepam at 1.25 and 2.5 
mg/kg. In the second experiment, the dose response curve for JY-XHe-053 (0; 2.5; 5; 10; 
20 and 40 mg/kg), and in the third, for SH-053-R-CH3-2T (0; 10; 20 and 30 mg/kg, in 
comparison with 2 mg/kg diazepam), were determined. The characterisation of SH-053-
S-CH3-2T in this test has been published previously.422 
Behavior in the Elevated Plus Maze 
The apparatus was constructed of sheet metal, with a black rubber floor. It 
consisted of a maze elevated to a height of 50 cm with two open (50 x 10 cm) and two 
enclosed arms (50 x 10 x 40 cm), connected by a junction area (central platform) 
measured 10 x 10 cm. A ledge of sheet metal (0.3 cm high) surrounding the open arms 
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was added. The illumination in the experimental room consisted of one red neon tube 
fixed on the ceiling, giving light intensity of 10 lux on the surface of the closed arms. At 
the beginning of the experiment, single rats were placed in the center of the maze, facing 
one of the enclosed arms, and their behavior was recorded for 5 minutes. An entry into an 
open or closed arm was scored when 90% of the animal crossed the virtual line 
separating the central square of the maze from the arm, whereas an exit occurred when 
more than 90% of the animal left the respective arm. After each trial, the maze was 
cleaned with dry and wet towels. 
Three experiments were performed, in which the dose response curves for SH-
053-2^ (0; 10; 20 and 30 mg/kg, in comparison with 1.25 mg/kg diazepam), JY-XHe-
053 (0; 2.5; 5; 10; 20 and 40 mg/kg), and SH-053-R-CH3-2'F (0; 10; 20 and 30 mg/kg) 
were determined. The characterisation of SH-053-S-CH3-2T in this test has been 
221 published previously. 
Behavior in the Morris Water Maze 
The water maze consisted of a black cylindrical pool (diameter: 200 cm, height: 
60 cm), with a uniform inner surface. The pool was filled to a height of 30 cm with 23°C 
(±1°C) water. The escape platform made of black plastic (15x10 cm) was submerged 2 
cm below the water surface. The platform was made invisible to rats by having it painted 
the same color as the pool wall.423 424 There were many distal cues in the testing room 
(doors, pipes on the walls and the ceiling, cupboards). An indirect illumination in the 
experimental room was provided by white neon tubes fixed on the walls near the pool. 
The rats received the appropriate treatment 20 minutes before a swimming block, each 
day for 5 consecutive days of spatial acquisition. Each block consisted of 4 trials, lasting 
a maximum time of 120 seconds, the intertrial interval being 60 seconds. For each trial 
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the rat was placed in the water facing the pool at one of four pseudorandomly determined 
starting positions. As during spatial learning the platform was hidden in the middle of the 
NE quadrant, the four distal start locations were chosen: S, W, NW and SE. Once the rat 
found and mounted the escape, it was permitted to remain on the platform for 15 seconds. 
The rat was guided to the platform by the experimenter if it did not locate the escape 
within 120 seconds. To assess the long-term spatial memory at the end of learning, a 
probe trial for 60 seconds, with the platform omitted, was given 24 hours after the last 
acquisition day. The probe trial, starting from the novel, most distant SW location, was 
performed without any pre-treatment. The tracking software virtually divided the pool 
into four quadrants, three concentric annuli and a target region consisting of the 
intersection of the platform quadrant and the platform (middle) annulus, as graphically 
represented in Savic et al., 2009. The central annulus was set up to 10% of the whole 
area; the platform annulus equaled 40%, whereas the area of the peripheral annulus was 
50% of the whole. 
Dependent variables chosen for tracking during the acquisition trials were: latency 
to platform (time from start to goal), total distance swam (path length), average swim 
speed and path efficiency (the ratio of the shortest possible path length to actual path 
length). All these indices are, to a lesser or greater degree, related to goal-directed 
behavior, i.e. spatial learning.221 As thigmotaxis (the tendency to swim or float near the 
pool wall) represents a factor which accounts for much of the variance in the water maze 
performance, and normally weakens during consecutive trials,46 we quantified the 
persistence of the thigmotaxis in the target (NE) quadrant. The loss of thigmotaxis is 
related to the procedural component of acquisition, and the percent of the distance swam 
in the target region (away from the wall) of the target quadrant may be seen as a measure 
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of procedural learning. The indices of memory, assessed during the probe trial, included 
the distance and time in the platform (target) quadrant, platform ring and target region, as 
well as the number of entries and distance swam in the area where the platform used to be 
during training. In addition, the distance swam during 60 seconds in the probe trial was 
taken as a measure of overall activity, while peripheral ring parameters (distance and 
time) were connected to the thigmotaxic behavior. 
Three experiments in the water maze were performed. In the first study, the dose 
response curve for the al selective agonist Zolpidem (0; 0.5; 1 and 2 mg/kg) was found. 
In the second experiment, water-maze activity of SH-053-2TM, SH-053-S-CH3-2T and 
SH-053-R-CH3-2T, all dosed at 30 mg/kg, was assessed. Finally, the influence of JY-
XHe-053 (0; 5; 20 and 40 mg/kg) on the water-maze behavior was determined. From 
earlier oocyte data from Sieghart et al., it was clear JY-XHe-053 exhibited slightly more 
agonist efficacy at al than did 81-1-053-2^ and SH-053-S-CH3-2T. 
Statistical Analysis 
All numerical data presented in the Figures were given as the mean ± SEM. For 
electrophysiological data Student's t-test was used. Data sets were checked for 
homogeneity of variance and normality prior to analysis by a one-way ANOVA (the 
activity assay and elevated plus maze), or a two-way ANOVA with repeated measures 
(the water maze test). Where applicable, Student-Newman-Keuls or Dunnett's test (post 
hoc comparisons) and analysis of covariance were also used. Statistical analyses were 
performed with ANY-maze Video Tracking System software (Stoelting Co., Wood Dale, 
IL, USA) and SigmaStat 2.0 (SPSS, Inc., Chicago, IL, USA). 
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Competition Binding Assays 
In vitro binding data for SH-053-2'N, SH-053-S-CH3-2T, SH-053-R-CH3-2T 
and JY-XHe-053. in parallel with those for diazepam and Zolpidem, are presented in 
Table 33. Broadly speaking, these ligands were binding at biologically relevant 
nanomolar to micromolar affinity to the BZ-sensitive recombinant human GABA(A) 
receptors, while were devoid of binding and activity in approximately 40 other receptor 
and enzyme assays (NIMH Psychoactive Drug Screening Program, UNC, available at 
https://kidbdev.med.unc.edu/pdsp). No major selectivity in binding at one over the other 
receptors was noticed (JY-XHe-053 was the most selective ligand, with approximately 
18-fold selectivity for GABA(A) receptors containing the 0C5 subunit, while Zolpidem 
exerted an approximately 5-fold selectivity for ai-GABA(A) receptors). It is of interest 
that none of the novel ligands had a relatively high affinity for the ai-containing 
receptors (once more, the highest a \-subtype affinity, the Kj of 22 nM, was possessed by 
JY-XHe-053). 
Table 33. Binding affinity at axp3y2 GABA(A) /BZ site subtypes. Measurements were made in 
duplicate. K; values are reported in nM. 
Compound al al a3 a4 a5 a6 
diazepam 14 7.8 13.9 NDa 13.4 NDa 
Zolpidem 29.6 160 380 NDa 10000 NDa 
SH-053-2'N 300 160 527 ND° 82 5000 
SH-053-2'Nc 118 148 365 5000 77 5000 
SH-053-R-CH3-2'F 759.1 948.2 768.8 NDfi 95.2 ND" 
SH-053-S-CH3-2'F 468.2 33.3 291.5 ND° 19.2 5000 
JY-XHe-053 22 12.3 34.9 ND" 0.7 ND" 
*ND, not determined 
b Binding at a4 and a6 subtypes have not been determined, but since the 6-phenyl group is present, the ligand will 
not bind to a4 and a6 subtypes 
cThe second independent set of experiments with SH-053-2'N 
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Electrophysiological Experiments 
The in vitro concentration-effect curves for the four novel ligands, in parallel with 
those for Zolpidem and diazepam, are presented in Figure 126, together with explicit data 
on percent potentiation of a within- and between- day stable EC3 GABA response at rat 
recombinant GABA(A) receptors. The efficacy data for 81-1-053-2^ and JY-XHe-053 
have been recently published,425'426 and all data are shown here together for comparison 
purposes. All four novel ligands exerted the lowest positive modulation at ai-containing 
subtypes of receptors relative to efficacy at the other subtypes. In regard to the other three 
receptor subtypes, the greatest separation of activity was noticed with SH-053-R-CH3-
2'F, which shows relatively low efficacies at (X2 and (X3, in addition to the ai -containing 
GABA(A) receptors. The other ligands exerted substantial potentiation of an EC3 GABA 
response at a.2 and ci3-containing receptors. At 100 nM concentration, which lies well in 
the range of typical brain levels of BZ site ligands achievable in vivo,335 this potentiation 
was slightly above (SH-053-2'N and JY-XHe-053) or slightly below (SH-053-S-CH3-
2'F) that one elicited through the as-containing subtypes. 
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Figure 126. Illustrated here are the concentration-effect curves for diazepam, Zolpidem, SH-053-2'N, 
SH-053-S-CH3-2'F SH-053-R-CH3-2'F and JY-XHe-053 on aip3y2 (•), ct2p3y2 (A), a3p3y2 (•), and 
a5p3y2 (•) GABA(A) receptors, using an EC3 GABA concentration. Data points represent means 
±SEM from at least four oocytes from > 2 batches. 
As explained in the Results Section, the efficacy data for SH-053-21N and JY-
XHe-053 have been published recently by Rivas.46 A concentration of 100 nM of 
diazepam resulted in 246 ± 16%, 400 ± 22%, 461 ± 34%, and 322 ± 7% of control current 
in al(33y2, a2p3y2, a3p3y2, and a5p3y2 GABA(A) receptors, respectively. A 
concentration of 100 nM of Zolpidem resulted in 180±14%, 132±4%, 121±3%, and non­
significant changes relative to control current in aip3y2, a2p3y2, a3p3y2, and a5p3y2 
GABA(A) receptors, respectively. A concentration of 100 nM of SH-053-2'N resulted in 
113 ± 2%, 165 ± 2%, 149 ± 3%, and 130 ± 3% of control current in aip3y2, a2p3y2, 
a3p3y2, and a5p3y2 GABA(A) receptors, respectively. A concentration of 100 nM of 
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SH-053-S-CH3-2T resulted in non-significant changes relative to control current at 
alp3y2, and 169 ± 5%, 138 ± 5%, and 218 ± 4% of control current in a2(33y2, a3p3y2, 
and a5p3y2 GABA(A) receptors, respectively. The effect of 1 |JM of SH-053-S-CH3-
2'F at aXpbyl receptors was significant relative to control (164 ± 6%). A concentration of 
100 nM of SH-053-R-CH3-2T resulted in 111 ± 2%, 124 ± 9%, 125 ± 8%, and 183 ± 7% 
of control current in alp3y2, a2p3y2, a3p3y2, and a5P3y2 GABA(A) receptors, 
respectively. A concentration of 100 nM of JY-XHe-053 resulted in 169 ± 10%, 307 ± 
14%, 345 ± 26%, and 220 ± 2% of control current in aip3y2, a2p3y2, a3p3y2, and 
a5p3y2 GABA(A) receptors, respectively. All values given were significantly different 
from the respective control currents (p <0.01, student's t-test). 
Results 
Motor Activity Assay 
In the experiment with 1.25 and 2.5 mg/kg diazepam and 30 mg/kg SH-053-2rN. 
ANOVA showed a significant effect of treatment on total distance travelled during 45 
min of monitoring (F(3,27) = 8.33, p<0.001) (Figure 127, graph al). According to 
Dunnett's test, the activity-depressing effect of all three treatments was significant 
compared with solvent control. The effect was more pronounced in the peripheral zone 
(F(3,27) = 8.56, p<0.001), than in the central zone (F(3,27) = 4.11, p=0.016). When the 
analysis of distance travelled was developed into 5-minute bins (Figure 127, graph bl), it 
turned out that hypolocomotion was significant during the first 20 minutes of monitoring, 
and again in the period 30-35 min, the effect of 30 mg/kg 81-1-053-2^ being somewhere 
in the middle between the effects of two tested doses of diazepam. 
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Figure 127. Illustrated here are the effects of diazepam (DZP 1.25 and 2.5 mg/kg) and SH-053-2'N 30 
mg/kg (left graphs, al and bl), JY-XHe-053 (2.5, 5, 10, 20 and 40 mg/kg) (middle graphs, a2 and b2) 
and DZP 2 mg/kg and SH-053-R-CH3-2 'F (10, 20 and 30 mg/kg) (right graphs, a3 and b3) on 
distance travelled in the central (hatched bars) and peripheral (open bars) zone of the activity 
chamber during 45 or 30 minute of recording (total activity corresponds to the height of the whole 
bar) (upper graphs, al, a2 and a3) as well as on distance travelled in 5-minute intervals (lower 
graphs, bl, b2 and b3). *,** and ***, P<0.05; 0.01 and 0.001, respectively, compared to solvent (SOL) 
group in each of three experiments. Numbers of animals per treatment group for consecutive groups 
on each of panels were 8,8,7,8 (left); 8,6, 6,8, 8,6 (middle) and 7, 5, 7,8,8 (right). 
The dose-response study with JY-XHe-053 showed a significant effect on total 
locomotor activity during 30 minutes of recording (F(5,36) = 2.85, p=0.029) (Figure 127, 
graph a2). The effective doses of JY-XHe-053 were 10 and 40 mg/kg. The effect on 
central zone activity was not discernible, while statistical analysis of peripheral zone 
distance revealed that the three higher doses of JY-XHe-053 were significantly different 
from control (not shown). The analysis of 5-min bins showed that during the first 5 min 
of recording the effect of JY-XHe-053 at 20 and 40 mg/kg was significant (Figure 127, 
graph b2). 
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In the third experiment, an ANOVA for total distance was also significant 
(F(4,30) = 4.50, p=0.006) (Figure 127, graph a3). According to Dunnett's test. 30 mg/kg 
of SH-053-R-CH3-2T, besides 2 mg/kg diazepam, significantly depressed locomotion. 
Notably, central zone activity was affected more profoundly (F(4,30) = 4.27, p-0.007) 
than peripheral locomotion (F(4,30) = 3.74, p=0.014), and SH-053-R-CH3-2T at 20 and 
30 mg/kg decreased central, but not peripheral locomotion. The analysis of 5-minute bins 
(Figure 134, graph b3) revealed that SH-053-R-CH3-2'F did not significantly decrease 
locomotion in neither of 6 intervals of recording, far different from diazepam (2 mg/kg), 
which induced overt sedation during the first 10 min of recording. 
A recent study with SH-053-S-CH3-2'F at 30 mg/kg has shown a significant 
decrease of locomotor activity, which was significantly depressed in the time period 5-20 
minutes, and only in the peripheral, but not central, zone. 
Elevated Plus Maze 
In regard to influence of SH-053-2'N on activity-related parameters (Figure 128) 
in the plus maze, the effect of treatment on closed arm entries did not reach statistical 
significance (F(4,24) = 2.73, p=0.053) (Figure 128a). However, statistical analysis by 
ANOVA showed a significant effect of treatment on total arm entries (F(4,24) = 5.10, 
p=0.004). Dunnett's test revealed the significant effect of the two higher doses of SH-
053-2^ in comparison to solvent group (p=0.020 and 0.048, respectively, Figure 128b). 
In regard to the total distance travelled, ANOVA pointed to the significant effect of 
treatment (F(4,24) = 3.85, p^O.015); however, post hoc test showed that neither of the 
doses tested was highly different in comparison to the solvent group (Figure 128c). 
Distance travelled imi Total entries Closed entries 
to 
sO 4^ 
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Figure 128. Illustrated here are the effects of diazepam (DZP 1.25 mg/kg) and SH-053-2'N (10, 20 
and 30 mg/kg) on the a) closed arm entries, b) total arm entries and c) total distance travelled in the 
EPM. *P<0.05 compared to solvent (SOL) group. Number of animals per treatment group (Figure 
131-132, for SOL through SH-053-2'N 30 mg/kg, respectively): 6,6, 5, 6, 6. 
The influence of 811-053-27^ on anxiety-related parameters was presented in 
Figure 129. There was a significant effect of treatment on distance travelled in the open 
arms (F(4,24) = 4.45, p=0.008) (Figure 129a); Dunnett's test showed that the influence of 
diazepam as a positive control was close to significant (p=0.071 related to control). 
Although the overall influence of treatment on the percentage of open arm entries had 
reached statistical significance (F(4,24) = 2.89, p=0.044) (Figure 129b), neither of the 
single doses was significant on its own (post hoc test). The influence on the percentage of 
time on open arms was significant (F(4,24) = 5.04, p=0.004) (Figure 129c), with SH-053-
2TM at 30 mg/kg being an effective treatment (p = 0.045, Dunnett's test). Because the 
parameter of total entries could not be seen as a relatively pure index of locomotor 
activity, i.e. sedation,419 an analysis of covariance in the anxiety-related parameters using 
the number of total arm entries as covariate was not necessary.399 However, we opted to 
conduct a new analysis of anxiety-related parameters, without data for diazepam as 
positive control. This revealed the preserved significance of effects of SH-053-2TM on the 
percentage of open arm entries and the percentage of time spent in open arms when an 
analysis of covariance was performed using the number of closed arm entries as covariate 
(respective F values: [F(3,18) = 3.276, p=0.045)] and [F(3,18) = 6.027, p-0.005]). This 
indicates that the anxiolytic-like effects of SFl-053-2'N were not directly related with a 
trend of hypolocomotion in rats treated with this ligand. 
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Figure 129. Illustrated here are the effects of diazepam (1.25 mg/kg) and SH-053-2'N (10,20 and 30 
mg/kg) on the a) distance travelled on open arms, b) percentage of entries in open arms and c) 
percentage of time spent on open arms of the EPM. *P<0.05 compared to solvent (SOL) group. 
JY-XHe-053, administered in a wide range of doses, was devoid of significant 
behavioral activity in the elevated plus maze, when analyzed both, general activity (data 
not shown) and anxiety-related parameters. In the Figure 130 are presented changes 
under this treatment of three anxiety-related parameters: distance in open arms (Figure 
130a), percent of open arm entries (Figure 130b) and percent of time spent in the open 
arms (Figure 130c). Despite a hint of an inverted U-shape activity and behavioral 
disinhibition at 5 mg/kg, discernible changes in behavior were lacking. 
Distance m op«n amis <m> Time ori opon afnii % Open dfn^ entries 
t-j 
sO 
00 
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Figure 130. Illustrated here are the influences of JY-XHe-053 (0; 2.5; 5; 10; 20 and 40 mg/kg) on the 
a) distance traveled on open arms, b) percentage of entries in open arms and c) percentage of time 
spent on open arms of the EPIM. Number of animals per treatment group (for SOL through JY-XHe-
053 40 mg/kg) was 7. 
The SH-053-R-CH3-2T in doses up to 30 mg/kg was completely devoid of 
changes of general activity- or anxiety-related parameters in the elevated plus maze, and 
hence this set of data was not presented. 
Our recent study with SH-053-S-CH3-2T has shown a significant effect of the 30 
mg/kg dose on the percentage of open arm entries and the percentage of time in the open 
arms, without concomitant effects on general activity-related parameters.46"48' 387"409 
Morris Water Maze 
For the dose response study of Zolpidem, the factors, treatment and days, but not 
the interaction treatment x days, were statistically highly significant for the latency to 
find the platform (treatment effect, F(3,l 24) = 21.01, p< 0.001; day effect, F(4,496) = 
42.87, p< 0.001; and treatment x day interaction, F( 12,496) = 1.31, p = 0.209) (shown in 
Figure 131), the distance swam before finding the platform (treatment effect, F(3,124) = 
4.71, p = 0.004; day effect, F(4,496) = 32.48, p< 0.001; and treatment x day interaction, 
F(12,496) = 1.21, p = 0.270), average swim speed (treatment effect, F(3,124) = 18.08, p< 
0.001; day effect, F(4,496) = 10.95, p< 0.001; and treatment x day interaction, F( 12,496) 
= 1.57, p = 0.097) and path efficiency (treatment effect, F(3,124) = 7.75, p< 0.001; day 
effect, F(4,496) = 23.68, p< 0.001; and treatment x day interaction, F(12,496) = 1.68, p = 
0.067). It is worth noting that maximum speed was also significantly different among 
treatments, but in such a counterintuitive way that zolpidem-treated animals tended to 
swim the faster (in the maximum) the higher the dose of Zolpidem was applied (data not 
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shown). Significant differences among treatments during training days, obtained by one­
way ANOVA applied to that day's latency to find the platform, are presented in Figure 
131a. The results of the post hoc analysis of overall influence for the factor treatment are 
summarized in Table 34. The analysis showed that the lowest tested dose of Zolpidem, 
0.5 mg/kg, was different related to control, but also that rats treated with higher doses of 
the drug (1 and 2 mg/kg) were behaviorally impaired related to 0.5 mg/kg Zolpidem. 
Table 34. Illustrated here is the significant differences among overall influence (averaged for five 
days of acquisition) on the Morris water maze learning parameters: latency to find the platform (L), 
distance swam before finding the platform (D), mean swim speed (S) and path efficiency (E) in the 
dose-response study of Zolpidem (ZOL, mg/kg). 
ZOL 0.5 ZOL 1 ZOL 2 
Solvent 
L: p=0.009 
S: p=0.009 
E: p=0.010 
L: p<0.001 
D: p=0.010 
S: p<0.001 
E: p<0.001 
L: p<0.001 
D: p=0.004 
S: p<0.001 
E: p<0.001 
ZOL 0.5 
-
L: p=0.018 
S: p=0.011 
L: p<0.001 
S: p<0.001 
ZOL 1 
- - L: p=0.014 
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Figure 131. Illustrated here are the effects of a) Zolpidem (ZOL 0.5, 1 and 2 mg/kg), b) SH-053-2'N, 
SH-053-S-CH3-2'F and SH-053-R-CH3-2'F (all dosed at 30 mg/kg) and c) JY-XHe-053 (5; 20 and 40 
mg/kg), on latency to platform. *,** and ***, P<0.05; 0.01 and 0.001, respectively, compared to 
solvent (SOL) group in each of three experiments. In graph a): +, ++, and +++, P<0.05; 0.01 and 
0.001, respectively, compared to ZOL 0.5 group; #, P<0.05 compared to ZOL 1.0 group; A and AA, 
P<0.05 and 0.01, ZOL 1 group compared to ZOL 0.5 group. In graph b): ++, P<0.01 compared to 
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SH-053-S-CH3-2T (30mg) group. Number of animals per each treatment group was 8 in a) and b), 
and 7 in c). 
The results of the probe trial showed an unexpected inconsistency in the data from 
the control group. Hence, it was decided to perform statistical analysis with Zolpidem on 
its own (Table 35). The incapacitating influence of the previous treatment with Zolpidem 
was discernible during the probe trial as well, when a number of indices of memory were 
dose-dependently adversely affected (number of entries in platform zone close to 
significantly, time in the target region significantly). Concomitantly, a significant 
increase in the peripheral ring distance, i.e. pronounced thygmotaxis, has shown that 
Zolpidem impaired learning the required water maze skills and strategies. The 
representative parameters of water maze performance in the probe trial of the Zolpidem 
(ZOL) dose-response experiment are illustrated in Table 30. The key to regions used in 
the analysis is given in Figure 132. 
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Table 35. Parameters of water maze performance with Zolpidem 
ZOL 0.5 ZOL 1.0 ZOL 2.0 
ANOVA, 
F(2,21) 
P 
Whole water maze parameters 
Distance 
(mtSEM) 
10-93±0.97 ll.SQt0.96 12.75+0 56 1.187 0.325 
Platform q uadrant (NE) parameters 
Distance 
(m±SEM) 
2.41+0.29 2.18+0.51 2.22+0.44 0.083 0.920 
Tune 
(s+SEM) 11.8d±1.44 
9.64+1.92 9.75t2.06 0.471 0.631 
Peripheral riij parameters 
Distance 
(mtSEM) 
4.16+0.61 609+0.89 7.85+0.82" 5.564 0.012 
Time 
(s±SEM) 33.48+3 68 39.8dtl.67 42.80+3.35 
2.473 0.109 
Platform ring parameters 
Distance 
(m±SEM) 
5.27+0 68 4.48+0.31 4.00+0 65 1.247 0.308 
Time 
(s+SEM) 21.46t3.05 17.31+1.38 14.50±2.60 
2.049 0.154 
Target region parameters 
Distance 
(mtSEM) 1.51±0.27 1.12±0.14 
0.99+0.22 1.520 0.242 
Time 
(s±SEM) 
7.26+1.36 4.03±0.52* 3.51±0.76* 4.596 0.022 
Platform parameters 
Number 
of entries 
(+SEM) 
1.25+0.41 0.38+0 18 0 50+0 19 2.813 0.083 
Distance 
(mtSEM) 
0.097±0.031 0.047+0.028 0.053+0.023 0.945 0.405 
*, P<0.05 compared to ZOL 0.5 group. 
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Figure 132. Scheme representing the virtual division of the water maze used in the analysis of rats' 
performance 
In regard to the two other experiments in the water maze, the results were 
generally dissimilar in relation to those obtained with Zolpidem. In the experiment with 
SH-053-S-CH3-2T, SH-053-R-CH3-2T and SH-053-2fN, all dosed at 30 mg/kg, only the 
factor days, but not the treatment or the interaction treatment x days, was statistically 
significant for the latency to find the platform (treatment effect, F(3,124) = 1.40, p = 
0.248; day effect, F(4,496) = 54.45, p< 0.001; and treatment x day interaction, F( 12,496) 
= 0.84, p = 0.611), the distance swam before finding the platform (treatment effect, 
F(3,124) = 0.95, p = 0.419; day effect, F(4,496) = 41.92, p< 0.001; and treatment x day 
interaction, F( 12,496) = 0.44, p = 0.947), swim speed (treatment effect, F(3,124) = 2.24, 
p - 0.087; day effect, F(4,496) = 9.13, p< 0.001; and treatment x day interaction, 
F(12,496) = 0.96, p = 0.489) and path efficiency (treatment effect, F(3,124) = 0.32, p = 
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0.812; day effect, F(4,496) = 7.90, p< 0.001; and treatment x day interaction, F(12.496) = 
1.31, p = 0.207). Similar results were obtained for the latency to find the platform 
(treatment effect, F(3,108) = 0.45, p = 0.718; day effect, F(4,432) = 90.88, p< 0.001; and 
treatment x day interaction, F( 12,432) = 1.03, p = 0.417), the distance swam before 
finding the platform (treatment effect, F(3,108) - 0.32, p = 0.812; day effect, F(4,432) = 
56.12, p< 0.001; and treatment x day interaction, F( 12,432) = 1.64, p = 0.079), swim 
speed (treatment effect, F(3,108) = 1.13, p = 0.340; day effect, F(4,432) = 7.50, p< 0.001; 
and treatment x day interaction, F( 12,432) = 1.11, p = 0.347) and path efficiency 
(treatment effect, F(3,108) = 0.90, p = 0.445; day effect, F(4,432) = 28.58, p< 0.001; and 
treatment x day interaction, F( 12,432) = 1.44, p = 0.144) of rats treated with JY-XHe-053 
in the 5 to 40 mg/kg dose range. The graphs representative of the latter two experiments, 
with latency to find the platform, are given in Figure 131b and 131c, respectively. The 
one-way ANOVA applied to latency to find the platform showed a significantly longer 
search time on the fourth day in rats treated with 30 mg/kg 811-053-21^ in comparison 
with control animals or those treated with 30 mg/kg SH-053-S-CH3-2T (Figure 131b). 
However, this result should be seen as an isolated case, since other learning parameters, 
such as path efficiency presented in Figure 133a, were not affected by SH-053-2TSf on 
either of the learning days. Furthermore, probe trial parameters were close to control 
throughout the water maze experiments performed with the newly-synthesized ligands. 
The lack of incapacitating consequences of the previous five-day treatment with SH-053-
S-CH3-2T, SH-053-R-CH3-2T and 811-053-2™ is illustrated in Figure 133b, with the 
parameter of platform zone entries during the probe trial presented. 
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Figure 133. Illustrated here are the effects of SH-053-2'N, SH-053-S-CH3-2'F and SH-053-R-CH3-
2'F, all dosed at 30 mg/kg, on a) path efficiency during 5-day acquisition sessions and b) number of 
entries to the zone of previous days' position of platform in the probe trial. 
In Figure 134, the distances the rats swam in the platform quadrant (NE) during 
acquisition trials are presented alongside the respective distance in the portion of NE 
quadrant lying in the platform annulus of the maze ("the target region"), for the chosen 
treatments from three experiments. Providing the rats have no preference for any part of a 
quadrant, the chance percent of distance swam in the target region would be 40%. The 
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influence of four novel ligands tested at relatively high doses on this parameter was 
comparable to control values. On the contrary, the rats treated with 2 mg/kg Zolpidem 
strikingly lacked the preferential activity in that part of the NE quadrant in which finding 
the platform was possible; even on day 5, only 40.5% of the distance they travelled in the 
NE quadrant was in the target region. 
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Figure 134. Illustrated here are the effects of b) Zolpidem (ZOL 2), c) JY-XHe-053 (30mg), d) SH-
053-2'N (30mg), e) SH-053-R-CH3-2'F and 0 SH-053-S-CH3-2T (30mg) (all doses in mg/kg) on the 
distance rats travelled in the NE quadrant and target region during 5-day acquisition trials in the 
water maze. The numbers inside the columns are the percent of the distance swam inside the target 
(NE) quadrant which was travelled in the target region. Control values (SOL) given in a) are taken 
from the experiment with ZOL. Numbers of animals are as in Figure 128. 
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Discussion 
A substantial body of evidence from both, genetic46 and pharmacological 
studies,14 supports the search for a new generation of positive allosteric modulators at 
GABA(A) receptors, which would mostly be devoid of the adverse effects of current BZ 
drugs. Most notably, GABA(A) receptors which contain the ai subunit are believed to 
be responsible for most of the untoward effects of BZs, and silencing the activity at this 
subunit has appeared as the most attractive approach.419 The in vitro and in vivo 
pharmacology of a number of novel BZ-site ligands, affinity- and/or efficacy-selective 
for one, two or three of the subtypes of BZ site, other than that at a ]-containing 
GABA(A) receptors, has supported the possibility of obtaining preclinical profiles 
substantially different from those related to standard BZ drugs.427 
The present experiments focused on the recently-synthesized ligands: SH-053-
2TST, SH-053-S-CH3-2T, SH-053-R-CH3-2T and JY-XHe-053, which as a common trait 
have moderately low to low affinity and mild to partial agonistic efficacy at ai-
containing GABA(A) receptors. Positive efficacy is more pronounced at the other BZ-
sensitive binding sites in comparison to the a i-subtype. These ligands were assessed in a 
battery of standard behavioral tests, and also compared, where appropriate, with effects 
of diazepam and Zolpidem, a nonselective and relatively ai -selective allosteric modulator 
at BZ site of GABA(A) receptors, respectively. Putting aside for the moment the 
subtle differences in the in vitro and in vivo pharmacology of novel ligands, it was 
observed that even with ligands that demonstrated efficacy "lower at the ai 
subtypes than at the rest of the subunits", the sedative-like potential of such 
GABA(A) modulation was not fully eliminated, while the spatial learning and 
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memory impairments, assessed in the water maze and usually seen with BZ site 
agonists, were completely circumvented; the latter finding represents the single 
most important result from the present study. 
The decreased locomotion induced by all four novel ligands (the effect of 30 
mg/kg SH-053-S-CH3-2T was presented by Savic et al.51'367"389) which were tested, may 
be rationalized in two ways. Firstly, although the lack of occupancy (in vivo potency) 
data for distinct receptor subtypes precludes drawing firm conclusions about the actual 
activity at ai-containing GABA(A) receptors, which are predominantly involved in the 
sedative actions of BZs according to genetic46 and pharmacological antagonism studies,"2 
it cannot be excluded that, even at presumably low fractional occupancy, moderately low 
to moderate positive modulation (partial agonism) at these a i-receptors may be sufficient 
for eliciting weak sedation.419 Secondly, growing neuroanatomical evidence points to the 
possible role of as-containing GABA(A) receptors in motor control,419 and Savic 
recently suggested that any locomotor activity changes induced by ligands possessing a 
substantial cu-agonist efficacy may be contributed by modulation at GABA(A) receptors 
containing this subunit. GABA(A) receptors containing the a5-subunit are 
functionally interrelated in some manner with those containing the a\-subunit. 
Importantly, knock-in mice harboring the as subunit insensitive to diazepam are 
refractory to development of tolerance to the sedative effects of diazepam dosed 
386 subchronically. Moreover, the as-subunit affinity- and efficacy-selective antagonist 
XLi093, at a dose presumably causing a complete antagonism of the effects of diazepam 
at as-containing GABA(A) receptors, has potentiated sedation induced by diazepam.47 
Based on these data, we hypothesized further that positive modulation at as GABA(A) 
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receptors may exert a dual action: to limit sedative effects elicited by supra-physiological 
stimulation of ai-containing receptors (e.g. by full agonists), and, oppositely, to enhance 
low activation of aj GABA(A) receptors (e.g. by partial agonists), and, hence, induce 
mild sedation.46 Such a modulation might be achieved if neurons involved in sedative 
actions are modulated strongly by al as well as more weakly by a5 receptors, and if the 
synapse or neuron mediating the al modulation is at the same time weakly regulated by 
a5 receptors. Then low activity at al receptors can overall be enhanced by a direct a5 
receptor activity on the same neuron, but strong a5 activity would downregulate the 
strong sedative action of al activity via its indirect effect on the synapse or neuron 
mediating the al modulation. Such a scenario could, at least partly, explain the 
unexpected finding that the mice lacking the a 1-containing GABA(A) receptors 
(knockout mice) were more sensitive to hypolocomotion and loss of righting reflex 
induced by diazepam, compared to wild-type controls.46 Similarly, tolerance 
development against the sedative effects of diazepam mediated via al receptors may be 
explained by upregulation of the putative indirect mechanism of a5 receptor activity. 
Further experiments will have to be performed to substantiate this speculation. The roles 
of these two receptor subtypes in exerting the locomotor effects of the ligands with 
limited a.\ activity, such as those presented here, may be supplementary and additive: the 
more avid binding and/or activation at as GABA(A) receptors, the more chance of 
eliciting sedation. The lack of observable decrease of locomotion with a novel ligand 
(WYS8) which possesses high affinity and partial agonistic efficacy at ai GABA(A) 
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receptors, but moderately low affinity and partial inverse agonistic efficacy at 015 
GABA(A) receptors (Savic, Sieghart, Cook, unpublished data), supports this notion. 
The differences in the capability to induce anxiolytic effects, observed with the 
ligands evaluated here, are not easily reconciled. Genetic studies have indicated the a2 
subunit was predominantly involved in the anxiolytic-like effects of positive modulation 
at GABA(A) receptors,46'406 while results with some novel selective ligands pointed to 
the role of the a3 subunit, as well.335 The ligand SH-053-R-CH3-2T was devoid of 
anxiolytic potential, in line with results of a congener with a similar profile of a5 
GABA(A) functional selectivity, SH-053-R-CH3.46 However, JY-HXe-053, a ligand 
with relatively high affinity and efficacy at a2 and a3-containing GABA(A) receptors, 
was devoid of discernible anxiolytic activity, too. When comparing this result with the 
anxiolytic-like properties of 811-053-2^ and SH-053-S-CH3-2T429 it was found that JY-
HXe-053 has a greater affinity at al-, and especially as-containing GABA(A) receptors, 
with substantial potentiation at these receptors achieved already at concentration of 100 
nM (169% and 220%, respectively). Since JY-HXe-053 has induced a hypolocomotor 
effect in the SLA at doses (10 mg/kg and above) lower than those observed with SH-053-
2T4 or SH-053-S-CH3-2T (30 mg/kg), it is possible that its activity at ai and, in parallel, 
ct5 receptors may have masked the expected anxiolytic-like effects mediated by the other 
two, a2 and a3-containing, subtypes of GABA(A) receptors. When one compares the in 
vitro profile of JY-XHe-053 with that of diazepam, it is clear that JY-XHe-053, but not 
diazepam, exhibits a preferential affinity for a5-GABA(A) receptors. The consequent 
'priority in activity' at as-GABA(A) receptors may have endowed this population of 
receptors with a relatively more distinct role in influencing the overall behavior of rats 
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treated with JY-XHe-053, rather than with diazepam. Finally, it is notable that the 
hypolocomotor influence of JY-XHe-053 in the SLA test was evident only when 
analyzing activity in the peripheral, but not in the central zone of the chamber. Hence, the 
motor depressant effects were not confounded by influence on emotional reactivity, and 
could be seen as a pure measure of sedation.429 On the contrary, the hypolocomotion 
induced by SH-053-R-CH3-2T was due to the inactivity in the central, but not the 
peripheral zone, which suggests that the sedation-like actions exerted through a,i and a? 
GABA(A) receptors are qualitatively different. 
It has been shown previously that, when observable, the anxiolytic-like effects of 
Zolpidem, the preferential al-subunit selective agonist with intermediate activity at a2 
and a3-containing GABA(A) receptors, are statistically dependent on the concomitant 
decrease of closed arm entries in the elevated plus maze, and hence confounded by 
general activity changes.429 Analysis of covariance for the current results with SH-053-
2TsT did not reveal analogous dependence of its anxiolytic-like effects on the concomitant 
signs of sedation. Nevertheless, it is possible the clinical separation of wanted anxiolytic 
from unwanted sedative effects would be lower for SH-053-2'N than for SH-053-S-CH3-
2'F, having in mind that the latter ligand was devoid of influence on the parameters 
related to general activity in the elevated plus maze.430 
The effects of Zolpidem on the acquisition and retention of place learning in the 
water maze have not been previously assessed. Zolpidem dose-dependently impaired the 
declarative component of both, learning the task, as assessed by path efficiency, the 
latency and distance before finding the platform across acquisition trials, and recalling 
the previous platform position, as assessed by time in the target region during the probe 
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trial. It also induced a decrease in average swim speed, accompanied by an increase in the 
maximum swim speed, which may be interpreted as 'bursts' of behavioral disinhibition 
(activation) interspersed among background sedative effects. By use of the treatment 
switch, McNamara and Skelton have shown419 that the reduced swim speed cannot 
account for deficits in platform localization induced by BZs. Namely, the rats acquiring 
the task under saline treatment continued to perform normally despite the switch to 
diazepam, which nonetheless elicited a decrease in swim speed.397 Hence, the data 
suggest that neither non-specific performance impairment, nor any sensorimotor deficit 
(according to our preliminary findings with Zolpidem in the task of finding the visible 
platform) was responsible for the observed acquisition deficit42 
Zolpidem also negatively affected the procedural component of the water maze 
task. Namely, suppression of an instinct to swim thigmotaxically appears to be necessary 
to effectively accomplish this task,46 and Zolpidem at 2 mg/kg induced an increase of 
peripheral annulus, and a decrease of platform annulus parameters throughout the test. It 
has been recently shown that both, the ai-subunit affinity-selective antagonist B-CC't, and 
the ot5-subunit affinity- and efficacy-selective antagonist XLi093, may, at least partially, 
prevent diazepam-induced impairment in the declarative and procedural component of 
the water maze task; however, the antagonistic effect of B-CCt was manifestly more 
profound.427 The results show, first, that the effects of Zolpidem, a ligand essentially 
inactive at a5 GABA(A) receptors, mirror those induced by diazepam, and secondly, 
that three novel ligands, with moderately low to low activity at al GABA(A) receptors, 
do not disturb water maze behavior. The conclusion is straightforward: a substantial 
amount of activity at al GABA(A) receptors is needed if spatial learning and 
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memory incapacitation is to be induced by positive allosteric modulation at BZ site. 
The positive modulation at as GABA(A) receptors may add to the incapacitating 
action effected through the ai subunit, but is neither necessary (cf. Zolpidem), nor 
sufficient (cf. SH-053-R-CH3-2T) for spatial cognition impairment in the water 
maze. 
The data and the above conclusions may thus significantly change the common 
knowledge on the function of individual receptor subtypes.431"433 From the data with 
knock-in mice, it was concluded that sedation is mediated by interaction of diazepam 
with al receptors. Present and previous data indicate, however, that a5 receptors may 
significantly affect the sedative effects of diazepam, as discussed above. Data from 
knock-in and knock-out mice indicate that a5 receptors are mainly mediating the effects 
of diazepam on learning and memory. However, we have discussed above that al 
receptors might be also important for mediating the incapacitating effects of diazepam on 
learning and memory. These conclusions do not completely invalidate the previous 
conclusions from the genetically modified mice, but reflect the more realistic view that 
more than one GABA(A) receptor subtype is modulating the same behavioral parameter 
and that depending on which parameter is being investigated; contributions of different 
receptor subtypes might be more or less strongly involved. We suggest a tentative 
hypothesis based on the existence of the fine equilibrium between the al- and a5-
GABA(A) receptors on the one hand, and a2- and a3- GABA(A) receptors on the other 
side, in terms of the influence of positive allosteric modulation on the crucial behavioral 
endpoints of sedation, anxiolysis and amnesia. It is clear that a substantial amount of 
positive modulation is needed by the al, coordinated in some manner with a5-
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GABA(A) receptors, if sedation and amnesia are to be elicited, while for the anxiolytic-
like actions the a2 and/or a3 GABA(A) receptors must be activated. The other pair of 
receptors, not primarily involved in mediation of the respective behavioral effect, may 
counteract, mask or in another way hinder the action of the responsible pair. 
Although the results of these studies suggest a possible role of a5-containing 
receptors on motor control, the data is in agreement with earlier oocyte studies from 
Sieghart et al. and the pharmacophore models and observations discussed in Part I. It 
was clear JY-XHe-053 exhibited slightly more agonist efficacy at al than did SH-053-
2isr and SH-053-S-CH3-2T. These studies are in agreement with the hypothesis 
proposed in previously64' 434 in which a) ligands with an electronegative group in the 2' 
position on the pendant phenyl position of analogs of XHe-II-053 will interact with the 
H2 group of the pharmacophore and can enhance binding and b) the selected ligands are 
selective for al, a3, and a5-containing receptors over al containing receptors. The lack 
of memory impairment by SH-053-2'N, SH-053-S-CH3-2T, SH-053-R-CH3-2T and JY-
XHe-053 is in agreement with previous in vitro binding data which shown that these 
ligands do not bind potently to the a 1-containing GABA(A) receptor subtypes, which is 
believed to be responsible for sedation and amnesia. Between the novel positive 
allosteric modulators presented here and previously,64 it appears that SH-053-S-CH3-2T 
may possess a pharmacological profile appropriate for further fine tuning, by diminishing 
the potential of sedation, probably through an additional decrease of activity at a 1 - and 
a5- GABA(A) receptors. However, besides the in vitro affinity and efficacy data 
discussed in the present study, a future, more elaborate analysis of the substrate of 
behavioral effects of BZ site modulators shall take into account target site occupancy, 
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quantitative neuroanatomical distribution of distinct receptor subtypes (which is very 
inhomogeneous in the case of BZ-sensitive GABA(A) receptors), differences among 
animal species and the receptor reserve (if any) of the behavioral effect under 
investigation.121 
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Search for Subtype Selective Ligands for a5(33y2 Subtypes 
In order to further the understanding of the stable conformations of GABA(A) -
benzodiazepine receptor bivalent ligands; the conformations of several bivalants were 
determined by low temperature NMR spectroscopy and confirmed by single crystal X-ray 
analysis. The stable conformations in solution correlated well with those in the solid 
state. The linear conformation was important for these dimers to access the binding site 
and exhibit potent in vitro affinity and was illustrated for a5 subtype selective ligands. 
Bivalent ligands with an oxygen-containing linker folded back upon themselves both in 
solution and the solid state. Dimers which are folded do not bind to Bz receptors. 
Currently, transforming monomers into a bivalent ligand is one of the successful 
strategies for developing potent ligands with enhanced selectivity.435 Bivalent ligands are 
defined as compounds which contain two pharmacophores joined through a connecting 
unit or linker. The general structure for bivalent ligands is described as P-X-P (P: 
pharmacophore; X: linker) (see Table 36). The proper selection of a suitable linker X is 
crucial for potent receptor binding. 
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Table 36. Stable conformations of selected compounds 
linker mono-
unit 1 
mono-
unit 2 
r .  M o n o  M o n o  S P a n n e r  C o n f o r m a t i o n  K ,  ( a n P 3 y 2 )  =  n M  
pas unit 1 unit 2 
0 X-ray NMR al a2 A3 a4 a5 a6 
21a A - C2H5 - - 28.4 21.4 25.8 5.3 0.49 2 8.8 
1 A A <CH2)3 linear linear >1000 >1000 858 1550 15 >2000 
18 A A (CH2)5 - linear 231 661 2666 ND 5.4 54.22 
3 C C (CH2)3 - linear 1852 4703 8545 ND 100.5 5000 
32 A A CH2OCH2 - folded 3795 2694 1864 ND 76.14 ND 
6a B - C2H5 - - 287 45 96 1504 13.8 1000 
19 B B (CH2)20(CH2)2 folded folded 460 5000 ND ND 5000 5000 
33 B B (CH2)3 linear linear 236 7.4 272 >5000 194.2 >5000 
a: monomer 
Recent studies on the binding selectivity of the inverse agonist RY-80 (31) indicated 
preferential binding to a5 BzR/GABA(A) subtypes.66 Therefore, the bivalent ligand Xli-
093 (1) was developed by incorporating the pharmacophore of 31 with a three-carbon 
linker.66 This bivalent ligand exhibited selective affinity for the a5 subtype and behaved 
as a selective antagonist of the effects of diazepam in oocytes only at the a5 subtype. 
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Effects at the other three diazepam-sensitive sites were minimal. Encouraged by this, a 
series of new bivalent ligands were designed and synthesized (Table 36). 
It was hoped that these new dimers might exhibit enhanced selectivity and 
potency at the a5 BzR/GABA(A) subtypes. It was also expected that insertion of an 
oxygen atom into the linker might increase water solubility and hence enhance molecular 
hydrophilicity which should play an important role in the pharmacokinetic properties of 
the ligand. 
The nature of the functional groups in a ligand plays an important role in receptor 
binding, of course, as well as the conformation in solution. The more information about 
the stable conformation(s) of molecules, the better the understanding of the structure-
activity relationships. It was essential from the beginning of the present study to 
determine the conformation of these bivalent ligands, which contained 3 to 5 atom 
linkers, since the steric requirements for affinity to the Bz receptor must be satisfied.66 
In traditional medicinal chemistry, computer assisted molecular modeling 
programs and X-ray analysis contribute greatly in the search for stable conformations. 
However, some problems with these methods should not be neglected. Using computer 
modeling to determine the stable conformation of molecules containing many free 
rotating bonds, such as those contained in bivalent ligands, is difficult. Although X-ray 
crystallography is the ultimate arbiter of chemical structure, it has many limitations 
beyond the obvious need for crystals: it often does not reflect accurately the conformation 
in solution, nor is it informative regarding conformational equilibria. This information is 
crucial in drug design. However, NMR spectroscopy is a powerful technique in drug 
discovery and its role in conformational analysis cannot be surpassed by other 
spectroscopic methods.436,437 
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Herein is described a method utilizing low temperature NMR for the 
determination of the solution stable conformation of a series of GABA(A) -
benzodiazepine bivalent ligands with different monomeric units and linkers. The 
conformations in solution were determined by NMR spectroscopy and compared with 
those in the crystal structure. The combination of low temperature NMR and X-ray 
analysis provided accurate structural information required for understanding structure-
activity relationships and drug design. The influence of the molecular structure of the 
linker on the conformation is also discussed. 
Results 
Recently it was shown the active dimer 1 existed in a linear conformation in the solid 
state while dimer 19 with a oxygen containing linker folded back upon itself, as 
illustrated in Figure 135.438"440 
(1, Xli-093) 
(19, DM-III-96) 
(33,DMH-D-053) 
Figure 135. Crystal structures of Xli-093, DMH-D-053, and DM-III-96. 
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Since the bioactive conformation in solution may or may not parallel that in the 
crystal structure, the lowest energy solution structure must be established in order to 
correlate conformation with biological activity. Thus, NMR experiments at variable 
temperatures were performed and data were collected in different solvents. In methylene 
chloride or chloroform at room temperature, only a single set of signals was detected for 
both bivalent ligands 1 and 19. At low temperature, it was found that the linear dimer 27 
exhibited only a small splitting of about 3 Hz for some of the aromatic protons in the 
'HNMR spectra,438"442 while two clearly separated sets of signals were observed for the 
folded dimer 19 (Figure 136). For example, as seen in Figure 136 for 19, the signal of 
HI (7.92 ppm at 298 K) was split into two peaks at 87.91 and 7.88 ppm, respectively, at 
193° K. Similar results were observed in the 13C spectrum where CI (134.9 ppm at 
298°K) split into two signals at 135.3 and 135.4 ppm at 198° K. The doubling of the 
signals is consistent with disruption of the symmetry between the two domains of the 
molecule as expected if 19 adopted a static folded structure similar to the crystalline state. 
323 
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263 K 
193 K 
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8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 ppm 
Figure 136. Aromatic region of 'HNMR spectra of 19 in CD2C12 at variable temperatures. 
However, the possibility could not be ruled out that the split in the signals was caused 
by slowing a dynamic process within each domain, such as conformational 
interconversion of the seven-membered ring. In order to investigate this possibility, the 
NMR spectra of the monomer 6 were run at low temperature as well. At temperatures as 
low as 173 K only one set of signals was observed in both the *H and 13C NMR spectra 
of 6 (Figure 137).437'443-445 At lower temperatures, however, this was quite different from 
what was observed for dimer 19 at room temperature; the spectra of 6 and 19 were 
indistinguishable at 25°C. Moreover, some additional line broadening of some of the 
aromatic signals was observed at the lowest temperature in both the monomer 6 and in its 
dimer 19. 
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Figure 137. Aromatic region of'HN1VIR spectra of 6 in CD2CI2 at different temperatures. 
The analysis of these data indicated that the line broadening at the lowest 
temperature was due to one of the conformational processes mentioned above, whereas 
the doubling of the peaks in 19 was caused by the presence of two domains. Certainly an 
interdomain interaction existed between the two heterocyclic units of 19, but not in 
monomer 6. It was therefore concluded the internal mobility of the molecule decreased 
when the temperature was lowered which permitted observation of the two sets of signals 
of 19 on the NMR time scale. It was thus suggested that only when the molecule 
preferred the folded conformation in solution were two sets of signals observed. The 
preferred conformations of the molecules in CDCI3 and CD2CI2 correlated quite well with 
those observed in the crystal structures (Table 36). 
The study was then expanded by varying the nature of the linker and monomer. 
Dimers 18 and 32 contain the same monomeric unit as 1, whereas 33 contains an all 
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carbon linker. It was found that 1, 3, 18, and 33 exhibited only one set of NMR signals 
at low temperature, whereas the NMR signals of ligands 19 and 32 split into two sets at 
low temperature. Low temperature NMR studies were performed in CD2CI2. It was 
concluded that 19 and 32 preferred a folded conformation, while 1, 3, 18, and 33 
assumed a linear conformation. These conclusions are supported by a crystal structure 
obtained for bivalent ligand 33 which indicated 33 was present in a linear conformation 
in the solid state. These results are illustrated in Table 36. 
Since the goal was to design and synthesize bivalent ligands for biological 
applications in aqueous solution, the question arose: Do the conformations in CDCI3 or 
CD2CI2 resemble those in aqueous solution? Attempts to run the NMR experiments in 
water failed since the ligands were not sufficiently soluble in D2O. However, the spectra 
of both the linear and folded dimer 1 and 19 could be carried out in MeOH-c/4. The 
solvating properties of methanol, of course, more closely resemble those of water, and 
this more closely mimics aqueous physiological condition as well. The conformations of 
dimers in MeOH-were consistent with conformations in hydrophobic solvents. 
Discussion 
From the results described above, it is clear that dimers which contain an oxygen 
atom in the linker tend to adopt a folded conformation. Analysis of these data indicated 
in the hydrophilic solvent, 19 also had a higher tendency to fold back upon itself than 1, 
as it did in the hydrophobic media (Figure 138 and Figure 139). In fact, the tendency of 
19 to assume a folded structure appeared to be higher in methanol than in CD2CI2 or 
CDCI3, as the free rotation of the molecule was limited (Figure 139). On the other hand, 
for dimer 27, which preferred a linear structure in the solid state and in lipophilic 
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solvents, only one set of signals was observed at room temperature in MeOH-c/^Figure 
138). 
298 K 
V. J\-
278 K J\ u 
258 K A ik.M 
"'I I I I I I I I I I !• 
8.6 8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 ppm 
Figure 138. Aromatic region of *H NMR spectra of 1 in MeOH-<W at different temperatures 
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8.6 8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 ppm 
Figure 139. Aromatic region of proton spectra of 19 in MeOH-rf4 at different temperatures. 
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8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 ppm 
Figure 140. Partial HSQC spectrum of 19 in MeOH-</¥ at 298 K. 
It is interesting to note that in the preparation of the samples, dimer 1 was less 
soluble in MeOH-c/4 than was 19. It has been established that ligands are easier to 
dissolve in a solvent when the ligands surface energy can be minimized. Bivalent ligand 
19 was more polar than dimer 1 and has a higher tendency to fold back. Consequently, 19 
was presumably, easier to dissolve in methanol because its surface energy was 
minimized. On the other hand, when ligand 21 was dissolved in a more polar solvent 
such as methanol, the surface energy may be forced to be minimized. 
Since the conformation of molecules 1 and 19 in methanol agree with those in 
CD2CI2 or CDCI3, the behavior of these ligands in CD2CI2 or CDCI3 should reflect those 
in aqueous solution. The stable conformation of the compounds determined in CD2CI2 or 
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CDCI3 were correlated with the newly generated receptor binding data (Table 31). In the 
pharmacophore/receptor model, the bivalent ligands in the linear conformation align well 
(Figure 141). 
Figure 141. Bivalent ligand 1 (Xli093) aligned in the included volume of the pharmacophore/receptor 
model for the a5p3y2 subtype. 
Importantly, bivalent ligands 1, 3, 18, and 33 with carbon only linkers prefered 
the linear conformation as the stable conformation, independent of the number of linker 
atoms. In contrast, replacing the middle carbon of either linker (CH2)3 or (CH2)s with an 
oxygen atom altered the stable conformation of the molecules 32 and 19 from linear to 
folded. The only difference between bivalent pairs 1 and 32 with linear and folded 
conformations as the stable ones, respectively, was the center atom. In compound 1 the 
middle atom was carbon, while in 32, oxygen was present. Consequently, it was decided 
330 
to focus attention on the conformational difference between carbon and oxygen 
containing linkers. 
It was well-known436,437,443-445 that the carbon chain in both small molecules and 
polymers favored the anti conformation which results in a linear arrangement of atoms. 
From examination of the linkers (Figure 142), it was easily seen that linkers C and D can 
be regarded as oligomers of oxymethylene (OCH2)2 and oxyethylene (OCFhCF^h. 
b c d e f ? 
A B 
C D 
Figure 142. The linkers of the bivalent ligands. 
It was well documented that the preference for the gauche-gauche conformation437 
446,447 Q|- a sjmpje open-chain acetal such as dimethoxymethane (CH3OCH2OCH3) could 
be predicted on the basis of the anomeric effect and related stereoelectronic effects. In 
this conformation the polar X-0 bonds are favorably oriented such that a lone pair orbital 
of the oxygen atom was almost antiperiplanar to the X-0 bond (Figure 143, lone pair 
orbital and X-0 bond in same color). This permits maximum overlap of the n orbital of 
the oxygen atom with the a* orbital of the X-0 bond. This was not possible in the anti-
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anti or gauche-trans conformations and the two rabbit-ear interactions448"450 (Figure 143) 
engendered by each pair of adjacent oxygen atoms in the anti-anti conformer are avoided. 
H3C CH3 
anti-anti 
Figure 143. The conformations for dimethoxymethane. 
Furthermore, in the related polymer of dimethoxymethane with the two-bond 
repeating sequence, poly(oxymethylene) (POM), the gauche conformation was, in fact, 
markedly preferred over trans and the polymer existed in a helical (all gauche) 
conformation451 rather than in the all-anti one. 
Similarly, much effort has been spent on the investigation of the conformational 
characteristics of 1,2-dimethoxyethane (glyme, CH3OCH2CH2OCH3) as a model 
molecule for understanding the conformations of poly(oxyethylene) (POE). It had long 
been established that POE chains have a large fraction of bonds in gauche conformations 
and assumed a helical conformation overall.452"456 It has been proposed that the oxygen 
0 
gauche-gauche 
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gauche effect437 and 1, 5-CHO interaction443 within the molecule were responsible for the 
gauche-rich conformations. 
Based on this pioneering work, the correlation was made that the conformation of 
the linkers in the bivalents 1,3, 18, and 33 and 32 and 19 adopt anti (B), gauche-gauche 
(C), trans-gauche-trans (D) conformations, respectively, regardless of the monomeric 
units which comprise them. The arrangement in space (disregarding the direction) of 
every unit in the linkers is depicted in Figure 144. The end-to-end distance of each unit 
(C and D) which adopted the gauche conformation was shorter than the one in the anti 
conformer. The more units in the linker, the shorter the gauche linker. Moreover, it was 
recognized that the C-0 bond length (1.43A) is often appreciably shorter than the C-C 
bond (1.54 A).324 Therefore, it was believed that the linkers with the oxygen atom in the 
middle favored the helical conformation and rendered the two monounits in each dimer 
sufficiently close to each other with suitable dihedral angles to facilitate the 
intramolecular lipophilic-lipophilic (aromatic-aromatic) interaction. This was regarded 
as one of the most important factors to stabilize the folded structure as the preferred 
conformation.310 For these same reasons, bivalent ligands with the linker B adopted the 
linear conformation. 
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Figure 144. Newman projection for linkers B, C and D. 
For the higher analog of POM and POE, namely, poly(trimethylene oxide) 
[(CH2)30]x (POM3), trans-gauche-gauche-trans was slightly preferred over all-/ram and 
trans-trans-gauche-trans comformers in the crystalline state.215,457,458 The preference for 
the gauche state in this case was only 0.2 kcal/mol where as in the POM and POE 
examples was 1.5 and 0.4 kcal/mol, respectively.19, 360 Since the energy difference 
between gauche and trans was low, the linker A had more flexibility than the other 
linkers (C and D) to rotate freely and less tendency to occur as gauche. This could lead 
to improper end-to-end distances or dihedral angles for the interaction between the 
aromatic monounits. Hence dimers connected with linker A could not be stabilized in the 
folded conformation even though the same aromatic monounits were contained in the 
molecules. 
Bivalent ligands were evaluated in competition binding assays for specific GABA(A) 
membrane proteins using [3H] flunitrazepam as the radiolabel. This assay measures the 
ability of the ligand to displace flunitrazepam. Data is reported as K, according to the 
Cheng-Prusoff equation.360 Biological data are presented in Table 36 for dimers 
synthesized using different spanners (or linkers). The linkers in 19 and 32 contained an 
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oxygen atom. Compounds 1, 3, 18, and 33 contained all carbon linkers. Binding data 
indicate decreased affinity when bivalents contain an oxygen atom in the linker. 
Compounds 1 and 18 showed increased selectivity for the a5 subtype as compared to 
parent monomer 21. Compound 32 which was analogous to 1 with the exception of the 
oxygen atom present in the linker, bound with less affinity at the a5 subtype. Likewise 
bivalent 33 showed increased selectivity versus monomer 6. However, the bivalent 19 
containing an oxygen atom in the linker did not bind. The data suggests that dimers 
which contain a single oxygen atom in the linker bind less (decreased affinity) to the Bz 
receptor. This is due to their propensity to adopt a folded conformation. A strategy to 
increase hydrophilicity and avoid a folded conformation is to extend the linker length and 
insert two opposing oxygen atoms. This research is currently underway. 
Comparison of the results of low temperature NMR studies to crystal structures has 
provided enough information to demonstrate that low temperature NMR can be used as a 
quick method to identify dimeric ligands with a tendency to fold back upon themselves, 
as compared with those preferring a linear conformation. A correlation with binding data 
shows that the suitability of a ligand in the a5 BzR/Gabaergic subtype is heavily 
influenced by its conformation in solution. Variable temperature NMR thus can be used 
as a tool for screening bivalent ligands for their in vivo suitability. It is also clear the 
presence of one oxygen atom in the linker was the principle cause for the dimer to fold 
back onto itself. Ligands which contain two offsetting oxygen atoms in the linker are 
now under study in our laboratory. Synthesis of bivalents was carried out using the 
techniques developed by Li.459 
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Chemistry 
In brief, isatoic anhydride and sarcosine were heated in DMSO, followed by 
bromination to provide the bromide . The conversion of bromide into the 
imidazobenzodiazepine , followed the classic work of Fryer et al. of the Roche group.302-
303 This bromide was converted into the silyl by a Heck-type coupling reaction303- 304 and 
the silyl group was removed in high yield on treatment with TBAF/H2O/THF.305 
Hydrolysis of the ester function provided the carboxylic acid in excellent yield and this 
material was subjected to a standard CDI-mediated coupling reaction to furnish bivalent 
ligand XLi093 1 in 73.4% yield. 
8-Ethynyl-5,6-dihy dro-5-methy l-6-oxo-4H-imidazo [ 1,5-
a][l,4]benzodiazepine-3-carboxylic acid 14: Ethyl 8-ethynyl-5-6- dihydro-5-methyl-6-
oxo-4H-imidazo[l,5-a][l,4]benzodiazepine-3-carboxylate (1.5g, 5.3 mmol) was 
dissolved in EtOH (100 mL), after which aq 2N NaOH (15 mL) was added to the 
solution. The mixture which resulted was heated at 70 °C for 1 hr. After the mixture was 
cooled to rt, the EtOH was removed under reduced pressure. Aqueous 2N HC1 was added 
to the residue to bring the pH to approximately 3-4. A precipitate formed and was 
removed by filtration, washed with water (3 X 50 mL) and dried. The 3-carboxylic acid 
was obtained as a white solid in 90% yield: mp 315-316 °C; IR (KBr) 3421, 1750, 1640, 
1497, 1210 cm"1; 'H NMR (CD3OD) 8 3.28 (s, 3H), 3.74 (s, IH), 4.50 (br, IH), 5.22 (br, 
IH), 7.69 (s, IH), 7.80 (dd, IH, J=2.5 Hz, J=10 Hz), 8.20 (s, IH); MS (EI) m/e (relative 
intensity) 281 (M+, 80), 277 (100), 263 (60), 235 (84), 207 (55). Anal. Calcd for 
C15H11N3O3: C. 64.04; H, 3.94; N, 14.95. Found: C, 64.40; H, 4.12; N, 14.76. 
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l,3-Bis(8-acetyIeno-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo|l,5a|[l,4]benzodiazepine-3-carboxy) propyl diester 1 (XLi093). To a solution 
of carbonyl diimidazole (230.3 mg, 0.57 mmol) in anhydrous DMF (5 mL) was added 8-
ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[l,5-a][l,4]-benzodiazepine-3-
carboxylic acid (200 mg, 0.71 mmol). The solution which resulted was stirred for 2 h at 
rt. Analysis by TLC (silica gel) indicated the absence of starting material. To the solution 
which resulted was then added 1,3-propanediol (27.1mg, 0.36 mmol) in dry DMF (0.5 
mL) and also DBU (114.2 mg, 0.75 mmol) in dry DMF (0.10 mL) at rt. The mixture was 
stirred at rt for 4.5 h until analysis by TLC (silica gel) indicated the reaction was 
complete. The reaction mixture was then poured into ice water (30 mL) and extracted 
with CH2CI2 (3 x 50 mL). The combined organic layer was washed with H2O (5 x 50 
mL), brine and dried (Na2S04). The solvent was removed under reduced pressure and the 
residue was purified by flash chromatography (silica gel, EtOAc/CH^OH, 4 : 1) to 
provide 27 (157 mg) as a white solid in 73.4% yield. 102: mp >230 °C (Dec.); IR (NaCl) 
3247, 1725, 1641, 1359, 1253, 1061 cm"1; H NMR (300 MHz, CDCI3) 8 2.37(m, 2H), 
3.24(s,2H), 3.26 (s, 6H), 4.40(s, 2H), 4.57(t, 4H, J= 6.2Hz), 5.31(br, 2H), 7.41(d„ 2H, 
J=8.3 Hz) 7.72(d,d, 2H, J = 6.43Hz, and J = 1.86Hz), 7.89 (s,2H), 8.19(d, 2H, J = 1.76Hz 
); 13C NMR (75.5 MHz, CDC13) 5 26.2, 34.4, 40.7, 60.2, 78.7, 79.7, 120.4, 121.6, 127.1, 
127.7, 130.1, 133.4, 134.1, 134.9, 161.3, 164.1; MS (FAB,NBA) m/e (relative intensity) 
603(M++1, 100). This material was employed for the X-ray crystal structure. It was 
homogenous in two independent TLC systems [Rf =0.31 in EtOAc/CHsOH, 4 :1; Rf 
=0.32 in CH2CI2/CH3OH, 9:1], Anal. Calcd for C33H26N606 »2/3 CH3OH: C, 64.81; H, 
4.63; N, 13.47. Found: C, 64.56; H, 4.72; N, 13.76. 
l,3-Bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo[l,5a][l,4]benzodiazepine-3-carboxy) propyl diester (XLi356): 1,3-Bis(8-
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acetyleno-5.6-dihydro-5-methyl-6-oxo-4H-imidazo[ 1,5 a] [ 1,4] -benzodiaze-pine -3-
carboxy) propyl diester 1 (500 mg, 0.83 mmol) was dissolved in EtOH (150 mL) after 
which Pd/C (176 mg) was added in solution at rt. The slurry was stirred for 5h under one 
atmosphere of H2(bench top, balloon of H2). The catalyst was removed by filtration and 
washed with EtOH. The EtOH was removed under reduced pressure to furnish a residue. 
This material was purified by flash chromatography (silica gel, EtOAc : EtOH/8 : 2) to 
provide XH356 (504 mg, 99%) as white crystals: mp 125-133°C; IR (NaCl) 3407, 2964, 
2358, 1725, 1640, 1499 cm"1; 'H NMR (CDC13) 8 1.29 (m, 6H), 2.39(m, 2H), 2.78 (dd, 
4H, J=7.5 Hz, 15.1 Hz), 3.26 (s, 6H), 4.48 (br, 2H), 4.56 (t, 4H, J=6.1 Hz, 12.2 Hz), 
5.16(br, 2H), 7.33 (d, 2H, J = 8.2Hz), 7.48 (d, 2H, J=1.8 Hz), 7.89 (t, 4H, J=3.2 Hz, 5.3 
Hz), 8.15; MS(EI) m/e (relative intensity) 611(M++1, 100). Anal. Calcd for C33H34N6O6 
•2H20: C, 61.33; H, 5.92; N, 13.00. Found: C, 61.74; H, 5.91; N, 12.63. 
Computational Assessment of Benzodiazepine Influence on Contextual Memory 
It has been hypothesized that ligands, acting selectively on GABA(A) receptors 
containing the a5 subunit, may prove useful in the remediation of age related cognitive 
loss. Consequently, the chemical determinants of selective binding and subsequent 
activation of a5p2y2 GABA(A) receptor subtypes were examined with the aim of 
gleaning the characteristics important to this selectivity. Ligand-receptor binding and 
electrophysiological responses were characterized in cells expressing defined GABA(A) 
receptor isoforms. A 3D-pharmacophore was developed from an initial diverse training 
set and was used as an initial basis for multivariate discriminant, fragment and 3D-QSAR 
analyses and used to develop criteria for selection of new compounds that should exhibit 
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optimal characteristics. The electrostatic potential near the ligands terminal substituents 
was found to correlate well with a compounds ability to exhibit 100-fold binding 
selectivity towards the a5p2y2 versus alp2y2 isoforms. Specific chemical properties, 
such as the Sterimol L parameter and HOMO-LUMO differences of fragments were also 
found to correlate with a compounds activity. Compounds with promising profiles were 
further assessed for their ability to attenuate scopolamine-induced impairment of fear 
conditioned contextual memory in mice. In marked contrast to prior literature reports, 
the electrophysiological nature of the compounds relative to the (X5P2Y2 GABA(A) 
receptor were found not to be highly predictive of whether the compound was able to 
attenuate scopolamine induced cognitive impairment in mice. Examples of a weak 
inverse agonist and antagonists with 100-1000 binding selectivity with respect to a5p2y2 
GABA(A) are shown to have an ability to reverse scopolamine induced cognitive 
impairment indicating that selective a5p2y2 GABA(A) antagonists may be effective 
memory agents lacking sedative, anxiogenic, and/or convulsive side effects. 
It has long been known that agonist binding to the benzodiazepine binding site lead 
to cognitive impairment in both animal and humans. 460 This impairment is thought to 
occur by augmentation of GABA-mediated CI" flux through the receptor and has been 
demonstrated to prevent the induction of Long Term Potentiation (LTP) in rodent 
hippocampal neurons. 461 Conversely, BDZ ligands that attenuate GABA-mediated CI" 
passage into neurons, potentiates LTP in rodent hippocampal neurons 462 resulting in the 
facilitation of learning and memory. 170'296'297'463 However, challenges exist in regard to 
developing benzodiazepine inverse agonists for therapeutic utilization, including the 
potential for convulsion, anxiogenesis and hyperactivity. Differing pharmacological 
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profiles associated with individual GABA(A) receptor isoforms has brought forward the 
potential to selectively target specific isoforms either through binding selectivity or 
particular activational profiles. Ligands that behave like an agonist at one behavioral end 
point and behave qualitatively different (i.e. as an antagonist, inverse agonist or no effect) 
at another behavioral end point48- 395 can often be explained by differences in binding 
affinities and/or activation profiles of these BDZR ligands at the multiple GABA(A) 
receptor subtypes throughout the brain. Therefore, this suggests that behavioral influence 
such as cognitive enhancement may, in principle, be separated within a compound class 
from undesirable side effects. For example, compounds such as Rol5-1788, R015-4513, 
ZK-93426 and Ro41-7812 were observed to lack sedative or convulsive properties yet are 
able to attenuate contextual memory impairment in a mouse model of cholinergic 
hypofunction.464"466 Interestingly, BDZR ligand antagonist that do not alter the efficacy 
of GABA, nevertheless possess some degree of intrinsic efficacy.50 
The association of GABA(A) receptor component composition with observed 
receptor mediated physiology has been advanced through the use of transgenic mice 
exhibiting specific point mutations within a subunits leading to altered BDZ ligand 
binding and activation.467 From such efforts, associations have been put forward 
including the involvement of the al subtype in sedative and myorelaxant effects while 
a.2 and a3 subtypes were found to be associated with anxiolytic and anticonvulsant 
effects. 19'21'12468 As stated previously, the a5 subunit, which is primarily expressed in 
the hippocampus and comprises about 20% of the GABA(A) receptors found there, has 
been suggested to be involved in associative temporal and spatial memory. ' Using 
transgenic "knockin" mice Crestani et al., 299' 312' 314 demonstrated a critical role of 
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hippocampal extrasynaptic GABA(A) receptors containing the a5 subunit in associative 
learning. They argue "extrasynaptic a5 subunit containing GABA(A) receptors contribute 
to the regulation of dendritic excitability of hippocampal pyramidal cells with the efficacy 
of excitatory inputs, thereby contributing to synaptic plasticity in regulating the temporal 
•*) oc *)Q8 
association of "threat cues". Furthermore, Maubach et al.," "" hypothesized that a 
compound with inverse agonism selective for a5-containing GABA(A) receptors might 
enhance hippocampally mediated cognitive function. Until recently, only modest 
progress had been made in the design of receptor-subtype specific ligands, however this 
is changing with a variety of papers now reporting success in achieving selectivity in the 
synthesis of BDZ ligands that exhibit 100-fold selectivity for particular GABA(A) 
receptors isoform.315'316'461 Unfortunately, BDZ ligands that exhibit true specificity to a 
single GABA(A) receptor subtype (affinities of a 1000 fold difference between one 
GABA(A) receptor isoform and all the other isoforms) are to date, not available. This 
can be achieved by either binding specificity or through activation specificity, in which a 
compound that does not possess binding specificity but instead elicits specificity through 
the preferential activation of only one subtype combination. Unfortunately, systematic 
diversification of a ligand template in order to increase binding selectivity to a particular 
GABA(A) receptor isoform often results in a deleterious impacts on its activation 
profile. Therefore, it's important to understand the links between ligands' 
physiochemical features and its binding affinity as well as the nature of the activity 
manifested at a particular receptor isoform. 
Senile dementia of the Alzheimer's type (SDAT) and age-related memory decline 
arises from progressive failure of the cholinergic system, leading to impaired memory 
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and deterioration of other cognitive functions.285 The reduction of postsynaptic inhibition 
of cholinergic excitation in the hippocampus may attenuate the impact of this process by 
influencing the functional regulatory pathways involved in cognition by manipulating the 
inhibitory nature of the neurotransmitter GABA. Interestingly, while most 
neurotransmitter receptor systems are degenerating in the brains of individuals with 
SDAT, the GABAergic infrastructure is relatively well preserved including the 
GABA(A) receptor population that contains the a5 subunit. 469' 470 Benzodiazepine 
receptor ligands modulate GABA's regulatory influence on numerous neuronal pathways, 
including the cholinergic pathways of the basal forebrain that project to the hippocampus. 
In situations where the cholinergic excitation is lessened due to the loss of cholinergic 
neurons, as it is in the case of SDAT, precise reduction in GABAergic inhibition in brain 
regions where the weakened cholinergic neurons project could potentially augment the 
functional impact of the ACh released.471 Moreover, numerous cognitive deficit models 
of cholinergic hypofunction, both human and animal, benefit cognitively when GABA 
activity is reduced. 472' 473 Lastly, lesion studies demonstrate that animals with 50-70% 
loss of cortical cholinergic fibers exhibit improved cognitive performance from BDZ 
ligand treatment.474' 475 As the loss of cholinergic neurons in aging and SDAT is 
commonly in the 40-70% range 476-478 until the very last stage, the effects of BDZR 
inverse agonists on restoring neural transmission in animals with partial loss of cortical 
cholinergic inputs suggest development of specific BZD ligands for the treatment of 
cognitive decline associated with aging and SDAT is warranted. 
Large changes in binding and pharmacological activity may be induced by small 
structural changes to active ligands. This has far reaching consequences in both lead 
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optimization but also in discovering new leads from pharmacophore based chemical 
database searches. This is also the basis for the 'latent-hit' phenomena in chemical 
databases.121 Therefore, multivariate statistical approaches embodied in QSAR and 
chemometrics are required to obtain meaningful correlations linking structural variation 
with changes in pharmacology. This affords one the possibility of detecting subtle 
patterns modulating either binding/non-binding and/or activation through a particular 
receptor subtype. However, small changes in a compounds' structural features can also 
elicit deleterious effects on binding and/or activation at a given GABA(A) receptor 
isoform. From such approaches there have been numerous instances of success in rational 
design 291'304'371 including the development of selective COX-2 inhibitors and selective 
seratonin reuptake inhibitors. Both structure based design 479 and indirect design187' 480 
approaches have been employed in guiding chemical transformation of lead compounds 
initially identified via mass-screening. Several groups have investigated the 
structural/chemical basis for binding477 or activational selectivity of particular GABA(A) 
receptor subtypes affecting memory.23''267'274'481 Both avenues are viable strategies for 
discovering pharmacological agents that may be palliative for senile dementia of the 
Alzheimer's type. 
Considerable effort has been made in order to develop pharmacophores that 
characterize the binding of BDZ ligands to their respective binding site between the a 
and y subunits of the various GABA(A) receptor isoforms. Our research group has 
employed hundreds of benzodiazepine site ligands from 10 diverse templates to develop 
the "Comprehensive pharmacophore". To the point of the present study, several groups 
of compounds synthesized by this group have proven to be a fruitful testing ground to 
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elucidate global features that are important for binding selectivity to a5-containing 
GABA(A) receptors, inverse agonism at this receptor subtype and scrutiny as to the 
importance of inverse agonism at these subtypes upon memory, learning and convulsions. 
Other smaller studies include a study of 21 flavanoids461 and an analysis of BDZR 
compounds from diverse templates that bind to and activate GABA(A) receptors 
involved in sedation and anxiolysis.476" 480' 482 While past validation efforts involved 
using these pharmacophores to extract compounds with binding affinity and activity at 
the behavioral endpoint of interest, the pharmacophores themselves are for the most part 
'non-specific'345 in that compounds extracted from chemical database searches bound to 
and activated multiple GABA(A) receptor isoforms. 3D-QSAR (COMFA and 
COMSIA) based on these overlap rules in fact results in equivalent statistics for binding 
models of the ligands regardless of the GABA(A) receptor composition (ie. ocipxy2 
(X2PXY2 (X5PXY2 ot,6Pxy2) (D. Harris; unpublished). As pointed out previously, it is 
important to remember the pharmacophores employed here were developed based on the 
binding affinity of the rigid ligands designed earlier by Trudell.187 
The core aim of this study was to address the structural/chemical basis for selectively 
influencing cognition through modulation of as subunit containing GABA(A) receptors. 
This first step in this process is to understand the structural constraints necessary to elicit 
both potent and selective binding at GABA(A) receptors that contain the as subunit, 
closely followed by developing an understanding of how the structural features influence 
the resulting electrophysiology at as subunit containing GABA(A) receptors. Once this is 
achieved compounds with favorable profiles can then be further evaluated for cognitive 
influence in a mouse model of cognitive impairment. 
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Organization of the Study 
In vitro and in vivo data from both in-house and literature sources were used to 
investigate the underlying basis of selective binding and activation of GABA(A) 
receptors containing the a5 subunit. Previously BDZ ligands were examined for their 
ability to influence spontaneous locomotor activity and contextual memory in adult 
C57B1/6 mice. 19 However, the compounds used in those studies were not selective 
enough in regards to binding to the a5(33y2 GABA(A) receptor isoform in order to 
establish that this receptor isoform is capable of influencing contextual memory on its 
own at a level that would be considered therapeutically viable. Initial computational 
work on that original set of compounds (Figure 145) suggested that particular 
stereoelectronic descriptors (e.g Sterimol L parameter) were discriminants of whether a 
compound that exhibited reasonable binding affinity to the a5f33y2 isoform could 
attenuate scopolamine-induced contextual memory impairment. This served as the initial 
criteria for selecting additional compounds to be used in the present study. In the current 
effort in vitro binding and electrophysiological assessments of the test set of compounds 
OI • 
were used in conjunction with computational methods. Consequently, this enabled one 
to develop a QSAR representative of selective binding and activation. We then sought to 
correlate structural, electrostatic, thermodynamic, and electronic properties of both in-
house and literature reported compounds of interest with their respective in vitro binding 
affinities and electrophysiological responses in cells only expressing one of the 
GABA(A) receptor variants. Compounds with desirable profiles were also assessed for 
their ability to attenuate contextual memory impairment in the previously characterized 
mouse model. 366 The goal was to discover chemical discriminants that favor selective 
influence over 015 containing GABA(A) receptors in order to test the hypothesis that one 
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can selectively influence contextual memory via a5Pxy2 receptors alone. Through this 
process it was also felt one would limit side effects (ie. sedation, convulsion, etc) that 
typically arise from non-selective binding of a compound to multiple GABA(A) receptor 
isoforms. The first step was to compare/contrast initial pharmacophore models 
previously developed for contextual memory influence and sedation. 396 The focus was 
restricted in the current work to binding affinities associated with just the aipxy2 and 
(x5Pxy2 receptor isoforms. Pharmcophore definitions were validated by using them to 
search chemical databases to find 'hits' that were then tested for binding to the otlpxy2, 
and/or a5Pxy2 GABA(A) receptor isoforms expressed individually in cell expression 
system. Physiochemical properties of compounds from the training set were then 
evaluated in regards to the requirements of the pharmacophores (alignment rules). 
Correlations were sought between chemical properties and both binding and activation of 
the cx5pxy2 GABA(A) receptor isoforms. This was achieved by multivariate 
discriminant analysis as well as 3D-QSAR/COMSIA and fragment QSAR approaches in 
order to identify descriptors that offered discrimination between aipxy2 and a5Pxy2 
receptor isoforms. Through this approach it was determined which chemical features are 
intimately connected with a compound's ability to exhibit binding specificity and/or a 
desirable electrophysiological activation profiles (Figure 145). 
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Figure 146. Examples illustrating subtle variations in scaffold substitutions that modulate 
behavioral profiles of each of the selected benzodiazepine ligands 
Binding and Activational Selectivity in the Development of a Palliative Memory 
Agent. 
Most BDZ ligands that bind to GABA(A) receptors do so with a lack of binding 
specificity. When developing a pallitive memory agent, lack of binding or activational 
selectivity can lead to unacceptable side effects. To demonstrate this point one looked at 
RY-80, RY-23, and RY-24 (Figure 147) all three are structurally similar BDZ ligands, 
which exhibit 40-70 fold more selectivity for a5(3xy2 containing GABA(A) receptor 
isoforms, over other GABA(A) receptor isoforms.16 Despite the reasonably good a5 
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selectivity of these three compounds, they each elicit convulsions at relatively low doses 
when administered systemically. This somewhat limits their usefulness in thoroughly 
examining a5 influence over contextual memory as well as potential therapeutic viability. 
The electrophysiological profile of one of these compounds, RY24 (Fig 147), serves to 
underscore several aspects that one must be cognizant of in order to employ compounds 
within this class for palliative treatment of memory deficits. In this example the 
electrophysiological response of RY24 relative to GABA(A) receptors containing one of 
the a subunit subtypes (1, 2, 3, 4, 5 and 6) in combination with the P3 and y2 subunits 
GABA(A) receptors expressed in Xenopus oocytes is illustrated. At nanomolar 
concentrations RY-24 modulated GABA-induced currents in an a5-subtype selective 
manner. To test for agonistic or inverse agonistic effects, the compound was coapplied 
with a concentration of GABA that induced approximately 20% of the maximum current 
amplitude. In GABA(A) receptors containing the al, a2 and a5 subunits nanomolar 
concentrations of RY-24 reduced GABA elicited currents in a concentration dependent 
manner. The EC50 for this effect was approximately 10 fold lower for a5 containing 
receptors than for those containing al and a2 (Table 37) receptors. In a3 containing 
receptors no apparent modulation of GABA elicited currents by RY-24 was seen. 
However, in these receptors l^iM RY-24 reduced the stimulation by 30nM diazepam 
(284.8 ± 48.7 % at GABA EC3) by 96.3 ± 4.7 %. In GABA(A) receptors that contain 0*4 
and a6 high nanomolar concentrations of RY-24 weakly stimulated GABA elicited 
currents (Figure 147). Due to the limited concentration range maximum modulation of 
GABA elicited currents by RY-24 was estimated by extrapolation (curve-fit by GraphPad 
Prism) (Table 37). Estimated maximum effect was dependent on the alpha-subunit, with 
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the a5 subunit showing bigger maximum effects than al and a2 (-40.4 ± 0.8%,-31.0 ± 
2.5% and -20.7 ± 1.2%, respectively). In a3 containing receptors, despite obvious 
binding of the compound (inhibition of diazepam) virtually no effect was seen (-
3.3±2.1%). With this in mind, the electrophysiological profile of RY24 displayed in 
Figure 147 indicated that the GABA(A) receptor isoforms that contain the al, a2 or a5 all 
reduced the relative amplitude of the current elicited by GABA thereby favoring neuronal 
excitation. The binding affinities of RY24 are relatively high at all the different GABA(A) 
receptor isoforms with selectivity for the a5 over the other a containing GABA(A) 
receptor isoforms being in the 10-70 range.16 Because the al (and a2) receptors comprise 
a large proportion of all the GABA(A) receptors found throughout the brain, the 
administration of RY-24 would favor an increase in excitatory tone in numerous brain 
regions (by al and a2 subtypes), subsequently resulting in proconvulsant or convulsive 
behavior. Conversely, by knowing the electrophysiology and binding affinities of RY-24 
in regards to the various a subunits, one can hypothesize about the a subunits that are 
likely to contribute to the convulsant effects of systemically administered RY-24. 
Furthermore, the al subtype has been reported to mediate, in part, the proconvulsant 
effects of PTZ. 483 The relatively high affinity binding of RY-24 at the al subtypes 
would be in line with that observation. As convulsant behavior is generally thought to 
result from an increase in neuronal excitation, the likely candidates include al,a2 and 
a5 containing GABA(A) receptors, which would each attenuate GABA's inhibitory 
effect in the presence of RY-24 (Fig 154). A similar observation was presented by Atack 
1 oo 
et al, for RY80 in which they suggest the proconvulsant effects of RY80 cannot be 
attributed solely to the a5 containing GABA(A) receptor isoform . When, RY-24 is 
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given systemically to mice it elicits convulsive behavior at a dose as low as 1 mg/kg. 
Thereby, confounding its evaluation for cognitive influence by systemic administration. 
However, when Bailey461 injected RY-24 (1 j_ig/|al) into the hippocampus they observed 
an increase in Pavlovian fear conditioning over that seen for vehicle alone. No 
convulsive behavior was noted by this administration route even at a dose of 10 \igi\xL. 
Since the expression of a subunits of the GABA(A) receptor is not equal in the 
hippocampus, with the following order of abundance al>a5>a2, a4>a3, one can begin 
to make assumptions as to the a subtype(s) that are potentially involved in the cognitive 
effects mediated by the hippocampus. Because RY024 exhibited a 60-70 fold higher 
affinity towards the a5-containing GABA(A) receptors over the al and a2 containing 
receptors (0.4 nM vs 26-27 nM), the lowest dose would largely affect the a5-containing 
GABA(A) receptors with the recruitment of al and a2 containing receptors as the dose 
increases. As can be seen in Figure 147 all three of these receptor isoforms elicit inverse 
agonism and may be mediating the fear conditioning effect. At the highest dose of 10 
|ig/|j.L the a4-containing receptors, which elicit an agonistic response, could potentially 
contribute to the decrease in anxiogenic effects observed by Bailey et al.297'484 The a3 
receptor is not likely to play a role in this observed behavior because it is not expressed 
">71 
to any appreciable degree in the hippocampus and is electrophysiologically silent while 
the a6 subunit was not expressed at all in the hippocampus. 
351 
a! 26.9 
a2 26.3 
a3 IK.7 
a5 0.4 
a6 5.1 
al 19" 
a2 143 
a3 255 
a5 2.61 
a6 5K.6 
al 2M 
a2 21.4 
a3 198 
a 5 1.68 
a6 >100 
I50n 
so 
0.1nM 1nM lOpM 100nM 
RY024 [logM] 
• a6P3y2 
D <*4p3Y2 
• a3P3Y2 
T 012P3Y2 
4 aiP3Y2 
" «5P3Y2 
o 
Figure 147. Structures of RY23/RY24/ and RY80 along with the electrophysiological characterization 
of RY24 
Illustrated in Figure 147 are the dose response curves for RY024 in oocytes 
expressing different subunit combinations of GABA(A) receptors. Subtype combinations 
are indicated in legends. cRNA-injected Xenopus oocytes were held at -60 mV under 
two-electrode voltage clamp. Increasing concentrations of RY024 were superfused 
together with a GABA concentration eliciting approximately 20% of the maximal current 
amplitude. RY024 was preapplied for 30 sec before the addition of GABA, which was 
coapplied with the drugs until a peak response was observed. Data were normalized for 
each curve assuming 100% for the response in the absence of RY024. RY024 was made 
up and diluted as stock solution in DMSO. Final concentrations of DMSO perfusing the 
oocyte were 0.1%. Values are presented as mean ± SD of at least four oocytes from at 
least two batches. Using the two electrode voltage clamp method currents in the (iA range 
were measured for all subunit combinations in response to application of a saturating 
concentration of GABA (10 mM). Two electrode voltage clamp experiments were 
performed to test whether RY-24 triggered chloride currents, modulated GABA-induced 
352 
currents or antagonized the effects of benzodiazepines in Xenopus oocytes that express 
GABA(A) receptors. In the absence of GAB A, RY-24 at concentrations up to 1 fiM was 
not able to trigger chloride currents in any of the tested subtypes of the GABA(A) 
receptor. It was a weak inverse agonist at al and a2 subtypes and a potent a5 subtype 
inverse agonist (negative modulator). Hence, the activity of RY24 is easy to understand. 
Enhanced cognition seen by Bailey and others is due to negative modulation at the a5 
subtype, while the proconvulsant/convulsant effects are due particularly to negative 
modulation at al subtypes with some contribution from negative modulation at a2 
subtypes. 
Table 37. Concentration-response data for modulation of control GABA EC2o by RY024 in 
different GABA(A) receptor subtypes 
Subtype EC50 (iM (95% confidence Estimated maximum modulation ± SD Number of oocytes 
interval) * 
cdp3y2 74.4 nM (38.3 -144.3) -31.0±2.5% 5 
0t2p3y2 95.5 nM (59.4-153.6) -20.7±1.2% 7 
Ct3p3y2 -3.3±2.1% 5 
ot4P3y2 324.4 |iM (22.6-4651.5) +43.0±15.9 8 
cx533y2 9.8 nM (8. 1 - 1 1 . 9 )  -40.4±0.8% 8 
a6p3y2 51.7 nM (35.8-74.6) +35.2±1.5% 7 
*estimated by curve-fit (GraphPad Prism) 
Because PWZ-029 (related to RY24) was subtype selective only at a5 receptor 
subtypes (see 56 below) it was selected for cognitive assessment based on its GABA(A) 
receptor subtype binding profile and computed properties consistent with discriminant 
analyses (see section 3D QSAR and Fragment QSAR). PWZ-029 was not observed to 
be convulsive up to 30 mg/kg in mice or even at higher doses. In fact, long after the 
studies in this dissertation were completed PWZ-029 was found to be a weak 
353 
anticonvulsant in mice (James Staples, NINDS, unpublished results). It cannot be 
proconvulsant or convulsant. 
Figure 148. PWZ-029 within the pharmacophore/receptor model for the a5p3y2 GABA(A) BzR 
subtype 
This observation suggests one of two interpretations, one being that the a5 
receptors were not primarily involved in eliciting the convulsive actions of previous 
compounds or that an overall reduction in the inhibitory tone of the brain via a 
combination of the al, a2, a3 and a5 containing GABA(A) receptors could result in a 
global increase in excitation thereby resulting in a seizure prone brain; that is 
proconvulsant or convulsant effects in vivo. 
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PWZ-029 362.4 180.3 328.2 ND 6.185 ND 
Either explanation bolsters the concept of potential therapeutic utilization, whether 
through highly selective binding and/or selective efficacy that is mediated through a5 
subunit containing GABA(A) receptors. However, RY10, a similar compound to RY24 
with selectivity for the a5 over the other a containing GAB A(A) receptors of between 15-
120 fold was tested in the concentration range of 0.1-10 p.M on HEK cells expressing the 
a5P2y2, RY10 elicited a relatively mild attenuation of GABA-induced CI" flux. 
However, when RY10, a compound from same compound class as RY24, was 
administered systemically at a dose range of 10-30 mg/kg it lacked convulsive effects and 
exhibited marginal, yet significant, attenuation of contextual memory impairment in the 
cognitively impaired mouse model.460'485"487 
Modulation of EC3 In oocytes currents 
By PWZ-029 
<*» 160-
o -•-« 1 (S3 2 N 
# 70 • 0=4 , , , r-
1nM iGnM lOOnW IpM 10pM 
[PWZ-029] 
355 
Affinity of PWZ for ax(33y2 (x=l-6) benzodiazepine receptor isoforms 
al a2 a3 a4 a5 a6 
Merck 
data 
>300 >300 >300 ND 38.5 >300 
Moltech 
data 
920 ND ND ND 30 ND 
UNC-Roth 
data 
362.4 180.330 328.2 ND 6.185 ND 
Due to the low selectivity of RY10 (see Figure 145 for structures) one can not clearly 
attribute its cognitive effects mainly to the a5 subunit containing GABA(A) receptors. 
Another approach to achieving cognitive influence is through functional selectivity, 
which has been demonstrated with the Merck compound a5IA, although it is not clear 
whether there was a fundamental understanding of the molecular facets underlying that 
functional selectivity.187' 461 While a5IA lacks binding selectivity for the a5 subunit 
containing GABA(A) receptors over other a subunit isoforms of the GABA(A) receptor, 
it exhibits only marginal electrophysiological effects at GABA(A) receptor isoforms 
containing the al, a2 or a3 with about a 30-40% reduction in the GABA-induced current 
amplitude only occurring at GABA(A) receptor isoforms that contain the a5 subunit. 
Compound a5IA was also observed to enhance performance in rats in the Morris water 
maze, a spatial memory test with some overlap with contextual memory, both are likely 
mediated by GABA(A) receptors containing the a5 subunit. 488 PWZ-029, like a5IA, is 
an inverse agonist at the a5 subunit, however unlike a5IA, PWZ-029 does not bind to 
al, a2, and a3 subtypes. 
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Validation of 3D Pharmacophore for Sedation and Contextual Memory Endpoints 
by 3D-Database Search and Testing (Harris, Delorey, Clayton et al.) 
Harris and Delorey developed a pharmacophore independently of the Milwaukee 
group for contextual memory and sedation endpoints centered on diverse sets of 
nonselective ligands based on 1,4-benzodiazepines, imidazobenzodiazepines, 
imidazopyridines, P-carbolines, pyrazoloquinolines, imidazoquinolines, 
imidazopyrimidines, and imidazothienodiazepines classes which have been characterized 
in relation to sedation (influence on spontaneous locomotor activity) and attenuation of 
scopolamine-induced contextual memory impairment.489 This set was dominantly 
comprised of benzodiazepine ligands that lacked selectivity to the benzodiazepine 
binding sites found on the various GABA(A) receptor isoforms. Using such ligands 
allowed one to first determine core features common to numerous classes of 
benzodiazepine ligands that mediate their behavioral effects through various GABA(A) 
receptors isoforms. Depicted in Figure 145 are a diverse set of compounds along with 
their binding affinities at the alp2y2, and a5p2y2 GABA(A) receptor isoforms. As is 
typical for most benzodiazepines, subtle structural changes to pendant groups attached to 
particular scaffolds/templates resulted in significant variations in binding profiles relative 
to the different GABA(A) receptor isoforms. Moreover, as demonstrated in Figure 146, 
small structural/chemical variations can drastically alter the observed behavioral 
pharmacology for a given compound template e.g. the CGS series in this Figure 
illustrates how permutation of a -H, to a -OCH3 or -CI group dramatically alters the 
pharmacological profile of the pyrizoquinolines (CGS8216, CGS9896, and CGS9895). 
While changes in the -(CH2)n- bridgehead and terminus of classic 
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imidazobenzodiazepines alters the activity profiles, as illustrated by Ro 15-1788 and 
Ro 16-6028 as well.489 
Distance 
No's 
Sedation Memory 
1-2 4.9±1.1 3.2±1.7 
1-3 5.6±1.8 3.5±1.0 
1-4 4.4±1.1 6.9±0.7 
1-5 2.3±0.9 
2-3 4.5±1.2 5.2±1.2 
2-4 4.7±1.2 8.9±1.4 
2-5 3.1 ±1.3 
3-4 5.1±1.1 4.9±0.0 
3-5 3.0±0.8 
4-5 7.8±1.3 
Figure 149. Harris pharmacophore. The inset table displays the distances between the 
pharmacophore points (1,2 = hydrogen bond acceptor, 3 = hydrophobic terminus, 4 = 
aliphatic/aromatic centroid with LUMO, 5 = ring system containing hydrogen bond acceptor) 
identified in benzodiazepines binding to and activating GABA(A) receptor subtypes associated with 
sedation and memory. In the upper right panel is a graphical depiction of 3D pharmacophore points 
for compounds having at the sedation and memory endpoints corresponding to the table in the upper 
left. Lower left and right panels show the overlap of several compounds complying with the sedation 
and memory pharmacophores, respectively, illustrating some of the commonalities: green spheres 
represent hydrogen bond acceptors, red spheres represent the polar core ring system, purple ring 
centroid represents the aromatic ring, LUMO center, blue sphere represents the hydrophobic group 
at one end of the ligands. 
Not surprisingly pharmacophores derived from non-selective compounds that 
were active at both the sedation and contextual memory endpoints exhibit similar 
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distance (pharmacophore) metrics. The pharmacophores depicted in Figure 149 were 
derived by: 1) development of conformational libraries based on nested rotation of all 
rotatable bonds in compounds previously examined for influence on sedation or 
contextual memory 489 2) the examination of whether a common set of inter-
pharmacophore point distances is/are present for at least 1-conformation of each ligand, 
between all compounds in the training set using a 2 A distance criteria and the lowest 10 
kcal/mol energy conformer. Illustrated in Figure 150, is a small subset of compounds 
that were extracted from the Maybridge Chemical database by employing the distance 
metrics representing the distances between the pharmacophore entities established for the 
contextual memory pharmacophore. Several of these compounds: 1) were found to 
exhibit sub-micromolar binding affinities at al(32y2 and/or a5p2y2 GABA(A) receptor 
isoforms and could be considered lead compounds for further refinement, 2) two of these 
compounds were able to influence spontaneous locomotor activity. These results 
illustrate that the contextual memory pharmacophore can serve to increase the likelihood 
of identifying compounds from a chemical database that are capable of binding to 
al(32y2, and/or a5p2y2 receptor isoforms and therefore 'enrich' the number of 
compounds extracted that bind to GABA(A) receptors. However, the Harris model itself 
does not encode sufficient information by itself to identify a5 subtype selective 
compounds from a binding or activational perspective. Rather the development of this 
pharmacophore served as a basis for overlapping structural features prior to performing 
3D-QSAR (COMSIA) computations and serves to select a particular set of conformations 
to be used in computing the Fragment QSAR. It is these QSARs, rather than the initial 
pharmacophore, that will actually provide the insights that will eventually aid in the 
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understanding of what is required to achieve the desired selectivity in the Harris model 
derived from the Milwaukee-based library of compounds. 
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Figure 150. Selected structures retrieved from pharmacophore directed searches of the May bridge 
Chemical Database with indicated binding affinities (IC50, |HJ|Rol5-4513 competition in a cell based 
binding assay, see Methods Section) to GABA(A) receptors with either the aip2y2 or a5p2y2 
stoichiometry. 
3D-QSAR (COMSIA) Models of a5P2y2 and aip2y2 Receptor Isoforms. 
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Displayed in Figure 151 is the use of the above mentioned overlap rule, to 
develop 3D-QSAR models based on the experimental binding data, which in turn 
provided a modest predictivity when diverse templates were used.187 Moreover, given 
that it was developed from a set of non-selective compounds, the same overlap rule gives 
rise to predictive 3D-QSARs for both a5p2y2 and aip2y2 receptor combinations. 
Illustrated in figure 151 is the predictive q2 for otl [32y2 binding to be 0.43 and a non-
crossvalidated r2 of 0.99 with a standard error of 0.50 while shown in Figure 152, using 
the same overlap rule, contains a model for a5p2y2 binding with a q2=0.41, q2=0.99 and 
a standard error of 0.52. The order of magnitude of q2 values are reflective of the typical 
predictivity for 3D-QSAR models developed from the use of compounds from diverse 
templates such as those depicted in Figure 145. The expectation value of q2 for such 
models involving a diverse training set is typically on the order of 0.3.121 Such QSAR's 
can be used to predict order of magnitude binding affinities as displayed in the histogram 
in the lower panel of Figure 158 showing both the predicted and actual Kds (in nM). The 
3D-QSAR (COMSIA) for compounds that bind nonspecifically to al [32y2 and a5p2y2 
would indicate comparable contributions of hydrophobic, electrostatic and steric 
COMSIA fields as indicated by the magnitude of the fractions, which reflect the relative 
contributions to the COMSIA regression equation, as reported in Table 38. The inset 
colored molecule in Figure 152 is of RY-023 and shows how variations in the 
electrostatic (red/blue) components explain variations in the compounds binding affinity. 
The ester functional group is included in the region where modulation of charge affecting 
electrostatics would affect the binding affinity. While the use of a diverse training set is 
useful for developing a model capable of providing predictions of binding affinities of 
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diverse compounds, one loses information as to what features are most important to 
binding selectivity when employing such an approach 121. 170 
RY-10 
Cmpd 44 
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Figure 151. COMSIA based on overlap rules and observed binding affinities for BZD training set 
ligands at aip2y2 subunits. 
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Figure 152. COMSIA model predictive of compounds binding to the aSp2y2 GABA(A) receptor 
isoform. 
Table 38. Normalization coefficients and fractions of the components in the COMSIA analyses for A, 
a diverse training set of benzodiazepines and B, a homogenous set consisting of 
im idazobenzodiazepines* 
A cl5/>2;'2 alp'2>-2 
component norm coeff fraction norm cue If fraction 
electrostatic I.4S 0.35 1.14 0.29 
steric 1.13 0.27 0.99 0.26 
hydrophobic 1.63 0.38 1.63 0.45 
B homogenou s set of imiilazobenzodiazepines" 
component norm coeff fraction norm coeff fraction 
electrostatic 0.12 0.041 1.14 0.256 
steric 1.04 0.35 1.15 0.29 
hydrophobic I.XI 0.61 1.73 0.44 
1 RY-10, RY-024, RY-066, RY-080, Rol5-1788, Rol5-4513, PWZ-029, PWZ-031, PWZ-035A, and 
cmpd 44. 
364 
We therefore next took a subset of 10 imidazobenzodiazepines that were more 
homogenous in order to analyze what characteristics lead to more selective binding in 
regards to the a5p2y2 receptor isoform. The analysis which resulted gave a q2=0.94, 
R2=0.99 and a standard error of 0.09. While an analysis based on a narrow compound 
class such as this has limited predictivity for templates other than 
imidazobenzodiazepines, it does provide a means to examine the relative importance of 
particular components in regards to influencing the modulation of binding affinities. For 
example, the lower portion of Table 38 provides an analysis of the importance of the 
contribution (fraction) of the electrostatic component in explaining the variations in the 
experimental binding affinity. The value of the electrostatic componet was found to be 
0.041, which is minor compared to the contributions of the hydrophobic and steric 
components, which were 0.61 and 0.35, respectively. Given that the more restrictive 
COMSIA model is suggestive of a discriminating factor for binding involving 
electrostatic factors we undertook a quantum mechanical study of this series to probe the 
underlying electrostatic potential surfaces. This information was then incorporated with 
the volumes of the fragments in a fragment QSAR for binding thereby providing an 
independent cross-check on the information gleaned from the COMSIA analysis. 
Fragment QSAR: Facets Effecting Differential Binding Between aip2y2 and a5P2y2 
GABA(A) Receptor Isoforms. 
We next sought to scrutinize the robustness of the conclusions deduced in the 
COMSIA analysis by performing an analysis via a fragment QSAR approach. While 3D-
QSAR often provides some clues as to variations in binding and/or activity with 
differences in molecular/grid based fields, the results are often sensitive to how the 
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compounds are aligned/overlapped. In principle, one should obtain similar conclusions 
about what is important from a fragment QSAR analysis as one does from COMSIA 
analysis from an analysis of the whole ligand if you are using a set of ligands based on a 
shared template (see Figure 153). The idea behind this additional analysis is illustrated 
through the four panels depicted in Figure 154, which displayed the computed molecular 
electrostatic potential (MEP) surfaces computed on top of the van der Waals surface of 
the ligands. Below each panel are listed the binding affinities at the a5p2y2 and a 1 P2y2 
GABA(A) receptor isoforms. In the present example we are computing the MEP for the 
whole molecule, rather than just the fragments/substitutions to the core template. Note 
that the effect of the substitution of the ethyl ester moiety in Rol5-1310 by successively 
less polar fragments (moving clockwise in the figure) to -CH2OCH3, -
(C=0)CH2CH2CH2CH3, and finally -CH2CH2CH2CH2CH3 does not provide a simple 
explanation as to the importance of electrostatic versus steric properties independent of 
each other. From this, one can deduce that the changes in the electrostatic potential 
surface minimum, close to the benzodiazepine ring -N-, is only slightly altered by the 
changes in the fragment a few angstroms away (i.e. there are changes, but there small). 
The changes in the second electrostatic minimum, closest to the fragment, are more 
pronounced. Note that as one proceeds clockwise from Rol5-1310 to PWZ-029 to 
compouds 32 and 40, the binding affinities to a5p2y2 and alp2y2 both drop, but that the 
binding affinity to ocip2y2 drops more rapidly than for a5p2y2 and appears to have an 
apparent correlation to the changes in the presence/absence and depth of the second 
electrostatic minimum proximate to the changing fragment. This analysis was performed 
after the quantitative fragment analysis, discussed below, and reveals in hindsight, the 
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chemical picture behind the following analysis. The pattern is not apparent from staring 
at the MEP'S computed for all the compounds shown in Figure 153. Illustrated in Figure 
155 is the fragment QSAR analyses for binding affinities as a function of the electrostatic 
potential minimum, computed for the fragment itself, the fragment volume and fragment 
hydropobicity. The analysis of the compounds in terms of these variables results in r2 
values of 0.84 and 0.94 for binding models for a5p2y2 and aip2y2, respectively. The 
QSAR equations highlighted in the figure indicated, analogous to the COMSIA analyses, 
that while the electrostatic component is finite for both a5p2y2 and aip2y2 receptor 
subtype binding models that it is more important for aip2y2 than a5p2y2. Therefore 
while, selectivity is enhanced by reduction in the polar components in the fragment, it 
takes place at the expense of reduced binding affinity to a5p2y2 receptor subtypes. The 
fragment QSAR analysis for binding have statistical significant with F3 7 values for the 
analysis are 12.0 and 36.1, which indicates that the regressions in terms of the variables 
indicated are significant at the 99% confidence level.490 
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Figure 153. Selected benzodiazepines employed in the fragment QSAR analyses for aip3y2 and 
a5P3y2 binding 
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Figure 154. Computed electrostatic potentials (computed using density function theory (B3LYP/6-
3G**) evaluated on the van der Waals surfaces of compounds showing selectivity of binding to 
a533y2 versus aip3y2 
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Figure 155. Fragment QSAR for the binding of compounds in figure 145 to <x5P3y2 (left) and alp3y2 
(right) receptor isoforms, illustrating, via the derived QSAR relations at the bottom of the figures, 
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that the electrostatic contributions (EL min) are more important for ligand binding to the <x5P3y2 
receptor isoform than to the aip3y2 isoform, as indicated by the larger magnitude of the coefficient 
of the electrostatic term for the a5p3y2 isoform compared to that for the aip3y2 isoform. SE = 
standard error. 
The pharmacophore depicted in Figure 149 created from information derived from 
compounds that exhibited activity at the contextual memory endpoint, revealed 
commonalities in the ligands capable of binding to and activating aip2y2 receptors, in 
other words the core features are in common and have similar distance relationships.491 
Most of the training set compounds, illustrated in Figure 145, have an ester moiety at one 
end of the ligand that appears to be essential to cause substantial binding affinities to the 
GABA(A) receptors associated with sedation and contextual memory effects. However, 
the results above show that the elimination of this hydrogen bond acceptor nevertheless 
resulted in a substantial binding affinity to the a5p2y2 receptor subtype (see PWZ-029), 
but with lesser binding affinities to other subtypes. This indicated that one of the 
pharmacophore points indicated in Figure 149 is not essential in order to elicit substantial 
binding affinity to the a5p2y2 isoform. However, it is not yet clear whether the inclusion 
of such a polar hydrogen bond accepting group at this location might not lead to an 
increase in the binding affinity by an order of magnitude. The compounds PWZ-029, 
PWZ-31A, and PWZ-35A in Figure 153, originally reported by Huang et al., 461 were 
reported only as having binding affinities of greater than 300 nM. Recently, binding 
assays were performed (see methods) in order to establish a more accurate value for 
compound 34. A binding affinity of 920 nM to aip2y2 and 8 |aM to a6p2y2 GABA(A) 
receptor isoforms compared to the binding affinity of this compound at a5P2y2 of 39 nM 
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(compound 34/ PWZ-029).492 By all indications the elimination of the ester moiety from 
the 1.4-BDZ template offered discrimination between aip2y2/a6p2y2 and a5p2y2 
receptor compositions. The extra hydrogen bond acceptor was virtually a requirement for 
binding to al p2y2/a6p2y2 BzR but not a5p2y2 isoforms. The pharmacological 
activities of these compounds will be further addressed below, 
GABA(A) receptors containing aip2y2, a2p2y2 and a5p2y2 subunit compositions 
are believed to be associated with sedative, anxiolytic, and memory effects, respectively. 
A fi 1 
Given the 70% sequence identity between a subunits, this implied that small 
differences in the BZD ligand binding site, situated at the interface between the ax and j2 
subunits, were responsible for large changes in binding and activation. Renard and 
coworkers illustrated this principle in site directed mutagenesis studies on a5p2y2 
subunits wherein they introduced a5-P162T, a5-E200G, and a5-T204S mutations.493-495 
The authors of that study argued that the first two mutations appeared to alter the binding 
pocket conformation whereas a5-T204S appeared to better allow the formation of a 
hydrogen bond with a proton acceptor in Zolpidem. The a5-T204S mutation itself 
seemed to confer a 1-like binding properties for Zolpidem in a receptor subtype that was 
essentially a5 in character in that it changed the binding affinity of Zolpidem from 
>10000 nM to ~300nM. Clearly fine tuning of the hydrogen bonding complementarity of 
ligand and receptor is a significant modulator of binding subtype selectivity for ligands 
binding to ct5p2y2 subunits. 
Computational Assessment of Molecular Properties Correlated with 
Electrophysiological Response 
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After examination of the molecular properties that provide insight into binding 
discrimination between a5p2y2 and aip2y2 receptor isoforms one next sought to 
determine what molecular properties (cf. Table 39) were correlated with the 
electrophysiological response and attenuation of scopolamine induced contextual 
memory impairment from an earlier study. 496 The early assessment of fear conditioned 
J.Q7 
contextual memory response used sterimol descriptors, polar and nonpolar volumes, 
hydrophobicities, free energies of solvation, electronic properties (HOMO, LUMO 
energetics), and solvent accessible surface areas in a discriminant variable test of the 
70 f\ ~)Q1 
ability to affect fear conditioned contextual memory results. ' These preliminary 
analyses indicated that the longest dimension of the ligands was able to discriminate 
between compounds that were able to attenuate scopolamine-induced contextual memory 
impariment from those that were not. This provided the working rationale to select an 
initial set of compounds for electrophysiological evaluation in regards to a5p2y2 
activation. Information was also supplemented from data on other compounds reported 
in the literature. COMSIA and fragment QSAR analyses of the electrophysiogical data of 
compounds were used to determine molecular descriptors that correlated with the 
electrophysiological response at the a5pxy2 subtype to see to what extent these 
descriptors correlated with descriptors derived from the analysis of the behavioral data 
set. 
O 
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Table 39. Fragment properties for the imidazobenzodiazepines shown in Figure 153. 
ln(Ea5+100) R, LI B1 (H-L)l HYD1 R 2 12 B2 (H-L)2 (HYD)2 
RY10 4.52 -C02Et 7.81 3.09 -12.46 0.06 -CH2CH, 5.44 2.64 -15.86 1.30 
R0151788 4.56 -C02Et 7.81 3.09 -12.46 0.06 -F 3.29 1.30 -20.78 3.77 
R0166028 4.97 -C02Et 7.81 3.09 -12.46 0.06 -H 3.02 1.17 -19.89 0.66 
R0154513 4.58 -C02Et 7.81 3.09 -12.46 0.06 -N, 5.71 2.25 -10.38 -2.45 
PWZ-29A 4.26 -CH2OCH, 6.44 2.75 -13.65 0.28 -CI 4.22 1.77 -14.20 0.66 
RY24 4.09 -C02tBu 7.73 3.87 -12.58 0.81 -CCH 5.69 1.76 -13.53 1.78 
RY23 3.69 -C02tBu 7.73 3.87 -12.58 0.81 -CCSi(CH,)3 7.87 4.16 -12.79 2.83 
PWZ-31A 4.55 -CH2C1 5.29 2.82 -12.92 0.99 -CI 4.22 1.77 -14.20 0.66 
PWZ-35A 4.60 -CH2OCH2CH, 7.65 2.69 -13.42 0.67 -CI 4.22 1.77 -14.20 0.66 
RY66/CMPD 4.42 -C02Et 7.81 3.09 -12.46 0.06 -CCSi(CH,)3 7.87 4.16 -12.79 2.83 
47 
RY80 4.10 -COjEt 7.81 3.09 -12.46 0.06 -CCH 5.69 1.76 -13.53 1.78 
COMSIA analyses 
Illustrated in Figure 156 are compounds are overlapped using the pharmacophore in 
Figure 149. Table 39 lists the results of a comparative molecular similarity index 
(COMSIA) analysis applied to electrophysiological data and employing steric, 
hydrophobic, and electrostatic COMSIA fields which surrounded the overlapped ligands 
(see Methods). In this type of analysis each of the physiochemical descriptors are given a 
gaussian weighted functional form and then similarity indices are computed between the 
training set compounds and a probe atom. 296,297 In Figure 153 are the structures of the 
ligands and the electrophysiological results at luM. The analysis provided a modestly 
predictive result with a q2 (predictive r2) of 0.35 and an r2 of 0.99 (Figure 157). The 
weighting of the COMISIA descriptors in this analysis indicated that steric and 
hydrophobic components between the ligands are key factors in explaining the 
differences in their electrophysiological activities at the a5p2y2 GABA(A) receptor 
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subtype. These initial results supported a correlation between substitutions altering the 
length of the ligands and the ligands activity, initially deduced from examination of the 
behavioral results. 
COMSIA_EFFICACY 
Q2=0.35 
R2=0.99 
4.7 
ln(Effa5+100) 
Figure 156. COMSIA analyses (bottom) for the electrophysiological responses (ln^aS) + 100|) of 
the imidazobenzodiazepines from Figure 153 relative to the a5p3y2 GABA(A) receptor isoform. The 
molecular superposition used to perform the COMSIA is shown (above). This COMSIA analyses 
highlights the importance of steric and hydrophobic features in explaining variations in the 
electrophysiological response: (Inl^aS) + 100]) at a5fS3y2 in that these coefficients (0.3 steric/0.06 
hydrophobic) are significantly larger than the electrostatic components (0.1 electrostatic). 
I Norm.Coeff. Fraction 
4.5 i " 
! STERIC 0.614 0.261 
4.3 * ELECTROSTATIC 0.258 0.109 
i HYDROPHOBIC 1.487 0.630 , 
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Figure 157. Fragment QSAR analyses of selected properties of the substituents on the common 
imidazobenzodiazepine template in Table 39. The coefficients of the terms in the QSAR equations 
indicate the correlations of the magnitude of the fragment Sterimoi L (LI and L2), HOMO-LUMO 
(HL1 and HL2), and hydrophobicities (HYD1 and HYD2) of the terminal substituents with the 
resulting electrophysiological response. The finding of significant QSAR coefficients for the fragment 
Sterimoi L values of the second substituents (Table 39) is consistent with the initial notion derived 
from COMSIA analyses (see A) that ligand length is correlated with electrophysiological response. 
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COMSIA analysis exhibits strong sensitivities to the overlap criteria applied to the 
compound set. Therefore, one took steps to independently verify that variations, which 
resulted in a change in the longest dimension of the ligands, which was correlated with 
the electrophysiological response seen in the a5p2y2 receptor subtype. The results in 
Figure 157 are the results of a fragment QSAR analysis in which variations in the 
electrophysiological response were modeled in terms of the length of the 'fragment' 
substitutions at either end of the ligand template along with a second variable: HOMO-
LUMO energy differences. A comparable analysis could be found using group-
hydrophobicity296, 297 as the 2nd parameter (results not shown). Both results indicated a 
reasonable correlation, r2=0.53 for Sterimol L/HOMO-LUMO 296'297'497 and r2=0.63 for 
Sterimol L/hydrophobicity in regard to the electrophysiological response. The statistical 
importance, however, was not as great as in the binding fragment QSAR in that the 
significance was only at the 80% confidence interval (compared to the 99% confidence 
interval seen with the binding analysis). 
In order to further validate the importance of the variables identified using our small 
test set, one sought to examine a larger published test set. For this a test set of ligands 
derived from studies by Chambers and coworkers was chosen.64 The structures of these 
ligands and their electrophysiological response are shown in Table 40. If there are 
particular molecular descriptors that correlate with electrophysiological effects at the 
cc5p2y2 GABA(A) receptor isoform they should correlate with activation independent of 
the core template. Illustrated in Figure 158 is an overlap at pharmacophore points for 
RY10 with the test set published by Chambers and corworkers297" 484 in the upper panel 
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and Ro 15-4513 with compound 43 (below). These overlaps make obvious 
correspondences between polar functional groups as well as hydrophobic/steric features 
in the two compound sets. Given that the same overlap rule applies, we probed whether 
the same sets of molecular features found to be important for imidazobenzodiazepines in 
Table 40 also are explanatory descriptors of the electrophysiological response of the 
compounds studied by Chambers and coworkers (Table 40). The fragment QSAR 
(Figure 159) was performed using the properties shown in Table 39 for just the L1/L2 
(Sterimol L value for the R1 and R2 substituent) variable set, which had an r"=0.5, an F 
value of 3.5, and a standard error of 0.2. When the analysis was performed in terms of 
Ll/(HOMO-LUMO)-l and L2/(HOMO-LUMO)2 one found an r2 of 0.5, an F value of 
1.5 and a standard error of 0.2. These independent results further verify the importance 
of the fragment length and HOMO-LUMO of the terminal substituents. Note that this test 
set, like our own, highlights the subtlety of minor size changes of substituents and their 
electronic effects. Moreover, compounds 43 and 44 of this set differ only in the insertion 
of an extra -(CH2)-/methylenic fragment and yet this alteration changes the 
electrophysiological response at a5 containing receptors from -38 to +25. Demonstrated 
in Figure 160 is the level of discrimination of inverse agonists from antagonists in this set 
based on the HOMO-LUMO energy differences. This independently verifies the 
importance of electronic factors in disciminating subtle differences in 
electrophysiological responses. 
Illustrated in Table 40 are fragments and selected fragment properties for a series 
of 6,7-dihydro-2-benzothiophen-4(5H)-ones L, Bl, Sterimol and electronic HOMO-
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LUMO (HLn) parameters used in a fragment QSAR for direct comparison with results 
for the imidazobenzodiazepines shown in Table 39. 
Table 40. (Above) Structures with binding affinities (top number) and efficacies (bottom number) of 
compounds studied by Chambers et. al.49 501 (Below) Fragments and selected fragment properties 
for a series of 6,7-dihydro-2-benzothiophen-4(5H)-ones L, Bl, Sterimol and electronic HOMO-
LUMO (HLn) parameters used in a fragment QSAR for direct comparison with results for the 
imidazobenzodiazepines shown in Table 39. 
Ki (ct5) nM 
s(a5) 
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B5 A5 L1 B1-1 HL1 L-2 B1-2 HL2 
5.2 -3 6.64 3.37 -10.4 5.53 2.67 -9.4 
1.4 -7 6.64 3.37 -10.4 8.01 3.36 -8.6 
3.9 -2 6.64 3.37 -10.4 6.66 3.37 -13.3 
1.7 -38 7.24 3.34 -10.2 5.53 2.67 -9.4 
5.8 -40 7.24 3.34 -10.2 5.53 2.67 -9.4 
9.1 -20 7.24 3.34 -10.2 5.53 2.67 -9.4 
0.5 -39 7.24 3.34 -10.2 7.82 2.59 -9.2 
2.2 -24 6.98 3.50 -9.6 5.53 2.67 -9.4 
1.6 -38 6.98 3.50 -9.6 7.82 2.59 -9.2 
4.7 +25 6.98 3.50 -9.6 8.22 3.82 -9.3 
1.4 -5 6.98 3.50 -9.6 8.01 3.36 -8.6 
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Figure 158. Overlap of ligands studied by Chambers and coworkers with RYIO (above) and Rol5-
4513 (below). Note the spatial correspondence of polar (red O/blue N/yellow S atoms) and 
hydrophobic (grey C/white H) regions. 
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Figure 159. Fragment QSAR for binding at a5f}3y2 with electrophysiological response 
(In(£(a5)+100]=0.73 Ll+0.22 L2 (upper panel) and lnIE(a5)+100)= 0.66 LI +0.21 HLl +0.09 
L2 + 0.04 HL2) (lower panel) where HLl and HL2 are the HOMO-LUMO energy 
differences for the substituents identified in Table 40. 
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Figure 160. HOMO-LUMO energy differences between inverse agonists and antagonists. 
In Figure 158, the overlap of ligands studied by Chambers and coworkers 46 with 
RY10 and Rol5-4513 is illustrated. Note the spatial correspondence of polar and 
hydrophobic regions. In Table 40, the structures and binding affinities of compounds 
studied by Chambers et. al. is presented. Fragment QSAR for binding at a5(32y2 left 
panel and multivariate discriminant analysis (whole ligands) are shown in Figure 158. 
The variable V7=E(HOMO)-E(LUMO) calculated is presented in Figure 160. 
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a5p2y2 BzR/GABA(A)ergic Subtype Selective Bivalent Antagonists Reverse 
Scopolomine Induced Cognitive Impairment. 
Earlier the profile of RY-80 as a selective ligand for a5 subtypes based on a 1,4-
benzdodiazepine template was discussed. However, it was also an inverse agonist at al 
and a2 receptor subtypes and was therefore proconvulsant/convulsant. In marked 
contrast, when RY80 was made into the bivalent molecule BiRY80 (created by linking 
together two molecules of RY80 at C-3 via a 3 carbon linker to the ester function), Figure 
161 it exhibited a selectivity for the a5p2y2 isoform with binding affinities of 70-150 
fold higher than for binding at other GABA(A) receptors. 46 A variety of reports have 
suggested the achievement of subtype selectivity, however, few have achieved this level 
of discrimination.46 This synthetic effort was successful in that it also reduced the 
convulsive potential of the new ligand compared to RY80 (unpublished data). 
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Figure 161. Van der Waal representations of compounds RY80, RY10 and their respective bivalent 
compounds BiRY80 and BiRYlO 
The binding affinities at the GABA(A) receptor isoforms that contain either the 
al or a5 subunits in combination with p3 and y2 subunits is presented along with van der 
Waals radii in Figure 161. The bottom two numbers represent the electrophysiological 
values determined in the presence of the EC20 of GABA at a 1 |iM concentration of the 
ligand being tested. 
However, the robust 30% attenuation of GABA mediated CI" currents through a5 
subunit containing GABA(A) receptors observed with RY80 was also diminished with 
BiRY80, which behaved more like an antagonist. Given that both RY80 and BiRY80 
effectively compete off the radioactive Rol5-4513 ligand suggest subtle facets that alter 
either BiRY80's binding orientation or its modulation of receptor conformation which 
leads to an alteration of the pharmacological activity profile. Given the antagonistic 
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outcome of BiRY80 in regards to electrophysiological measurements this compound was 
expected to lack effects on attenuating cognitive impairment in our mouse model. 
However, this proved not be the case as BiRY80 was found to significantly attenuate 
scopolamine-induced contextual memory impairment in a mouse model used for 
Alzheimer's early screening of ligands (Figure 162). We also saw a similar effect with 
BiRYlO (a bivalent molecule made by connecting two molecules of RY10 via their ester 
groups) (Figure 162). In a similar fashion to BIRY80, BIRY10 led to an increase in the 
selectivity of binding for the a5P2y2 GABA(A) receptor isoform resulting in about a 20-
80 fold selectivity for a5 subunit containing GABA(A) receptors over other isoforms. 
Like BiRY80, BiRYlO was also able to reverse scopolamine induced contextual memory 
(Figure 162). In order to determine if the cognitive effects may have been produced by 
interacting with another receptor class this compound was further screened for effects on 
other receptor classes in the NIH Case Western Reserve Drug Screening Program and 
found to be without appreciable binding to other major classes of receptors. Therefore, one 
is left with the observation that highly selective antagonists of a5 subunit containing 
GABA(A) receptors are able to influence contextual memory. This in itself is not a new 
observation as the classic BZD antagonist Ro 15-1788 (flumazenil), with high affinity 
binding towards most GABA(A) receptor isoforms, has also been consitently reported to 
exhibit effects by itself, both clinically and electrophysiologically. However, depending on 
the screen the effects of Ro 15-1788 have been agonist sometimes, antagonist sometimes 
and inverse agonist at times.489 
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Figure 162. Pavlovian fear conditioned contextual memory. Each mouse was injected ip with 
either vehicle (0.9% saline containing 2.5% encapsin), 1.5 mg/kg scopolamine, or 1.5 mg/kg 
scopolamine + drug (top) 10 mg/kg BiRY80 or (center) 10 mg/kg BiRYlO or (bottom) 10 
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mg/kg PWZ-029. Twenty minutes after injection mice were fear conditioned to the context 
and tested 24 hours later, well after the drugs and scopolamine have cleared. A reduction 
in freezing, as observed in mice that received scopolamine alone, is reflective of a low level 
of contextual memory. Each drug, tested in the absence of scopolamine, was found not to 
differ significantly from vehicle administered alone; *p < 0.05, data not shown; ***p < 
0.001. N = 12 male C57BL/6J mice per vehicle or drug. This is an important set of results. 
Finally, the selective a5 isoform agonist, SH-053-R-CH3,296' 297 was also 
assessed in mice in order to ascertain whether it is able to impair contextual memory in 
the absence of scopolamine. SH-053-R-CH3 (30 mg/kg) was indeed able to impair 
contextual memory in the absence of scopolamine (Figure 163), thereby providing further 
"proof of principle" that compounds displaying selective influence on a5 isoforms, 
whether by potentiation or attenuation of GABA's effect on a5 isoforms, lead to 
significant effects on contextual memory. In stark contrast to the findings of Savic et 
al.,371 one did not observe a significant reduction (p = 0.284) in locomotion between 
mice given either 30 mg/kg SH- 053-R-CH3 or vehicle during a 40 min post injection 
observation period, as measured by automated assessment of spontaneous locomotor 
activity (1026 ± 57 versus 770 ± 210, respectively). In addition, chamber 
circumnavigation was also assessed during the initial 4 minute exploration phase of the 
fear conditioning protocol prior to shock delivery and no significant difference (p = 0.63) 
in this locomotor parameter between mice receiving SH-053-R-CH3 or vehicle (data not 
shown) was found. In a similar fashion, Savic et al., did not observe a change in 
distance traveled between mice receiving SH-053-R-CH3 or vehicle when evaluated in 
the elevated plus maze protocol. It was beyond the scope of this study to systematically 
investigate the affects of structural substitutions on the imidazobenzodiazepine template 
that would lead to robust electrophysiological agonism at a5Pxy2 GABA(A) receptor 
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isoforms. However, if one were to juxtapose the structures of the majority of 
imidazobenzodiazepines in this study (e.g., see Figure 153) with SH-053-RCH3 and 
Ro 16-6028, both robust electrophysiological agonists of a5 isoforms, one quickly 
discerns that both compounds involve structural changes in a region outside of our 
present pharmacophore, which was primarily designed to aid in predicting inverse 
agonism. 
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Figure 163. 30 mg/kg SH-053-R-CH3 in the absence of scopolamine. 
Further confirmation that the activity of XH356 (BiRYlO) was hippocampal-driven was 
the observation that in audio cued memory experiments there was no increase in freezing 
(see Audio Cued data for XH356 in the Appendix). 
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Whereas at the dosages used of either BiRY80 or BiRYlO, they would not be 
expected to attenuate GABA influence on CI flux, the interpretation of such results are not 
clear and again raises the question, "Is there the presence of an endogenous modulation of 
the BDZ site that is being antagonized by these bivalent molecules?" Over the years many 
investigators have attempted to identify a natural ligand for this site with results heavily 
debated. This potential endogenous modulator, termed endozepine (endogenous BDZ-like 
compounds), has been suggested as being involved in reducing anxiety, seizure thresholds 
and muscle relaxation as well as modulating vigilance.502 There also exists the possibility 
that a metabolite of BiRY80 is acting perhaps more like an inverse agonist in vivo then 
would be expected from antagonistic results seen in the in vitro electrophysiological 
studies of BiRY80. 
XU356 and PWZ-029 PDSP data 
Reports from Roth at NIMH Psychoactive Drug Screening Program (PDSP) at the 
University of North Carolina Chapel Hill Medical School have shown PWZ-029 and 
XH356 (BiRYlO) were quite clean BzR ligands (Figure 164). Examination of the binding 
affinity of XH356 and PWZ-029 in a battery of receptors indicated both bound to 
benzodiazepine receptors but did not potently bind to other receptors run to date. 
Receptors in the PDSP screen include cannabinoids, histamines, prostoglandins, 
glutamate, Ca+ channel, transporters, adrenergic, acetylcholine, dopamine, serotonin, 
opiates, and others (See Appendix for complete PDSP data and code numbers). 
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Figure 164. BzR ligands binding to other receptors. Data represent mean % inhibition (N = 4 
determinations) for compounds tested at receptor subtypes. 
Numerous papers have reported the cognitive influence, attenuating or potentiating, that 
benzodiazepine ligands elicit. However, due to potential side effects (ie. convulsive or 
preconvulsive tendencies of the inverse agonists) therapeutic viability has been questioned. 
As more subtype selective BZD ligands are beginning to turn up in the literature, one is 
able to begin the process of determining if there are isoforms of the GABA(A) receptors 
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that contribute to cognitive effects separate of convulsive potential. With this goal in mind, 
pharmacophores were initially developed based on a set of nonselective ligands with high 
binding affinities to GABA(A) receptor subypes at al p2y2 and a5(32y2. The 
pharmacophores were used to search chemical databases. A selected set of "hits" were 
tested for binding affinities to GABA(A) receptors with aip2y2 and a5p2y2 subtype 
compositions and several of these hits demonstrated sub uM binding affinities (ranging 
from 200 nM to 1 uM). A set of imidazobenzodiazepines displaying a higher degree of 
selectivity towards the a5 subunit containing isoforms over al subunit containing 
isoforms were then analyzed in order to glean principles underlying binding selectivity 
towards a5p2y2 relative to aip2y2 GABA(A) isoforms. Examination of computed 
molecular electrostatic potential surfaces, fragment QSAR, and COMSIA analyses for 
this series independently revealed the greater importance of one of the hydrogen bond 
acceptor pharmacophore points for binding to the aip2y2 isoform relative than to the 
a5f52y2 isoform. The early chemometric analysis of the effects of benzodiazepine 
ligands on the reversal of scopolomine induced memory deficit indicated the ligands with 
a sterimol L parameter <14 did not reverse effects of scopolamine. COMSIA and 
fragment QSAR indicated the importance of the size of the terminal substituents on the 
imidazobenzodiazepine template and HOMO-LUMO (fragment) energy difference to be 
correlated with the electrophysiological response at ot5p2y2. If such discriminants of 
activation are to be meaningful they should apply to other training sets. For this reason 
we examined the compounds published by Chambers and coworkers503'504 and found the 
same fragment/substituent properties to be correlated with the electrophysiological 
response at a5p2y2. In agreement with our computational assessments one was able to 
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demonstrate the cognitive influence of several BZD ligands that exhibited reasonable 
selectivity towards GABA(A) receptor isoforms containing the a5 subunit over other a 
subunits. Analysis of the the data supported the notion that selective binding to and/or 
activation of GABA(A) receptors that contain the a5 subunit may prove valuable in 
addressing potential treatment regimes for memory loss, which result from hypocholinergic 
mechanisms. 
Further investigations found that compound PWZ-029, which exhibited reasonable 
binding selectivity toward GABA(A) receptors containing the a5 subunit and possessed a 
favorable electrophysiological profile, was able to attenuate scopolamine induced 
contextual memory impairment in mice. In a similar fashion, Dawson et al.,'05 
demonstrated that compound a5IA, which also selectively decreased GABA-induced 
activation of a5 isoforms was able to enhance rat performance in the Morris water maze, a 
spatial memory task sharing similarities with contextual memory tasks. Therefore, one is 
left with the conclusion that selective attenuation of the activational influence of GABA 
(either by binding or efficacy) on GABA(A) receptors that contain the a5 subunit may 
prove valuable in addressing conditions that result in contextual/spatial memory 
impairment. The additional observation that compound SH-053-R-CH3, which selectively 
potentiates GABA's influence on GABA(A) receptors containing the a5 subunit, impairs 
contextual memory further supports the "proof of principle" that a5 subunit containing 
GABAA receptor isoforms can be selectively exploited in order to influence processes 
involved in contextual memory. PWZ-029, 56, enhanced cognition specifically and 
demonstrated a weak anxiolytic effect506 using rhesus monkeys in the conflict model and 
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weak anticonvulsant activity in rodents. The ligand, PWZ-029 enhances memory 
but cannot possibly be proconvulsant nor convulsant. 
Given the electrophysiological profiles of the two bivalent compounds in relationship 
to their cognitive effects poses some intriguing questions into the nature of the molecular 
mechanisms by which these compounds are influencing contextual memory. 
The electrophysiological profiles of the bivalent compound BiRY-080, an a5 selective 
antagonist, when juxtaposed with its ability to attenuate scopolamine-induced contextual 
memory impairment, raises intriguing questions into the nature of the molecular 
mechanism by which a compound such as this is able to influence contextual memory. One 
observed that the ability of a5 selective antagonists and weak inverse agonists to affect 
memory was dependent on ligand size (Sterimol L parameter). These results are not unlike 
other nonclassical inhibition patterns, where the ability to inhibit appears to correlate better 
with ligand size rather than affinity.391,392 While beyond the scope of this dissertation, 
these results suggest that either (1) the earlier hypotheses of endogenous ligand 
displacement by an antagonist, in this case only requiring antagonism of a5 subunit 
containing GABA(A) receptor isoforms, is sufficient for behavioral alteration; (2) 
alternatively, an additional GABA(A) receptor isoform (i.e., a4p3y),46' 64 not originally 
expected to have an effect, is mitigating the observed effects. Our results lend support 
toward the notion that compounds that selectively influence a5Pxy2 GABA(A) receptors, 
whether by inverse agonism, antagonism, or agonism, are each capable of modulating 
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contextual memory; the former two ligands enhance cognition, the former two ligands 
enhance cognition, the later decreases it. 
Preparation of Cloned mRNA 
Cloning of GABA(A) receptor subunits al, P3 and y2 into pCDM8 expression 
vectors (Invitrogen, CA) for these studies has been described elsewhere. 507 The 
GABA(A) receptor subunit a4 was cloned in an analogous way. The cDNAs for 
subunits a2, a3 and a5 were gifts from P. Malherbe and were subcloned into pCI-vector. 
The cDNA for subunit a6 was a gift from P. Seeburg and was subcloned into the vector 
pGEM-3Z (Promega). After linearizing the cDNA vectors with appropriate restriction 
endonucleases, capped transcripts were produced using the mMessage mMachine T7 
transcription kit (Ambion, TX). The capped transcripts were polyadenylated using yeast 
poly(A) polymerase (USB, OH) and were diluted and stored in diethylpyrocarbonate-
treated water at -70°C.187'480 
Functional Expression of GABA(A) Receptors 
The methods used for isolating, culturing, injecting and defolliculating of the 
I 87 480 
oocytes were identical with those described by E. Sigel. Mature female Xenopus 
laevis (Nasco, WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-
aminobenzoate, Sigma, MO) before decapitation and removal of the frogs ovary. Stage 5 
to 6 oocytes with the follicle cell layer around them were singled out of the ovary using a 
platinum wire loop. Oocytes were stored and incubated at 18°C in modified Barths' 
Medium (MB, containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM 
NaHC03, 1 mM KCl, 0.82 mM MgS04, 0.41 mM CaCl2, 0.34 mM Ca(N03)2) that was 
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supplemented with 100 U/mL penicillin and 100 fig/ml streptomycin. Oocytes with 
follicle cell layers still around them were injected with 50 nL of an aqueous solution of 
cRNA. This solution contained the transcripts for the different alpha subunits and the beta 
3 subunit at a concentration of 0.0065 ng/nL as well as the transcript for the gamma 2 
subunit at 0.032 ng/nL. After injection of cRNA, oocytes were incubated for at least 36 
hours before the enveloping follicle cell layers were removed. To this end, oocytes were 
incubated for 20 min at 37°C in MB that contained 1 mg/mL collagenase type IA and 0.1 
mg/ml trypsin inhibitor I-S (both Sigma). This was followed by osmotic shrinkage of the 
oocytes in doubly concentrated MB medium supplied with 4 mM Na-EGTA. Finally, the 
oocytes were transferred to a culture dish containing MB and were gently pushed away 
from the follicle cell layer which stuck to the surface of the dish. After removing of the 
follicle cell layer, oocytes were allowed to recover for at least four hours before being 
used in electrophysiological experiments. 
Electrophysiological Experiments with Sieghart et al.508 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath 
of Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 
7.4), 1 mM MgCh, 1 mM KC1 and 1 mM CaCb) The oocytes were constantly washed by 
a flow of 6 mL/min XR which could be switched to XR containing GABA and/or drugs. 
Drugs were diluted into XR from DMSO-solutions resulting in a final concentration of 
0.1 % DMSO perfusing the oocytes. Drugs were pre-applied for 30 sec before the 
addition of GABA, which was coapplied with the drugs until a peak response was 
observed. Between two applications, oocytes were washed in XR for up to 15 minutes to 
ensure full recovery from desensitization. For current measurements the oocytes were 
impaled with two microelectrodes (2-3 mQ), which were filled with 2 mM KC1. All 
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recordings were performed at room temperature at a holding potential of -60 mV using a 
Warner OC-725C two-electrode voltage clamp (Warner Instruments, Hamden, CT) or a 
Dagan CA-1B Oocyte Clamp (Dagan Corporation, Minneapolis, MN). Data were 
digitised, recorded and measured using a Digidata 1322A data acquisition system (Axon 
Instruments, Union City, CA). Results of concentration response experiments were fitted 
using GraphPad Prism 3.00 (GraphPad Software, San Diego, CA). The equation used for 
fitting concentration response curves was Y=Bottom + (Top-Bottom)/(1+10A(X-
LogECso)); X represents the logarithm of concentration, Y represents the response; Y 
starts at Bottom and goes to Top with a sigmoid shape. 
In vivo Assessments 
Male C57B1/6 mice were obtained from Charles Rivers Laboratories (Holister, CA) at 6 
weeks of age. Mice used in fear conditioning were between 7 and 12 weeks of age. Animals 
were housed eight to a cage in rooms with a normal 12-h lightr 12-h dark cycle lights on 700-
1900 hr with free access to food and water. Tests were conducted during the light phase between 
1300 and 1700 h with a 30-min acclimation period in the testing room prior to drug or vehicle 
administration. All animal protocols used in this study conform to the guidelines determined by 
the National Institute of Health, Office for Protection from Research Risks and are approved by 
the Animal Care and Use Committee of the Palo Alto Veterans Administration Medical Center, 
Palo Alto, CA, USA . 
Pavlovian Fear Conditioning 
Before testing each day, the mice were moved to a holding room and allowed to 
acclimate for at least 30 minutes. Each mouse received an i.p. injection of one of the 
following: vehicle, benzodiazepine binding site ligand 2-30 mg/kg , scopolamine 1 
mg/kg , scopolamine 1 mg/kg combined with one of the benzodiazepine binding site 
ligands 2-30 mg/kg . The dose level chosen for each compound was one that neither 
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elicited convulsions nor impaired locomotion. Twenty minutes after injection, the mice 
were placed individually in one of four identical experimental chambers (Med 
Associates, St. Albans, VT) that had been scented with 0.3% ammonium hydroxide 
solution before testing. Chambers were back-lit with fluorescent light with a white noise 
generator providing 70 dB of background noise. After 4 minutes in the chamber, mice 
were exposed to a loud tone 85 dB, 2.9 kHz for 32 sec with the last 3 seconds coupled 
with a 0.75-mA scrambled footshock. This procedure was repeated for a total of three 
episodes with a 1 minute period separating each episode. One minute after the final 
footshock, the mice were returned to their home cages. Twenty-four hours later, 
contextual memory was assessed by placing the mice back into the freshly re-scented 
0.3% ammonium hydroxide conditioning chambers in which they were trained, for a 4 
minute test period in the absence of footshock. Conditioned fear to the context was 
assessed by measuring the freezing response according to the methods of Fanselow and 
Bolles. 509 Freezing was defined as the absence of all visible movements of the body 
aside from those necessitated by respiration. Scoring was done using the FreezeScan 
(Clever Systems Inc., Reston, VA). These data were transformed to a percentage of total 
observations. Data were analyzed by one-way analysis of variance ANOVA using 
GraphPad PRISM 2.01 (GraphPad Software). Separate treatment effects between groups 
were analyzed post hoc using Dunnett's or Bonferroni's multiple comparisons. 
Conformational Libraries for Pharmacophore/Overlap Rule Development. 
Conformational libraries were developed using a nested rotation approach wherein 
the energy was evaluated by varying each of the rotatatable bonds by 30°. constraining 
their values at this geometry, and then energy minimizing (using Conjugate Gradients) 
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the remainder of the structure until the RMS changes in the gradient were smaller than 
0.01. All force field parameters used were from the Quanta/CHARMM (Chemistry at 
Harvard Macromolecular Mechanics) force field. The net atomic charges used, based on 
parameterization in this program, were also consistent with the fact that all of the 
compounds are neutral. The initial structures were then energy minimized using 200 steps 
of steepest descents followed by 2000 - 3000 steps of conjugate gradients or until the 
RMS changes in the gradient were smaller than 0.01 A. A long 90 A potential truncation 
was used to minimize effects on structure due to potential truncation via a switching 
function. 
Initial Pharmacophore Development 
MOLMOD developed in the laboratory of Harris and Delorey 510 was used to 
develop 3D pharmacophores from input of conformational libraries for each of the 
ligands, independent distance criteria for conformational clustering and pharmacophore 
distance-criteria, a trial pharmacophore definition in terms of a set of ligand or receptor 
based pharmacophore points [including hydrogen bond donor/acceptor, hydrophobic 
centers, centroids of ring systems or functional groups, and/or user-defined classes based 
on user-defined property definitions] and an energy window criteria for consideration of 
ligand conformers. The program first performs conformational clustering and determines 
if there is at least one conformer from each ligand in the training set in the energy-
windows specified that has the same 3D distance metrics within the 'tolerances' specified 
by the user. The program allows for difference 'tolerances' for each pharmacophore point 
to allow for conformational/sterically allowed variation in particular regions. If the 3D-
distrance metrics between pharmacophore points is the same at least one conformation of 
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each ligand and the pharmacophore distance metrics are reported and the ligands 
superimposed via a quaternion/least squares procedure for those conformers complying 
with the pharmacophore. The latter superposition(s) may then be used in 3D-QSAR 
applications and properties evaluated for those conformers that comply with the 
pharmcophore for use in multivariate statisitical analysis to ascertain the determinants of 
recognition or activation. 
Validation of Overlap Rules/Pharmacophores Via Database Searches 
The overlap rules were input to SYBYL/UNITY as sets of hydrogen bond acceptors 
and centroids. Databases were searched using a distance window of ±2 angstroms. In 
particular, Unity, Chapmann & Hall, and May bridge databases were searched for two 
distinct purposes: 1) to ensure compounds with known GABA(A) receptor binding and 
activation were retrieved, 511 and 2) to extract new compounds for binding, 
electrophysiological, and behavioral assessment. 
Quantum Chemical Evaluation of Properties in Conformations Complying with 
Pharmacophores for Use in QSAR 
Following development of the initial pharmacophores the properties of all 
compounds were evaluated in their conformations complying with the pharmacophore 
definition and were evaluated using a combination of semi-empirical quantum mechanics 
c  I  -y 
and a MOPAC-7 AMI Hamiltonian density functional theory as incorporated in 
c  1 -j 
Gaussian and Jaguar (Schrodinger, Portland, OR). This included both whole molecule 
properties as well as those of 'fragments' corresponding to substituent replacements on 
particular templates. In an effort to understand the SAR of these substitutions we 
computed: (i) frontier orbital energetics (HOMO/LUMO/HOMO-LUMO), (ii) Sterimol 
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parameters, (iii) group hydrophobicities, (iv) volumes, (v) areas, (vi) solvent-accessible 
surface areas, (vii) polar and nonpolar volumes, (viii) globularities, (ix) electrostatic 
potentials on the van der Waals surface using MOPAC-AM-derived properties developed 
by the in-house program GRAPHA and (x) solvation energies. In the case of fragment 
properties, the substituents were 'capped' with H's prior to calculation of properties. 
Fragment and 3D-QSAR Analyses 
Both the TRIPOS QSAR module as well as MS-EXCEL were used to form 
multivariate QSAR analyses for both binding and electrophysiological response as a 
function of substitutions. The TRIPOS COMSIA module (Tripos QSAR (St. Louis, MO)) 
was used to perform molecular similarity index analysis (CoMSIA) employing field 
descriptors around ligands superimposed using MOLMOD. 
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Molecular Modeling, Synthesis, and Pharmacological Studies of Some Tetracyclic 
1,3-Diazepinium Chlorides (with Grant et al.) 
Seven new 1, 3-diazepinium chlorides exhibiting structural similarities to the 1,4-
benzodiazepines were synthesized Grant et al.513"518 and evaluated in the Milwaukee 
based pharmacophoric model. In a Hippocratic screen using mice, three of these salts, 3-
methoxy-6-oxo-7,13-dihydro-6//-benzofuro[2,3-e]pyrido[l,2-a][l,3]diazepin-12-ium 
chloride 8a, 3-methoxy-9-methyl-6-oxo-7,13-dihydro-6//-benzofuro[2,3-e]pyrido[l,2-
a][l,3]diazepin-12-ium chloride 8c, and 3-methoxy-l 1 -methyl-6-oxo-7.13-dihydro-6//-
benzofiiro[2,3-e]pyrido[l,2-a][l,3]diazepin-12-ium chloride 8e, were examined for their 
effect on the central nervous system, and their activities compared to that of diazepam. 
On their own, salts 8a, 8c, and 8e solicited no sedative effects on the behaviour of the 
animals. However, they elicited significant effects in combination with diazepam on 
diazepam-induced activities such as decreased motor activity, ataxia and loss of righting 
reflex. Compounds 8a and 8c were fitted into the pharmacophore/receptor model 
developed by Clayton in Milwaukee with interactions at the Li, Hi and A2 sites indicating 
that they are potential inverse agonists of the Bz receptor. The compounds displayed 
some affinity for the al isoform of the GABA(A) /BzR (Loi interaction) but were 
nonselective for a5 (no L2 interaction). Results of binding affinity studies showed that 
compound 8a is mildly selective for the al receptor although not very potent (K, = 746.5 
nM). The significant potentiation of diazepam-induced ataxia and decreased motor 
activity by compounds 8a and 8c in the Hippocratic screen may be associated with al 
activity. However, this is preliminary data. Experimentation to confirm this needs to be 
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done on other receptor systems (for example cholinergic, ganglionic, and adrenergic 
receptors). 
Other benzodiazepine analogues such as, the 1,3- 2,3- and 1,5-Bzs are known but 
have received much less attention in comparison to the 1,4-Bzs. Several of the 2,3- and 
1,5-Bz analogues have displayed pharmacological activities similar to those of the 1,4-
Bzs, while a few 1,3-Bzs, which were synthesized as part of a drug development program 
for new psychotic drugs, have exhibited antidepressant activity comparable to that of the 
classic tricyclic antidepressant amitriptyline.519-522 
In 1997, Jackson and Williams512 reported the synthesis of the pyridinium bromide 
1 - a 1,3-diazepinium salt- from the readily available 7-hydroxy-4-methylcoumarin. 
Structural comparison of compound 1 with the well known 1,4-Bzs is shown in Figure 
Both have a 7-membered heterocyclic ring fused to an aromatic ring, but the 
nitrogen atoms of the heterocyclic rings are in different relative positions. The 4,5-
double bond of the 1,4-Bz is J3- to the amide functionality and has an aryl moiety attached 
whereas in salt 1, the double bond is part of an a,(3-unsaturated amide and the aryl 
substituent is rigidly fixed by a fused furan ring. 
H ,0 3 
165. 
Br D 
^OME 
1 1,4-Benzodiazepines 
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Figure 165. Comparison of the structure of 1,3-diazinium 
bromide to 1,4-benzodiazepines 
Since tetracyclic 1,3-diazepinium bromide (1) displays some resemblance to the 
1,4-Bzs, Grant and Jackson proposed to synthesize analogues of this type with a view 
to conducting pharmacological studies to evaluate these compounds as potential 
therapeutic agents. 
Bromides are not ideal for pharmacological studies since they are toxic to the 
body.512 Iodides also have chronic effects and are unsuitable here.33'34,71,74 Chlorides, on 
the other hand, are non-toxic and found naturally in the body and were therefore used in 
their studies. 
A") 
Outlined here are the reports on pharmacological studies (Hippocratic screen) and 
molecular modeling of some tetracyclic 1,3-diazepinium chlorides of type 8. The 1,3-
diazepinum compounds were fitted into the pharmacophore/receptor model for 
GABA(A) /BzR subtypes and observed for selectivity towards any of the BzR subtypes 
at Milwaukee. The results were then correlated with those of the pharmacological screen 
(see Appendix for Chemistry). 
Pharmacology 
Pharmacological assessment of the 1,3-diazepinium chlorides was done using the 
Hippocratic screen.42 Of the seven salts prepared, only salts 8a, 8c and 8e were tested 
since they were more soluble in the sample vehicle.524 The observed activities of the 
chlorides were compared with those of diazepam. 
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Animals 
Albino male and female mice, aged 7-8 weeks with a weight of 16-25 g were 
obtained from the Animal House of the University of the West Indies, Mona. The animals 
were provided with food and water ad libitum. The studies were performed according to 
protocols approved by the Faculty of Medicinal Sciences/University Hospital of the West 
Indies Ethics Committee. 
Preparation of Drug Samples 
Diazepam was dissolved in corn oil (5 mg/mL) and compounds 8a, 8c and 8e were 
dissolved in distilled water (2 mg/ mL). 
Hippocratic Screen 1 
Mice were randomly assigned to six groups with six animals in each group. 
Animals in groups one (CI) and two (C2) were administered distilled water and corn oil 
respectively. Group three (DZ1) was administered the diazepam solution and groups four 
to six administered solutions of 8a, 8c, and 8e, respectively. All administrations were 
done by intraperitoneal ip injection at a dosage volume of 0.2 mL/10 g of body weight. 
The grouping and dosing of the animals was done independent of the observer, hence all 
observations were made without prejudice. Activities measured in the Hippocratic screen 
include: decreased motor activity, ataxia, loss of righting reflex, analgesia, anesthesia, 
pinnal reflex, loss of screen grip, paralysis, respiratory rate, tremor and startle reaction. 
All observations were made at +5, 10, 15, 30, 45, 60, 90 and 120 minutes, then 24 
and 48 hours from the time of injection and the activities were rated as -, ±, +, ++, +++ or 
++++, in all cases, - represented no change compared to the control animals. 
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Hippocratic Screen 2 
In a second set of experiments, the animals were divided into four groups of six. 
Distilled water was given 15 minutes prior to administering diazepam to animals in group 
one (DZ2) and the remaining groups two to four (8a+DZ, 8c+DZ and 8e+DZ) were 
administered salts 8a, 8c and 8e, respectively, 15 minutes before diazepam. All 
administrations were done by IP injection at a dosage volume of 0.2 mL/10 g of body 
weight. All observations are unbiased. Activities measured and assigned ratings were the 
same as in Hippocratic Screen 1. All observations are made at +5, 10, 15, 30, 45, 60, 90 
and 120 minutes, then 24 and 48 hours from the time of diazepam injection. 
Statistical Analysis 
The ratings: -, ±, +, ++, +++ or ++++ were quantified to 5, 4, 3, 2, 1 or 0 
respectively. Statistical analysis of the data was performed using SPSS version 12.0 and 
consisted of General Linear Model (Repeated Measures) with Dunnett t (2-sided) Post 
Hoc test, the Kruskal-Wallis test followed by the Mann-Whitney test. Differences were 
considered statistically significant when associated with a probability level of less than 
0.05. 
Hippocratic Screen 1 
Diazepam significantly induced decreased motor activity, ataxia, loss of righting 
reflex and screen grip within 10 minutes of administration to the animals (p < 0.01). The 
effects of diazepam persisted for more than 2 hours, but activities were restored within 24 
hours. These results confirm the CNS sedative activity of diazepam in the Hippocratic 
screen. Diazepam, however, had no influence on the animals' pinnal reflex, respiratory 
rate or analgesic and anesthetic response. It also produced no paralysis or tremor and did 
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not significantly affect the startle reaction of the animals. Compounds 8a, 8c and 8e were 
found to have no significant effect on the behaviour of the animals. 
Hippocratic Screen 2 
The 1,3-diazepinium chlorides (8a, 8b and 8c) had some significant effects on the 
animals' response to diazepam. Activities affected include decreased motor activity, 
ataxia, righting and pinnal reflex. 
Decreased Motor Activity 
Salts 8a and 8c potentiated the decrease in motor activity produced by diazepam by 
shortening the time taken to reach maximum efficacy for 10 to 15 minutes (p < 0.01 and 
0.05 respectively, Figure 166). Salt 8e attenuated the animals' response to diazepam-
induced decreased motor activity (p < 0.05) which persisted for over 2 hours (p < 0.01). 
Ligand 8c potentiated diazepam-induced decreased motor activity (p < 0.01) and caused 
it to persist for more than 24 hours (p < 0.01) but less than 48 hours. Ligand 8c also 
significantly increased the maximum efficacy induced by diazepam (p < 0.05). 
Decreased Motor Activity vs Time/mins 
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Figure 166. Effects of 8a, 8c and 8e on diazepam-induced decreased motor activity in mice. 
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Ataxia 
Salt 8a enhanced the onset of ataxia induced by diazepam to within 5 minutes (p < 
0.05) and augmented the maximum of diazepam-induced ataxic effect (p < 0.05). 
However, 8e retards the onset of the ataxia to greater than 15 minutes (p < 0.05) but does 
not interfere with the maximum induced ataxic effect of diazepam (Figure 167). Ligand 
8c also produced a significant increase in the maximum of the diazepam-induced ataxic 
effect (p < 0.001) (Figure 167). Both salts 8a and 8c potentiated the efficacy of diazepam 
(p < 0.01 and p < 0.05 respectively). 
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Figure 167. Effects of 8a, 8c and 8e on diazepam-induced ataxia in mice. 
Loss of Righting Reflex 
Salts 8a, 8c and 8e did not significantly affect the onset nor the overall efficacy of 
diazepam-induced loss of righting reflex, however, 8c attenuated the effect caused by 
diazepam at times greater than 1 hour after diazepam was administered (p < 0.01) (Figure 
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168). None of the compounds prolonged the loss of righting reflex induced by diazepam 
for more than 2 hours. 
Loss of Righting Reflex vs Time/mins 
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Figure 168. Effects on 8a, 8c, and 8e on diazepam-induced loss of righting reflex in 
mice. 
Pinnal Reflex vs Time/mins 
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Figure 169. Effects of 8a, 8c and 8e on pinnal reflex in mice when treated with diazepam. 
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Pinnal Reflex 
The dose of diazepam did not affect the pinnal reflex in mice (Figure 169). 
However, 8a produced an overall reduction in the efficacy of diazepam on pinnal reflex 
in mice (p < 0.01). Salts 8c and 8e had no effect on the activity of diazepam towards 
pinnal reflex (Figure 169). 
The effect of diazepam on the animals with respect to screen grip, respiratory rate, 
analgesia, anesthesia, paralysis, tremor and startle reaction was not significantly affected 
by 1,3-diazepinium chlorides 8a, 8c and 8e. 
The 1,3-diazepinium chlorides (8a, 8c and 8e), on their own, had no effect on the 
behaviour of the animals but elicited significant effects on diazepam-induced decreased 
motor activity, ataxia and loss of righting reflex. This suggests that the chlorides may 
either be binding to specific sites on the GABA(A) /BzR and influencing the CNS 
depressant or sedative activity of diazepam or be undergoing a synergistic effect with the 
diazepam. 
Chlorides 8a and 8c potentiated the maximum decreased motor activity and 
disrupted coordinated movement (ataxia) caused by diazepam. This indicates that they 
are diazepam agonists. In particular, chloride 8a enhanced the onset of these activities 
which means that it promotes the binding of diazepam more readily. However, chloride 
8c inhibited the loss of righting reflex, caused by diazepam, after 1 hour which suggests 
antagonist or inverse agonist effects over time. The chlorides did not significantly alter 
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loss of screen grip, thus indicating no effect on the muscle skeletal activity of diazepam 
on the animals. Chloride 8c also decreased the efficacy of pinnal reflex in the animals 
thereby indicating some CNS depressant activity. 
Chloride 8e attenuated the diazepam-induced decreased motor activity and ataxia. 
This suggests that 8e either blocks the diazepam binding site or binds at another site and 
inhibits the binding of diazepam to its receptor site. Chloride 8e neither affects loss of 
righting reflex caused by diazepam nor pinnal reflex in the animals. Chloride 8e appears 
to be an antagonist of diazepam in this screen. 
Molecular Modeling 
Alignment of compounds 8a and 8c within the pharmacophore/receptor model for 
the aip3y2 subtype is shown in Figures 170 and 171 respectively. The centroid of ring D 
in 8a and 8c is overlapped with the lipophilic region Li. The lone pair of electrons of the 
C6 amide carbonyl oxygen is hydrogen-bonded to Hi of the receptor (bond length of 1.84 
A and bond angle of C=0-Hi is 135°). There was also potential hydrogen bonding 
between the lone pair of electrons of the furan oxygen (05) and the Hi site giving rise to 
a 3-centered hydrogen bond interaction with the C6 carbonyl oxygen, Hi and 05 (C=0-
Hi-05). The N7 proton interacts with the A2 site (bond length of 1.84 A and bond angle 
of N7-H-A2 is 180°). Although 8a and 8c are aligned similarly into the model, 8a fits 
better as the methyl substituent at position 9 on ring A of 8c sticks out into the 
extracellular region (Figure 171b). 
When compared to diazepam, it is clearly seen that 8a and 8c did not occupy the L2 
nor L3 regions of the pharmacophore/receptor model (Figure 172). Also, there was no 
lone pair of electrons available on the iminium ion at the junction of rings A and B for 
interaction with the H2 descriptor. Compounds 8a and 8c are, therefore, not expected to 
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be foil agonists like diazepam, since they do not have the required interactions in the 
model for positive allosteric modulation of the Bz receptor, 
a) b) 
Figure 170. a) Alignment of 1,3-diazepinium chloride 8a within the pharmacophore/receptor 
model for the aip3y2 GABA(A) /BzR subtype; b) Alignment of 8a in the model rotated 90°. 
a) b) 
Figure 171. a) Alignment of 1,3-diazepinium chloride 8c within the pharmacophore/receptor 
model for the aip3y2 GABA(A) /BzR subtype; b) Alignment of 8c in the model rotated to 90° 
showing methyl group on ring A sticking out into the extracellular region. 
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Figure 172.1,3-Diazepinium chloride 8a overlaid with diazepam (yellow) in the 
pharmacophore/receptor model. 
On the other hand, 8a and 8c are potential Bz receptor inverse agonists or 
antagonists since they have interactions at the Li, Hi and A2 sites. 3-Methoxy-l 1-methyl-
6-0X0-7,13-dihydro-6//-benzofuro[2,3-e]pyrido[ 1,2-a] [ 1,3]diazepin-12-ium chloride, 8e 
exhibited some inverse agonist activities in the Hippocratic screen and although it was 
not fitted into the pharmacophore model, it was expected to align in similar fashion to 8a 
and 8c. 
The lack of occupation of the L2 lipophilic region by 8a and 8c implies that they 
have no affinity for the a5 isoform.510 However, there may be some al activity as there 
appears to be some occupation of the LD| region of the receptor by ring A of 8a and 8c. 
The /i-carbolines generally display some selectivity at the al-containing receptor 
subtypes which, based on experimental evidence, is due to occupation of the LDj site of 
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the molecules in the receptor model.419 Inverse agonist methyl-6,7-dimethoxy-4-ethyl-p-
carboline-3-carboxylate (DMCM) occupies the Lpi region of the pharmacophore model 
and has a high affinity (K, = 5.7 nM) for the al P3y2-subtype64 78-121 
In the Hippocratic screen, both 8a and 8c produced significant potentiation of 
diazepam-induced ataxia and decreased motor activity. These effects could be associated 
with al activity. Binding affinity studies showed that compound 8a exhibited poor 
affinity at the al, a2, a3 and a5 receptor subtypes (Table 41). Compound 8a, however, 
shows very slight selectivity at the a 1-containing receptor subtype (K, = 746.5 nM) and 
therefore, could be used for the design of a next generation ligand, once its clear that 8a-
8c do not bind to other types of receptors. 
Table 41. Affinity of 3-methoxy-6-oxo-7,13-dihydro-6//-benzofuro|2,3-£|pyrido|l,2-
a||l,3jdiazepin-12-ium chloride, 8a, for axp3y2 (x = 1-6) BzR isoforms. 
OMe 
8a 
K, (nM) 
Ligand al a2 a.3 a4 a5 a6 
8a 746.5 8081 1543 ND 2364 ND 
(ND = NOT DETERMINED) 
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Primary binding experiments in the PDSP (see Appendix) also revealed that 
compound 8a inhibited norepinephrine and serotonin transporters with a mean % 
inhibition of 81.3 and 62.5%, respectively (significant inhibition is considered > 50%). 
By inhibiting these transporters compound 8a would prevent the reuptake of the 
neurotransmitters and cause prolonged neuronal activity. This is a characteristic feature 
of many antidepressant drugs. Some of these antidepressants also exhibit anticholinergic 
activity which can lead to ataxia.525'526 
In summary, seven new tetracyclic 1,3-diazepinium chlorides with structural 
similarities to the 1,4-Bzs were synthesized via intramolecular cyclization of the 
respective allyl chlorides.64'128 Three of these chlorides (8a, 8c and 8e) were evaluated in 
a Hippocratic screen and their activities compared to diazepam. On their own, 
compounds 8a, 8c and 8e had no notable effect on the behaviour of the animals (mice) 
but, they significantly affected diazepam-induced ataxia, decreased motor activity, 
righting and pinnal reflex. Compounds 8a and 8c exhibited CNS depressant-like effects 
since they enhanced these diazepam-induced activities, while 8e attenuated these 
activities and therefore displayed antagonist or antidepressant-like effects (other 
receptors). Compounds 8a and 8c were aligned into the pharmacophore/receptor with 
interactions at the Li, Hi and A2 sites and some occupation of the Lo, region of the 
model. These results indicate that the compounds are potential inverse agonists/ 
antagonists with possible al selectivity. Binding affinity studies confirmed that there is 
very slight selectivity of compound 8a for the al subtype but the compound is not very 
potent (K, = 746.5 nM). Hence, the potentiation of diazepam-induced ataxia and 
decreased motor activity by compounds 8a and 8c in the Hippocratic screen may have 
resulted from al associated effects but it is difficult to confirm since they bound to other 
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receptors. Compound 8a may also display antidepressant activity since it significantly 
inhibited the norepinephrine and serotonin transporters (> 50%). Certainly, the modeling 
here indicates that 8a-8c could bind to BzR receptors, but they lack the required 
functionality at specific descriptors necessary for potent BzR mediated response (see 
Figure 172). 
The Role of al and a5 containing GABA(A) Receptors in Mediating Diazepam 
Effects on Spontaneous Locomotor Activity and Water Maze Learning and Memory 
in Rats 
The clinical use of benzodiazepines (BZs) is hampered by sedation and cognitive 
deterioration. Although genetic and pharmacological studies suggest that «r and as-
containing GABA(A) receptors mediate and/or modulate these effects, their molecular 
substrate is not fully elucidated. By the use of two selective ligands: the ai-subunit 
affinity-selective antagonist fi-CCt, and the as-subunit affinity- and efficacy-selective 
antagonist XL1093, Savic et al.419 examined the mechanisms of behavioral effects of 
diazepam in the tests of spontaneous locomotor activity and water maze acquisition and 
recall, the two paradigms indicative of sedative and cognition-impairing effects of BZs, 
respectively. The locomotor activity decreasing propensity of diazepam (significant at 1.5 
and 5 mg/kg) was antagonized by B-CCt (5 and 15 mg/kg), while it tended to be 
potentiated by XLi093 in doses of 10, and especially 20 mg/kg. Diazepam decreased 
acquisition and recall in the water maze, with a minimum effective dose of 1.5 mg/kg. 
Both antagonists reversed the thigmotaxis induced by 2 mg/kg diazepam throughout the 
test, which suggests that both GABA(A) receptor subtypes participate in BZ effects on 
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the procedural component of the task. Diazepam-induced impairment in the declarative 
component of the task, as assessed by path efficiency, the latency and distance before 
finding the platform across acquisition trials, and also by the spatial parameters in the 
probe trial was partially prevented by both 15 mg/kg 8-CCt and 10 mg/kg XLi093. 
Combining a BZ with B-CCt results in the near to control level of performance of a 
cognitive task, without sedation, and may be worthy of testing on human subjects. 
The aim was to elucidate, by the use of two selective ligands: the preferential oi|-
subunit affinity-selective antagonist 13-CCt, and the a5-subunit affinity- and efficacy-
selective antagonist XLi093, to what extent GABA(A) receptors containing cci and as 
subunits contribute to the well-established behavioral effects of diazepam in the tests of 
spontaneous locomotor activity and water maze acquisition and recall, the two paradigms 
mainly, but not exclusively, indicative of sedative and spatial cognition impairing effects 
of classical BZs, respectively. The selectivity of B-CCt and XLi093 has been confirmed 
in in vitro experiments of affinity and efficacy at recombinant GABA(A) receptors,421 as 
well as in in vivo studies of inhibition of [3H] flumazenil binding in distinct brain regions, 
which differ in the GABA(A) receptor subtype expression.422 
Drugs 
XU093 (4H-imidazo[l,5-a][l,4]benzodiazepine-3-carboxylic acid, 8-ethynyl-5,6-
dihydro-5-methyl-6-oxo-, 1,3-propanediyl ester), the a5-subunit affinity- and efficacy-
se l ec t ive  an t agon i s t ,  and  B-CCt  ( t -bu ty l -B-ca rbo l ine -3 -ca rboxy la t e ) ,  t he  p re fe ren t i a l  a l -
subunit affinity-selective antagonist were synthesized as described in detail previously.527 
Diazepam was obtained from Galenika (Belgrade, Serbia). 
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Behavioral Experiments by Savic et al.429'528 
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, 
Serbia), weighing 220-250 g. All procedures in the study conformed to EEC Directive 
86/609 and were approved by the Ethical Committee on Animal Experimentation of the 
Faculty of Pharmacy in Belgrade. The rats were housed in transparent plastic cages, six 
animals per cage, and had free access to pelleted food and tap water. The temperature of 
the animal room was 22±1°C, the relative humidity 40-70%, the illumination 120 lux, and 
the 12/12 h light/dark period (light on at 6:00 h). All handling and testing took place 
during the light phase of the diurnal cycle. Separate groups of animals were used for two 
behavioral paradigms. The behavior was recorded by a ceiling-mounted camera and 
analyzed by the ANY-maze Video Tracking System software (Stoelting Co., Wood Dale, 
IL, USA). The drugs were dissolved/suspended with the aid of sonication in a solvent 
containing 85% distilled water, 14% propylene glycol, and 1% Tween 80, and were 
administered in a total volume of 2 ml/kg, 20 min before behavioral testing. The first 
treatment indicated in combination was administered into the lower right quadrant of the 
peritoneum, and the second treatment immediately afterwards into the lower left quadrant 
of the peritoneum. 
Measurement of Locomotor Activity 
Twenty minutes after receiving the appropriate treatment, single rats were placed 
in a clear Plexiglas chamber (40 x 25 x 35 cm). Activity under dim red light (20 lux) was 
recorded for a total of 30 minutes, without any habituation period, using ANY-maze 
software. Besides the total distance travelled, behavior was analyzed by dividing the 
locomotor activity data into 5 minute bins. 
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Two experiments were performed. In the first one, the dose response curve for 
diazepam (0; 0.5; 1.5 and 5.0 mg/kg) was determined. In the second study, the design 
included the factors agonist (the same doses of diazepam as those used in the dose-
response study) and antagonists (B-CCt at 0; 5 and 15 mg/kg. and XLi093 at 0; 10 and 20 
mg/kg), thus generating 20 experimental groups in total. 
Behavior in the Morris Water Maze 
The water maze consisted of a black cylindrical pool (diameter: 200 cm, height: 
60 cm), with a uniform inner surface. The pool was filled to a height of 30 cm with 23°C 
(±1°C) water. The escape platform of black plastic (15x10 cm) was submerged 2 cm 
below the water surface. The platform was made invisible to rats by having it painted the 
same color as the pool wall.529 There were many distal cues in the testing room (doors, 
pipes on the walls and the ceiling, cupboards, a camera suspended above the centre of the 
maze). An indirect illumination in the experimental room was provided by white neon 
tubes fixed on the walls (Figure 173). 
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Figure 173. The scheme representing the virtual division of the water maze used in the analysis of 
rats' performance. 
The rats received the appropriate treatment 20 minutes before a swimming block, 
each day for 5 consecutive days of spatial acquisition. Each block consisted of 4 trials, 
lasting a maximum time of 120 seconds, the intertrial interval being 60 seconds. For each 
trial the rat was placed in the water facing the pool at one of four pseudorandomly 
determined starting positions. As during spatial learning the platform was hidden in the 
middle of the NE quadrant, the four distal start locations were chosen: S, W, NW and SE 
(Figure 173). Once the rat found and mounted the escape, it was permitted to remain on 
the platform for 15 s. The rat was guided to the platform by the experimenter if it did not 
locate the escape within 120 s. To assess the long-term spatial memory at the end of 
learning, a probe trial for 60 s, with the platform omitted, was given 24 h after the last 
acquisition day. The probe trial, starting from the novel, most distant SW location (in 
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order to ensure that any spatial bias is a consequence of the spatial memory of escape 
location, rather than of a specific swim strategy422 was performed without any pre-
treatment. A drug-free probe trial422 was chosen because diazepam impairs acquisition, 
but not retrieval of place preference in the water maze,419 and confounding effects of 
possible sensorimotor, i.e. non-cognitive actions of treatment on recall performance were 
avoided by such a protocol. The tracking software virtually divided the pool into four 
quadrants, three concentric annuli and a target region consisting of the intersection of the 
platform quadrant and the platform annulus (Figure 173). Similarly to the approach used 
by Cain,46'48'52'366 the central annulus was set up to 10% of the whole area; the platform 
annulus equaled 40%, whereas the area of the peripheral annulus was 50% of the whole. 
Dependent variables chosen for tracking during the acquisition trials were: latency 
to platform (time from start to goal), total distance swam (path length), average swim 
speed and path efficiency (the ratio of the shortest possible path length to actual path 
length). All these indices are, to a lesser or greater degree, related to goal-directed 
behavior, i.e. spatial learning.419 As thigmotaxis (the tendency to swim or float near the 
pool wall) represents a factor which accounts for much of the variance in the water maze 
performance, and normally weakens during consecutive trials,48, 366 we quantified the 
persistence of the thigmotaxis in the target (NE) quadrant. The loss of thigmotaxis is 
related to the procedural component of acquisition, and the percent of the distance swam 
in the target region (away from the wall) of the target quadrant may be seen as a measure 
of procedural learning. 
The indices of memory, assessed during the probe trial, included the distance and 
time in the platform (target) quadrant, platform ring and target region, as well as the 
number of entries and distance swam in the area where the platform used to be during 
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training (Figure 173). In addition, the distance swam during 60 sec in the probe trial was 
taken as a measure of overall activity, while peripheral ring parameters (distance and 
time) were connected to the thigmotaxic behavior. 
Three experiments in the water maze were performed. In the first study, the dose 
response curve for diazepam (0; 1; 1.5; 2 and 5 mg/kg) was determined. In the second 
experiment, the influences of 6-CCt (5 and 15 mg/kg) and XLi093 (10 and 20 mg/kg) on 
the effects of 1.5 mg/kg diazepam (the minimal effective dose from the dose-response 
study) were assessed. The inclusion of the groups treated by the antagonists without 
diazepam would have made the experiment overly long, on each of five training days. In 
preliminary experiments with the current protocol, the lack of behavioral activity was 
observed at the higher doses of 8-CCt and XLi093 used here (15 mg/kg and 20 mg/kg, 
respectively). In the third water maze experiment, the capability of B-CCt (15 mg/kg) and 
XLi093 (10 mg/kg) to antagonize the behavioral effects of a higher dose of diazepam (2 
mg/kg) was assessed. 
Statistical Analysis 
All numerical data presented in the Figures were given as the mean ± SEM. Data 
from the activity assay were assessed by a one-way or two-way ANOVA, whereas the 
results from the water maze test were analyzed using a two-way ANOVA with repeated 
measures. Post hoc comparisons, where applicable, were performed using Student-
Newman-Keuls or Dunnett's test. Statistical analyses were performed with ANY-maze 
Video Tracking System software (Stoelting Co., Wood Dale, IL, USA). 
Results 
Time (min) 
Figure 174. The effects of diazepam (Sol+DZP 0.5,1.5 and 5.0 mg/kg) on total distance (a) and 
distance travelled in 5-min intervals (b). * p<0.05 compared to solvent (Sol+Sol) group;** p<0.01 
compared to solvent. Animals per treatment (n=8). 
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Motor Activity Assay 
An ANOVA showed a significant effect of diazepam treatment on total distance 
travelled during 30 minutes of monitoring (F(3,28) = 5.63, p=0.004) (Figure 174a). 
According to Dunnett's test, the activity-depressing effect of two higher doses of 
diazepam was significant compared with solvent control. When the analysis of distance 
travelled was developed into 5 minute intervals (Figure 174b), it turned out that diazepam 
at 5 mg/kg highly significantly decreased locomotion in the period 0-15 minutes, whereas 
the dose of 1.5 mg/kg was effective in the period 20-25 minutes. 
Figure 175. The effect of combinations of drugs. 
The effects of combinations of diazepam (DZP), at doses of 0, 0.5, 1.5 and 5.0 
mg/kg, and the antagonists b-CCt (0, 5,15 mg/kg) and XLi093 (0, 10, 20 mg/kg), on total 
distance travelled in the spontaneous locomotor activity test (Figure 175). * p<0.05, 
compared to solvent (Sol+Sol) group; + p<0.05 compared to DZP 0.5+Sol group; ## 
p<0.01 compared to XLi093 10+Sol group; t p<0.05, fft p<0.001 compared to XLi093 
20+Sol group. Animals per treatment (n=6). 
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Figure 176. Mean distance travelled in successive 5-min blocks for groups 
On the other hand, while devoid of discernible activity of their own, B-CCt and 
XLi093 exerted differential effects on the hypolocomotor effect of diazepam (Figure 
176). Their influences were evaluated by separate statistical analyses. A two-way 
ANOVA for the analysis of the influence of B-CCt has shown a significant effect of the 
dose of diazepam (F(3Jl) = 3.95, p=0.012), whereas the dose of the antagonist as a 
factor, as well as the agonist x antagonist interaction did not reach significance (F(2,60) = 
2.30, p=0.109, and F(6,71) = 0.49, p=0.811, respectively). Post hoc Student-Newman-
Keuls method revealed that the existing significant differences between the levels of 
diazepam itself (5 mg/kg vs. 0 mg/kg and 5 mg/kg vs. 0.5 mg/kg) disappeared when 
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multiple comparisons were made within the 5 mg/kg fl-CCt dose (respective p values 
0.419 and 0.339), as well as within the 15 mg/kg 6-CCt level (respective p values 0.251 
and 0.302). When analyzing the overall influence of XLi093 as an antagonist, there was a 
significant effect of the dose of diazepam (F(3,71) = 15.323, p<0.001), whereas the dose 
of XLi093 as a factor, as well as the agonist x antagonist interaction were insignificant 
(F(2,60) - 0.806, p=0.451, and F(6,71) = 0.846, p=0.540, respectively). Oppositely to 
the antagonism exerted by 6-CCt, post hoc analysis revealed that the existing effects of 
diazepam (5 mg/kg vs. 0 mg/kg, p=0.027, and 5 mg/kg vs. 0.5 mg/kg, p=0.041) were 
potentiated by XLi093 (Figure 175). Namely, comparisons within the 10 mg/kg XLi093 
level have shown highly significant differences in the effects of 1.5 mg/kg and 5 mg/kg 
doses of diazepam versus the effect of the antagonist itself (p values of 0.003 in both 
cases), whereas within the dose of 20 mg/kg XLi093, all three levels of diazepam (0.5; 
1.5 and 5 mg/kg) were statistically different from the antagonist (respective p values: 
0.013, 0.002 and below 0.001). Similar conclusions can be reached while statistically 
analyzing (not shown) the data obtained by dividing the locomotor activity into 5 minute 
bins (Figure 176). As a rule, locomotor activity of animals treated with a combination of 
diazepam and 6-CCt, irrespective of the doses employed, was near to, or slightly above, 
the control value, whereas XLi093, especially at the higher dose, tended to deepen, or 
unveil, the sedation induced by diazepam. 
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Figure 177. Latency to platform data 
The effects of diazepam 1.0, 1.5, 2.0 and 5.0 mg/kg (DZP 1.0+Sol to DZP 
5.0+Sol) on (a) latency to platform, (b) total distance, (c) average swim speed and (d) 
path efficiency of rats during 5 d acquisition trials in the water maze is illustrated in 
Figure 177. * p<0.05,** p<0.01, *** p<0.001 compared to solvent (Sol+Sol) group; 
+p<0.05, ++ p<0.01, +++ p<0.001 compared to DZP 1.0+Sol group; # p<0.05, ## 
p<0.01, ### p<0.001 compared to DZP 1.5+Sol group; t p<0.05, ft p<0.01 compared to 
DZP 2.0+Sol group. Animals per treatment (n=7). 
426 
Morris Water Maze 
For the dose response study of diazepam, the factors treatment and days, as well 
as the interaction treatment x days, were statistically highly significant for the latency to 
find the platform, the distance swam before finding the platform, swim speed and path 
efficiency; significant differences among treatments during training days are presented in 
Table 42. The results of the post hoc analysis for the factor treatment are summarized in 
Table 43. The analysis showed that the lowest effective dose of diazepam was 1.5 mg/kg. 
Illustrated in Table 42 are the significant differences among overall influences 
(averaged for five days of acquisition) on the water maze learning parameters: latency to 
find the platform (L), distance swam before finding the platform (D), mean swim speed 
(S) and path efficiency (E) in the dose-response study of diazepam (DZP mg/kg). 
Table 42. Differences among influence of diazepam on water maze learning 
DZP 1.0+Sol DZP1.5+Sol DZP2.0+SO1 DZP 5.0 +Sol 
Sol + Sol L: p =0.004 L: p< 0.001 L:p<0.001 L: p< 0.001 
D : p <0.001 D: p=0.001 D: p=0.002 
E: p< 0.001 E:p<0.001 S: p < 0.001 
E:p<0.001 
DZP 1.0+Sol L: 
i
 
0
 
V f
t. 
L: p —0.001 L: p<0XX)l 
D :p =0.002 D: p=0.014 D: p=0.030 
E: p = 0.001 E: p = 0XX)l S: p < 0.001 
E: p=0.001 
DZP 15 +Sol L:p=0.007 
S:p< 0.001 
DZP 2.0 +Sol L:p=0.002 
S: p < 0.001 
Sol, Solvent. 
Table 43 illustrates the representative parameters of water maze performance in 
the probe trial of the diazepam (DZP mg/kg) dose-response experiment. The key to 
regions used in the analysis is given in Figure 173. *,** and ***, P<0.05; 0.01 and 0.001, 
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respectively, compared to solvent (SOL + SOL) group; + and ++, P<0.05 and 0.01, 
respectively, compared to DZP 1.0 +SOL group. 
Table 43. Performance in water maze 
Sol + Sol DZP 1.0 +Sol DZP1.5 + Sol DZP 2.0 +Sol DZP 5.0+Sol 
ANOVA 
F(4,30) p 
Whole water maze parameters 
Distance (m) 13.97+1.19 11.54 + 0.4*! 
Platform quadrant (N£> parameters 
Distance (m) 3.87 + 0.45 2.33±039 
Time (s) 16.26±1.42 11.44±1.98 
Peripheral ring parameters 
Distance (m) 6.67 + 0.95 5.34+1.13 
Time (s) 30.61 + 237 29.41 ± 5.33 
Platform ring parameters 
Distance (m) 6.09± 0.75 5.00 ±0i>l 
Time (s) 24.79 ± 237 24.90 ± 3.67 
Target region parameters 
Distance (m) 2.00 ±026 1.01 ±0.20" 
Time (s) 7.81 ± 1.24 4.59 ± 0.92* 
Platform parameters 
No. of entries 1.00 ±0.38 0.43 ±020 
Distance (m) 0.102 ± 0.042 0.043 ±0.022 
15.01 ±1.26 
2.92 ±0.34 
11.29±1.23 
11.79+1.67*' ' 
48.44 ± 3.30**' 
2.59 + 0.82" 
9.43+ 2.72**' 
0.40 ±0.12*** 
1.36 + 0.41***' 
0.00 ±0.00 
0.000 ±0.000 
14.51 ±0.78 
2.95 ±037 
11.94 ±1.50 
10.67 ±0.77*' ' 
47.33 ±2.75**' 
3.26 ±0.61* 
10.73 + 237**' 
0.67 ±020*** 
2.14 ±0.74***' 
0.43 ±030 
0.047 + 0.034 
13.70 ±0.69 
2.34 ±0.36 
8.63 ±1.38* 
10.62 + 0.46*' ' 
50.19 ±1.95**' 
2.69 ±0.51** 
8.63+1.65**' 
0.55 ±0.20*** 
1.64 ± 0.60***' 
0.29 ±0.18 
0.012 ±0.008 
2.051 
2.661 
3255 
6.914 
9.361 
5.371 
10.100 
10.108 
10.704 
2.167 
2.261 
0.112 
0.052 
0.025 
<0.001 
<0.001 
0.002 
<0.001 
<0.001 
<0.001 
0.097 
0.086 
Values are mean±s.E.M. 
*/> <0.05, ** p<0.01, *** p< 0.001, compared to solvent (Sol + Sol) group. 
' p<0.05, ' ' p< 0.01, compared to DZP 1.0 +Sol group. 
The incapacitating influence of previous treatment with diazepam were 
discernible during the probe trial as well (Table 43), when a number of indices of 
memory (time in the platform quadrant, time and distance in the platform ring, time and 
distance in the target region) were dose-dependently adversely affected. Concomitantly, 
a significant increase of peripheral ring parameters, i.e. pronounced thygmotaxis (Table 
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38), has confirmed that learning the required water maze skills and strategies was 
impaired under diazepam. 
Based on the dose response study presented here, Savic performed a further 
experiment in which two doses of each of the antagonists tested in the locomotor activity 
assay were combined with 1.5 mg/kg diazepam/ However, in this experiment, the 
effect of diazepam did not reach significance compared with control for any of the 
learning measures calculated. A two-way ANOVA with repeated measures for this 
antagonism study revealed significant variability in regard to latencies to find the 
platform (treatment effect, F(5,138) = 6.59, p< 0.001; day effect, F(4,552) = 50.39, p< 
0.001; and treatment x day interaction, F(20,552) = 1.80, p = 0.018) and path efficiencies 
across the five days (treatment effect, F(5,138) = 4.67, p = 0.001; day effect, F(4,552) = 
17.61, p< 0.001; and treatment x day interaction, F(20,552) = 1.88, p = 0.012). The 
respective significant differences among treatments during days are presented in Figures 
178a and 178d. The factors, but not the interaction, also reached significance when swim 
distances (Figure 178b) and average swim speed (Figure 178c) were analyzed (treatment 
effect, F(5,138) = 5.42, p< 0.001; day effect, F(4,552) = 34.27, p< 0.001, and treatment x 
day interaction, F(20,552) = 1.50, p = 0.075, and treatment effect, (5,138) = 5.02. p< 
0.001; day effect, F(4,552) = 21.08, p< 0.001, and treatment x day interaction, F(20,552) 
= 1.22, p = 0.233, respectively). Having in mind especially the latency to platform 
(Figure 178a), it appears that antagonism of the effects of diazepam at GABA(A) 
receptors containing a5 subunits (1.5 mg/kg diazepam + 10 mg/kg XLi093) may enhance 
acquisition in the earliest stages of spatial learning, while addition of a higher dose of the 
antagonist (1.5 mg/kg diazepam + 20 mg/kg XLi093) may even impair the later phases of 
learning. Throughout the acquisition trials there were no discernible effects of adding 
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pCCt, at either dose, to diazepam. In the probe trial, the significant differences in 
dependent measures of performance were generally absent, probably due to the lack of 
clear behavioral activity of the dose used of diazepam, and these data are not presented. 
Finally, the results of the experiment with a higher effective dose of diazepam (2 
mg/kg), on its own and in combination with 10 mg/kg XLi093 and 15 mg/kg PCCt, are 
shown in Figures 179 and 180, and Tables 44 and 45. A two-way ANOVA with repeated 
measures of latencies to find the platform across the five days (Figure 179a) revealed the 
following results: treatment effect, F(3,100) = 11.65, p< 0.001; day effect, F(4,400) = 
56.74, p< 0.001; and treatment x day interaction, F(12,400) = 0.96, p = 0.484. Similar 
tendencies were evident when swim distances (Figure 186b) and path efficiencies (Figure 
179d) were analyzed (treatment effect, F(3,100) = 6.34, p = 0.001; day effect, F(4,400) = 
28.17, p< 0.001; and treatment x day interaction, F(12,400) = 1.46, p = 0.135, and 
treatment effect, F(3,100) = 5.98, p = 0.001; day effect, F(4,400) = 27.68, p< 0.001; and 
treatment x day interaction, F( 12,400) = 1.03, p = 0.422, respectively). The interaction 
only reached significance when swim speed was analyzed: treatment effect, F(3,100) = 
6.29, p = 0.001; day effect, F(4,400) = 14.03, p< 0.001; and treatment x day interaction, 
F( 12,400) = 1.92, p = 0.031, and significant differences among treatments during days 
are given in Figure 179c. As treatment as factor was statistically significant for all four 
learning parameters illustrated, the respective significances for single treatments are 
shown in the Table 39. PCCt (15 mg/kg) completely prevented acquisition-impairing 
actions of diazepam administered at the dose of 2 mg/kg, whereas addition of XLi093 (10 
mg/kg) was effective in this sense for all parameters considered, with the exception of the 
mean swim speed (Table 45). It is noteworthy to point out that statistical analysis 
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revealed no overall significant difference in maximum speed among treatments; 
moreover, on the first day, the rats treated with diazepam were even faster, in maximum, 
than control ones (1.16±0.44 m/s vs. 0.78±0.14 m/s), which is a hint of transient 
behavioral disinhibition. 
In Figure 180, the distances the rats swam in the platform quadrant (NE) during 
acquisition trials are presented alongside the respective distance in the portion of the NE 
quadrant lying in the platform annulus of the maze ("the target region"). The rats treated 
with 2 mg/kg diazepam strikingly lacked the preferential activity in that part of the NE 
quadrant in which platform finding was possible; even on day 5, only 49.4% of the 
distance they travelled in NE quadrant was in the target region; the respective values for 
control, 2 mg/kg diazepam+15 mg/kg pCCt and 2 mg/kg diazepams-10 mg/kg XLi093 
groups were 75.4%, 82.9% and 69.8%. 
In Table 41, a number of parameters calculated from the probe trial performance 
in the antagonism study with 2 mg/kg diazepam are presented. The total distance swam 
was not different, and also there were not significant differences among groups in 
distance and time spent in the platform quadrant. On the other hand, the animals treated 
for 5 days with diazepam exerted a strong bias towards the peripheral annulus, which was 
reversed by both antagonists. Concomitantly, previous treatment with diazepam resulted 
in significant avoidance of platform annulus, which was also antagonized by both, pCCt 
(15 mg/kg) and XLi093 (10 mg/kg). The changes of these two parameters are indicative 
of influences on previous days' behavioral strategies of learning, i.e. the procedural 
component of water maze spatial memory. There were no significant difference in the 
target region activity, whereas diazepam treatment tended to decrease platform site 
entries and significantly decreased the distance in the platform position. The latter effect, 
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indicative of influence on the declarative spatial component of memory, was attenuated, 
but not reversed, by both antagonists. 
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Figure 178. Acquisition trials in the water maze. 
Illustrated in Figure 174 are the effects of diazepam (DZP 1.5+Sol), diazepam and 
b-CCt (DZP 1.5+b-CCt 5 and DZP 1.5+b-CCt 15) and diazepam and XLi093 (DZP 
1.5+XLi093 10 and DZP 1.5+XLi093 20) (all doses in mg/kg) on (a) latency to platform, 
(b) total distance, (c) average swim speed and (d) path efficiency of rats during 5 d 
acquisition trials in the water maze. * p<0.05, ** p<0.01 compared to solvent (Sol+Sol) 
group; + p<0.05 compared to DZP 1.0+Sol group; # p<0.05, ## p<0.01 compared to DZP 
1.5+b-CCt 5 group; t p<0.05, ft p<0.01 compared to DZP 1.5+b-CCt 15 group. The 
animals per treatment group (n=6). 
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The al- and a5-containing GABA(A) receptors have been repeatedly implicated, 
to a different degree, in mediation or modulation of widely known sedative and amnesic 
effects of agonists at BZ-sensitive GABA(A) receptors.46 The present experiments, 
using the selective antagonists at the BZ sites of ai- and as-containing GABA(A) 
receptors, demonstrated that the activity-decreasing propensity of diazepam, as a measure 
of sedation, is the consequence of its binding at a i-containing GABA(A) receptors, 
whereas spatial learning and memory deficits induced by diazepam are related to action 
at both of these receptor populations (al and a5).530,531 
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Figure 179. Acquisition trials in the Morris water maze 
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Illustrated in Figure 179 are the effects of diazepam (DZP 2+Sol), diazepam and 
b-CCt (DZP 2+b-CCt 15) and diazepam and XLi093 (DZP 2+XLi093 10) (all doses in 
mg/kg) on (a) latency to platform, (b) average total distance, (c) average swim speed and 
(d) path efficiency of rats during 5 d acquisition trials in the water maze. * p<0.05 
compared to solvent (Sol+Sol) group; + p<0.05 compared to DZP 2+Sol group; tp<0.05 
compared to DZP 2+b-CCt 15 group. The animals per treatment group, for Sol+Sol to 
DZP 2+XLi093 10 (n=6, 6, 7, 7, respectively). 
The findings in the motor activity assay on the predominant role of a\ GABA(A) 
receptors are in accordance with genetic studies.51 What appears to be the most 
surprising result of this part of study, combining diazepam with XLi093, especially with 
the higher (20 mg/kg) of the two tested doses of the antagonist, potentiated sedation 
induced by diazepam. The 20 mg/kg dose of XLi093 presumably caused a complete 
antagonism of the effects of diazepam at as-containing GABA(A) receptors (cf. 
occupancy of about 65% of as GABA(A) receptors in mice at 10 mg/kg of XLi093 in 
Shinday et al.367"389). We have recently put forward the hypothesis that locomotor activity 
changes induced by ligands possessing a substantial as-efficacy may be, at least partly, 
contributed to by modulation at GABA(A) receptors containing the a5 subunit.51 It 
appears that the role of positive modulation at a5 GABA(A) receptors depends on the 
concomitant activity at ai-containing GABA(A) receptors. Moreover, a.5 GABA(A) 
receptors may exert a dual control on the state of vigilance: to limit sedative effects 
elicited by supra-physiological stimulation of ai-containing receptors, and, oppositely, to 
enhance basal/endogenous activation of ai GABA(A) receptors, and, hence, induce mild 
sedation. Three sets of data may indirectly support the notion of the modulatory role of 
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this population of receptors. Firstly, it is notable that as- containing GABA(A) receptors 
are at least moderately present in both regions believed to be involved in the sedative 
properties of GABA(A) receptor activators,532 ventral horn of the spinal cord,52 and 
pyramidal neurons of the neocortex, especially the layer V." ' Secondly, there is a 
conspicuous association between ai and as subunits: the co-localization within individual 
neurons,52 and even within the single GABA(A) receptor.429 Thirdly, the knock-in mice 
harboring the as subunit insensitive to diazepam are refractory to development of 
tolerance to the ai-mediated sedative effect of diazepam dosed subchronically.334 
Finally, Mohler, Rudolph and others have shown that the tolerances to some of the effects 
of diazepam are due to the coupling of al receptors to a5 receptors; one is down-
regulated while the other is upregulated on chronic dosing of diazepam. 
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Figure 180. Distance data during 5 day acquisition trials in the water maze. 
Illustrated in Figure 180 are the effects of (a) solvent (Sol+Sol) ; (b) diazepam 
(DZP 2+Sol), (c) diazepam and b-CCt (DZP 2+b-CCt 15) and (d) diazepam and XLi093 
(DZP 2+XLi093 10) (all doses in mg/kg) on the distance rats travelled in the SE quadrant 
and target region during 5 d acquisition trials in the water maze. The numbers inside the 
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columns are the percent of the distance swam inside the target (NE) quadrant which was 
travelled in the target region. 
The effects of diazepam on the acquisition and retention of place learning in the 
water maze have been previously assessed in two settings, similar but not identical to the 
present procedure.334 The lowest dose effective in our experiment (1.5 mg/kg) lies 
between those found by Arolfo and Brioni (1.0 mg/kg) and Cain (3.0 mg/kg diazepam). 
However, the antagonism study showed that the 1.5 mg/kg dosage level was a borderline 
dose of diazepam, unreliable in affecting rats' behavior under the conditions used in the 
current water maze protocol. Nevertheless, in such settings, an impairment of the later 
phases of water maze learning produced by the combination of diazepam (1.5 mg/kg) and 
the higher dose of XLi093 (20 mg/kg) was revealed. We hypothesize that this finding 
may be connected with the profound sedation observed with the same combination in the 
procedure measuring locomotor activity. Namely, it is possible that the supposed 
complete antagonism at as-containing GABA(A) receptors forestalls development of 
tolerance to sedation and/or decreased vigilance, and hence impairs learning; this 
question could be partly resolved with the further studies of repeated dosing of diazepam 
and XLi093 in the locomotor activity test. " 
In the antagonism study with 2.0 mg/kg diazepam, both antagonists tended to 
reverse its effects, which may be seen as corroborating previous conclusions that the 
water maze acquisition impairment is not due to the sedative effect of diazepam.334'335 
The fact that rats treated with a combination of diazepam 2 mg/kg + B-CCt 15 mg/kg 
were even faster swimmers, in overall, than both, the group treated with diazepam and 
the group treated with combination diazepam 2 mg/kg + XLi093 10 mg/kg, replicates our 
previous finding with the combination midazolam 2 mg/kg + B-CCt 30 mg/kg, which 
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potentiated intertrial crossings during acquisition sessions of the active avoidance 
paradigm.379 In regard to the cognitive function-related parameters, B-CCt antagonized 
the inhibitory effect of midazolam on procedural memory tested through active avoidance 
retention,534 and attenuated the deteriorating effect of the BZ on declarative memory in 
• » 
passive avoidance paradigm. In the anxiety-related paradigms (elevated plus maze 
and acquisition session of active avoidance), the potentiation of the anti-anxiety action of 
midazolam was observed.529 As the emotionally arousing experiences tend to be well 
remembered, it is widely accepted that suppression of arousal and anxiety by BZs may 
impair some aspects of cognitive functioning.429 However, the present water maze 
results, together with the previous findings, dismiss the suggestion534 that the diazepam-
induced place learning impairment may be mainly related to its anxiolytic properties. 
Despite the fact that the anti-anxiety effect of diazepam may have only been preserved or 
potentiated, not abolished, by 13-CCt, the overall performance during 5 acquisition days 
was at least equal to that of the control group. The present and previous results 
suggest that combining a Bz with B-CCt may result in the near to control level of 
performance of a cognitive task, without sedation, but with highly desirable 
preserved anti-anxiety activity. 
Illustrated in Table 44 are the significant differences among overall influence 
(averaged for five days of acquisition) of the tested treatments (mg/kg) on the water maze 
learning parameters: latency to find the platform (L), distance swam before finding the 
platform (D), mean swim speed (S) and path efficiency (E). 
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Table 44. Differences on influences on water maze learning 
Sol + Sol DZP 2 4- /?CCt 15 DZP2 + XU093 10 
DZP 2 + Sol L: p <0.001 L: p<0.001 L:p = 0.002 
D: p=0.001 D: p = 0.001 D:p = 0.011 
E: p=0.024 S: p=0.001 E:p = 0.025 
E: p<0.001 
DZP 2 + XLi093 10 S: p=0.005 
DZP, Diazepam; Sol, solvent. 
Illustrated in Table 45 are the representative parameters of water maze 
performance in the probe trial. The key to regions used in the analysis is given in Figure 
180. *P<0.05 compared to solvent (SOL + SOL) group; **P<0.01 compared to solvent; + 
P<0.05 compared to diazepam 2 mg/kg group (DZP 2 + SOL); ++ P<0.01 compared to 
DZP 2 mg/kg group. 
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Table 45. Parameters of water maze performance in the probe trial 
Sol + Sol DZP2 + SoI DZP 2 +/iCCt 15 DZP 2 + XLi093 20 ANOVA, F 
Whole water maze parameters 
Distance (m) 10.74 ± 1.62 
Platform quadrant (NE) paramc 
Distance (m) 2.11+0.48 
Time (s) 10.50 ±2.05 
Peripheral ring parameters 
Distance (m) 3.80 ±0.99 
Time (s) 29.45 + 4.18 
Platform ring parameters 
Distance (m) 6.26 + 0.91 
Time (s) 27.05 + 3.19 
Target region parameters 
Distance (m) 1.48 + 0.44 
Time (s) 5.63+1.82 
Platform parameters 
No. of entries 1.33 ± 0.49 
Distance (m) 0.146 + 0.051 
DZP, Diazepam; Sol, solvent. 
Values are mean + s.E.M. 
DZP, fiCCt, XLi093 treatments in mg/kg. 
*p<0.05 compared to solvent (Sol +Sol) group; ** p <0.01 compared to solvent; ' p <0.05 compared to DZP 2 mg/kg group 
(DZP 2 + Sol); ' ' p <0.01 compared to DZP 2 mg/kg group. 
On the other hand, Cain429 suggested that the acquisition deficits may result from 
the sensorimotor disturbances that diazepam causes. Namely, the author found that non-
spatial pretraining without pretreatment eliminated swimming in the periphery of the 
pool, platform deflections and swimovers, and resulted in the normal, rapid acquisition of 
the water maze task under diazepam.529 Nevertheless, McNamara and Skelton536 found 
that treatment with diazepam after the rats acquired the location of the platform did not 
affect further water maze activity, while it did impair finding of the newly-located 
platform. Bearing in mind the interaction between arousal, cognitive function and 
anxiety,430 it is difficult to say that the present results support the view of either pure 
learning-impairing430, 537 or non-selective incapacitating422 effects of diazepam as the 
11.74 ±0.40 12.45 + 0.58 
fters 
2.39 ± 0.28 
11.98± 159 
1.72 + 0.4 7 
733 ±2.13 
7.86 ± 0.84** 
44.82 + 2.39" 
5.16 ±0.60' 
29.19 ±2.81 ' 
198 ±055* 
11.75 ±232** 
6.03 ±0.50' 
25.87 ± 1.98 1 
0.78 ± 0.26 
3.20 ±1.09 
1.06±0.22 
3.94 + 1.05 
0.17±0.17 057 ±0.20 
0.007 ± 0.007* 01)51 ±0.019 
11.43 ±0.96 0.531 0.67 
1.65 + 0.29 
931 ±2.06 
0.522 
0.971 
0.52 
0.42 
5.11 ±0.61 ' 
32.20 + 2.42' 
4.77 
5.81 
0.010 
0.004 
5.08 ±0.71 * 
2231 ±2.29' 
4.62 
7.66 
0.012 
0.001 
1.12 ±0.27 
4.79 ±1.24 
0.86 
0.61 
0.48 
0.62 
0.86 ±0.26 
0.076 ±0.034 
2.52 
3.11 
0.084 
0.047 
441 
explanation for its effects on spatial learning. Both types of influence may be partly 
operating in the learning impairment induced by diazepam in the Morris water maze. 
The results from the probe trial show that the platform quadrant parameters are 
not a reliable measure of spatial memory influence of the doses used of diazepam.536 As 
an example, the rats treated during previous days with 2.0 mg/kg diazepam spent three 
quarters of the probe trial time in balanced circling throughout the peripheral annulus, 
and it was not possible to detect any lack of preference for the target quadrant during the 
resting 15 seconds. Suppression of an instinct to swim thigmotaxically appears to be 
necessary to effectively accomplish the maze task.367 B-CCt as well as XLi093 reversed 
both, the increase of peripheral annulus, and decrease of platform annulus parameters, 
induced by 2 mg/kg diazepam. The results from the recall trial as well as from 
acquisition trials suggest that it is sufficient to antagonize the activity of diazepam at 
either ar or as-containing GABA(A) receptors in order to forestall its influence on 
learning the required water maze skills and strategies, i.e. procedural components of this 
. 40 memory task. 
Despite the expected relatively low control group activity in the platform zone on 
its own,49 the anterograde amnesic influence of previous treatment with 2 mg/kg 
diazepam still reached statistical significance, and was only partially prevented by both 
antagonists used, i.e., they attenuated, but not antagonized, the spatial memory deficit. In 
fact, the parameters related to the previous platform location in the probe trial are the 
only ones in the antagonism study with 2 mg/kg diazepam which did not tend to be at 
least a bit more preserved in combination with B-CCt than with XLi093. The water maze 
is usually seen as a hippocampal-dependent memory model,430' 537 and abundant staining 
in the rat hippocampus was shown for the ai- as well as as-subunit.538 There are several 
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experimental findings related to the role of the as-subunit in spatial memory. Thus, the 
as-knock-out mice, compared to the wild-type animals, performed significantly better in 
a working memory protocol of the water maze, ' while an inverse agonist selective 
for GABA(A) receptors containing as subunits facilitated the acquisition and recall of 
rats in a similar protocol of working memory.534 The present protocol enabled the long-
term consolidation of spatial memory to happen, so that it can be hypothesized that 
potentiation of inhibitory transmission at both, the as- and ai-containing GABA(A) 
receptors contributes in an interactive way to impairment in the declarative spatial 
component of the task.334 It is conceivable that besides the hippocampus, with its crucial 
role in long-term spatial memory,334 335' 375 the ap and as-containing GABA(A) 
• I 7 
receptors in neocortex may be of significance for spatial memory deficits induced by 
diazepam. 
Curran concluded that sedative effects of benzodiazepines in humans are much 
more easily reversed than amnesic effects;42 a similar conclusion may have been applied 
A] ft 488 
to rats' behavior in the active avoidance task ' and to a certain degree to the present 
results. It appears that the procedural component (strategy learning) of the water maze 
learning deficit induced by diazepam is more prone to reversion by ai- and as-subtype 
selective antagonists, the role of ai-containing GABA(A) receptors being more salient, 
while the declarative spatial memory component of learning deficit is less prone to 
attenuation by antagonists, and may be more related to as- containing GABA(A) 
receptors. Bearing in mind the previous results with the combination of a non­
selective BZ site agonist and the at selective antagonist B-CCt,218'539 it appears that 
behavioral effects of such a polypharmacy approach may be highly attractive. In the 
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quest for anxioselective anxiolytics, such a combination may be worth testing on 
human subjects, and it could be especially useful in treating those forms of 
emotional disorders which are accompanied by psychomotor slowing. 
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Where To Go From Here- Next Generation Ligands 
Although one of the goals of my research in drug design is 400 fold selectivity of 
GABA(A) ergic a5p3y2 subtypes over sedating, ataxic aip3y2 subtypes, subtype 
selectivity of >1000 fold is desirable. Since al GABA(A) ergic subtypes are principally 
responsible for the sedative, ataxic and amnesic properties of benzodiazepine receptor 
ligands,64 poor affinity and/or efficacy at these al subtypes are a requirement here for 
ligands. Based on molecular modeling 526 and the cognition enhancement activity of 
lead BzR ligand PWZ-029,42 a series of new a5 subtype selective ligands have been 
designed. As depicted in Table 46, PWZ-029, YT-II-76, YT-I-78, JY-I-03, SH-I-75, JY-
1-10, and Xli-093 have been synthesized on 30 milligram scale and the Kj's determined 
by our collaborators at UNC (B. Roth and Dr. Samarpan Majumder). The type of 
chemistry necessary to prepare such ligands has been reported in preliminary form in 
patents.539 Although PWZ-029 is only 60 fold more selective for a5 subtypes over al 
subtypes, the subtype selective efficacy (see oocyte data, Figure 193) of this ligand was 
extremely high. However, the subtype selectivity (a5 vs. al) for most of the ligands in 
Table 46 is even better [B. Roth, J. Cook, et al., unpublished results, Ki's in nM, YT-II-
76 (2370 fold), YT-I-38 (236 fold), JY-I-03 (200 fold), SH-I-75 (8000 fold), JY-I-10 
(400 fold), XLi-093 (65 fold)] and provides support for both the modeling and the 
medicinal chemistry strategy. Although the bivalent lead is only 65 fold more selective, 
this ligand has been shown to be the first a5 subtype selective antagonist both in vitro42 
and in vivo.526 For the first time, a subtype selective antagonist (Xli-093), active in vivo, 
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at a5 GABA(A) ergic Bz receptors is in hand which can be employed to confirm biology 
mediated via a5 subtypes. Moreover, (see oocyte profile), the R-enantiomer (SH-I-75) is 
about 8000 fold selective for a5 subtypes over al receptors and is an agonist at a5 BzR 
providing another selective tool to confirm data resulting from this research. It is a 
positive control and should be amnesic. Moreover, it would be expected to reverse the 
effects of ligands such as PWZ-029 in the cognition models providing both face and 
construct validity to this approach. 
Because a5 BzR GABA(A) ergic subtypes are found primarily in the 
hippocampus, these are the subtypes of interest.526 The synthesis of 5-10 grams of lead 
ligands PWZ-029 , Xli-093, and agonist SH-I-75 has been carried out for studies in 
rodents. This can be followed by the synthesis of 40-100 mgs of the PWZ-029 analogs in 
Scheme 2 and finally approximately 1 to 2 grams of the other a5 subtype selective 
ligands in Table 46 (for studies in mice) will be completed. The analogs in Scheme 2 can 
be synthesized on small scale in order to search for more subtype selective analogs of 
PWZ-029. The new analogs should be prepared on small scale for receptor binding, and 
the best of these tested for functional efficacy in oocytes. Synthesis of existing analogs in 
Schemes 1, 3, 4, 5, and 6 on gram scale for rodent and primate studies, as well as the new 
analogs (Scheme 2) on 40-100 milligram scale provides a two-pronged attack toward 
clinical agents for treatment of age associated memory deficits and Alzheimer's disease. 
The synthesis of these ligands is based upon previous chemistry in Milwaukee 
and the precedents are fully cited at the bottom of each scheme. The steps in the route 
have been carried out previously and reported.416'488,526 
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Illustrated in Scheme 2 are the new PWZ-029 analogs. In the upper left hand 
corner is YT-I-76 (5) recently shown to be 2360 times more selective for the desired a5 
subtypes over the undesired al subtypes. In brief, the PWZ-intermediate 3, from 
Scheme 1, can be converted into the new PWZ-analogs 5, 6, and 7 via known, cited 
chemistry. The fluoro analogs 6, 7, 9, and 11 provide enhanced metabolic stability, but 
still interact with the a.5 receptor isoform in the same fashion as the R-CH2OCH3 group 
of PWZ-029.540 These analogs have been modeled and fit the included volume well. 
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In Scheme 2 is illustrated the synthesis of a hybrid analog (see 8) of PWZ-029 
(56) and the cyclopropyl substituted subtype selective ligand (5). Reduction of YT-II-76 
(5) with lithium borohydride, followed by the standard methylation with methyl iodide 
will provide hybrid ligand 8. The synthesis of the fluoro analogs will be carried out 
employing the usual DAST-mediated fluorination process. All of these analogs 5, 6, 7, 8, 
9, 10, and 11 will be prepared as mentioned, on 40-100 milligram scale for receptor 
binding and functional oocyte efficacy (on the most a5 subtype selective ligands). Since 
drug design is an iterative process, the molecular modeling and analog improvement must 
await some in vitro and in vivo data in order to improve subtype selectivity, 
bioavailability, and metabolic stability (fluoro analogs). 
The synthesis of the first a5 subtype selective antagonist416'488'526 is illustrated in 
Scheme 3. At least 1-5 grams of Xli-093 and the closely related bivalent ligand Xli-210 
have been prepared. The antagonist, Xli-093 is a key tool with which to establish face 
and construct validity. It is the only a5 subtype selective antagonist whose antagonist 
activity at a5 subtypes in vivo mirrors that reported in vitro.541 Certainly Xli-093 is a 
critical tool in this study and Xli-210 might be even better. This remains to be 
established in future research. 
Depicted in Table 46 is the structure and a5 subtype selectivity of three new 
ligands recently developed. Illustrated in Scheme 5 is a hybrid ligand (YT-TC-3) 
between active inverse agonist PWZ-029 and a5 subtype selective antagonist Xli-093. 
Since PWZ-029 and Xli-093 are active in rodents ip, it is clear these types of ligands 
cross the blood brain barrier.64 
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Figure 181. Overlay of cyclopropyl analogs of PWZ-029 
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The chemistry used to design fluoro analogs of PWZ-029 can be adapted to design 
ligands of XHE-053 with less potential for metabolization by esterases. Fluorines in 
place of the carbonyl group satisfy current included volumes and electronegativity 
requirements of the Milwaukee-based pharmacophore receptor model. The covalent 
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radius of a hydrogen is 37 pm whereas a fluorine is 71 pm, whereas an oxygen atom with 
lone pairs (carbonyl) is 57 pm (picometers). 
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Figure 182. Fluoro analogs of the XHe-II-053 
Figure 183. Alkyl ether fluoro analogs of XHe-II-053 
Again, molecular modeling of a methyl ether flouro analog of XHe-II-053 appears 
reasonable. Due to known binding, the methyl ether which appears exposed in the Figure 
is not expected to be a problem. 
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Due to the concern that fluoro ethers would auto hydrolyze to form hydrofluoric 
acid by way of the mechanism shown below, these types have not been made. 
H 
OH 
+HF 
This approach is in agreement by a recent compounds patented by Roche.64 Several new 
analogs have been proposed and docked in the Milwaukee based pharmacophore. 
PWZ-029 and Roche Cmpd 7 
Affinity for axp3y2 (x= 1-6) benzodiazepine receptor isoforms 
Alpha 1 Alpha 2 Alpha 3 Alpha 4 Alpha 5 Alpha 6 
Roche 174.3 183.4 79.6 ND 4.6 ND 
CI 
Affinity of PWZ-029 for axp3ir2 (x= 1-6) benzodiazepine receptor isoforms 
Alpha 1 Alpha 2 Alpha 3 Alpha 4 Alphas Alpha 6 
Merck >300 >300 »300 ND 38.5 >300 
Moltech 920 NO ND ND 30 ND 
UNC-Roth 362.4 180.330 328.2 ND 6.185 ND 
Figure 184. Binding data for PWZ-029 and Roche Compound 7. 
Figure 185. Roche Compound 7 docked in the pharmacophore of the aSP3y2 receptor subtype 
p \^CH2OMe 
Figure 186. Proposed analog of PWZ-029 
^NY-NHCH3 
Figure 187. Proposed analog of PWZ-029. 
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Figure 188. Proposed amine analog of PWZ-029 
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TSC35 
C02Et 
TSC36 
Table 46. Alpha 5 GABA(A) ergic Subtype Selective Ligands 
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Figure 189. Control compound SH-I-75 
Examination of the data at the bottom of Table 41 clearly illustrates SH-I-75 (21) 
is the most potent (>2000 fold selective) a5 subtype selective agonist ever prepared. Its 
functional efficacy and selectivity render it the perfect positive control for this work. The 
ligand 21 should have properties exactly opposite that of PWZ-029. It is believed; ligand 
21 will cause amnesia, will antagonize the effects of PWZ-029 and again lend face and 
construct validity to this research. Positive controls and an ct5 antagonist render this a 
very strong approach to hippocampal-mediated drug design in regard to the development 
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of agents to treat cognition deficits in Alzheimer's and related age-associated memory 
deficits. 
Again, it is known from previous work526 that ligands 4 and 15 are active i.p. in 
vivo and ligands closely related in structure to SH-I-75 (21) are orally active in rodents 
(Stables, J.; NINDS; anticonvulsant screening program).526 These a5 subtype selective 
analogs cross the blood brain barrier. 
Biology 
Diazepam significantly impairs performance in a holeboard memory task, in 
which mice learned the location of 4 baited holes (out of 16 possible) over the course of 4 
trials. This performance impairment suggests a diazepam-induced working memory 
deficit. The novel antagonist XLi-093 showed appreciable selectivity for the a5 
GABA(A) receptor in vivo, consistent with previous finding in vitro.54 The memory-
impairing effects of diazepam were blocked (Figure 190) by a dose of Xli093 (3.0 mg/kg) 
that occupied -66% of a5GABA(A) binding sites but < 25% (non-significant) of 
al GABA(A) and a2/3 GABA(A) binding sites (Figure 198).488 Memory impairment 
measured via the holeboard task occurred at a dose of diazepam that resulted in a 
relatively high degree of a5 GABA(A) binding site occupancy (64%). Interestingly, 
even at a saturating dose of diazepam (10 mg/kg), XH093 was still able to block 
diazepam's memory impairing effects. The data suggests a5 GABA(A) receptors play 
an important role in diazepam-induced memory impairments. Identification of 
compounds with reduced a5 GABA(A) activity may result in nonsedating-anxiolytics 
(a2/a3 mediated) that lack memory-impairing effects of classical benzodiazepines.416 
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Figure 190. Reversal of Diazepam-induced memory deficit 
XLi-093 (3.0 mg/kg) blocked the DZ-induced suppression of performance ratio 
on the holeboard task. Note that XLi-093 showed no effect when administered with 
vehicle. Percent of a5 GABA(A) binding sites occupied by XLi-093 and DZ at doses 
used in the behavioral studies: n=8. 
In vivo binding studies (Figure 191) with XLi-093 showed negligible occupancy 
of al GABA(A) and a2/3GABA(A) binding sites; however, occupancy of a5 GABA(A) 
binding sites was significant at 1.0 mg/kg and above. 
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Figure 191. In vivo binding assay of Xli-093 
To determine the binding site occupancy at al and a2/3GABA(A) receptors, 
mice were injected with [3H]flumazenil ([3H]FLZ) (1.5 [iCi/mouse, i.v.) (Figure 191). 
Pretreatments of 30 minutes included: DZ (0.3-10.0 mg/kg, i.p.), XLi-093 (0.03-10.0 
mg/kg, i.p.), flunitrazepam (30.0mg/kg, i.p., used to determine non-specific binding). 
Mice were sacrificed 3 min after i.v. injection of tritiated ligand. Cerebellum and spinal 
cord were quickly removed, homogenized, and stored in ScintiSafe. All samples were 
processed with a Packard 1900CA liquid scintillation analyzer. For binding site 
occupancy at a5 GABA(A) receptors, methods followed those above using 
[3H]L655,708 (1.5|nCi/mouse, i.v.). Non-specific binding was determined using 
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bretazenil (5.6 mg/kg, i.p.). Mice were sacrificed 1 min after injection with tritiated 
ligand and the forebrain was quickly removed and prepared as described above. 
The ability of a novel a5 GABA(A) subtype selective antagonist, Xli-093(Xli; 
0.3-10.0mg/kg), to occupy a5 GABA(A) receptors in vivo binding (in vivo [3H]L-
655,708 binding) has also been evaluated (Figure 192). Based on percent binding 
occupancy, we assessed the ability of a range of Xli-093 doses to reverse impairments 
induced by the minimal effective dose of DZ (3.0 mg/kg). Xli-093 reversed DZ-induced 
impairments at doses of 1.0 and 3.0 mg/kg, which occupied -50-65% of [3H]L-655,708 
binding. In contrast, these doses resulted in only -20% occupancy of al GABA(A) and 
a2/3 GABA(A) receptors in cerebellum and spinal cord, respectively (determined by in 
- j  . . .  
vivo [ Hjflumazenil binding). These findings are consistent with a key role for 
a5GABA(A) receptors in BZ-induced impairments in learning and memory. 
Ligand (Dose, ip) % a5 GABA(A) Occupancy 
XH093 (3.0) 65.8 
DZ (1.0) 63.8 
DZ (3.0) 83.5 
DZ (10.0) 99 
Figure 192. a5 GABA(A) occupancy in the brain416 
Illustrated in Figure 192 are the percent of a5 GABA(A) binding sites occupied by XLi-
093 and DZ at doses used in the behavioral studies. 
The novel ligand PWZ-029, which we synthesized and characterized 
electrophysiologically, possesses in vitro binding selectivity and moderate inverse agonist 
functional selectivity at a5-containing GABA(A) receptors (Figure 193). 
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Figure 193. Oocyte and binding data for PWZ-029 by Sieghart et al.416 
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Illustrated in Figure 193 are the concentration-effects curve for modulation of 
GABA(A) elicited currents by PWZ-029 on Xenopus oocytes expressing GABA(A) 
receptor subtypes alp3y2, a2p3y2, a3p3y2, and a5p3y2. Concentrations of GABA(A) 
that elicit 3% of the maximum GABA(A) -triggered current of the respective cells were 
applied alone and with various concentrations of PWZ-029. Control currents represent 
responses in the absence of PWZ-029. Data points represent means±SEM from 4 oocytes 
from >2 batches. The 1 (j.MPWZ-029 resulted in 114±4%, 105±8%, 118±5% and 80±4% 
of control current (at GABA(A) EC3) in aip3y2, a2P3y2, a3p3y2, and a5p3y2 receptors, 
respectively. All these values except the one for a2p3y2 receptors were significantly 
different from that of the respective control currents ( p<0.01, Student's t-test). Note that 
100 nM is the pharmacologically relevant concentration. 
u5p2y2 Selective Ligands Attenuate Scopolamine Induced Contextual Memory 
Impairment. 
The new analogs of PWZ-029 are of strong interest due to the recent contextual 
memory impairment data wherein doses of scopolamine decreased memory while the a5 
ligand reversed this. PWZ-029 was assessed for its ability to attenuate scopolamine-
induced impairment of Pavlovian fear conditioned contextual memory in mice. PWZ-029 
possesses reasonable selectivity towards a5 subunit containing GABA(A) receptor 
isoforms (Figure 193).420 
SH-I-075 will be of special interest to future research as it exhibits selective 
agonism towards the a5p3y2 GABA(A) receptor isoform as determined by 
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electrophysiological recordings (Table 41). This compound will serve to support the 
"proof of principle" that compounds selective for a5 subunit containing GABA(A) 
receptor isoforms can be exploited in order to influence contextual memory. PWZ-029 
was selected for contextual memory assessment based on its GABA(A) receptor binding 
profile and its electrophysiological effect. In addition, it was without convulsive effect up 
to a dose of 30 mg/kg with no locomotor effects in mice up to 10 mg/kg. PWZ-029 
administered i.p. at a dose of 10 mg/kg was able to robustly attenuate the scopolamine-
induced impairment of contextual memory (Figure 194). In addition, PWZ-029 was 
screened for effects on a series of common receptor classes in the NIH Case Western 
Reserve Drug Screening Program and found to be without appreciable binding to other 
major classes of receptors (B. Roth et al, NIMH Psychoactive Drug Screening Program, 
UNC, unpublished results, available at https://kidbdev.med.unc.edu/pdsp or see 
Appendix). 
Veh 1 mg/kg Scopolamine PWZ-029 + Scop 
Figure 194. Fear conditioned contextual memory 
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This ligand has also been examined in rats in the passive and active avoidance 
test, spontaneous locomotor activity, elevated plus maze and grip strength tests, primarily 
predictive of the effects on the memory acquisition, basal locomotor activity, anxiety 
level and muscle tone, respectively. The improvement of task learning was detected at the 
dose of 5 mg/kg in the passive avoidance task (Figure 195). The passive avoidance task 
is a one trial fear-motivated avoidance task in which the mouse learns to refrain from 
stepping through a door to an apparently safer but previously punished dark 
compartment. The latency to refrain from crossing into the punished compartment serves 
as an index of the ability to avoid, and allows memory to be assessed. PWZ-029 at 5 
mg/kg, administered before the acquisition session, significantly increased retention 
session latency relative to the control group.46'M'542'543 
The inverse agonist PWZ-029 had no effect on anxiety or muscle tone, whereas 
at higher doses (10 and 20 mg/kg) it decreased locomotor activity. This effect was 
antagonized by flumazenil and also by the lower (but not the higher) dose of an agonist 
(SH-053-R-CH3-2'F) selective for GABA(A) receptors containing the a5 subunit. The 
hypolocomotor effect of PWZ- 029 was not antagonized by the antagonist (3CCt which 
exhibits a preferential affinity for al- subunit-containing receptors. These data suggest 
that moderate negative modulation at GABA(A) receptors containing the a5 subunit is a 
sufficient condition for eliciting enhanced encoding/consolidation of declarative memory, 
while the influence of higher doses of modulators at these receptors on motor activity 
shows an intricate pattern whose relevance and mechanism await to be defined.42' M'390, 
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542-544 jn jn t^e conf]ict paradigm in Rowlett's lab in rhesus monkeys, PWZ-029 was 
a weak anxiolytic, with no sedation observed in either the suppressed or nonsuppressed 
portion of the test. Recently, Stables et al. at NINDS has shown PWZ-029 to be a weak 
anticonvulsant with no effect on locomotor activity. Consequently, this partial a5 
inverse agonist cannot be proconvulsant nor convulsant. 
300 
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50 • 
f ,50' 
& 100-
250 • 
0 
Figure 195. Passive avoidance task .64, 542-544 
The effects of DMCM (0.2 mg/kg) and PWZ-029 (2, 5 and 10 mg/kg) on retention 
performance in a passive avoidance task (*p<0.05 compared to solvent (SOL) group) as 
illustrated in Figure 195. Number of animals per treatment group : 10. 
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Experimental 
Competition Binding Assays 
Competition binding assays were performed in a total volume of 0.5 mL at 4°C 
for 1 hour using [3H] flunitrazepam as the radiolabel. For these binding assays, 20-50 jag 
of membrane protein harvested with hypotonic buffer (50 mM Tris-acetate pH 7.4 at 4 
degree) was incubated with the radiolabel as previously described.46 64 Nonspecific 
binding was defined as radioactivity bound in the presence of 100 jiM diazepam and 
represented less than 20% of total binding. Membranes were harvested with a Brandel 
cell harvester followed by three ice-cold washes onto polyethyleneimine-pretreated 
(0.3%) Whatman GF/C filters. Filters were dried overnight and then soaked in Ecoscint 
A liquid scintillation cocktail (National Diagnostics; Atlanta, GA). Bound radioactivity 
was quantified by liquid scintillation counting. Membrane protein concentrations were 
determined using an assay kit from Bio-Rad (Hercules, CA) with bovine serum albumin 
as the standard. 
Preparation of Cloned mRNA (with Dr. R. Furtmiiller, Dr. Ramerstorfer and Dr. 
W. Sieghart).545,546 
Cloning of GABA(A) receptor subunits al, p3 and y2 into pCDM8 expression 
vectors (Invitrogen, CA) has been described elsewhere.46'64 The GABA(A) receptor a4 
subunit was cloned in an analogous way. The cDNAs for subunits al, a3and a5 were 
gifts from P. Malherbe and were subcloned into a pCI-vector. The cDNA for the a6 
subunit was a gift from P. Seeburg and was subcloned into the vector pGEM-3Z 
(Promega). After linearizing the cDNA vectors with appropriate restriction 
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endonucleases, capped transcripts were produced using the mMessage mMachine T7 
transcription kit (Ambion, TX). The capped transcripts were polyadenylated using yeast 
poly (A) polymerase (USB, OH) and were diluted and stored in diethylpyrocarbonate-
treated water at -70°C.46- 64 
Functional Expression of GABA(A) Receptors (with Dr. R. Furtmuller, Dr. 
Ramerstorfer and Dr. W. Sieghart).36,37 
The methods used for isolating, culturing, injecting and defolliculating 
the oocytes were identical with those described by E. Sigel.46 Mature female Xenopus 
laevis (Nasco, WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-
aminobenzoate, Sigma, MO) before decapitation and removal of the frog ovary. Stage 5 
to 6 oocytes with the follicle cell layer around them were singled out of the ovary using a 
platinum wire loop. Oocytes were stored and incubated at 18°C in modified Barths 
medium (MB, containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM 
NaHC03, 1 mM KCl, 0.82 mM MgS04, 0.41 mM CaCl2, 0.34 mM Ca(N03)2) that was 
supplemented with 100 Units/mL penicillin and 100 jj.g/mL streptomycin. Oocytes with 
follicle cell layers still around them were injected with 50 nL of an aqueous solution of 
the cRNA. This solution contained the transcripts for the different alpha subunits and the 
beta 3 subunit at a concentration of 0.0065 ng/nL as well as the transcript for the gamma 
2 subunit at 0.032 ng/nL. After injection of the cRNA, oocytes were incubated for at 
least 36 h before the enveloping follicle cell layers were removed. 
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To this end, oocytes were incubated for 20 minutes at 37 °C in MB that contained 
1 mg/mL collagenase type IA and 0.1 mg/mL trypsin inhibitor I-S (both Sigma). This 
was followed by osmotic shrinkage of the oocytes in doubly concentrated MB medium 
supplied with 4 mM Na-EGTA. Finally, the oocytes were transferred to a culture dish 
containing MB and were gently pushed away from the follicle cell layer which stuck to 
the surface of the dish. After removal of the follicle cell layer, oocytes were allowed to 
recover for at least 4 h before being used in electrophysiological experiments.457- 547 
Electrophysiological Experiments (with Dr. R. Furtmtiller, Dr Ramerstorfer and 
Dr. W. Sieghart).64'310 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath 
of Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES NaOH (pH 
7.4), 1 mM MgCb, 1 mM KC1 and 1 mM CaCh). The oocytes were constantly washed 
by a flow of 6 mL/min XR which could be switched to XR containing GABA and/or 
drugs. Drugs were diluted into XR from DMSO solutions resulting in a final 
concentration of 0.1 % DMSO perfusing the oocytes. Drugs were preapplied for 30 
seconds before the addition of GABA, which was coapplied with the drugs until a peak 
response was observed. Between two applications, oocytes were washed in XR for up to 
15 minutes to ensure full recovery from desensitization. For current measurements the 
oocytes were impaled with two microelectrodes (2-3 mQ) which were filled with 2 mM 
KC1. 
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All recordings were performed at room temperature (rt) at a holding potential of-
60 mV using a Warner OC-725C two-electrode voltage clamp (Warner Instruments, 
Hamden, CT).357- 547 Data were digitized, recorded and measured using a Digidata 
1322A data acquisition system (Axon Instruments, Union City, CA). Results of 
concentration response experiments were fitted using GraphPad Prism 3.00 (GraphPad 
Software, San Diego, CA). The equation used for fitting concentration response curves 
was Y=Bottom + (Top-Bottom)/(l+10A((LogEC50-X)*HillSlope)); X represents the 
logarithm of concentration, Y represents the response; Y starts at Bottom and goes to Top 
with a sigmoid shape. This is identical to the "four parameter logistic equation."548'549 
Synthesis of Bivalents 
Inverse agonist 13 was synthesized via the reported procedure.420 Hydrolysis of the 
ester function of 13 provided the acid 14 in excellent yield and this material was 
subjected to a standard CDI-mediated coupling reaction to furnish bivalent ligands 15, 
18, and 23 in 60% yield (Scheme 7).396 
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Scheme 7. Synthesis of bivalent analogs of Xli-093. 
0 
O'CH^CHj 2N NaOH/EtOH,70t; 'H 
10%aq HCI 
O 
CDI, DMF; 
diol.DBU 
o 
15 X= CH2 ,  n= 1 18 X = CH2  n= 3 
23 X = O, n = 1 
The acid 39, obtained from the ester 38, which was available from the literature,324 
was stirred with CDI in DMF, followed by stirring with the required diol and DBU to 
provide bromide dimers 40 or 41, respectively. They were converted into the trimethyl-
silylacetylenyl 42 or 43, respectively under standard conditions (Pd-mediated, Heck-type 
coupling).550 The bisacetylene 19 or 33 (individually) was easily obtained by treatment of 
the trimethylsilyl ligand 42 or 43 with fluoride anion, as shown in Scheme II. 
Scheme II. Synthesis of bivalent analogues of DMH-D-053. 
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40 X- CH2OCHJ 
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N^s/ ^ "Br 
42 X=CH2OCHJ 
43 X= CHJ 
19 X=CHJOCH3, 
33 X=CH2 
Materials and General Instumentation 
Chemicals were purchased from Aldrich Chemical Co. or Tokyo Chemical Industries 
and were used without further purification except where otherwise noted. Anhydrous 
THF was distilled from sodium/benzophenone ketyl. TLC analyses were carried out on 
Merck Kieselgel 60 F254, and flash column chromatography was performed on silica gel 
60b purchased from E. M. Laboratories. Melting points were taken on a Thomas-Hoover 
melting point apparatus or an Electrothermal Model IA8100 digital melting point 
apparatus and are reported uncorrected. NMR spectra were recorded on a Bruker 300 or 
500 MHz multiple-probe spectrometer. Infrared spectra were recorded on a Nicolet DX 
FTIR BX V5.07 spectrometer or a Mattson Polaris IR-10400 instrument. Low-resolution 
mass spectral data (EI/CI) were obtained on a Hewlett-Packard 5985B GC-mass 
spectrometer, while high resolution mass spectral data were taken on a VG 
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autospectrometer (Double Focusing High Resolution GC/Mass Spectrometer, UK). 
Microanalyses were performed on a CE Elantech EA1110 elemental analyzer. 
Competition Binding Assays 
Competition binding assays were performed in a total volume of 0.5 mL at 4°C 
for 1 hour using [3H] flunitrazepam as the radioligand. For these binding assays, 20-50 
mg of membrane protein harvested with hypotonic buffer (50 mM Tris-acetate pH 7.4 at 
c i -y 
4 degree) was incubated with the radiolabel as previously described. Nonspecific 
binding was defined as radioactivity bound in the presence of 100 fiM diazepam and 
represented less than 20% of total binding. Membranes were harvested with a Brandel 
cell harvester followed by three ice-cold washes onto polyethyleneimine-pretreated 
(0.3%) Whatman GF/C filters. Filters were dried overnight and then soaked in Ecoscint 
A liquid scintillation cocktail (National Diagnostics; Atlanta, GA ). Bound radioactivity 
was quantified by liquid scintillation counting. Membrane protein concentrations were 
determined using an assay kit from Bio-Rad (Hercules, CA) with bovine serum albumin 
as the standard. 
Radioligand Binding Assays (Drs. McKernan and Atack)551 
In brief, the affinity of compounds for human recombinant GABA(A) receptors 
•j 
was measured by competition binding using 0.5 nM [ H]flunitrazepam. Transfected HEK 
cells (beta2 gamma2 and desired alpha subtype) were harvested into phosphate-buffered 
saline, centrifuged at 3,000 g and stored at -70°C until required. On the day of the assay, 
pellets were thawed and re-suspended in sufficient volume of 50 mM Tris/acetate (pH 7.4 
at 4°C) to give a total binding of approximately 1500-2000 dpm. Non-specific binding 
was defined in the presence of 100 mM (final concentration) diazepam. Test compounds 
were dissolved in DMSO at a concentration of 10 mM and diluted in assay buffer to give 
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an appropriate concentration range in the assay, such that the final DMSO concentration 
in the assay was always less than 1%. Total assay volume was 0.5 mL and assays were 
carried out in 96-well plates and incubation time started by the addition of 0.1 mL of re-
suspended cell membranes. Following incubation for 1 hour at 4°C, assays were 
terminated by filtration through GF/B filters, washed with 10 mL ice cold buffer, dried 
and then counted using a liquid scintillation counter. The percentage inhibition of [3H] 
flunitrazepam binding, the IC50 and the Kj values were calculated using the Activity Base 
Software Package (ID Business Solutions, Guildford , UK ) according to the Cheng-
Prusoff equation.552'553 
l,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo|l,5a]|l,4]benzodiazepine-3-carboxy) propyl diester 1 (XLi093) (Procedure 
A). To a solution of carbonyl diimidazole (230.3 mg, 0.57 mmol) in anhydrous DMF (5 
mL) was added 8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4Himidazo[l,5-a][l,4]-
benzodiazepine-3-carboxylic acid 14 (200 mg, 0.71 mmol). The solution which resulted 
was stirred for 2 h at rt. Analysis by TLC (silica gel) indicated the absence of starting 
material. To the solution which resulted was then added 1,3-propanediol (27.1mg, 0.36 
mmol) in dry DMF (0.5 mL) and also DBU (114.2 mg, 0.75 mmol) in dry DMF (0.10 
mL) at rt. The mixture was stirred at rt for 4.5 h until analysis by TLC (silica gel) 
indicated the reaction was complete. The reaction mixture was then poured into ice 
water (30 mL) and extracted with CH2Cl2(3 x 50 mL). The combined organic layer was 
washed with H20 (5 x 50 mL), brine and dried (Na2S04). The solvent was removed 
under reduced pressure and the residue was purified by flash chromatography (silica 
gel, EtOAc/CHOH, 4 : 1) to provide 1 (157 mg) as a white solid in 73.4% yield. 1: mp 
>230° C (dec.); IR (NaCl) 3247, 1725, 1641, 1359, 1253, 1061 cm"; H NMR (300 
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MHz, CDC13) 5 2.37(m, 2H), 3.24(s,2H), 3.26 (s, 6H), 4.40(s, 2H), 4.57(t, 4H, J= 
6.2Hz), 5.31 (br, 2H), 7.41(d„ 2H, J-8.3 Hz) 7.72(d,d, 2H, J = 6.43Hz, and J = 1.86Hz), 
7.89 (s,2H), 8.19(d, 2H, J = 1.76Hz ); "c NMR (75.5 MHz, CDC13) 5 26.2, 34.4, 40.7, 
60.2, 78.7, 79.7, 120.4, 121.6, 127.1, 127.7, 130.1, 133.4, 134.1, 134.9, 161.3, 164.1; 
MS (FAB,NBA) m/e (relative intensity) 603(M +1, 100). This material was employed 
for the X-ray crystal structure. It was homogenous in two independent TLC systems [Rf 
=0.31 in EtOAc/CH3OH, 4 :1; Rf =0.32 in CH2C12/CH30H, 9 : 1]. Anal. Calcd for 
C33H26N606 -2/3 CH3OH: C, 64.81; H, 4.63; N, 13.47. Found: C, 64.56; H, 4.72; N, 
13.76. 
1,5-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [ 1,5a] [ 1,4] 
benzodiazepine -3carboxy) pentyl diester 18 (XLi210). Ligand 18 was prepared by 
following the procedure above with acid 14 by replacing the 1,3-propanediol with 
1,5-pentanediol to provide 18 as a white solid in 89.2% yield. 18: mp 132-138°C ; IR 
(KBr) 3422, 3280, 2931, 1714, 1635, 1487, 1249, 1064 cm"; 'H NMR (500 MHz, 
CDC13) 8 1.90(m, 4H), 3.24(s,6H), 3.52 (s, 2H), 4.39(s, 8H), 5.29(s, 2H), 7.36(dd, 
2H, J=8.1Hz, 16Hz), 7.70(m, 2H) 7.70(m, 2H), 7.86 (s,2H), 8.18(s, 2H); MS 
(FAB,NBA) m/e (relative intensity) 631(M +1, 13). Anal. Calcd for C35H30N6O6 -5/3 
H20: C, 63.61; H, 4.83; N, 12.72. Found: C, 63.16; H, 4.72; N, 13.06. 
13-Bis(8-ethyl-5,6-dihydro-5-methyi-6-oxo-4H-
imidazo[l,5a][l,4]benzodiazepine-3-carboxy) propyl diester 3 (XLi356): 1,3-Bis(8-
acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[ 1,5a] [ 1,4]-benzodiaze-pine -3-
carboxy) propyl diester 1 (500 mg, 0.83 mmol) was dissolved in EtOH (150 mL) after 
484 
which Pd/C (176 mg) was added in solution at rt. The slurry was stirred for 5h under one 
atmosphere of H2(bench top, balloon of H2). The catalyst was removed by filtration and 
washed with EtOH. The EtOH was removed under reduced pressure to furnish a residue. 
This material was purified by flash chromatography (silica gel, EtOAc : EtOH/8 : 2) to 
provide 3 (504 mg, 99%) as white crystals: mp 125-133°C; IR (NaCl) 3407, 2964, 2358, 
1725, 1640, 1499 cm"1; !H NMR (CDC13) 5 1.29 (m, 6H), 2.39(m, 2H), 2.78 (dd, 4H, 
J=7.5 Hz, 15.1 Hz), 3.26 (s, 6H), 4.48 (br, 2H), 4.56 (t, 4H, J=6.1 Hz, 12.2 Hz), 5.16(br, 
2H), 7.33 (d, 2H, J = 8.2Hz), 7.48 (d, 2H, J=1.8 Hz), 7.89 (t, 4H, J=3.2 Hz, 5.3 Hz), 8.15; 
MS(EI) m/e (relative intensity) 611(M++1, 100). Anal. Calcd for C33H34N6O6 *2^0: C, 
61.33; H, 5.92; N, 13.00. Found: C, 61.74; H, 5.91; N, 12.63. 
Bis(8-acety leno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [ 1,5a] [ 1,4] benzodiazepine-
3-carboxy) dimethyl glycol diester 23 (XLi374). Ligand 23 was prepared by 
following the procedure for 1 and acid 14, by replacing 1,3-propanediol with methylene 
glycol to afford dimer 23 (80% yield): mp >220 °C (dec.); IR (KBr) 3419, 3237, 2910, 
1714, 1635, 1561, 1498 cm"; *H NMR (500 MHz, CD2C1) 8 d 3.18(s, 6H), 3.31(s,2H), 
4.37 (br, 2H), 5.29(br, 2H), 5.74 (s, 4H), 7.40(d, 2H, J=8.1 Hz), 7.74(dd, 2H, J=1.6Hz 
and J=8.2Hz), 7.90 (s, 2H), 8.15 (s, 2H); MS(FAB,NBA) m/e (relative intensity) 
605(M +1, 100). Anal. Calcd for C32H24N607 -3/2 CH3COOC2H5: C, 61.99; H, 4.93; N, 
11.41. Found: C, 61.36; H, 4.52; N, 11.96. 
8-Bromo-6-phenyl-4H-benzo [f] imidazo [ 1,5-a] [ 1,4] diazepine-3-carboxy lie acid 39. 
The ester 38 (2g) was dissolved in EtOH (50 mL) and aq sodium hydroxide (10 mL, 2N) 
was added to the solution. The mixture was heated to reflux for 0.5 hour. After the EtOH 
was removed under reduced pressure, the solution was allowed to cool. The pH value was 
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adjusted to 4 by adding 10% aq HC1 dropwise. The mixture was filtered and the solid was 
washed with water and ethyl ether. The solid was dried to provide 39(1.8g, 96.6%): mp 
>250 °C; IR (KBr) 3450 (b), 2844, 1707, 1615, 1493, 1166, 700 cm" 'H NMR (300 MHz, 
DMSO-i/) 5 4.14 (d, 1H, J=12.6Hz), 5.79 (d, 1H, 12.6Hz), 7.41-7.54 (m, 6H), 7.88 (d, 
1H, J=8.7Hz), 8.03 (dd, 1H, J=8.7Hz, J=2.1Hz), 8.47 (s, 1H); MS (EI) m/e (rel intensity) 
381 (M, 20), 383 (19). This material was used directly in the next experiment. 
1,3-Bis(8-bromo-6-phenyl-4H-benzo [f] imidazo [ 1,5-a] [ 1,4] diazepine-3-carboxy) 
propyl diester 41 (DMH-D-070). 
(Procedure B) The carboxylic acid 39 (2 g, 5.2 mmol) was dissolved in DMF (20mL), 
after which CDI (1.02 g, 6.3 mmol) was added at rt and the mixture was stirred for 2 h. 
Then 1,3-propanediol (0.19 mL, 2.6 mmol) and DBU (0.78 mL, 5.2 mmol) were added to 
the mixture and stirring continued overnight. The reaction solution was then cooled with 
an ice-water bath, after which water was added to precipitate a solid. This material was 
purified further by flash chromatography on silica gel (gradient elution, EtOAc:EtOH 
20:1, 15:1, 10:1) to provide the bisbromide 41 (DMH-D-070) as a white solid (1.3 g, 
61.9%): mp 187.5-189 °C; IR (KBr) 3112, 2968, 1708, 1610, 1559, 1491, 1269, 1160, 
1123, 1073 cm"; 'H NMR (300 MHz, CDC13) 5 2.35 (m, 2H), 4.08 (d, 2H, J=12.6Hz), 
4.55 (m, 4H), 6.05 (d, 2H, J=12.6Hz), 7.37-7.53 (m, 12H), 7.6 (d, 2H, J=2.1Hz), 7.81 
(dd, 2H, J=2.1Hz, 8.6 Hz), 7.93 (s, 2H); "C NMR (75.5 MHz, CDC13) 5 28.2, 44.9, 61.4, 
120.7, 124.2, 128.3, 129.0, 129.3, 129.6, 130.6, 134.1, 134.4, 134.7, 135.0, 138.9, 138.9, 
162.6, 167.9; MS (FAB, NBA) m/e (rel intensity) 803 (M+l, 15); Anal. Calcd. For 
C39H28N6°4Br2: C' 58-23; H' 3.51; N, 10.45. Found: C, 57.92; H, 3.43; N, 10.29. 
1,3-Bis(8-trimethyIsilyIacetylenyl-6-phenyl-4H-benzo[f] imidazo [ 1,5-a] [ 1,4] -
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diazepine-3-carboxy) propyl diester 43 (DMH-D-048). (Procedure C). To a 
suspension of bisbromide 41 (1.005 g, 1.25 mmol) in acetonitrile (50 mL) and 
triethylamine (65 mL), was added bis(triphenylphosphine)-palladium (II) acetate (0.15 g, 
0.2 mmol). The solution which resulted was degassed and trimethylsilylacetylene (0.7 
mL, 5 mmol) was added after which it was degassed again (argon followed by vacuum). 
The mixture was heated to reflux and stirring maintained overnight. After removal of the 
solvent under reduced pressure, the residue was dissolved in CH2C12 and washed with 
water. 3-Mercaptopropyl functionalized silica gel (0.6g) was added into the organic layer 
and stirring continued for 1 hour. The silica gel/Pd complex was removed by filtration 
and the filtrate was concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (gradient elution, EtOAc:EtOH 20:1, 15:1, 
10:1) to furnish the bistrimethylsilyl dimer 43 (DMH-D-048, 680 mg, 60.8%) as a white 
solid: mp 169-172 °C; IR (KBr) 3449, 2950, 1725, 1720, 1715, 1496, 1250, 1160, 1080, 
847 cm"; H NMR (300 MHz, CDC13) 8 0.25 (s, 18H), 2.35 (m, 2H), 4.05 (d, 2H, 
J=12.6Hz), 4.55 (m, 4H), 6.02 (d, 2H, J=12.6Hz), 7.37-7.55 (m, 14H), 7.75 (dd, 2H, 
J=1.8Hz, 8.4Hz), 7.94 (s, 2H); "C NMR (75.5 MHz, CDC1.) 8 -0.3, 28.3, 44.9, 61.4, 97.4, 
102.3, 122.4, 122.6, 128.0, 128.3, 129.0, 129.4, 130.5, 134.1, 134.9, 135.1, 139.0, 139.2, 
139.2, 162.6, 168.5; MS (FAB, NBA) m/e (rel intensity) 839 (M+l, 100); Anal. Calcd. 
For C49H46N604Si2: C, 70.14; H, 5.53; N, 10.02. Found: C, 69.97; H, 5.35; N, 9.77. 
13-Bis(8-acety leny 1-6-pheny l-4H-benzo[fj imidazo[l ,5-a] [ 1,4] diazepine-3-
carboxy)propyl diester 33 ( DMH-D-053). A solution of bistrimethylsilyl dimer 43 (330 
mg, 0.4 mmol) in THF (70 mL) was stirred with tetrabutylammonium fluoride hydrate 
(250 mg, 0.96 mmol) at -78°C for 5 min. After this, H20 (35 mL) was added to the 
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solution to quench the reaction and stirring continued at low temperature for one half 
hour. The solution was extracted with EtOAc (3x100 mL), and the organic layer was 
washed with water. After removal of the solvent under reduced pressure, ethyl ether was 
added to the residue to precipitate a solid. The mixture was filtered and the solid was 
washed with CH2C12-Et20 (ca 1:15) to provide the bisacetylenyl dimer 33 (DMH-D-053, 
220 mg, 80%) as a yellow solid which crystallizes in CH2CI2: mp 172-175 °C; IR (KBr) 
3450, 3280, 2950, 1720, 1715, 1495, 1250, 1120, 1050cm"1; 'H NMR (300 MHz, CDC13) 
8 2.35 (m, 2H), 3.18 (s, 2H), 4.08 (d, 2H, J=12.3Hz), 4.56 (m, 4H), 6.04 (d, 2H, 
J=12.6Hz), 7.36-7.59 (m, 14H), 7.78 (dd, 2H, J=8.4Hz, 1.7Hz), 7.95 (s, 2H); "c NMR 
(75.5 MHz, CDC1,) 8 28.8, 45.4, 61.9, 80.2, 81.3, 121.4, 122.7, 128.1, 128.3, 129.0, 
129.3, 130.5, 134.2, 135.2, 135.3, 135.6, 138.9, 139.2, 162.6, 168.5; MS (FAB, NBA) 
m/e (rel intensity) 695 (M+1, 100). Anal. Calcd. For C^oNgO/ziCH^: C, 72.63; H, 
4.30; N, 11.75. Found: C, 72.36; H, 4.27; N, 11.36. 
Bis(8-bromo-6-pheny I-4H-benzo [f] imidazo [ 1,5-a] [ 1,4] diazepine-3-carboxy) 
diethylene glycol diester 40(DM-III-93). Ligand 40 was prepared from acid 39, under 
the same conditions employed in procedure B, by replacing 1,3-propanediol with 
diethylene glycol to yield a yellow solid (93.7%) 40: mp 165-168°C; IR (KBr) 3060, 
2956, 1725, 1610, 1558, 1491, 1267, 1161, 1123, 1074 cm"'; H NMR (300 MHz, 
CDCI3) 8 3.93 (t, 4H, J=4.8 Hz), 4.06 (d, 2H, J=12.6Hz), 4.54 (m, 4H), 6.05 (d, 2H, 
J=12.6Hz), 7.39-7.50 (m, 12H), 7.57 (d, 2H, J=2.7Hz), 7.80 (dd, 2H, J=2.1Hz, 8.4 Hz), 
7.90 (s, 2H); NMR (75.5 MHz, CDC13) 8 44.9, 63.6, 69.0, 120.7, 124.2, 128.3, 129.0, 
129.3, 129.6, 130.6, 134.1, 134.4, 134.6, 135.0, 138.9, 139.0, 162.5, 167.9; MS (FAB, 
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NBA) m/e (rel intensity) 833 (M +1, 5). Anal. Calcd. For C40H30Br2N605*0.15CHCl3: C, 
56.72; H, 3.57; N, 9.88. Found: C, 56.61; H, 3.55; N, 9.92. 
Bis(8-trimethylsilylacetyIenyl-6-phenyl-4H-benzo[f]imidazo[l,5-a][l,4]diazepine-
3-carboxy) diethylene glycol diester 14 (DM-III-94). 
Ligand 42 was prepared from dibromide 40, under the same conditions employed in 
Procedure C by replacing 1,3-propanediol with diethylene glycol to produce a yellow 
solid (49.5%) 42: mp 205-208°C; IR (KBr) 3433, 2960, 1730, 1700, 1612, 1493, 1255, 
1169, 1120, 1071, 847 cm '; H NMR (300 MHz, CDC13) 5 0.25 (s, 18H), 3.93 (t, 4H, 
J=5.4Hz), 4.04 (d, 2H, J=12.6Hz), 4.55 (m, 4H), 6.04 (d, 2H, J=12.6Hz), 7.37-7.53 (m, 
14H), 7.74 (dd, 2H, J=1.2Hz, 8.4Hz), 7.91 (s, 2H); "c NMR (75.5 MHz, CDC13) 5 -0.3, 
45.0, 63.6, 69.0, 97.5, 102.4, 122.5, 122.7, 128.1, 128.3, 129.0, 129.4, 130.5, 134.2, 
135.0, 135.1, 135.2, 139.1, 139.3, 162.7, 168.6; MS (FAB, NBA) m/e (rel intensity) 869 
(M +l, 100). Anal. Calcd. For C50H4gN6O5Si2«!/4H2O: C, 68.81; H, 5.60; N, 9.62. Found: 
C, 68.88; H, 5.66; N, 9.51. 
Bis(8-acetylenyl-6-phenyl-4H-benzo[fjimidazo[l,5-a][l,4]diazepine-3-carboxy) 
diethylene glycol diester 19 (DM-III-96). Ligand 19 was prepared from diester 42, 
under the same conditions employed in procedure B, by replacing 1,3-propanediol with 
diethylene glycol to provide a yellow solid (81.6%) 19: mp 173-177°C; IR (KBr) 3432, 
3280, 1720, 1715, 1496, 1254, 1175, 1120, 1074cm"'; H NMR (300 MHz, CDC13) 5 3.12 
(s, 2H), 3.93 (t, 4H, J=4.5Hz), 4.06 (d, 2H, J=12.6Hz), 4.55 (m, 4H), 6.05 (d, 2H, 
J=12.6Hz), 7.38-7.56 (m, 14H), 7.75 (dd, 2H, J=8.4Hz, 1.8Hz), 7.91 (s, 2H); "c NMR 
(75.5 MHz, CDC13) 5 45.0, 63.6, 69.0, 79.8, 81.3, 121.3, 122.7, 128.1, 128.3, 129.0, 
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129.3, 130.5, 134.2, 135.2, 135.3, 135.6, 139.0, 139.1, 162.6, 168.4; MS (FAB, NBA) 
m/e (rel intensity) 725 (M+l, 63). Anal. Calcd. For C44H32N605*'/4Et0Ac»)<H20: C, 
69.89; H, 4.82; N, 10.87. Found: C, 70.12; H, 4.45; N, 10.58. 
X-ray Crystallographic Data. Crystallographic data (excluding structure factors) for the 
structures in this thesis have been deposited with the Cambridge Crystallographic Data 
Centre as supplementary publication nos. 687205(DMH-D-053), 222395(Xli093), and 
222396(DM-III-96). Copies of the data can be obtained, free of charge, on application to 
CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)l 223-336033 or email: 
deposit@ccdc.cam.ac.uk). 
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Appendix I. Key Amino Acid Sequences 
Data Table 1. Amino acid sequence of the alpha subunit of the acetylcholine 
receptor in the lymnaea stagnalis (Great Pond Snail) 
>sp|P58l54|ACHP_LYMST Acetylcholine-binding protein OS=Lymnaea stagnalis PE=1 SV=1 
MRRNIFCLACLWIVQACLSLDRADILYNIRQTSRPDVIPTQRDRPVAVSVSLKFINILEV 
NEITNEVDVVFWQQTTWSDRTLAWNSSHSPDQVSVPISSLWVPDLAAYNAISKPEVLTPQ 
LARVVSDGEVLYMPSIRQRFSCDVSGVDTESGATCRIKIGSWTHHSREISVDPTTENSDD 
SEYFSQYSRFEILDVTQKKNSVTYSCCPEAYEDVEVSLNFRKKGRSEIL 
Data Table 2. Amino acid sequence of the alpha subunit of the acetylcholine 
receptor in the Torpedo californica (Pacific Electric Ray) 
>sp|P02710|ACHA_TORCA Acetylcholine receptor subunit alpha OS=Torpedo californica GN=CHRNA1 PE=1 
SV=1 
MILCSYWHVGLVLLLFSCCGLVLGSEHETRLVANLLENYNKVIRPVEHHTHFVDITVGLQ 
LIQLISVDEVNQIVETNVRLRQQWIDVRLRWNPADYGGIKKIRLPSDDVWLPDLVLYNNA 
DGDFAIVHMTKLLLDYTGKIMWTPPAIFKSYCEHVTHFPFDQQNCTMKLGIWTYDGTKV 
SISPESDRPDLSTFIVIESGEWVIVlKDYRGWKHWVYYTCCPDTPYLDITYHFIIVfQRIPLYFVV 
NVIIPCLLFSFLTGLVFYLPTDSGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGK 
YMLFTMIFVISSIIITVVVINTHHRSPSTHTMPQWVRKIFIDT1PNVMFFSTMKRASKEK 
QENKIFADDIDISDISGKQVTGEVIFQTPLIKNPDVKSAIEGVKYIAEHMKSDEESSNAA 
EEWKYVAMVIDHILLCVFMLICIIGTVSVFAGRLIELSQEG 
Data Table 3. Amino acid sequence of the alpha 1 subunit of the rat GABA(A) 
receptor 
>sp|P62813|GBRAl_RAT Gamma-aminobutyric acid receptor subunit alpha-1 OS=Rattus norvegicus 
GN=Gabral PE=1 SV=1 
MKKSRGLSDYLWAWTLILSTLSGRSYGQPSQDELKDNTTVFTRILDRLLDGYDNRLRPGL 
540 
GERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASKI 
WTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACP 
LKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVMT 
THFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTIMTTLSISAR 
NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDPL 
IKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKIDR 
LSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ 
Data Table 4. Amino acid sequence of the gamma 2 subunit of the rat GABA(A) 
receptor 
>sp|P18508|GBRG2_RAT Gamma-aminobutyric acid receptor subunit gamma-2 OS=Rattus norvegicus 
GN=Gabrg2 PE=1 SV=1 
MSSPNTWSTGSTVYSPVFSQKMTLWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPKV 
PEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQTW 
YDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLYT 
LRLT1DAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQFS 
FVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDAV 
PARTSLGiTTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFVS 
NRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCCF 
EDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL 
Data Table 5. Amino acid sequence of the alpha 1 subunit of the human GABA(A) 
receptor 
>sp|P14867|GBRAl_HUIMAM Gamma-aminobutyric acid receptor subunit alpha-1 OS=Homo sapiens 
GN=GABRA1 PE=1 SV=3 
MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG 
LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLIViASK 
IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC 
PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM 
TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA 
541 
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVYPEKPKKVKDP 
LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID 
RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ 
Data Table 6. Amino scid sequence of the gamma 2 subunit of the human GABA(A) 
receptor 
>sp|P18507|GBRG2_HUMAN Gamma-aminobutyric acid receptor subunit gamma-2 OS=Homo sapiens 
GN=GABRG2 PE=1 SV=2 
MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPK 
VPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQT 
WYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLY 
TLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREE1VYQWKRSSVEVGDTRSWRLYQF 
SFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDA 
VPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFV 
SNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCC 
FEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL 
Data Table 7. Amino acid sequence of the Beta 2 Subunit of the Human GABA(A) 
Receptor 
>sp|P47870|GBRB2_HUMAN Gamma-aminobutyric acid receptor subunit beta-2 OS=Homo sapiens 
GN=GABRB2 PE=1 SV=1 
MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPV 
AVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDT 
YFLNDKKSFVHGVTVKNRM1RLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIES 
YGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKYVFSTGSYPRLSLSFKLKR 
NIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIP 
YVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKM 
DPHENILLSTLEIKNEMATSEAVMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALER 
HVAQKKSRLRRRASQLKITIPDLTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN 
Appendix II. 
Data Table 8. Coordinates of the Pharmacophore 
REMARK File generated by Swiss-PdbViewer 4.00b0 
REMARK http://www.expasy.org/spdbv/ 
HETATM 1 * hip 0 2.246 2.113 1.413 0.00100.00 
HETATM 2 O hip 0 -5.691 -0.267 -4.151 0.00100.00 
HETATM 3 HI hip 0 0.742 3.154 -3.474 0.00100.00 
HETATM 4 H2 hip 0 -2.472 -1.062 0.681 0.00100.00 
SPDBVT 1.0000000000 0.0000000000 0.0000000000 
SPDBVT 0.0000000000 1.0000000000 0.0000000000 
SPDBVT 0.0000000000 0.0000000000 1.0000000000 
SPDBVT 0.0000000000 0.0000000000 0.0000000000 
SPDBVT 0.0000000000 0.0000000000 0.0000000000 
SPDBVV default; 
SPDBVV 15.426431672954 1678.699418606842 20.000000000000 
SPDBVV 0.4758893755 0.5102135228 -0.7163877885 
SPDBVV 0.3084772896 0.6659613576 0.6792181034 
SPDBVV 0.8236328455 -0.5442220423 0.1595346499 
SPDBVV -1.7224999666 1.0460000038 -1.3689999580 
SPDBVV 0.0000000000 0.0000000000 0.0000000000 
SPDBVf27 
SPDBVI 1.00 1.00 1.00 
SPDBVb 0.00 0.00 0.20 
SPDBVg 64 
SPDBVi 111011110100100 
SPDBVp 0 
END 
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Appendix III. Pharmacology 
Extraction of Diazepam from Valium® Tablets (5 mg) 
Valium® tablets (5 x 5 mg), contributed by the University Health Centre, U.W.I., 
Mona, were crushed with a mortar and pestle then placed in a 50 mL round bottom flask 
fitted with reflux condenser and calcium chloride guard tube. Chloroform (25 mL) was 
added and the mixture heated at reflux for 2 hours with stirring. The mixture was then 
filtered and the chloroform evaporated under vacuum to give diazepam (23 mg, 92%) as 
pale yellow crystals; mp 129-132 °C, [lit.512 125-126 °C (acetone/ petroleum ether)]; 
'H-NMR 5 = 3.42 (s, 3H, -NCH3), 3.80 (d, J = 11 Hz, 1H, H-3), 4.86 (d, J = 11 Hz, 1H, 
H-3), 7.33 (m, 2H, H-3' and H-5'), 7.45 (m, 2H, H-2' and H-6'), 7.51 (dd, J= 1 and 7 Hz, 
1H, H-8), 7.55 (m, 1H, H-4'), 7.62 (d, J= 1 Hz 1H, H-6), 7.64 ppm (d, J = 7 Hz 1H, H-
9); l3C-NMR 5 = 35.2, 57.4, 122.9, 128.9, 129.7, 129.9, 130.3, 130.5, 131.1, 131.8, 
138.6, 143.0,169.3, 170.3 ppm. 
Hippocratic Screen Activities 
The following activities were measured in the Hippocratic screen: 
a) Decreased motor activity - spontaneous movement of the animals: ±, is quiet but 
moves spontaneously; +, does not move spontaneously but moves rapidly when 
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handled; ++„ moves slowly when handled; +++, moves very sluggishly when 
handled; ++++, does not move at all when handled. 
b) Ataxia - coordinated movement of the animals: +, shows slight incoordination; ++. 
has difficulty walking in a straight line but its course is true; +++, cannot walk in a 
straight line and its course is erratic; ++++, cannot walk on any course. 
c) Loss of righting reflex - the animals' response when placed on their sides or back: 
+, can be placed on one side; ++, can be placed be placed on either side equally 
well; +++, can be placed on back as well as both sides; ++++, cannot get up from 
back position on its own. 
d) Analgesia - animals' response to pain inflicted across the instep and toes: ±, 
sluggish response with vocalization and or attempts to bite or escape; +, no 
vocalization nor attempts to bite or escape but does attempt to calmly withdraw 
foot; ++, no response 
e) Anesthesia - animals' response when a hypodermic needle is pressed to foot pad: 
±, a sluggish response; no response to needle pressure; ++, no response to needle 
penetration. 
f) Pinnal reflex - the animals' response to a gentle touch with a probe (brush bristle) 
into the ear canal: ±, sluggish response; +, no response 
g) Loss of screen grip - animals' ability to remain on a wire screen when tilted at 45 -
180° or gently shaken in a horizontal plane when inverted: ±, unequivocal loss; +, 
falls at first shake when screen is inverted; ++, falls when screen is inverted; +++, 
falls at 90°, ++++, falls at 45°. 
h) Paralysis - animals were inspected for signs of paralysis in forelegs, hind legs and 
neck: ±, unequivocal; +, complete. 
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i) Respiratory rate - animals' rate of breathing per minute compared to the period 
before the animal is tested: +, 10 % change; ++, 20 % change; +++, 40 % change; 
++++, 80 % change. 
j) Tremor - animals were observed for any signs of abnormal or excessive shaking: ±, 
unequivocal presence; +, definite but periodically; ++, continuous; +++, 
convulsions. 
k) Startle reaction - The animals' response when the observation rink was sharply 
slapped with a flat metal object: ±, a mild startle; +, animal visibly jerks; ++, animal 
jerks, jumps and attempts to escape; +++, animal goes into convulsions. 
Appendix IV. Tetracyclic 1,3-Diazepinium Chemistry (with Grant et al.) 
In the synthetic pathway outlined by Jackson and Williams,554 tetracyclic 1,3-
diazepinium bromide 1 was prepared by intramolecular cyclization of bromomethyl 
amide 6a which readily occurred in refluxing acetone. Amide 6a was obtained from 7-
hydroxy-4-methylcoumarin (2) as shown in Scheme 1. It was proposed that this 
synthetic route could be modified to produce the required 1,3-diazepinium chlorides by 
cyclization of the respective chloromethyl amides (Scheme 1) or by ion exchange of the 
1,3-diazepinium bromides (Scheme 2). 
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ref. 18 HO' MeO' 
2a R- H 
2b R'= OMe 
and 29 
3a R'= H 
3b R- OMe 
R-iL^? 
^ A 
N NH2 
4a R= H, X=C 
4b R= 3-Me, X= C 
4 c  R =  4 - M e ,  X = C  
4d R= 5-Me, X= C 
4e R= 6-Me, X= C 
4f R= 5-CI, X= C 
4g R= H, X= N 
5a R= H, X=C, R'= H 
5b R= 3-Me, X= C, R'= H 
5c R= 4-Me, X=C, R'= H 
5d R= 5-Me, X= C, R'= H 
5e R= 6-Me, X= C, R'= H 
5f R= 5-CI, X= C, R'= H 
5g R= H, X= N, R'= H 
5h R= H, X= C, R- OMe 
8a -h 
MeO 
7a-h 6a-h 
Scheme 1. Reagents and conditions: (ai) 2a, K2CO3, Me2S04, acetone, reflux, 13 h, 97%; 
(aii) 2b, K2C03, Mel, acetone, reflux, 8 h, 89%; (b) K2C03, Br2, CHC13, 70 °C, 3 h, 74% 
(for 2a), 90% (for 2b); (c) NaOH, EtOH, reflux, 3 h, 98% (3a), 90% (3b); (d) i) SOCl2, 
pyridine, CH2CI2, rt, 30 min; ii) 4a-g, pyridine, toluene, reflux, 5 h, 51-77%; (e) NBS, 
CCI4, hv, 2-3 h, 44-76%; (f) NaCl, [CH3(CH2)3]4N+ I", CHC13, H20, reflux, 3-12 h, 68-
88%; (g) acetone, reflux, 3-5 days, 12-50%, (8b, 2%). 
547 
Methylation of 7-hydroxy-4-methylcoumarin (2a) with Me2S(VK2C03 followed by 
bromination with Brj/K^CCVCHCb, then hydrolysis and subsequent rearrangement of 
the 3-bromocoumarin in ethanolic NaOH, produced acid 3a in 85% overall yield. 5,6-
Dimethoxy-4-methylcoumarin (3b) was also prepared, in similar fashion, from 6,7-
dihydroxy-4-methylcoumarin (2b) in 72% overall yield.555 Treatment of acid 3a with 
thionyl chloride followed by substituted pyridines and pyrimidines (4a-g) produced 
amides 5a-g and acid 3b reacted, under these conditions, with amine 4a to give amide 
Sg- It was found that when the reaction was carried out in the typical way i.e. addition of 
a solution of the amine (1.1 molar equiv.) in pyridine to the acid chloride, 2-amino-3-
picoline (4b) reacted with 3a to give imide 9 (96%). Under these conditions, 2-amino-5-
picoline (4d) also reacted to produce imide 10 (26%) along with desired amide 5d (56 
The experimental data confirmed the double acylation of 4b and 4d which was 
perhaps due to the effect of the electron donating methyl group in ortho and para 
positions respectively, to the reacting amino group. Synthesis of amide 5b was achieved 
by slowly adding the acid chloride mixture to a solution of 4b (3 molar equiv.) in 
pyridine then heating the mixture at reflux for 3 hours. 
%). 
MeO 
R' 
9. R= Me, R'= H 
10. R= H, R'= Me 
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Attempts at allylic chlorination of the amides using /-butyl hypochlorite in methyl 
formate, dichloromethane or carbon tetrachloride to give chloromethyl amides 7a-h were 
futile. Hence, amides 5a-h were treated with NBS in CCI4 and irradiated, in a darkened 
box, with a 150 W tungsten lamp for 2-2.5 hours to give the respective bromomethyl 
amides 6a-h in modest yields. Formation of the allyl bromide was readily confirmed by 
I 13 both H-NMR and C-NMR spectra. The methyl group attached to the benzofuran 
system of the respective amides appears at about 8 2.6 in the 'H-NMR spectrum and at 8 
9.5 in 13C-NMR spectrum, while the CH2-Br of the same system resonates further 
downfield at about 5 5.2 in the 'H-NMR spectrum and 8 21.20 in the 13C-NMR spectrum. 
It should be noted that irradiation of the amides with NBS for longer than 3 hours caused 
cyclization of the bromomethyl amides to their respective tetracyclic bromide salts. This 
was not surprising as Jackson and Williams had reported this in their reaction with 5a. 
Allylic bromination of 5b and 5g proved less straightforward than for the other 
analogues. When amide 5b was treated with NBS in CCI4 and light, 3-bromomethyl-6-
methoxy-Ar-(3-methylpyridin-2-yl)benzofuran-2-carboxamide (6b) was obtained as a 
mixture with 6-methoxy-jV-(3-bromomethylpyridin-2-yl)-3-methylbenzofuran-2-
carboxamide, in a crude yield of 89%. Analysis of the crude mixture confirmed that ratio 
of the desired 6b to the other product was 3:2 and this crude mixture was used in the next 
step i.e. halogen transfer. Treatment of amide 5g with NBS in CCI4 and light for 1-3 
hours produced the desired bromomethyl amide 6g as a mixture with the 1,3-diazepinium 
bromide 11 in a ratio of 1:2. When the reaction was extended beyond 3 hours, only the 
bromide salt 11 was obtained, indicating that bromomethyl amide 6g is very susceptible 
to ring closure, and reacts to produce the salt 11 as soon as it is formed. Since 
intermediate 6g consists of a pyrimidine ring with not one, but two ring nitrogen atoms in 
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positions which are available for interaction with the -CHa-Br moiety of the molecule to 
effect cyclization, this process occurs readily. 
Bromomethyl amides 6a-f and 6h were then converted to the respective 
chloromethyl amides 7a-f and 7h under phase transfer conditions,512 using a NaCl 
solution (25% aqueous) and tetra-w-butylammonium iodide as the phase transfer catalyst. 
The chloromethyl amides were easily distinguished from the corresponding bromomethyl 
compounds by their l3C-NMR spectra, wherein the carbon atom of the -CH2-CI group 
resonated at approximately 5 35.0, as compared to 8 21.2 for the analogous -CH2-Br. 
Chloromethyl amides 7b and 7d were obtained in crude yields of 58 and 96% 
respectively. Analysis of NMR data confirmed the presence of the products and the crude 
products were used in the cyclization reaction. 
Jackson and Williams accomplished cyclization of a 0.7% solution of bromomethyl 
amide 6a in refluxing acetone in 70% yield512 however, when the corresponding chloro 
analogue 7a was treated under similar conditions for 28 hours, 1,3-diazepinium chloride 
8a was obtained in only 6% yield. Heating 10-20% solutions of chloromethyl amides 7 a-
f and 7h at reflux in the more polar and higher boiling 1,4-dioxane for several days, 
however, furnished the corresponding 1,3-diazepinium chlorides in 12-50% yield, 
except in the case of 7b where the tetracycle was obtained in only 2% yield. In the 'H-
and 13C-NMR spectra, the methylene protons resonate at about 8 6.0 and 8 50.0 
respectively. 
Since the tetracyclic 1,3-diazepinium bromides were so readily formed, especially 
for compound 11, we also considered converting these bromides to their respective 
chlorides. Yamazaki and later Cook reported the conversion of quaternary ammonium 
iodides to chlorides using AgCl in anhydrous MeOH. However, compounds 1 and 11 
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were found to be insoluble in MeOH and even when the reaction was heated at reflux, 
only the starting bromides were obtained. 
Scheme 2. Reagents and condition: (a) AgCl, MeOH, rt. 
Experimental Data for the Tetracyclic 13-Diazepinium Chlorides 
Chemistry 
Unless otherwise stated, the following generalizations apply. Evaporation means 
evaporation under reduced pressure. Melting points were determined on a Thomas-
Hoover apparatus and are uncorrected. 'H-NMR and 13C-NMR spectra were obtained in 
deuteriochloroform solution on ACE 200 Bruker spectrophotometers (200 MHz or 500 
MHz) instruments. Chemical shifts are reported in ppm. The abbreviations are as follows: 
s, singlet; d, doublet; dd, double doublet; dt doublet of triplets; m, multiplet. Infrared 
spectra were obtained on a Bruker Vector FT-IR spectrophotometer and are for NaCl 
discs. Elemental analyses were carried out at MEDAC Ltd., Brunei Science Centre, 
United Kingdom. Column chromatography was performed using silica gel (40-63 urn). 
The solvent systems used were: A = ethyl acetate/hexane (1:1); B = ethyl acetate/hexane 
(1:2); C = ethyl acetate/dichloromethane (1:1) and D = ethyl acetate/dichloromethane 
General Preparation of 6-Methoxy-3-Methylbenzofuran-2-Carboxamides (5a-h) 
To a 100 mL round bottom flask fitted with a reflux condenser and a calcium 
chloride guard tube was added a 10% mixture (wt./vol.) of acid 3 (1.00 g, 4.85 mmol) in 
I  x=c 
I I  X = N  
8a x=c 
8g X=N 
(1:2). 
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dichloromethane (10 mL). Thionyl chloride (2 molar equiv., 0.70 mL) and pyridine (2 
ml) were then added to the mixture which was stirred at room temperature for 30 min. 
The amine (4a-g) (1.1 molar equiv.) in pyridine (4 mL) and toluene (3 mL) was then 
added and the mixture heated at reflux for 5 h. The mixture was concentrated then 
pyridine was removed by azeotroping with toluene and evaporating under vacuum. The 
crude was purified by flash-column chromatography on silica which had been treated 
with 5% triethylamine in eluting solvent, to give corresponding amides 5a-h. 
6-Methoxy-3-methyl-iV-(pyridin-2-yl)benzofuran-2-carboxamide (5a) 
Acid 3a was reacted with 2-aminopyridine (4a) and column eluted with solvent 
system D to give amide 5a, (0.92 g, 67%) as off-white crystals; mp 168-170 °C (MeOH), 
[lit. 167-169 °C]; IR vmax 1688, 3408 cm"1; 'H-NMR 5 = 2.57 (s, 3H, -CH3), 3.81 (s, 3H, 
-OCH3), 6.89 (m, 2H, H-5 and H-7), 7.00 (m, 1H, H-5'), 7.42 (m, 1H, H-4), 7.68 (m, 1H, 
H-4'), 8.28 (m, 2H, H-3', 6'), 9.00 ppm (1H, s, -NH); l3C-NMR 6 = 9.6, 56.2, 95.8, 
113.5, 114.4, 120.2, 121.7, 123.5, 125.4, 138.8, 141.8, 148.4, 151.6, 155.1, 158.6, 161.1 
ppm. 
Di-(6-methoxy-3-methylbenzofuran-2-carbonyl)(3-methylpyridin-2-yI)amine (9) 
Acid 3a was reacted with 2-amino-3-picoline (4b) and column eluted with system B 
to give imide 9, (1.13 g, 96%) as off-white crystals; mp > 300 °C (MeOH); IR vmax 1612, 
1620 cm"1; 'H-NMR 5 = 2.43 (s, 3H, py-CH3), 2.57 (s, 6H, furan-CH3), 3.80 (s, 6H, -
OCH3), 6.73 (d, J= 2 Hz, 2H, H-7' and H-7"), 6.87 (dd, J= 2 and 9 Hz, 2H, H-5' and H-
5"), 7.18 (dt, J = 5 and 8 Hz, 1H, H-5), 7.43 (d, J = 9 Hz, 2H, H-4' and H-4"), 7.67 (d, J 
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= 8 Hz, 1H, H-4), 8.92 ppm (d, J= 5Hz, 1H, H-6); 13C-NMR 5 - 9.9, 18.2. 56.1, 95.6. 
113.7. 121.8, 123.0, 123.5, 128.1, 131.2, 140.0, 145.4, 147.1, 151.9, 155.7, 161.3, 163.0 
ppm. Anal, calcd for C28H24N2O6: C, 69.41; H, 4.99; N, 5.78. Found: C, 69.33; H, 4.84; 
N, 5.59. 
6-Methoxy-3-methyl-iV-(4-methylpyridin-2-\i)benzofuran-2-carboxamide (5c) 
Acid 3a was reacted with 2-amino-4-picoline (4c) and column eluted with system B 
to give amide 5c, (0.73 g, 51%) as off-white crystals; mp 184.5-185.5 °C (MeOH); IR 
vmax 1672, 3409 cm1; 'H-NMR 5 = 2.40 (s, 3H, py-CH3), 2.66 (s, 3H, furan-CH3), 3.89 
(s, 3H, -OCH3), 6.94 (m, 3H, H-4, H-5 and H-7), 7.50 (dd, J = 3 and 5 Hz, 1H, H-5'), 
8.20 (m, 2H, H-3' and H-6'), 8.92 ppm (s, 1H, -NH); 13C-NMR 5 = 9.6, 21.8, 56.2, 95.9, 
113.5, 114.9, 121.4, 121.8, 123.5, 125.4, 141.8, 148.1, 150.3, 151.6, 155.1, 158.7, 161.1 
ppm. Anal, calcd for Ci7H16N203: C, 68.91; H, 5.44; N, 9.45. Found: C, 68.60; H, 5.54; 
N, 9.00. 
6-Methoxy-3-methyl-A-(5-methylpyridin-2-yI)benzofuran-2-carboxamide (5d) 
Acid 3a was reacted with 2-amino-5-picoline (4d) and column eluted with system B 
to give amide 5d, (0.81 g, 56%) as cream needle-like crystals; mp 150-151 °C (MeOH); 
IR vmax 1670, 3408 cm'1; 'H-NMR 8 = 2.35 (s, 3H, py-CH3), 2.68 (s, 3H, furan-CH3), 
3.91 (s, 3H, -OCH3), 6.96 (dd, J = 2 and 9 Hz, 1H, H-5), 6.98 (d, J= 2 Hz, 1H, H-7), 7.52 
(d, J = 9 Hz, 1H, H-4), 7.58 (dd, J= 2 and 9 Hz, 1H, H-4'), 8.18 (d, .7=2 Hz, 1H, H-6'), 
8.29 (d, J = 9 Hz, 1H, H-3'), 8.94 ppm (s, 1H, -NH); 13C-NMR 5 = 9.6, 18.2, 56.2, 96.0, 
113.5, 113.9, 121.7, 123.6, 129.6, 139.3, 142.0, 148.4, 149.5, 155.1, 158.5, 161.1 ppm. 
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Anal, calcd for C17H16N2O3: C, 68.91; H, 5.44; N. 9.45. Found: C, 68.62; H. 5.31; N. 
9.31. 
Di-(6-methoxy-3-methylbenzofuran-2-carbonyl)(5-methyIpyridin-2-yl)amine (10) 
Acid 3a was reacted with 2-amino-5-picoline (4d) and column eluted with system B 
to give imide 10, (0.31 g, 26%) as off-white crystals; mp > 300 °C (MeOH); IR vmax 
1634, 1628 cm"1; 'H-NMR 5 = 2.37 (s, 3H, py-CH3), 2.59 (s, 6H, furan-CH3), 3.82 (s, 6H, 
-OCH3), 6.80 (d, J = 2 Hz, 2H, H-7' and H-7"), 6.91 (dd, J= 2 and 9 Hz, 2H, H-5' and H-
5"), 7.31 (d, J= 8 Hz, 1H, H-4), 7.47 (d, J = 9 Hz. 2H, H-4' and H-4"), 7.60 (d, J= 8 Hz, 
1H, H-3), 8.23 ppm (s, 1H, H-6); 13C-NMR 5 = 9.5. 18.0, 55.7, 95.4, 113.4, 120.8, 121.5, 
122.6, 127.7, 131.6, 138.6, 143.2, 149.2, 150.6, 155.5, 161.0, 163.0 ppm. Anal, calcd for 
C28H24N206: C 69.41, H 4.99, N 5.78; found C 69.06, H 5.15, N 5.63. 
6-Methoxy-3-methyl-7V-(6-methylpyridin-2-yl)benzofuran-2-carboxamide (5e) 
Acid 3a was reacted with 2-amino-6-picoline (4e) and column eluted with system B 
to give amide 5e, (1.09 g, 76%) as pale-yellow crystals; mp 130-132 °C (MeOH); IR 
vmax 1675, 3412 cm"1; 'H-NMR 8 = 2.51 (s, 3H, py-CH3), 2.65 (s, 3H, furan-CH3), 3.89 
(s, 3H, -OCH3), 6.94 (m, 3H, H-4, H-5 and H-7), 7.50 (d, J= 8 Hz, 1H, H-5'), 7.63 (t, J = 
8 Hz, 1H, H-4'), 8.17 (d, J = 8 Hz, 1H, H-3'), 8.89 ppm (s, 1H, -NH); l3C-NMR 5 = 9.6, 
24.5, 56.2, 95.9, 111.2, 113.5, 119.7, 121.7, 123.6, 125.2, 139.0, 141.9, 150.9, 155.1, 
157.4, 158.6, 161.0 ppm. Anal, calcd for C17H16N2O3: C, 68.91; H, 5.44; N, 9.45. Found: 
C, 68.49; H, 5.45; N, 9.25. 
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V-(5-Chloropyridin-2-yl)-6-methoxy-3-methylbenzofuran-2-carboxamide (5f) 
Acid 3a was reacted with 2-amino-5-chloropyridine (4f) and column eluted with 
system B to give amide 5f, (1.19 g, 77%) as pale yellow crystals; mp 147-149 °C 
(MeOH); IR vmax 1680, 3396 cm"1; 'H-NMR 8 = 2.63 (s, 3H, -CH3), 3.88 (s, 3H, -
OCH3), 6.94 (m, 2H, H-5 and H-7), 7.48 (d, J= 9 Hz, 1H, H-4), 7.70 (dd, J= 3 and 9 Hz, 
1H, H-4'), 8.29 (d, J = 3 Hz, 1H, H-6'), 8.36 (d, J = 9 Hz, 1H, H-3'), 9.01 ppm (s, 1H, -
NH); l3C-NMR 8 = 9.2, 55.8, 95.4, 113.5, 113.3, 114.6, 121.4, 123.0, 125.5, 126.7, 
138.0, 141.1, 146.7, 149.6, 154.7, 158.0, 160.8 ppm. Anal, calcd for C16H13N2O3CI: C, 
60.67; H, 4.14; N, 8.84. Found: C, 60.25; H, 4.10; N, 8.46. 
6-Methoxy-3-methyI-Ar-(pyrimidin-2-yl)benzofuran-2-carboxamlde (5g) 
Acid 3a was reacted with 2-aminopyrimidine (4g) and column eluted with system C 
to give amide 5g, (0.98 g, 69%) as a cream crystals; mp 169-171 °C, [lit.52 156-158 °C]; 
IR vmax 1704, 3421 cm"1; 'H-NMR 8 = 2.58 (s, 3H, -CH3), 3.80 (s, 3H. -OCH3), 6.86 (m, 
2H, H-5 and H-7), 7.00 (t, J= 5 Hz, 1H, H-5' ), 7.42 (d, J = 8 Hz, 1H, H-4), 8.6 (d, J= 5 
Hz, 2H, H-4' and H-6'), 9.04 ppm (s, 1H, -NH); 13C-NMR 8 = 9.6, 53.9, 56.2, 95.9, 
113.7, 117.2, 122.0, 123.5, 126.7, 141.7, 155.1, 157.4,157.9, 158.9, 161.3 ppm. 
6-Metho\y-3-methyl-/V-(3-methylpyridin-2-yl)benzofuran-2-carboxamide (5b) 
To a 50 mL round bottom flask fitted with a calcium chloride guard tube was added 
a 10% mixture (wt./vol.) of acid 3a (1.02 g, 4.97 mmol) in dichloromethane (10 mL). 
Pyridine (5 mL) and SOCI2 (2 molar equiv.) were then added and the solution stirred at 
room temperature for 40 min. A 20% solution of amine 4b (3 molar equiv.) in 
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pyridine/toluene (4:3) was made up in a 100 mL two-neck round bottom flask fitted with 
a constant pressure dropping funnel, reflux condenser and calcium chloride guard tube. 
The acid chloride mixture was transferred to the constant pressure dropping funnel and 
added dropwise over a period of 90 min then the whole heated at reflux for 3 h. The 
mixture was concentrated and pyridine removed by azeotroping with toluene and 
evaporating under vacuum. The crude was purified by flash-column chromatography on 
silica which had been treated with 5% triethylamine, and eluted with solvent system B, to 
give amide 5b (1.03 g, 70%) as pale yellow crystals; mp 171-172 °C, IR vmax 1603, 3273 
cm"'; 'H-NMR 5 = 2.41 (s, 3H, py-CH3), 2.64 (s, 3H, furan-CH3), 3.90 (s, 3H, -OCH3), 
6.97 (dd, J =  2 and 9 Hz, IH, H-5), 6.99 (d, J  =  2Hz, IH, H-7), 7.16 (dd, J  = 5 Hz and 8 
Hz, IH, H-5'), 7.51 (d, J = 9 Hz, IH, H-4), 7.64 (d, J = 8 Hz, IH, H-4'), 8.35 (d, J = 5 
Hz, IH, H-6'), 8.64 ppm (s, IH, -NH); 13C-NMR 8 = 9.1, 18.4, 55.8, 95.5, 113.0, 121.3, 
121.7, 123.1, 124.7, 128.5, 139.8, 141.8, 145.9, 149.0, 154.7, 158.2, 160.5 ppm; Anal, 
calcd for C17H16N2O3: C, 68.91; H, 5.44; N, 9.45. Found: C, 68.86; H, 5.47; N, 9.29. 
5,6-Dimetho\y-3-methyl- V-(pyridin-2-yi)benzofuran-2-carboxamide (5h) 
5,6-Dimethoxy-3-methylbenzofuran-2-carboxylic acid (3b) (0.60 g, 2.53 mmol) 
was reacted with 2-aminopyridine (4a) (0.29 g, 3.03 mmol). Column was eluted with 
solvent system D to give amide 5h, (0.49 g, 62%) as off-white crystals; mp 230-232 °C 
(EtOH); IR vmax 1695, 3417 cm"1; 'H-NMR 5 = 2.68 (s, 3H, -CH3), 3.97 (s, 3H, -OCH3), 
3.98 (s, 3H, -OCH3), 6.98 (s, IH, H-7), 6.99 (s, IH, H-4), 7.08 (m, IH, H-4'), 7.76 (m, 
IH, H-5'), 8.37 (m, 2H, H-3', 6'), 8.98 ppm (s, IH, -NH); 13C-NMR 5 = 9.7, 56.7, 56.8, 
95.3, 101.5, 114.4, 120.1, 122.0, 125.5, 138.7, 141.8, 147.7, 148.5, 149.0, 151.5, 151.7, 
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158.5 ppm. Anal, calcd for C|7H16N204: C, 66.04; H, 5.85; N, 8.55. Found: C, 65.97; H, 
5.81; N, 8.25. 
General Preparation of Bromomethyl Amides (6a-h) 
A solution of amide in carbon tetrachloride was made up in a round bottom flask 
fitted with reflux condenser and calcium chloride guard tube. jV-bromosuccinimide (1.1 
molar equiv.) was added with stirring and the mixture irradiated, in a darkened box, with 
a 150 W tungsten lamp for 2-3 h. The suspension was filtered and the filter cake washed 
with hot CCI4. The filtrate was then concentrated and recrystallized to give the respective 
bromomethyl amide. No elemental analysis was carried out on these allyl bromides. 
3-(Bromomethyl)-6-methoxy-/V-(pyridin-2-yl)benzofuran-2-carboxamide (6a) 
Amide 5a (0.40 g, 1.42 mmol) reacted in CCI4 (24 mL) to give 6a (0.39 g, 76%) as an 
off-white solid, mp 158-160 °C (MeOH); [lit. 123-124 °C]; IR vmax 1578, 1665, 3401 
cm"1; 'H-NMR 8 = 3.90 (s, 3H, -OCH3), 5.14 (s, 2H, -CH2Br), 7.00 (m, 3H, H-4, H-5 and 
H-7), 7.73 (m, 2H, H-4' and H-5'). 8.36 (m, 2H, H-3' and H-6'), 9.01 ppm (s, 1H, -NH); 
13C-NMR 8 = 21.2, 56.2, 96.1, 114.3, 114.6, 120.6, 121.0, 122.1, 125.0, 138.8, 141.9, 
148.5, 151.1, 155.3, 157.7, 161.4 ppm. 
3-(Bromomethyl)-6-metho\y-A-(4-methylpyridin-2-yl)benzofuran-2-carboxamide 
(6c) 
Amide 5c (1.12 g, 3.78 mmol) reacted in CCI4 (95 mL) to give 6c (0.73 g, 51%) as 
a pale yellow solid, mp 191-193 °C (EtOH); IR vmax 1558, 1619, 3393 cm"1; IR vmax 
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1578, 1665, 3401 cm"1; 'H-NMR 5 = 2.41 (s, 3H, -CH3) 3.90 (s, 3H, -OCH3), 5.14 (s, 2H, 
-CH2Br), 6.93 (dd, J= 1 and 5 Hz, 1H, H-5), 7.03 (m, 2H, H-4 and H-7), 7.67 (dd, J= 1 
and 8 Hz, 1H, H-5'), 8.20 (m, 2H, H-3' and H-6'), 8.97 ppm (s, 1H, -NH); l3C-NMR 5 = 
21.2, 21.8, 56.2, 96.1, 114.3, 115.2, 121.0, 121.8, 122.1, 125.0, 141.9, 147.9, 150.6, 
151.1, 155.3, 157.7, 161.4 ppm. 
3-(Bromomethyl)-6-methoxy-A-(5-methylpyridin-2-yl)benzofuran-2-carbo\amide 
(6d) 
Amide 5d (0.80 g, 2.70 mmol) reacted in CCI4 (80 mL) to give 6d (0.45 g, 44%) as 
a pale yellow solid, mp 178-180 °C (EtOH); IR vmax 1599, 1673, 3430 cm"1; 'H-NMR 8 
= 2.36 (s, 3H, -CH3), 3.91 (s, 3H, -OCH3), 5.12 (s, 3H, -CH2Br), 6.99 (dd, J= 2 and 9 Hz, 
1H, H-5), 6.98 (d, J = 2 Hz, 1H, H-7), 7.52 (d, J= 9 Hz, 1H, H-4), 7.58 (dd, J = 2 and 9 
Hz, 1H, H-4'), 8.18 (d, J= 2 Hz, 1H, H-6'), 8.29 (d, J= 9 Hz, 1H, H-3'), 8.98 ppm (s, 1H, 
-NH); 13C-NMR 8 = 18.3, 21.3, 56.3, 96.1, 114.2, 114.4, 121.1, 122.2, 125.4, 139.4, 
139.7, 148.5, 149.0, 151.0, 155.3, 158.6, 161.4 ppm. 
3-(BromomethyI)-6-methoxy-\-(6-methylpyridin-2-yl)benzofuran-2-carboxamide 
(6e) 
Amide 5e (0.85 g, 2.87 mmol) reacted in CCI4 (60 mL) to give 6e (0.74 g, 69%) as 
a pale yellow solid, mp 150-152 °C (EtOH); IR vmax 1597, 1670, 3414 cm"1; 'H-NMR 8 
= 2.79 (s, 3H, -CH3) 3.92 (s, 3H, -OCH3), 5.07 (s, 2H, -CH2Br), 7.02 (m, 3H, H-4, H-5 
and H-7), 7.67 (m, 2H, H-4' and H-5'), 8.20 (d, J= 8 Hz, 1H, H-3'), 9.06 ppm (s, 1H, -
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NH); l3C-NMR 5 = 21.2, 24.2, 56.2, 96.1, 112.0, 114.3, 120.1, 122.1, 123.9, 125.7, 
139.9, 142.2, 151.0, 155.6, 157.8, 158.9, 161.6 ppm. 
3-(BromomethyI)-Ar-(5-chloropyridyl)-6-methoxybenzofuran-2-carboxamide (6f) 
Amide 5f (1.17 g, 3.70 mmol) reacted in CCI4 (100 mL) to give 6f (0.95 g, 65%) as a 
pale yellow solid, mp 218-220 °C (EtOH); IR vmax 1577, 1678, 3394 cm"1; 'H-NMR 8 = 
3.90 (s, 3H, -OCH3), 5.12 (s, 2H, -CH2Br) 7.01 (m, 2H, H-5 and H-7) 7.68 (d, J= 9 Hz, 
IH, H-4), 7.73 (dd, J = 3 and 9 Hz, 1H, H-4'), 8.31 (d, J = 9 Hz, 1H, H-3'), 8.37 (d, J  = 3 
Hz, 1H, H-6'), 9.00 ppm (s, 1H, -NH); l3C-NMR 5 = 20.6, 55.8, 95.7, 114.0, 114.9, 
120.6, 121.8, 125.1, 127.3, 138.1, 141.2, 146.7, 149.1, 155.0, 157.2, 161.2 ppm. 
3-Methoxy-6-oxo-7,13-dihydro-6//-benzofuro [2,3-eJpyrimido [ 1,2-a] [ 1,3] diazepin-12-
ium bromide (11) 
Amide 5g (0.40 g, 1.41 mmol) reacted in CCI4 (24 mL) to give 11 (0.11 g, 28%) as 
a light brown solid; mp. 283-285 °C (decomp.); IR vmax (KBr) 1708, 3404 cm"1; *H-
NMR (DMSO-d6) 5 = 3.86 (s, 3H, -OCH3), 6.03 (s, 2H, -CH2N"), 7.18 (dd, J= 2 and 9 
Hz, 1H, H-2), 7.41 (d, J= 2 Hz, 1H, H-4), 7.92 (m, 1H, H-10), 8.00 (d, J= 9, 1H, H-l), 
9.30 (dd, J= 2 and 5 Hz, 1H, H-9), 9.38 ppm (dd, J= 2 and 5 Hz, 1H, H-ll); l3C-NMR 
(DMSO-d6) 5 = 51.8, 56.4, 96.4, 113.68, 115.1, 118.1, 119.0, 122.8, 123.3, 152.4, 152.7, 
157.0, 157.2, 161.7, 166.2 ppm; Anal, calcd for CisH^NsOsBr: C, 49.74; H, 3.34; N, 
II.60. Found: C, 49.46; H, 3.40; N, 11.67. 
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3-(Bromomethyl)-5,6-dimethoxy-Ar-(pyridin-2-yI)benzofuran-2-carboxamide (6h) 
Amide 5h (0.38 g, 1.20 mmol) reacted in CCU (40 mL) to give 6h (0.11 g, 23%) as 
an off-white solid, mp 216-218 °C (EtOH); IR vmax 1574, 1643, 3379 cm"1; 'H-NMR 8 = 
4.01 (s. 3H, -OCH3), 4.02 (s, 3H, -OCH3), 5.18 (s, 2H, -CH2Br), 7.05 (s, 1H, H-7), 7.14 
(dd, J - 2 and 5 Hz, 1H, H-4'), 7.16 (s, 1H, H-4), 7.80 (dt, J = 2 and 8 Hz, 1H, H-5'), 8.38 
(d,, J = 5 Hz, 1H, H-3'), 8.41 (d, J = 8 Hz, 1H, H-6'), 9.05 ppm (s, 1H, -NH); 13C-NMR 
8 = 21.6, 56.8, 56.9, 95.4, 101.6, 114.7, 119.8, 120.6, 125.2, 139.0, 141.9, 148.2, 148.5, 
149.3, 151.2, 151.9, 157.7 ppm. 
Preparation of Chloromethyl Amides (7a-f and 7h) 
A solution of bromomethyl amide in chloroform was placed in a round bottom flask 
fitted with a reflux condenser. Tetra-n-butylammonium iodide (0.3 molar equiv.) was 
added to the solution with stirring, followed by an equal volume of 25% aqueous sodium 
chloride solution. The mixture was then heated at 90 °C for 3-12 h. The layers were 
separated and the organic layer washed with 2% HC1 (2 x 20 mL), then 2% NaOH (2 x 
20 ml) and finally water (2 x 20 ml). The resultant organic layer was dried with 
anhydrous sodium sulfate, filtered, concentrated and recrystallized to give the 
corresponding chloromethyl amide. No elemental analysis was carried out on these allyl 
chlorides. 
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3-(Chloromethyl)-6-niethoxy-A-(pyridin-2-yl)benzofuran-2-carboxamide (7a) 
Bromomethyl amide 6a (0.43 g, 1.19 mmol) reacted in chloroform (20 mL) for 3 h 
to give 7a (0.26 g, 68%) as light brown needle-like crystals, mp 163-165 °C (MeOH); IR 
vmax 1565, 1672, 3411 cm"1; 'H-NMR 5 = 3.90 (s, 3H, -OCH3), 5.28 (s, 2H, -CH2C1), 
7.07 (m, 3H, H-4, H-5 and H-7), 7.74 (m, 2H, H-4' and H-5'), 8.36 (m, 2H, H-3' and H-
6'), 9.03 ppm (s, 1H, -NH); 13C NMR 5 = 35.0, 55.8, 95.7, 114.0, 114.3, 120.3, 120.7, 
122.0, 124.3, 138.5, 141.8, 148.2, 150.8, 155.0, 157.3, 161.0 ppm. 
3-(Chloromethyl)-6-inethoxy-/\-(4-methylpyridin-2-yl)benzofuran-2-carboxamide 
(7c) 
Bromomethyl amide 6c (0.29 g, 0.77 mmol) reacted in chloroform (25 mL) for 6 h 
to give 7c (0.20 g, 81%) as beige crystals, mp 179-181 °C (EtOH); IR vmax 1524, 1602, 
1675, 3427 cm"1; 'H-NMR 5 = 2.41 (s, 3H. -CH3) 3.90 (s, 3H, -OCH3), 5.28 (s, 2H, -
CH2C1), 6.93 (dd, J = 2 and 5 Hz, 1H, H-5), 6.99 (d, J= 2 Hz, 1H, H-7) 7.03 (d, J= 5 Hz, 
1H, H-4), 7.71 (dd, J = 2 and 7 Hz, 1H, H-5'), 8.19 (m, 2H, H-3' and H-6'). 8.97 ppm (s, 
1H,-NH); 13C NMR 8 = 21.8, 35.3, 56.2, 96.0, 114.3, 115.1, 121.1, 121.8, 122.3, 124.5, 
142.3, 148.1, 150.4, 151.1, 153.3, 155.3, 161.3 ppm. 
3-(Chloromethyl)-6-methoxy-,V-(6-meth\ipyridin-2-yI)benzofuran-2-carboxamide 
(7e) 
Bromomethyl amide 6e (0.55 g, 1.47 mmol) reacted in chloroform (40 mL) for 12 h 
to give 7e (0.41 g, 88%) as beige crystals, mp 143-144 °C (EtOH); IR vmax 1544, 1664, 
3413 cm1; 'H-NMR 5 = 2.51 (s, 3H, -CH3) 3.90 (s, 3H, -OCH3), 5.28 (s, 2H, -CH2C1), 
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7.00 (m, 3H, H-4, H-5 and H-7). 7.69 (m, 2H, H-4' and H-5'), 8.17 (d, J =  8 Hz, IH, H-
3'), 8.94 ppm (s, IH, -NH); 13C NMR 5 = 24.5, 35.4, 56.2. 96.0, 111.4, 114.3, 120.2, 
122.4, 123.9, 125.5, 139.1, 142.1, 151.8, 155.3, 157.7. 158.7, 161.3 ppm. 
3-Chloromethyl-A-(5-chloropyridin-2-yl)-6-methoxybcn/ofuran-2-carboxamide (7f) 
Bromomethyl amide 6f (0.55 g, 1.47 mmol) reacted in chloroform (40 mL) for 4 h 
to give 7f (0.41 g, 88%) as beige crystals, mp 207-208 °C (EtOH); IR vmax 1549, 1666, 
3398 cm'1; 'H-NMR 8 = 3.90 (s, 3H, -OCH3), 5.26 (s, 2H, -CH2C1), 7.01 (m, 2H, H-5 and 
H-7), 7.73 (m, 2H, H-4 and H-4'), 8.30 (d, J - 6 Hz, IH, H-6'), 8.36 (d, J = 9 Hz, IH, H-
3'), 9.01 ppm (s, IH, -NH); 13C-NMR 5 = 34.8, 55.8, 95.6, 114.0, 114.9, 120.6, 122.0, 
125.1, 127.3, 138.1, 141.4, 146.7, 149.1, 155.8, 157.5, 161.4 ppm. 
3-(Chloromomethyl)-5,6-dimethoxy-/V-(pyridin-2-yl)benzofuran-2-carboxamide (7h) 
Bromomethyl amide 6h (0.13 g, 0.33 mmol) reacted in chloroform (12 mL) to give 
7h (0.41 g, 68%) as beige crystals, mp 207-208 °C (EtOH); IR vmax 1557, 1669, 3403 
cm"1; 'H-NMR 8 = 4.00 (s, 3H, -OCH3), 4.01 (s, 3H, -OCH3), 5.14 (s, 3H, -CH2C1), 6.99 
(s, IH, H-7), 7.00 (s, IH, H-4), 7.13 (m, IH, H-4'), 7.80 (m, IH, H-5'), 8.40 (m, 2H, H-3' 
and H-6'), 8.98 ppm (s, IH, -NH), 13C-NMR 8 = 35.6, 56.8, 56.9, 95.4, 101.9, 114.6, 
119.9, 120.6, 125.2, 139.1, 142.0, 147.9, 148.0, 149.0, 151.5, 151.9, 157.8 ppm. 
Preparation of Tetracyclic Salts (8a-f, 8h) 
In a round bottom flask fitted with a reflux condenser and calcium chloride guard 
tube, was placed a solution (10-20%) of chloromethyl amide in 1,4-dioxane. This was 
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heated at reflux for several days. The resultant precipitate was collected by filtration and 
was washed with hot acetone to give the respective tetracyclic chloride salt. 
3-Methoxy-6-oxo-7,13-dihydro-6//-benzofuro[2,3-*'|pyrido[ l,2-a][l,3]diazepin-12-
ium chloride (8a) 
Chloromethyl amide 7a (0.35 g, 1.11 mmol) in 1,4-dioxane (2 mL) for 3 days gave 
8a (0.15 g, 43%) as a pale gray solid, mp 285-287 °C; IR vmax 1721, 3430 cm"1, 'H-NMR 
(DMSO-d6) 5 = 3.88 (s, 3H, -OCH3), 6.10 (s, 2H, -CH2N+), 7.17 (dd, J= 1 and 9 Hz, 1H, 
H - 2 ) ,  7 . 4 3  ( d ,  J =  1  H z ,  1 H ,  H - 4 ) ,  7 . 8 3  ( d d ,  J =  2  a n d  8  H z ,  2 H ,  H - 8  a n d  H - 9 ) ,  8 . 0 7  ( d ,  J  
= 9 Hz, 1H, H-l), 8.49 (dt, J = 2 and 6 Hz, 1H, H-10), 9.1 (d,J=6Hz, 1H, H-ll), 12.21 
ppm (s, 1H, -NH); 13C-NMR (DMSO-d6) 6 - 50.2, 56.4, 96.5, 115.0, 118.1, 121.9, 122.9, 
123.1, 123.6, 143.6, 143.7, 146.8, 148.4, 157.2, 157.8, 161.6 ppm; Anal, calcd for 
C,6H13N203C1: C, 60.67; H, 4.14; N, 8.84. Found: C, 60.49; H, 4.21; N, 8.82. 
3-Methoxy-8-methyI-6-oxo-7,13-dihydro-6/r-benzofuro[2,3-^]pyrido[l,2-
a||l,3|diazepin-12-ium chloride (8b) 
Crude chloromethyl amide 7b (0.44 g) in 1,4-dioxane (4 mL) for 3 days gave 8b 
(0.019 g, 2% from amide) as a brown solid, mp > 300 °C; IR vmax 1708, 3467 cm"1, 'H-
NMR (DMSO-d6) 5 = 2.42 (s, 3H, -CH3), 3.90 (s, 3H, -OCH3), 6.12 (s, 3H, -CH2N+), 
6.97 (dd, J = 2 and 9 Hz, 1H, H-2), 7.00 (d, J = 2 Hz, 1H, H-4), 7.23 (dd, J= 5 and 8 Hz, 
1H, H-10), 7.58 (d, 7 = 9 Hz, 1H, H-l), 7.76 (d, J= 8 Hz, 1H, H-9), 8.64 (d, J = 5 Hz, 
1H, H-ll), 11.94 (s, 1H, -NH), l3C-NMR (DMSO-d6) 5 = 18.6, 50.0, 55.9, 95.8, 113.0, 
121.3, 121.7, 123.3, 124.8, 128.5, 139.8, 141.8, 146.2, 149.0, 155.2, 158.0, 160.9 ppm. 
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3-Methoxy-9-methyl-6-oxo-7,13-dihy dro-6/f-benzofuro [2,3-ej py rido [ 1,2-
a][13]diazepin-12-ium chloride (8c) 
Chloromethyl amide 7c (0.074 g, 0.23 mmol) in 1,4-dioxane (4 mL) for 3 days gave 
8c (0.036 g, 49%) as a cream solid, mp 283-285 °C; IR vmax 1711, 3485 cm"1, 'H-NMR 
(DMSO-d6) 8 = 2.52 (s, 3H, -CH3), 3.85 (s, 3H, -OCH3), 5.90 (s, 2H, -CH2N+), 7.13 (dd, 
J= 2 and 9 Hz, 1H, H-2), 7.38 (d, J = 2 Hz, 1H, H-4), 7.54 (s, 1H, H-8), 7.62 (d, J = 6, 
1H, H-10), 8.01 (d, J= 9 Hz, 1H, H-l), 8.85 (d, J = 6 Hz, 1H, H-l 1), 12.13 ppm (s, 1H, -
NH); 13C-NMR (DMSO-d6) 8 = 22.2, 49.9, 56.9, 80.0, 97.0, 115.4, 118.6, 122.0, 123.4, 
123.9, 143.0, 144.5, 148.5, 157.5, 158.6, 159.7, 161.9 ppm; Anal, calcd for 
C,7H,sN203C1: C, 61.73; H, 4.57; N, 8.47. Found: C, 61.56; H, 4.50; N, 8.25. 
3-Methoxy-10-methy l-6-oxo-7,l 3-dihydro-6H-benzofuro [2,3-e] py rido [1,2-
a][l,3]diazepin-12-ium chloride (8d) 
Crude chloromethyl amide 7d (0.20 g) in 1,4-dioxane (2 mL) for 3 days gave 8d 
(0.05 g, 24%) as a pale gray solid, mp > 300 °C; IR vmax 1716, 3465 cm"1, 'H-NMR 
(DMSO-d6) 8 = 2.41 (s, 3H, -CH3), 3.88 (s, 3H, -OCH3), 6.05 (s, 2H, -CH2N+), 7.17 (dd, 
J = 2 and 9 Hz, 1H, H-2), 7.42 (d, J = 2 Hz, 1H, H-4), 7.76 (d, J = 9 Hz, 1H, H-l), 8.05 
(d, J = 9 Hz, 1H, H-9), 8.37 (d, J =9, 1H, H-8), 9.03 (s, 1H, H-ll), 12.12 ppm (s, 1H, -
NH); l3C-NMR (DMSO-d6) 8 = 17.9, 50.6, 56.9, 97.0, 115.5, 118.6, 121.8, 123.6, 124.2, 
133.8, 142.9, 144.1, 146.6, 148.2, 157.7, 158.4, 162.1; Anal, calcd for C,7H,5N203C1: C, 
61.73; H, 4.57; N, 8.47. Found: C, 61.56; H, 4.58; N, 8.41. 
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3-Methoxy-1 l-methyl-6-oxo-7,13-dihydro-6//-ben/ofuro [2,3-^1 py rido [1,2-
a][l,3]diazepin-12-ium chloride (8e) 
Chloromethyl amide 7e (0.38 g, 1.20 mmol) in 1,4-dioxane (2 mL) for 5 days gave 
8e (45 mg, 12%) as a cream solid, mp 260-261 °C; IR vmax 1707, 3458 cm"1. 'H-NMR 
(DMSO-d6) 8 = 2.82 (s, 3H, -CH3), 3.76 (s, 3H, -OCH3), 5.81 (s, 2H, -CH2N+), 7.05 
(dd, J = 2 and 9 Hz, 1H, H-2), 7.32 (d, J= 2 Hz, 1H, H-4), 7.63 (dd, J= 2 and 8 Hz, 2H, 
H-8 and H-10), 8.04 (d, J - 9 Hz, 1H, H-l), 8.56 (t, J= 8 Hz, 1H, H-9), 12.07 ppm (s, 
1H, -NH); 13C-NMR (DMSO-d6) 8 - 21.7, 45.0, 56.4, 96.6, 115.2, 117.9, 119.5, 122.9, 
123.8, 124.6, 144.8, 145.8, 149.0, 152.9, 157.3, 158.0, 161.5 ppm; Anal, calcd for 
C17H15N2O3CI: C, 61.73; H, 4.57; N, 8.47. Found: C, 61.37; H, 4.51; N, 7.91. 
10-Chloro-3-methoxy-6-oxo-7,13-dihydro-6//-benzofuro[2,3-£]pyrido[l,2-
a|[l,3]diazepin-12-ium chloride (8f) 
Chloromethyl amide 7f (0.10 g) in 1,4-dioxane (0.5 mL) for 3 days gave 8f (0.052 
g, 50%) as a pale gray solid, mp 204-206 °C; IR vmax 1720, 3431 cm"1, 'H-NMR 
(DMSO-d6) 5 = 3.88 (s, 3H, -OCH3), 5.75 (s, 2H, -CH2N+), 7.08 (dd, J = 2 and 9 Hz, 1H, 
H-2), 7.28 (d, J= 2 Hz, 1H, H-4), 7.80 (d, J= 9 Hz, 1H, H-l), 8.00 (dd, ./= 2 and 9 Hz, 
1H, H-9), 8.19 (d, J = 9 Hz, 1H, H-8), 8.48 (d, J = 2 Hz, 1H, H-11), 10.61 ppm (s, 1H, -
NH); l3C-NMR (DMSO-d6) 8 = 55.4, 56.3, 96.5, 114.4, 116.3, 120.4, 122.5, 124.0, 
126.7, 138.5, 142.6, 147.1, 149.1, 150.1, 155.0, 157.9, 161.0 ppm; Anal, calcd for 
C16H12N2O3CI2: C, 54.72; H, 3.44; N, 7.98. Found: C, 54.40; H, 3.48; N, 8.01. 
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23-Dimethoxy-6-oxo-7,13-dihydro-6//-benzofuro[2,3-£]pyrido[l,2-a][l,3]diazepiii-
12-ium chloride (8h) 
Chloromethyl amide 7h (0.35 g, 1.11 mmol) in 1,4-dioxane (2 mL) for 3 days gave 
8h (0.15 g, 34%) as a pale gray solid, mp 256-258 °C; IR vmax 1701, 3461 cm"1, 'H-NMR 
(DMSO-d6) 5 = 3.88 (s, 3H, -OCH3), 3.90 (s, 3H, -OCH3), 6.17 (s, 2H, -CH2N+), 7.45 
( s ,  2 H ,  H - l  a n d  H - 7 ) ,  7 . 8 4  ( m ,  2 H ,  H - 8  a n d  H - 1 0 ) ,  8 . 5 0  ( t ,  J =  8  H z ,  1 H ,  H - 9 ) ,  9 . 1 1  ( d ,  J  
= 6 Hz, 1H, H-l 1), 12.15 ppm (s, 1H, -NH); 13C-NMR (DMSO-d6) 8 = 50.2, 56.8, 56.9, 
95.5, 102.0, 114.5, 120.0, 120.8, 125.1, 139.1, 141.6, 147.9, 148.1, 149.0, 151.4, 152.3, 
158.2 ppm; Anal, calcd for CnH^C^Cl: C, 58.88; H, 4.36; N, 8.07. Found: C, 58.74; 
H, 4.30; N, 7.96. 
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Appendix V. UWM Compound Table 
In the following pages is a reprint of the UWM compound table. The actual interactive 
database exists in a Microsoft excel spreadsheet with an add-in for ChemDraw Ultra 
12.0. The add-in allows for additional spreadsheet functionality explained in the text. In 
the table, Kj values are reported in nM unless a percentage is listed. 
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PDSP compound number assignment: 
03-0934 DMH-D-070 (C39H28N604Br2) 802 
03-0935 DMH-D-048 (C49H46N604Si2) 838 
03-0936 DMH-D-053 (C43H30N604) 694 
03-0937 DM-ll-26 (C41 H32N604Br2) 830 
03-0938 DM-ll-41 (C51 H50N604Si2) 866 
03-0939 DM-lll-97 (C45H34N604) 722 
03-0940 DM-lll-93 (C40H30N605Br2) 832 
03-0941 DM-lll-94 (C50H48N605Si2) 868 
03-0942 DM-lll-96 (C44H32N605) 724 
03-0943 DM-ll-20 (C22H14N302F3) 408 
03-0944 DM-ll-30 C20H13N302BrF3) 463 
03-0945 DM-ll-33 (C20H13N302BrCI3) 511 
03-0946 DM-ll-35 (C25H22N302SiF3) 481 
03-0947 DM-lll-01 (C18H12N302Br) 381 
03-0948 DM-ll-72 (C15H10N20BrCI) 348 
03-0949 DM-ll-90 (C17H12N4BrCI) 386 
03-0950 XLi-JY-DMH-TMS C22H21N4SiCI) 404 
03-0951 XLi-JY-DMH (C19H13N4CI) 332 
03-0952 Hz111 C20H16N3CI02 365.81 
03-0953 Hz120 C20H16N3I02 457.26 
03-0954 Hz141 C21H23N3Si 345.51 
03-0955 Hz146 C21H23N30Si 361.51 
03-0956 Hz150C16H14N30Br 344.21 
03-0957 Hz147 C18H15N30 289.33 
03-0958 Hz157 C19H19N30Si 333.46 
03-0959 Hz158 C20H21N30Si 347.49 
03-0960 Hz160 C17H13N30 275.3 
03-0961 Hz165 C24H24N402Si 428.56 
03-0962 Hz 166 C21H16N402 356.38 
03-0963 Hz148 C18H15N3 273.33 
03-0964 Hz135 C16H14N3Br 328.21 
03-0965 Hz 164 C19H15N402Br 411.25 
03-0966 WYS1 C45H50N406 774.9 
03-0967 WYS2 C35H34N404 574.67 
03-0968 WYS3 C35H38N404 578.7 
03-0969 WYS4 C48H56N408 816.98 
03-0970 WYS5 C37H42N404 606.25 
03-0971 WYS6 C37H35N404 599.7 
03-0972 WYS7 C21 H28N404Si 364.51 
03-0973 WYS8 C18H16N202 292.33 
03-0974 WYS9 C16H15IN202 394.21 
03-0975 WYS10 C14H9F3N202 294.23 
03-0976 WYS11 C15H11F3N203 324.25 
03-0977 WYS12 C20H18N202S 350.44 
03-0978 WYS13 C20H18N203 334.37 
03-0979 WYS14 C34H29F3N404 614.61 
03-0980 WYS15 C22H20N202 344.41 
03-0981 WYS16 C18H22N202 298.38 
03-0982 WYS17 C17H18N202 306.36 
03-0983 WYS18 C21H22N202 334.41 
03-0984 WYS19 C26H32N204Si 464.63 
03-0985 WYS20 C23H24N204 392.45 
03-0986 WYS21 C21H23IN204 494.32 
03-0987 WYSC1 C16H16N202 268 
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03-0988 WYSC2 C15H11F3N202 308 
03-0989 JYI-01 (C19H20N303Br) 418 
03-0990 JYI-02 (C24H29N303Si) 437 
03-0991 JYI-03 (C21H21N303) 363 
03-0992 JYI-04 (C21H23N303) 365 
03-0993 JYI-06 (C23H23N304) 405 
03-0994 JYI-19 (C23H23N303S) 421 
03-0995 JYI-20 (C25H25N303) 415 
03-0996 JYI-10 (C17H13N303F3Br) 444 
03-0997 JYI-11 (C22H22N303F3Si) 462 
03-0998 JYI-15 (C19H14N303F3) 389 
03-0999 JYI-12 (C19H16N303F3) 390 
03-1001 JYI-13 (C21H16N304F3) 431 
03-1002 JYI-14 (C17H14N303F3) 365 
03-1003 JYI-21 (C23H17N303F3) 441 
03-1004 JYI-32 (C20H15N302BrF) 428 
03-1005 JYI-38 (C25H24N302FSi) 445 
03-1006 JYI-56 (C24H18N304F) 373 
03-1007 JYI-50 (C24H18N302SF) 469 
03-1008 JYI-49 (C20H12N302F4Br) 482 
03-1009 JYI-53 (C23H21 N302F4Si) 475 
03-1010 JYI-59 (C22H13N302F4) 427 
03-1011 JYI-54 (C24H15N303F4) 469 
03-1012 JYI-60 (C17H11N20F) 278 
03-1013 JYI-64 (C17H12N4FBr) 371 
03-1014 JYI-70 (C19H13N4F) 316 
03-1015 JYI-72 (C22H21N4SiF) 388 
03-1016 PS-1-27 C21H16N5BrO 434.3 
03-1017 PS-1-28 C26H25N50Si 451.6 
03-1018 PS-1-26 C23H17N50 379.4 
03-1019 PS-1-34B C20H17N 409.3 
03-1020 PS-1-35 C23H22N: 464.4 
03-1021 PS-1-36 C28H31N: 481.7 
03-1022 PS-1-37 C25H23N: 409.5 
03-1023 XLi268 C17H13BrN4 353 
03-1024 XLi269 C22H22N4Si 370 
03-1025 XLi270 C19H14N4 298.34 
03-1026 XLi223 C22H20BrN302 438.32 
03-1027 XLi224 C27H29N302Si 455.62 
03-1028 XLi225 C24H21N302 383.44 
03-1029 CM-D45 C19H21N304 355.39 
03-1030 RY-024 C19H19N303 337.37 
03-1031 XHell-053 C22H17N302 355.39 
03-1032 XLiXHell-048 C25H25N302Si 427.57 
03-1033 RY-023 C22H27N303Si 409.55 
03-1034 RY-080 C17H15N303 309.32 
03-1035 XLi337 C21H23N303 365.43 
03-1036 XLi340 C26H25N302 411.5 
03-1037 XLi339 C23H22N4 354.45 
03-1038 XLi275 C20H19N303 349.38 
03-1039 XLi356 C33H34N606 610.66 
03-1040 XLi347 C34H28N607 632.62 
03-1041 XLi351 C21H21CIN20Si 380.94 
03-1042 XLi343 C20H19CIN20Si 366.92 
03-1043 XLi350 C17H11CIN20 294.73 
03-1044 XLi352 C18H13CIN20 308.76 
03-1045 XLi338 C23H21CIN4 388.89 
03-1046 XM366 C22H21N302 359.42 
03-1047 XLI368 C24H25N302 387.47 
03-1048 JC184 C13H9BrN20S 321 
03-1049 JC207 C18H18N20SSi 338 
03-1050 JC208 C15H10N20S 266 
03-1051 JC209 C19H20N20SSi 352 
03-1052 JC222 C16H12N20S 280 
03-1053 JC217 C18H14BrN302S 416 
03-1054 JC220 C23H23N302Ssi 433 
03-1055 JC221 C20H15N302S 361 
STRUCTURE PDSP COOK CODE MOL FORMULA MOL WEIGHT a1 a2 33 a4 a5 a6 
C-.H..N .0 3 EBC C13H12N20 . 
C14H14N20 
212.247 6.43 25.1 28 2 826 1000 
\ 
\ { 
/ 
O0-
H 
CmM14N?0 3 PBC 226.274 5 3 52.3 688 591 1000 
P  o-— 
/=( 
o y  
C,»H„N.O 3-BENZOXY bC C18H14N20 274.317 830 3000 3000 10000 10000 
\ 
^ 
CijH,#NJQ 3-isobutoxy bC C15H16N20 240.3 249 123.6 139.2 1000 10000 
J~^ —J 
C„H„N,0 3-isopenfoxv bC C16H18N20 254 327 3502 3000 3000 3000 10000 
mj" 
3MBC C12H10N20 198.221 
) 
! \ 
'H 
fXX^ 
U.sH^N.-O, 6-PBC C18H20N204 328.362 049 1 21 2 2 2 39 1343 
o a \ 
/ !L/^ v_/"° 
CX ^jT: V/V-'^x|pv\i 
c»h,4n,o« ABECARNIL C24H24N204 404.458 12.4 15.3 7 5 6 1000 
Yx» 
rvi 
c, Xjy) 
C,-H,,aN, alprazolam C17H13CIN4 308 765 0.8 0.59 1.43 1 54 10000 
N> 
/ 0 
\s=o 
rrv 
H 
C,.H„N,0, BCCE C14H12N202 240.257 1.2 4.9 5,7 26 8 2700 
BCCt C16H16N2Q2 18.9 268.31 0.72 110.8 5000 
BRETAZENIL C19H20BrN3Q3 418 284 035 064 0.2 05 12 7 
C-383 C18H19CIN20 314.809 1000 1000 1000 1000 1000 
CD-214 C16H14CIN303 482 425 331.754 16.4 168 
C16H11N30 CGS8216 261 278 0.13 46 
C17H13N302 CGS9895 291 304 0.21 
CGS9896 C16H10CIN3Q 295.723 0.28 181 
CL 218.872 C13H9F3N4 278.233 1964 1161 561 10000 
CM-A100 C16H15IN202 394.207 14.49 44.91 1238 1000 65 31 1000 
Jr-
M i "  
\H 
C„H„N..O. CM-A49(R) C16H16N202 268.31 7.7 32.5 43 69 1000 
\J^ 
^ \ 
C„Ht#N202 CM-A50(S) C16H16N202 268.31 17 59 88 144 1000 
^ ii 
\ 
H 
C,»H,,FN;0 CM-A57 C15H13FN20 256.275 3.7 27 40 254 1000 
C,sH,̂ N; CM-A58 C15H15FN2 242.291 16 120 184 1000 1012.2Nm 
y y  
*< 
\̂ Ss'N 
\ H 
C,«M,sN,0? CM-A64 C16H16N202 268 31 18 60 116 216 1000 
Cx09 
\h 
CM-A69 C16H13F3N202 322.282 1000 1000 1000 1000 1000 
v>C 
CX0N 
\ 
CM-A71 C20H16N202 316.353 333.57 1000 1000 1000 1000 3000 
\ 
CkH.jN^O CM-A77 C17H18N20 266 338 11.51 51.9 105.16 1000 42 62 1000 
Ccp 
\ 
C„H„N;0 CM-A77a C22H30N20 338 486 27.4 111.5 301.3 1000 61.61 1000 
en >*j 
VI 
\ 
C»NJ.N?OJ CM-A82a C20H24N202 324.417 2.78 8.93 24.51 1000 7.49 1000 
a y Y ~  
^ \ 
C^H^FNjO; CM-A87 C16H15FN202 286.301 1.62 4.54 14.73 1000 4.61 1000 
•c$ 
0 
CnHjnBrN^Oj CM-A95(ss) C19H20BrN303 418.284 141.5 225 59.45 30.36 146.3 107.1 
X" 
.X^S 
0 
C ijH^BrNtO, CM-A97(sr) C19H20BrN303 418284 70.81 89.48 30.64 4073 67.01 38.12 
0 
YYp" 
N 
\n 
C14H.,IN..O; CM-B01 C14H11IN202 366 154 4 8 31 34 1000 286 1000 
o 
Ct.H^CWjOi CM-B31c(ss) C19H20CIN303 373.833 118 319 173 37 15 137 
cH N — // V 
,0$ 
0 
C^H^NjOJ. CM-B31i(ss) C19H20IN303 465 285 90 184 78 18 4.9 121 
frC?" 
X$ 
0 
Ci#H)7BrF ,N,Oi CM-B34 C19H17BrF3N303 472 256 472 451 223 114 17 175 
0 
Ci»H?0FNjO, CM-B44(ss) C19H20FN303 357 379 32 43 12 379 4 3 485 
Ul 
-si 
> 
o 
CltH,^lFjNjO, CM-B45 C19H17CIF3N303 427 805 230 557 336 265 15 230 
o 
C„,H,,F4NjO, CM-B47 C19H17F4N303 411.35 32 63 34 2007 4.4 717 
0 
C,.H„BrF,N,0, 
\ 
CM-C28(SR> C19H17BrF3N303 472256 176 752 244 290 14 141 
\ 
H 
CM-D30(R) C15H11F3N202 308 255 27 343 3 453 3000 1847 2000 
^ / N 
\ 
C^H.iF,N,0.. CM-D30(S) C15H11F3N202 308255 90 931 172 3000 1000 3000 cn vi oo 
o 
u
,
 
/
 
o
 CM-D44 C17H17N304 327 335 34 3 56 3 20 7 0.33 0 57 0.92 
0 
C.#H2,NJ04 03-1029 CM-D45 C19H21N304 C19H21N304 355 388 90 5 65 5 303 0 15 1.65 0 23 
0 
CmH,«F IN\04 CM-E09a C18H16F3N304 395.333 176 192 122 490 9.2 718 
rK^ 
0 
Cl^-NA CM-E09b C19H21N304 355.388 20 22 19 55 045 69 
0 
X $ 5 ~ 0  
0 
CM-E10 C23H21N304 403431 23 26 14 215 0.51 96 
Ln 
0 
CjoH^O, CM-E11 C20H23N304 369.414 333 308 161 394 14 750 
C|«H,,CIN?0 diazepam C16H13CIN20 284.74 14 20 15 11 
cr*r-
Cj.H^N.O; DM-139 C21H26N403 382.456 58 169 925 325 
N ° 1 
o1# 
c„h„n4o, DM-146 C22H28N403 396.483 6.44 148 423 247 
C^H.,N,0 DM-173 C19H24N403 356419 13.1 38 1 078 118 Ln oo o 
0 
C„H;,NjO« DM-215 C18H21N304 343.377 6.74 7.42 0293 828 
rw+ 
AT 
0 
CuH„N<iO, DM-239 C17H19N304 329.35 1.5 0.53 0 14 6.89 
0 
. / N 
o 
CVH.KN-O. DMCM C17H18N204 314.336 5.69 8.29 4 1 04 134 
/V'S \V '^A 
y^'r ' y \ i .  
0 0 
C«H,N9O4S1j 03-0935 DMH-D-048 (C49H46N604Si2> C49H46N604Si2 839.098 5000 5000 5000 5000 5000 
jriw'l 
/A-.' V^\ 
 ̂ _,s 
V cy 
C^M^NnO, 03-0936 DMH-D-053 (C43H30N604) C43H30N604 694 736 236 7.4 272 5000 1942 5000 
LTI 
00 
fyl A 
\ V V V^l 
.'•-A,' OCX e> ^ 91 
A A 
U 1/ 
03-0934 DMH-D-070 (C39H28N604Br2) C39H28Br2N604 804.485 5000 1901 5000 5000 
A U 
A A 
\J \J 
CuH^NeOs 03-0942 DMH-lll-96 (C44H32N605) C44H32N605 724 762 460 5000 5000 5000 
J  
CM 
B, N 
C2SH,,8'NjO^ DM-l-070 C20H16BrN302 410 264 
AA 
C»H;,N,0, DM-l-81 C26H21N302 407.464 2000 2000 2000 2000 176 2000 
03-0943 DM-ll-20 (C22H14N302F3) C22H14F3N302 409.361 5000 54.3 27.14 35.68 15.35 
03-0944 DM-ll-30 C20H13N3Q2BrF3) C20H14F3N3Q2 385.339 17.6 13.4 28.51 78 5000 
03-0945 DM-ll-33 (C20H13N3Q2BrCI3) C20H13BrCI3N3Q2 513.599 886 85 .6 26.2 5000 11 CaM,|B.C|,N)0| 
05-1734 DM-ll-34 C20H13Br4N3Q2 646.952 
cn 
00 ui 
03-0946 DM-ll-35 (C25H22N302SiF3) C25H22F3N302Si 481.542 11380 327 380 5000 
03-0938 DM-ll-41 (C51H50N6Q4Si2) C51H50N6Q4Si2 867 152 missino 
03-0948 DM-ll-72 (C15H10N20BrCI) C15H10BrCIN2Q 349.61 5000 1 37 202 5000 
03-0949 DM-ll-90 (C17H12N4BrCI) C17H12BfCIN4 387 661 0.505 0.63 0.37 5000 
rr :̂ 
C,aH,;B'NiOr 03-0947 DM-lll-01 (C18H12N302Br) C18H12BrN302 382 211 5000 12 4 73 5000 
AA,A 
/v"" y\\ 
1 \ '< ii 
,A/y; Iv^A. 
A A 
U ly 
CwHjcBfjN^O, 03-0940 DM-lll-93 (C40H30N605Br2) C40H30Br2N605 834 511 351 5000 179 5000 
/\A 
*/A/^' ,,,v^\' 
/ A, \ 
V 
CvH4„N,0.SI^ 03-0941 DM-lll-94 (C50H48N605SI2) C50H48N605Si2 869 124 240 5000 5000 5000 5000 
/\_J^ ; ^AN 
^ v\ 
-AA^ /V^N # v «» - \ 
A > 
V' 1/ 
C. ĵ.N.O, 03-0939 DM-lll-97 (C45H34N604) C45H34N604 722.789 280 5000 5000 5000 
CJ.H.JN, EDC-I C21H13N3 307.348 165 797 382.3 10000 
) 
\ 
C„H„N,0, EDC-l-042 C27H24N203 424.491 183 20.5 300 270 10000 
\~o 
C.iH^N.O, EDC-l-071 C11H6N404 258 19 12.9 83 1 314 5000 
N=^C=^S 
s YTr 
CijH^NJS. EDC-l-093 C13H6N4S2 282.344 13 6 423 2912 5000 
U1 
00 
CTi 
L & 
— j n  
^ N 
CJ4HvN,O. EDC-ll-012 C24H32N204 412.522 1000 3000 3000 3000 3000 
V (_y° 
—0"v^Y''''''1:::;:^^ /N 
\ 
C:.,H1,N-0. EDC-ll-015 C25H34N204 426.548 3000 3000 3000 3000 3000 
C^H^O, EDC-ll-024 C24H32N203 396 522 3647 29749 35060 12683 30000 
\ ' 
V O 
0 
C;.H^N,0, EDC-ll-031 C25H34N2Q3 410.549 1000 1000 1000 1000 1000 
tfl 
00 VI 
EDC-ll-044 C27H24N204 440.49 293 323 1000 
05-1713 EMJ-l-025 C22H15N50 365 367 288 316 86 5000 474 
EMJ-l-025 C22H15N5Q 365 387 
05-1714 EMJ-l-026 393 441 5000 135 1027 152 5000 
01 
00 
oo 
CwH,#NjO EMJ-l-026 C24H19N50 393 441 A / !  
Ci o 
Ci;H ,eCIN^O; FG8205 C17H16CIN502 357.794 0.4 2.08 1.16 1.54 227 
^X±j 
C.sM,.FN,0, FLUNITRAZEPAM C16H12FN303 313 283 2 2 2.5 4 5 2 1 2000 
fV\ 
Ci 
C„H„CWj$ 05-1771 FMR-1 C18H12CIN3S 337 826 
rV\ 
^ V 
C„H„N,0S 05-1772 FMR-2 C19H15N30S 333 407 Ln oo 
05-1774 FMR-3 C20H17N30S 347.433 
C21H17N302S HDA-343 375.444 82.6 588 159 10000 
HDA-90-I C20H25CIN2Q4 392.877 256 105.4 163.1 160.1 10000 
HDA-ll-96 C16H19N302 285.341 236 3000 3000 3000 10000 
08-007 HJ-l-037 C21H15FN40 358.368 15.07 8 127 28.29 0818 Ul UJ O 
08-010 HJ-l-040 1070 8694 1123 6 1065 
. fJ ^ CK 
C„H16CIN5O. 03-0952 Hz111 C20H16N3CI02 C20H16CIN302 365 813 46.65 34 776 246 842 
— 0  
O 
C»H.«A 03-0953 HZ120ANX2 C20H16IN302 457 264 5000 35 78 5 206 32 2 
\H 
.IX) 
C„M„BrN, 03-0964 Hz135 C16H14N3Br C16H14BrN3 328.206 94.03 182 97 5000 
U1 10 
V 
C,.H?,N3Si 03-0954 Hz141 C21H23N3Si C21H23N3Si 345 513 6480 5000 5000 737 5000 
H 
o° 
CJ,HjiN,OSI 03-0955 Hz146C21H23N30Si C21H23N30Si 361.512 5000 5000 5000 5000 
rVi 
SC v° 
0 
Ct«H,.,N,0 03-0957 Hz147 C18H15N30 C18H15N30 289.331 5000 5000 5000 5000 
V 
C„h,5N3 03-0963 Hz148 C18H15N3 C18H15N3 273.332 1098 5000 256 5000 
\ 
NH 
rVS 
o 
&
 
u 
C,(H„BfN,0 03-0956 Hz150 C16H14N30Br C16H14BrN30 344 206 485 469 5000 419 5000 
en 
ro 
iry~f 
1 O 
03-0958 Hz157 C19H19N30Si C19H19N30Sj 333459 5000 5000 5000 5000 5000 
CHH^NjOSI 03-0959 Hz 158 C20H21N30Si C20H21N30Si 347.486 5000 5000 5000 5000 5000 
^ J-Y 
^X5 
/ 
C„H„N,0 03-0960 Hz160 C17H13N30 C17H13N30 275.305 492 2633 334 87 3 5000 
• r7 
CM 
Cii,H,,BrN4Oj 03-0965 Hz164 C19H15N402Br C19H15BrN402 411.252 99.18 150 459 108 2 494 
ui 
ID u> 
J 
o 
QS> 03-0961 Hz165C24H24N402Si C24H24N402Si 428 558 5000 5000 5000 5000 
C?,H,«N,OJ 03-0962 Hz166 C21H16N402 C21H16N402 356.377 118 148 365 5000 76.88 5000 
Xtf 
1 s 
C„H»BFNJOS 03-1048 JC184 C13H9BrN20S C13H9BrN20S 321 192 9.606 10.5 6.709 
- / 
C.GH.ENPSS. 03-1049 JC207 C18H18N20SSi C18H18N20SSi 338 499 104 8 169 7 68 16 
rff 
r s 
C,SH,NN,OS 03-1050 JC208 C15H10N20S C15H10N20S 266 318 22.42 18 89 5.039 LP 
UD 4^ 
C19H20N2QSSi 352 525 294.6 334.7 249 5 03-1051 JC209 C19H20N2QSSi 
03-1053 JC217 C18H14BrN302S C18H14BrN3Q2S 416292 
C23H23N302SSi 03-1054 JC220 C23H23N302Ssi 433.598 
03-1055 C20H15N3Q2S JC221 ANX1 361.417 106.175 182 49.405 7.7495 362 
03-1052 JC222 C16B12N20S C16H12N20S 280 344 867 45.11 17 63 ID 
Ln 
if 
(3 
C.-OH • 08-26 JIE-l-12 C20H15N302S 361 417 3576 454 8 7683 4416 
rX+ 
0 
CI»H,NBRNJOI 03-0989 JYI-01 fC 19H20N303Br> C19H20BrN303 418.284 59.2 159 96 106 2.88 
0-̂  
_^S1 0 
' \ 
C,4H,»N,0 ISI 03-0990 JYI-02 (C24H29N303SI) C24H29N303Si 435 591 missinq 
C/IH,N)0; 03-0991 JYI-03 (C21H21N303) C21H21N303 363.41 185.4 107 0.954 3.34 
Ln 
V£> 
cr> 
0 
0 
C„M,,N,0, 03-0992 JYI-04 (C21H23N303) C21H23N303 365426 28 3 16 0.51 1.57 
< J f  
03-0993 JYI-06 (C23H23N304) C23H23N304 405 446 16.5 5.48 5000 126 5000 
0 
C„H,,8*^,0, 03-0996 JYI-10 (C17H13N303F3BD C17H13BrF3N303 444 203 5000 368 12.3 23 
0 
\V-VO 
a 
C;;H,;.F .N,Q,Sl 03-0997 JYI-11 (C22H22N303F3Si) C22H22F3N303SI 461 509 5000 5000 648 397 
0 
fAA"^' 
0 
C„H„F,N,0, 03-0999 JYI-12 (C19H16N303F3) C19H16F3N303 391.344 91 39 4.5 6.8 
U1 
0 
C;,H)EPIN,04 03-1001 JYt-13 (C21H16N304F3) C21H16F3N304 431.365 5000 63.7 16 838 
N 0 
Orb ' X  
o 
CI ?HT4F,N10- 03-1002 JYI-14 (C17H14N303F3 ) C17H14F3N303 365.307 32 25 13 565 
0 
^yb 
0 
C,«HMF,N,O, 03-0998 JYI-15 (C19H14N303F3) C19H14F3N303 389 328 205 812 48 22 
ĉ + \__-S CF 
C«H;IN,OLS 03-0994 JYI-19 {C23H23N303S) C23H23N303S 421 512 2 176 205 34 12 7 
cK 
fY^yO 
C^MNN.O, 03-0995 JYI-20 (C25H25N303) C25H25N303 415 484 20.96 611 54 40.46 
i-n 
<X> oo 
r N-_ 
rr°Y 
> 
,N / 
- 7 \  
-h 
0 
CI^,,FsN101 03-1003 JYI-21 (C23H17N303F3) C23H18F3N303 441.403 113.7 5000 209 60 96 
.r> 
J 
0 
C*,H^BrFN,0, 03-1004 JYI-32 (C20H15N302BrF) C20H15BrFN302 428.254 3.07 496 2 92 52.24 
ll "l 
Z-7 
0~\ 
1! 1 
,s. 
x r v 
CJ5H;,,FN,0,Sl 
) 
J 
03-1005 JYI-38 (C25H24N302FSi) C25H24FN302Si 445.561 5000 314 55 4 5000 
xO* & \-ss5N 
C„Hla8ffN,0 05-1737 JYI-42 C15H10BrFN20 333.155 0.257 0.146 0.278 0 256 
Ln U3 
LD 
0 
f\JL 
Ci»HiiB»f NjOj 05-1738 JYI-47 C18H11BrFN302 400.201 2.759 2.282 0.511 0.427 
0 
Ci4H,,FNiO] 05-1735 JYI-48 C24H18FN303 415.416 75 59 90 68 12.78 31 28 
0 ' 
iX^ 
C20H,7Brir«N,O. 03-1008 JYI-49 (C20H12N302F4Br) C20H12BrF4N302 482.226 1 87 2.38 6.7 3390 
* 
C^.H^FN^S 03-1007 JYI-50 (C24H18N302SF) C24H18FN302S 431.482 106.4 200 37.6 5040 
0' J 
fy\ 
ii^V" \ 
1 
C*H„F«N,07SI 
& 
03-1009 JYI-53 (C23H21N302F4SH C25H21 F4N302Si 499.532 77.4 40.4 183 133 3650 
If 
\J 
y-> 
o J 
Z"5*5^ X^-^-F 
/  I f  
CmM^F.NA 
Vi 
03-1011 JYI-54 (C24H15N303F4) C24H15F4N303 469 388 289 172 6.7 57 1890 
1 
C^H^NJOS. 
a';1! \^S5£N 
Vi 
05-1739 JYI-55 C20H19FN20Si 350 462 41.39 0.504 24.75 
rN °J 
CT 
CJ<H„FNJ0J 
& 
03-1006 JYI-56 {C24H18N304F} C24H18FN303 415.416 952 346 131 346 4140 
xp 
05-1736 JYI-57 C17H12BrFN4 371.206 0.076 0.076 0.131 0.036 
> 
N P" 
V-( 
CWH„F4N,0; 03-1010 JYI-59 (C22H13N302F4) C22H13F4N302 427 351 1.08 2.6 11.82 11.5 5000 
x0° 
C,?M11FN?0 03-1012 JYI-60 (C17H11N20F) C17H11FN20 278.28 3.73 1.635 4.3 1.7 5000 
XX? 
X 
C..H:.B>FN, 03-1013 JYI-64 (C17H12N4FBr) C17H12BrFN4 371.206 0.305 1.111 0.62 0.87 5000 
cr> 
o 
NJ 
03-1014 JYI-70 (C19H13N4F) 316.332 C19H13FN4 6.3 0.56 5000 
03-1015 JYI-72 (C22H21N4SiF) C22H21FN4Si 388 513 48 5 18.5 5000 
JYI-73 C17H12BrFN4 371.206 
JY-XHE-053 C22H16FN302 37338 ,FN,Q. 
T1" 
LD-9 C22H19N302 357 405 156 3000 10000 
C„H,ENJO LJD-I-0036A C17H16N20 264 322 245 818 869 10000 10000 
X) 
H 
C-,HSCIN, LJD-ll-87 C16H9CIN4 292.722 3000 3000 3000 10000 10000 
HN 
C,8H,0N. UD-III-15E C16H10N4 258.277 1 93 14 19 70.8 1000 
/) 
C„H,0N« LJD-III-22A C16H10N4 258.277 105 227.5 284 3000 10000 
* 0 
Ocm 
H 
C,.HuN,0 MA-3-PROPOXYL C14H14N20 226.274 5.3 52.3 688 591 1000 
JO# .vC 
C,3H„FJN3O, MH-1 (Parkistan) C13H14F3N302 301 264 3000 3000 3000 3000 3000 3000 
cxj 
Y> 
C,iH„F,N3OS MH-2 (Parkistan) C13H13F3N20S 302 315 3000 3000 3000 3000 3000 3000 
C,„H1SN MJP-Il-34 C19H15N3 285.343 240 391 1360 10000 
rvyj" 
CirMnN, MLT-l-70 C17H11N3 257.289 1.1 1.2 1.1 40.3 1000 f 
/ X 
CxV N 
C,7M,uFN3 MLT-ll-16 C17H10FN3 275.28 5.05 10.41 18.4 260 10000 
O 
Qp" 
C1?M,oCIN3 MLT-ll-18 C17H10CIN3 291.734 39 12 2 24 4 210 10000 
<s 
HN'//^SnTX^*^ 
rvO" 
C„H„N,0 MLT-ll-18 C18H13N30 287.315 3.4 11.7 11 225 10000 
& 
/ N CcV 
CwHinBfN, MLT-ll-29 C17H10BrN3 336.185 
OH 
Mj" 
H 
C,7H,.N,0 MLT-ll-34 C17H11N30 273.289 704 15.95 223 158 1000 
rri' 
^ N 
v H 
CMH„H,O MLT-ll-87 C24H17N30 363.411 432 3000 3000 10000 10000 
F 
. o 5 f  
0 
C„M„BFF,N)0, MMB-ll-37 C18H15BrF3N303 458 229 872 2602 1003 95 98 115 
f 
•<%? 
0 
CI,H,^BFF INIOJ MMB-ll-43 C18H15BrF3N303 458 229 1353 5173 1535 98 132 78 
^ H | ̂ 
^ "N 
\ 
H 
CNH.TFJNJO; MMB-ll-57 C15H11F3N202 308.255 90 931 172 3000 1000 3000 
\ y~h  
J 0 1 
op" 
C,SH,,F(N,0, MMB-II-68A C15H11F3N202 308.255 27 343.3 453 3000 1847 3000 F 
C.^.F^O, MMB-ll-74 C14H9F3N202 294 229 3 24.5 41.7 500 125 7 1000 
J#? 
0 
MMB-ll-87 C19H17BrF3N303 472 256 200 333 107 109 54 333 
cn 
o oo 
C18H12BrF6N3Q3 512.201 333 333 333 333 333 
C18H18BrN303 MMB-ll-90 404 258 57 0.25 
C19H21N3Q4 355 388 MMB-ll-99 333 333 333 333 333 333 
C18H19N3Q3 325.362 1.97 1074 0.26 211 
C18H13F6N3Q3 433.305 117 140 3500 976 
_„H O 
C,.H„N,O. MMB-lll-019 C19H21N304 355.388 3333 3333 3333 3500 889 3500 
O  F ^ /  
0 
C,,H,.F,N,OA MMB-lll-14 C18H16F3N303 379.333 13 13 6.9 333 1.1 333 
0 
ClH.J.NJOJ MMB-lll-16 C18H19N303 325 362 3 1.97 2 1074 0 26 211 
CXp 
0 
CIFHIJF.NJOJ MMB-lll-18 C18H13F6N303 433.305 117 140 78 3500 14 976 
0 
C.H.N 0, MMB-lll-19 C19H21N304 355 388 3333 3333 3300 3500 889 3500 <T> M 
O 
0 ^ 
C,,H1BN,0 MSA-0-28 C15H16N20 240 3 36.9 194 245 1000 1000 
^ 
( \ y J  
H 
CUHUN,0 MSA-3-IPBC C14H14N20 226274 283 3000 3000 10000 10000 
CI 
C.,HTCIN; MSA-l-71 C11H7CIN2 202.64 60.4 125 3 126 1000 10000 
\ 
\̂i 
C„H,N,S MSA-ll-35 C12H7N3S 225.269 67.2 120 141 3000 10000 
CMM^N^O MSA-IV-35 C15H14N20 238284 2.1 16 21 995 3000 
MSR-l-032 C18H20N2Q4 328.362 18.7 74.9 LN;0. 
MSR-l-036 C17H20N4Q3 328 366 46 422 400 107 5 300 
MSR-l-046 C16H19N302 285.341 540 700 380 3000 
MSR-l-049 C16H18N403 314.339 896 1000 570 91.5 3000 
\ 
0 
C,<,H,4N;0, MSR-l-056 C19H24N203 328405 24.6 214.4 2704 331.9 1000 
1 
0,^,0, MSR-l-057 C17H20N203 300352 300 300 300 300 300 
,0. / N 
"XXV 1 
CNHI.NAO, MSR-l-100 C16H18N203 286.326 300 300 300 300 300 
09-07 MVL-Vl-13 
09-08 MVL-VI-33 
09-09 MVL-VI-34 
Q^-Cl 
\ 
CuH„CtN,0 N-111 C17H17CIN20 300.783 691 4209 3000 3439 3000 
° 
\ 
H 
C,,M„CW,O N-112 C17H18CIN30 315.797 296 5260 3000 3000 3000 
\H 
C l tH.„CiN O. N-120 C18H19CIN202 330 809 422 1000 3000 932 3000 
° 
1 x 
C,,H„ClN,0 N-26 C17H17CIN20 300 783 1000 3000 3000 3000 3000 
CrO-a 
\ 
C,gH„CIN>0 N-30 C19H21CIN20 328 836 1491 2000 2000 2000 2000 
\H 
C«H..,ClN,0. N-80 C19H21CIN202 344 835 1614.4 2000 2000 2000 2000 
J# 
C^H.^O OMB-18 C18H13FN20 292 307 3.9 12 3.4 1733 0.8 5 
C^H.iFNiO OMB-19 C19H15FN20 306.334 22 4.6 20 3333 3.5 40 <T> 
Ln 
R' ^ \  
C,}H17N,O 03-1018 PS-1-26 C23H17N50 C23H17N50 379414 933.5 366 260 393 5 5000 
xx̂  
C^.H^BRNIO 03-1016 PS-1-27 C21H16N5BrO C21H16BrN50 434.289 182 294 86 5000 
ivY" I // \ ̂ 
03-1017 PS-1-28 C26H25N50Si C26H25N50Si 451.595 5000 5000 5000 5000 
V"  ̂ X-f' 
Xd 
CWH,RBFN,0 03-1019 I-1-34B C20H17N4E C20H17BrN40 409 279 4 198 3.928 
ry 
°yX. 
0 
C„H„BrN,0 03-1020 1-1-35 C23H22N5C C23H22BrN50 464.358 16 03 24.41 
,^CQ" 
T 0 
C?#MjiNjOSi 03-1021 5-1-36 C28H31N5C C28H31N50Si 481 664 939 1 
P' •U 
_ X/"  
^co 
C^H„N,0 03-1022 S-1-37 C25H23N5 C25H23N50 409.483 193 35 435 22 5000 
• 
X# 
0 
C„.H,BBfN,0, PS-2-58 C18H18BrN303 404.258 
VI 
C16H14BrN3Q3 376205 PS-2-58 
C13H9BrN20S 05-1742 PS-l-68 321.192 3134 481.3 679 5 101.3 
\/ 
05-1740 C20H20N4SSi 376 55 145.8 122 8 PS-l-71 214 2 119.2 
05-1741 PS-l-72 C17H12N4S 304 369 123 386 5000 
CTl 
00 
f>A_ 
0 
C«H,SNA PWIII-012 C16H15N302 281.309 1000 1000 1000 166 1000 
P 
N-
C„H,„CIN,0 PWZ-0071 C16H10CIN30 295.723 0.23 0 17 0.12 0.44 17.31 
P 
"x£~ 
C,7H,5N3O , PWZ-007A C17H13N302 291.304 0.11 0.1 0.09 02 10 
P 
C^H,,N,0, PWZ-009A1 C17H13N302 291.304 1.34 1.31 1.26 0.84 2 03 
rv" 
x# 
C„HuCIN,0: PWZ-029 C14H14CIN302 291 733 300 300 300 388 300 
XJ^' 
0 
C,,H,,Cl,N,0 PWZ-031A C13H11CI2N30 296 152 300 300 300 28.5 300 
N ,0H 
x(f 
o 
C„H„C1N,0. PWZ-034A C13H12CIN302 277 706 300 300 300 300 300 
( 
0 
C,,H„CIS,0; PWZ-035A C15H16CIN302 305.759 300 300 300 82.7 300 
0 
0 
C„H„CIN3O3 PWZ-049 C17H18CIN302 331 797 1581 2865 2739 166 2930 
0 
CMH,;CINJO;, PWZ-051 C14H12CIN302 289.717 17535 33834 22125 2612 29500 
N ^ 
,-O^X 
0 
C,FH?,CIN,0 PWZ-057 C17H21CIN40 332.828 9483 30000 15409 2583 30160 
XQ 
0 
C,SHJSCIN«0 PWZ-058 C19H25CIN40 360.881 4201 12590 6266 1346 8600 
0 
C,4H,4CIN,0 PWZ-066 C14H14CIN30 275.733 408 1527 1125 182 3648 cr> M 
o 
C,.HwClN,0 PWZ-068 C17H20CIN30 317.813 2050 2900 2907 369 960 
C„H„N,0, PWZ-085 C16H17N304 315 324 4 86 13 8.5 0.55 40 
~c£T 
0 
CUM«NJQ4 PWZ-096 C17H19N304 329.35 11.1 36 16.9 1.07 51.5 
o 
0 ^ 
H 
C,.H1?CIN,0; PZII-028 C17H12CIN302 325.749 0.2 0 2 0 32 1 9 
<Ti to NJ 
C18H15N303 PZII-029 321.33 0 34 0.79 0 52 
QH-133 C15H10N8Q 318 293 2164 4620 1635 1000 
C16H12N405 QH-146 340 29 049 0.76 10000 
QH-149 C16H12N8Q 332319 
C13H9FN20S QH-27 175 335 405 150 300 CT1 NJ 
UJ 
x# f 
r S 
C„H,,FN,OS QH-28 C14H11FN20S 274 313 141 215 205 65.5 300 
. J #  N' N^-SN 
11 / /? 
0 rV 
C„H„N,0, QH-65 C15H10N405 326.264 
op 
QH-ll-058b C15H12N20 236.269 288 233 350 140 3000 
dp 
o 
CLEM14N;0 QH-ll-059 C16H14N20 250 295 81 138 318 98 3000 
cn NJ 
( \ 
B,A> KJi 
\ 
C,«H„BrN70 
J 
QH-ll-063 C16H13BrN20 329.191 9.4 9.3 31 7.7 3000 
/v 0̂ 
1 
C2.H^N;OS. 
0 
QH-ll-065 C21H22N20Si 346.498 94 73 203 63 3000 
V
l-Y 
I ) 
0 
QH-ll-066 C16H14N20 274.317 76.3 42.1 47.4 2000 6 8 3000 
6* 
CnH^BfN,©, QH-ll-067a C15H10BrN303 360.162 16 31 52 199 3000 
f YS° v 
rS 
CirHoN,0 
u 
QH-ll-072 C17H13N30 275.305 320 310 350 265 3000 
Br 
0 
N-—'~N 
C„|H,jBrN)0 QH-ll-075 C16H10BrN30 340 174 0.18 0.21 025 1.3 40 
rP 
C,*M10BrN,0 QH-ll-077 C16H10BrN30 340.174 0.06 0.08 0.05 0.12 4 
\/ 
Si 
j 
w 
C?1M„N,OSi QH-ll-080b C21H19N30Si 357.481 3 3.7 4.7 24 1000 
P 
^1 
C?iH,flN-iOSt QH-ll-082 C21H19N30Si 357.481 1.7 1.8 1.6 6.1 100 cn ro 
cr> 
p 
C,„H,,N.O QH-ll-085 C18H11N30 285 299 008 006 0.02 0 08 
P 
N—""N, 
ay-
C,eH,,N,0 QH-II-090(CGS-8216) C16H11N30 261.278 0.05 0.08 0.12 0.25 17 
H 
C«H„N,0 QH-ll-092 C18H11N30 285.299 0.07 0.03 0.04 0 17 
irf A I \-J 
CJ.H^NjOSF QH-IV-014 C23H22N2QSi 370.519 3000 3000 3000 3000 3000 
cr> 
NJ 
QH-IV-016 C20H14N2Q 298 338 3000 3000 3000 3000 3000 
QH-IV-019 C22H24N20Si 360 524 3000 3000 3000 3000 3000 
QH-IV-021 C19H16N20 288.343 3000 3000 3000 3000 3000 
Ro 15-1788 C15H14FN3Q3 303288 0.8 0.9 1.05 0.6 148 
CT> ro 
oo 
0 
C,,H,4NSO. R015-4513 C15H14N603 326 31 3 3 26 2 5 026 3.8 
08-34 RSK-ll-35 2007 47 03 94 66 38 38 
o 
RY-008 C18H17N303 323 346 3 75 7.2 4.14 1 1 1  44.3 
0 
WAS RY-020 C23H29N303Si 423.58 275 387 337 23 301 
NJ 
O—R 
rPr 
L 
03-1033 merck? RY-023 C22H27N303Si C22H27N303Si 409.554 197 142.6 255 7.8 2.61 58.6 
^ ^ J T \  0 
C,»H14N,O. 03-1030 RY-024 C19H19N303 C19H19N303 337 372 26.9 26 3 18.7 0.4 5.1 
JX  ̂
o 
C„H,TNJ03 RY-031 (RY-10) C17H19N303 313.351 20.4 27 26.1 1.5 176 
0 
RY-033 C18H21N303 327 378 14.8 56 25.3 1 72 22.9 ^ ^ >-/ 
OX) 
C,7H,,NJOS RY-035 C17H12N20S 292 355 980 590 775 92.5 3000 
cr> 
UJ o 
GXf 
C„H,4N7OS RY-037 C18H14N20S 306.382 300 300 300 300 300 
o J 
ST 0 
C.-.-H:SN .0 ,SI RY-047 C22H25N303S) 407 538 200 124 79 4 340 
0 
RY-049 C24H17N502 407.424 
0 
RY-053 C17H16BrN303 390.231 49 29 15 1 46 
J 
0 
C,AH„N,0, RY-054 C19H17N303 335 357 59 44 27 1.3 126 
(7) 
ID 
JV5 
0 
RY-057 C21H19N502 373.408 73 85 97 48 333 
0 
C^M,,NIO; RY-058 C20H17N502 359 381 86 40 85 24 150 
J^yS 
0 
RY-059 C19H15N502 345 355 89 70 91 37 301 
H 
oxf 
C,.H„NJO; RY-060 C17H12N202 276289 1000 1000 1000 1000 1000 
<J> 
UJ 
NJ 
p* c< 
o ^ 
\ 
0 
1 
C,»HuBrN10, RY-061 C16H14BrN303 376 205 17 13 6.7 0.3 31 
r> -Q 
0 
—H \ 0 
~y o \— 
C,»H,sBrN.04 RY-062 C19H15BrN404 443.251 1000 1000 500 172 2000 
r V  
t 
X-^SSN 
o° 
C„H,«N,O, RY-062 C18H14N202 290.316 300 300 300 300 300 
I Y^ c 
C^H^O-.SI RY-066 C21H23N303Si 393 511 83 60 48 2 6 180 
en u» u> 
C18H15N3Q3 RY-067 321 33 0 37 
C24H24N404Si RY-068 460.557 500 877 496 1000 
RY-069 C21H16N404 506 388.376 692 622 1000 
RY-071 C18H13N502 331.328 7.2 266 
12 7 RY-072 C19H15N502 345 355 220 150 184 361 
RY-073 C20H17N5Q2 359.381 156 122 267 
RY-075 C23H15N502 393.398 
RY-076 C15H14BrN3Q3 364 194 
RY-079 C20H23N3Q3Si 381 5 121.1 I 141.9 I 198.4 j 159 113 7 cn CO 
cn 
,-ep 
o 
03-1034 RY-080 C17H15N303 C17H15N303 309.319 28 4 21.4 258 5.3 049 28.8 
O 
C},H«N3O,S. RY-097 C21H25N303Si 395.527 300 300 300 300 300 
0 
Ci»H,7N,Q, RY-098 C18H17N303 323 346 10.1 22.2 16.5 1 68 100 
 ̂°-/ 
0 
C,H„,0r»<,O, RY-l-26 C17H16BrN303 390.231 1000 1000 1000 1000 1000 
cn u> 
cn 
RY-l-29 C19H15N502 345.355 1000 1000 1000 157 1000 
RY-l-31 C16H14N403 310.307 10 19 45 6 1000 
cn u> -j 
09-95 SA-SH-053-2'N-R-CH3 406 73565 3392 16843 
06-003 C22H16FN3Q2 373 38 21 99 12.34 34 9 0671 
SH-053-2'F-R-CH3 06-009 C23H18FN3Q2 387 406 759.1 948.2 768.8 95.17 
06-010 SH-053-2'F-S-CH3 C23H18FN302 387 406 468.2 33.27 291 5 19.2 
05-1768 SH-053-2'N C21H16N402 356.377 300 160 527 5000 cn 
OJ 
00 
SH-053-7N C21H16N402 356.377 
06-002 SH-053-2'N-S-CH3 C22H18N402 370.404 6951 2331 2655 744.1 
06-001 SH-053-R-CH3 C23H19N3Q2 369.416 2377 1183 2026 949.1 
SH-053-R-CH3 C23H19N3Q2 369.416 
Ol U> 
U3 
' 6 
C„H„N30; 06-007 SH-053-S-CH3 C23H19N302 369.416 1666 1263 1249 206.4 
CI.H„N,0; 05-1750 SH-053-S-CH3 C23H19N302 369416 5000 551 540 1 201 5000 
: 
|A/^' "' — —\ /V^ 
f\> "\J <J 
C«*MYF ,N*OJ 06-030 SH-222A C46H34F2N604 772.797 2058 292.3 51.24 
\ 
C.,H^F,N.O. 06-029 SH-223A C45H32F2N604 758.77 1231 2008 3609 261 3 
CT> •t* O 
fv/ • ~v/ ^ 
0" 
C»H„FN3O. 06-028 SH-223B C36H28FN304 585.624 4117 4785 10661 911 
0C5= 
0 
C„H,.N,0 06-020 SH-I-029B C16H14N20 250.295 489 576.5 706.1 208.8 
xp" 
C.,H,„BFN,0 05-1762 SH-I-02B C14H10BrN30 316 153 2982 1315 18 74.05 
C„MNB^4,0 06-005 SH-l-030 C16H13BrN20 329.191 14.42 11.04 19.09 1.89 
0 ^ 
CM 
C.^L.SBRN.O, 05-1766 SH-I-031A C19H15BrN402 411.252 84.05 141.3 150.5 151.2 <T> 
r^7 
Cj.HMN.OTS. 05-1767 SH-I-031B C24H24N402Si 428.558 981.9 1004 2046 3562 
<s 
Jl 
C^H^BfNjOi 06-017 SH-I-034(S) C21H18BrN302 424 291 7934 746 8 5446 1564 
ccl 
C„H„NjO 06-015 SH-I-035A C16H14N20 250.295 7389 6049 16811 15793 
xrf. 
C„H,,BfN,0 05-1752 SH-I-035B C16H13BrN20 329,191 7439 11084 3021 4043 
/ = = N  
C,«HnBfN,0 06-021 SH-I-035B C16H13BrN20 329.191 11218 4571 3841 7035 
C;,H,,8rN!0; 05-1748 SH-l-036 C21H18BrN302 424.291 587 587 9 280 2 150 8 
C*Hj,NJO,SI 05-1749 SH-l-038 C26H27N302Si 441.597 
X 
N. ^ 
C„H,^}rN, 05-1763 SH-l-04 C16H12BrN5 354 204 7.3 6 136 5.1 7664 
06-022 SH-l-040 R C21H18BrN302 424 291 774.4 334.1 584 3559 
05-1754 SH-l-041 C26H27N302Si 441.597 
06-018 SH-l-044 C16H12BrFN2Q 347.182 5633 2034 6658 3521 
05-1761 SH-l-047 C21H17BrFN302 442281 1710 17.52 1222 1519 
XO-
C,.H„BfFN?0 06-006 SH-I-048A C16H12BrFN20 347.182 0.774 0.1723 0 383 0 11 
C2lH,,Bff KJOJ 05-1757 SH-I-048B C21H17BrFN302 442.281 
•^cc 
o 
C„H„Bri4<0 SH-I-049R C15H12BrN30 330.179 
jTY1 0̂ 
B r — \  
O* 
06-014 SH-I-049S C15H12BrN30 330 179 155.6 137.2 88.5 11094 
•  r J  
C»H»FHsO& 06-013 SH-l-055 C26H26FN302Si 459 587 5109 1638 1394 2234 
05-1764 SH-l-06 C21H21N5Si 371.51 
^ Cj 
W.0,8. 06-004 SH-l-064 C26H26FN302SI 459.587 4249 3970 3412 1215 
C„H.,N,0; SH-l-067 C21H15N302 341.363 
SH-l-085 C20H12BrFN4Q 423238 06-011 11.08 4 866 13.75 024 
06-023 SH-l-75 C22H17N302 355 389 1487 989.9 773 0 1825 
06-019 SH-I-89S C18H15BrN4 367.242 12.78 8.562 8 145 323 
06-012 SH-I-R66 C23H16F3N3Q2 219.5 423.387 169 1 87 01 47.97 
N /? 
CM 
CjjM.gFjNjO? 06-008 SH-I-S66 C23H16F3N302 423 387 22.93 30 36 55.26 0.69 
0 
C,sH„8fN,0 05-1769 SH-053-2'N-S-CH3 C15H12BrN30 330.179 
Cr 
05-1759 SH-053-S-CH3-2'F C23H18FN302 387 406 350 141 1237 16 5000 
X0-
C„H,.N. 06-027 SH-TR-CH3 C20H16N4 312 368 7367 1534 8213 1948 5 
06-027 SH-TR-CH3 <r> 
oo 
05-1765 SH-TRI-108 ANX4 C18H13N5 299.329 143.9 81 29 1039 4564 
06-024 SH-TSC-KPWZ-029) C14H14CIN302 291.733 3624 1803 3282 6 185 
06-025 SH-TSC-2(BCCT) C16H16N202 268 31 0.03 0.0419 0.035 
06-026 SH-TSC-3(Xll-093) C33H26N6Q6 602.596 1295 7449 1814 33 99 
SH-TSC-5(SH-l-047) C21H17BrFN3Q2 442.281 356.7 169.4 285 75.31 
<T> 
vo 
Q^° 
C„H„BfN,0, SH-TSC-6(SH-l-034) C21H18BrN302 424291 913.2 283 300 436.8 
J  
£& 
Ci-H„BmA SH-TSC-7(SH-l-040) C21H18BrN302 424.291 709 1997 1256 727.4 
jf 
C„H»N, 06-016 SH-TS-CH3 C20H16N4 312.368 107.2 50.09 20.95 8 068 
B< 
6 
/ 
H 
C„H„BrN,0 SHU-1-07 C18H14BrN30 368 227 108 260 175 940 155 2535 CT1 
O 
CI 
0 
H 
C,,HUCIN,0 SHU-1-15 C18H14CIN30 323.776 81 63 86 2175 174 2167 
P 
Cr4HrsN,0 SHU-1-19 C18H15N30 289.331 4 12 7 48 14 84 
lY~1° 
"i rf 
C»HjoNJOS' SHU-221 (XLI-250) C20H20N20Si 332.471 492 439 339 3000 118 3000 
J0C> 
C,.H,jN,0 SHU-221-1 C17H12N20 260.29 66 41 43 3000 9 3000 
>co 
" K f C  
Ci.H.N.Si SHU-223 C20H22N2Si 318488 1000 1000 1000 1000 1000 1000 
XQ 
SHU-224 C20H22N2Si 318.488 1000 1000 1000 1000 1000 1000 
HN V 
CO 
H 
C,BH„,N,O SHU-525 C18H18N20 278.348 667 667 667 667 667 429 
SHU-528 C17H11N3 257 289 667 667 667 667 667 429 
i
Q
 
V
 
o
 
SHU-530 C10H10N20 174.199 667 667 667 667 667 429 
0 
C„H„N.O, SHU-537 C20H13N302 327 336 333 333 333 333 667 429 cn Ui 
NJ 
C#-
/A 
SHU-547 C17H16N20 264.322 667 667 667 667 667 429 
oC£-
C,-H,8N;0 SHU-550 C17H16N20 264 322 333 333 333 333 333 429 
CioMgO> SHU-lll-032 C10H802 160.169 1000 1000 1000 1000 1000 1000 
0 
C«M„FNfl SHU-lll-24 C20H18FN30 335.375 1000 1000 1000 1000 1000 1000 
C„H„0; SHU-lll-32 C12H1002 186.207 1000 1000 1000 1000 1000 1000 CD 
Ln u> 
0 
C„M,,0, SHU-lll-33 C14H1203 228.243 1000 1000 1000 1000 1000 1000 
jxo 
C.-H^O, SHU-lll-34 C14H1002 210.228 1000 1000 1000 1000 1000 1000 
CMHMO} SHU-lll-36 C14H1402 214.26 1000 1000 1000 1000 1000 1000 
^jOCO 
C„M,A SHU-lll-37 C15H1202 224 255 1000 1000 1000 1000 1000 1000 
cco 
C'iHlNl , , SHU-III-40 C12H8N2 180 205 1000 1000 1000 1000 1000 1000 ( J )  
cn 4* 
SHU-lll-42 C10H8Q3 176.169 1000 1000 1000 1000 1000 1000 
SHU-III-42A C10H10Q3 178 165 1000 1000 1000 1000 1000 1000 
SHU-III-42B C8H802 136.148 1000 1000 1000 1000 1000 1000 C.H.O, 
SHU-IH-44 C11H10Q2 174.196 1000 1000 1000 1000 1000 1000 
an 
U1 l/i 
rr^ 
C,„H.,0, SHU-lll-45 C10H1202 164.201 1000 1000 1000 1000 1000 1000 
1 
SHU-lll-66 C12H1202 188.222 1000 1000 1000 1000 1000 1000 
1 
rr° 
/K o/ 
C„H„NO, SHU-lll-87 C13H13N02 215.248 1000 1000 1000 1000 1000 1000 
I "" 
6 
C..H.NO, SHU-lll-88 C11H9N02 187.195 1000 1000 1000 1000 1000 1000 
<-n cn 
rY-i 
l 
I! 
C,JH„N02_ SHU-lll-90 C13H11N02 213.232 1000 1000 1000 1000 1000 1000 
rrV 
u 
C„H,4NO, SHU-lll-93 C17H15N02 265.306 1000 1000 1000 1000 1000 1000 
rrY^ UUJ 
0 
C„H„NO? SHU-lll-94 C17H13N02 263 291 1000 1000 1000 1000 1000 1000 
o/YTr" 
^ N 
C.,H,nN,0., SLL-ll-25 C17H10N402 302 287 244 500 532 1560 10000 
vL 
/YY\i" 
M 
C,FH„N?0. SPH-121 C17H18N204 314 336 0.14 1.19 1.72 4 479 
n) 
Q-
ay 
C1#H,«N}O3 SPH-165 C16H16N203 284 31 0.63 2.79 4.85 104 1150 
) 
YYM" 
\H 
C?JH„N?O3 SPH-166 C23H22N203 374.432 20.8 78.3 587 67.3 10000 
> 
0 
C„H„CIN,OF SPH-178 C17H19CIN202 318.798 1000 1000 1000 1000 1000 
<Ti 
in 00 
x> 
/ 
°WxP 
Cj,H,«N30j SPH-195 C21H18N203 346.379 7.2 168 5 283 5 271 10000 
SPH-38 C16H16N204 300.309 2 5.4 10.8 18.5 3000 
09-01 SR-ll-25 1593 2592 3919 1611 
09-02 SR-ll-30 724 1 470.6 7902 770 
09-03 SR-ll-54 174.1 363.2 946 4 966 6 Ch 
Ln 10 
09-04 SR-ll-57 169.2 480.8 667.1 729.5 
0 
C„H SVO-8-14 C18H19N303 325 362 8 25 8 6 9 0.9 14 
o 
SVO-8-20 C20H23N304 369 414 11 40 28 19 86 138 
iTfj^ 
\—-0 s ^ 
C„H„N,0, SVO-8-30 C19H17N304 351 356 1.1 5.3 5.3 2 8 06 15 
Cj,M1s1MJ0J SVO-8-67 C21H19N303 361 394 7 41 26 15 2 3 191 en 
01 o 
08-27 TC-T-JG-24 C16H13CIN203 316739 746.5 8081 1543 2364 
08-30 TC-YT-ll-76 C18H19N3Q3 325 362 101.1 1.897 5.816 11.99 
TC-YT-lll-19 08-011 C34H36N804 620.701 2772 24918 4842.3 4925 
TC-YT-TC-2 08-25 C30H26CI2N6Q6 637.47 643 2657 737. 1973 
. J 
0 
C„M17N,O. TG-4-29 C17H17N303 311.335 8.3 10.2 6.9 0.4 761 
TG-4-29 2.8 3.9 2.7 2.1 0.18 39 
CM  ̂
C.sH-rNjOjS TG-4-39 C19H17N303S 367.422 16 34 24 56 1.4 23 
. O 
C^H^NJO, TG-l-97 C16H16N203 284 31 
cn <r> 
M 
TG-ll-82 C17H18N2Q3 298 336 1000 
TJH-6AZ C13H9N502 267.243 
TJH-IV-43 C20H19N3Q2 333.384 5.42 30.19 48.9 475 10000 
TJH-IV-50 C24H21N302 383.442 30 7 205 271 814 10000 
<71 <T> 
OJ 
a 
0 
C„h.-«N.O: TJH-IV-51 C19H23N302 325.405 2 39 17.4 14 5 316 10000 
r^H~ 
\sssiO 
xxP 
^ H 
C,«H,N,0,5 TJH-V-88 C14H9N302S 283.305 3.41 30 1409 10000 
V< 
Ci XJ 
/^S5SS^w^*Cl 
VJ 
C,rH„Cl?N« triazolam C17H12CI2N4 343.21 1 
\ o 
,/
V
 v
J
 I 
nr K^l 
cnHj|Ni° 
0 
05-1745 TSC-l-93 C25H21N30 379.454 5000 5000 5000 304 5000 
C»H;iNsO 05-1744 TSC-l-94 C26H23N30 39348 ^r, 
CMH„CtNj 05-1743 TSC-l-95 C24H18CIN3 383.873 
Xxxxr1-̂  
C,aH,.N,0; 03-0973 WY-A-99-2(WYS8) C18H16N202 292 332 0.972 111 102 2000 208 1980 
N^_—-0 f 
'YVAj" 
^ \ 
ci>WV>i WY-B-08 C15H7F6IN202 488.123 78 301 131 3000 681 3000 
<x> 
CT> 
Ul 
oP 
\ 
Ci«HeFnNjOj WY-B-09-1 C15H8F6N202 362 227 3 99 8 32 1000 461 2000 
F 
1 f 
\ 
H 
WY-B-09-2 C14H9F3N202 294.229 1000 2000 2000 3000 1000 3000 
\ 
C,,H„N?0;Sl 
) 
03-0972 merck WY-B-14(WYS7) C21H24N202Si 364 513 684 30 36 2000 108 1000 
\ 
H 
C},H,4N,0,SI 
3 
03-0972 WY-B-14(WYS7) C21H24N202Si 364 513 8.5 165 245 1786 5000 
vr 
\m 
C,.H,,N,Oa WY-B-15 C14H11N304 285255 0.92 083 0.58 2080 4 42 646 
C' 
\H 
C„H,,CI,NJOJ WY-B-17 C15H11CI3N202 357.619 2000 2000 2000 3000 2000 5000 
F 
V I 
'YVu" 
\ 
C„H,F ,INrO. WY-B-20 C14H8F3IN202 420.125 12 39 47 2000 122 3000 
O 
r* 
( ^ y J  
\ 
C.,H,CI,N,0, WY-B-23-1 C14H9CI3N202 343.592 10 33 43 1000 189 2000 
cn 
cn 
N\ 
H 
C„H,,?»,<>, 03-0976 merck WY-B-23-2(WYS11) C15H11F3N203 324 255 4.2 37 7 39 2000 176 694 
-•yX' 
of 
CISHNFJ^A 03-0976 WY-B-23-2(WYS11) C15H11F3N203 324.255 4.2 37.7 73 176 694 
& 
~^\ 
WY-B-24 C18H9F3N202 342 271 22 02 177 44.78 3000 422 3000 fV 
05=R^° 
f ^ y y j  
x» 
C,SH„F1NJ03S> WY-B-25 C19H17F3N202Si 390.431 7.6 40 66 2000 263 2000 
F 
\ / ' 0 F 
„ r\ 
YYV 
\ 
C„H,F,N;0, WY-B-26-2 C16H9F3N202 318.25 4.45 44.57 42.66 2000 124 2000 
O ^ 1 '  
\ 
C,.H„FJN,0, WY-B-27-1 C18H11F3N203 360.287 26 143 117 3000 127 2000 
F 
V o/ F 
<VrO 
^ \ 
C„H,,F,N,0,S WY-B-27-2 C18H11F3N202S 376.352 9.19 111 72 2000 449 2000 
\ 
C^HNF^O, WY-B-29-2 C20H13F3N202 370.325 25 137 125 2000 299 2000 
r 0= -̂° 
V 
CIJH^NJOJS- WY-B-99-1 C19H20N202Si 336.46 4 4 4.5 5.58 2000 47 2000 
\A,/\J V\A/ 
A A 
C14HWN4OE 03-0966 WYS1 C45H50N406 C44H46N408 758 858 missing 
CCO '̂ 
H 
CUHJFJNA 03-0975 WYS10 C14H9F3N202 C14H9F3N202 294 229 0.88 36 256 548.7 15 3 
CWHLSN?OJS 03-0977 WYS12 C20H18N202S C20H18N202S 350 434 37 166 314 2861 5000 
CAJH^NJO, 03-0978 WYS13 C20H18N203 C20H18N203 334.369 2.442 13 27.5 163 5000 cr> ^sj 
o 
f 
Y '/V 
C-mH„F,N,0. 03-0979 WYS14 C34H29F3N404 C33H25F3N404 598.571 798 5000 5000 5000 
C^H^NO: 03-0980 WYS15 C22H20N202 C22H20N202 344 406 3.63 202 44 3 76.5 5000 
MO 
C,iH14N202 03-0981 WYS16 C18H22N202 C15H14N202 254.284 5000 5000 5000 5000 
C„H,,N,0, 03-0982 WYS17 C17H18N202 C17H12N202 276289 missing 
cxxxr 
CMH„NJOJ 03-0983 WYS18 C21H22N202 C20H18N202 318.369 missing 
/NV 
kA,/ 
A 
C»H„N,O.SI 
0 
0 
03-0984 WYS19 C26H32N204Si C26H32N204Si 464.629 0.89 
'v\/V VVV' 
CU.H „,N,0. 03-0967 WYS2 C35H34N404 C34H30N404 558 626 5000 5000 5000 5000 5000 
/fv Vv^Ww\\A 
'V\A/ V\A/ 
C„H«N.O. 03-0967 (merck) WYS2 C35H34N404 C34H30N404 558.626 30 124 100 300 300 4000 
M 
XX? 
Cj,H,.N,0, 
V-
03-0985 WYS20 C23H24N204 C23H24N204 392.448 450 5000 5000 5000 
W' 
0^0 
1 
—1— 
C;,H. ,IN.'0« 03-0986 WYS21 C21H23IN204 C21H23IN204 494 323 missing 
U,A> 
CWHUN*0. 03-0968 WYS3 C35H38N404 C34H34N404 562.658 241 5000 1841 5000 5000 
I 
c 5 
I : 1 ; 
/yVV_Y\ A—jAAA 
WV \A,A/ 
A: A 
C«H«,N40. 03-0969 WYS4 C48H56N408 C46H46N408 782.879 missina 
A^VX^AAA/y^ 
vU> 
C„M„N4O4 03-0970 WYS5 C37H42N404 C37H42N404 606.754 5000 5000 5000 5000 
Y Y 
VO 0^° 
^ V \  / V ^  
C^H^N.O* 03-0971 WYS6 C37H35N404 C36H32N404 584 664 120 1059 3942 5000 5000 
. ^ ^ 1 >1 
H 
03-0974 WYS9 C16H15IN202 C16H15IN202 394.207 2.72 22.2 23 1 562 122 
o 
^ N 
03-0987 WYSC1 C16H16N202 C16H16N202 268.31 1.094 5.44 12.3 698 21.2 
dc 
H 
CiiHpFjNiOj 03-0988 WYSC2 C15H11F3N202 C15H11F3N202 308.255 14.14 113 170 518 61.2 
xToOAA 
C„H,eN;0. WY-TSC-4IWYS8) C18H16N202 292 332 109 431 2374 5 16564 2663 5 
WY-TSC-4(WYS8) 0.007 0.99 1.63 51.04 
Pr" 
Jn-. 
// 
1 
5N 
C,»M„NJO WZ-030 C19H14N20 286.327 279 210 200 45.15 1000 
X •J 
V j  
) 
WZ-032 C20H16N20 300.354 965 345 590 150 3000 
a J*~-5" 
V j 
C„H,3FNJO WZ-069 C19H13FN20 304.318 40 30.5 38.5 12.6 1000 I 1 
SSN 
V j 
C,-GM ,.FN ,0 WZ-070 C20H15FN20 318.344 72 7 30 7 532 18.6 300 
w 
CMH,3CIN,OS WZ-113 C14H13CIN20S 292 784 19.2 13 2 13.4 11.5 300 
r o 
CUHNCLNJO} WZ-148 C14H13CIN202 276.718 300 300 300 300 300 
C,»H,,FN7O WZ-153 C19H13FN20 304 318 199 151 3 191 6 73 5 1000 
9y^ 
vA /̂ 
O" 
CJNH.,FN;0 WZ-154 C20H15FN20 318.344 300 300 300 300 300 
<T> 
WZ-175 C19H13FN20 304 318 1000 1000 1000 1000 1000 
C20H15FN2Q WZ-176 318 344 300 300 300 300 300 
C13H15FN20 234.269 300 300 300 WZ-185 300 300 
C14H13CIN20S WZ-198 292.764 300 300 300 300 300 
Ol 
WZ-201 265.267 C15H11N302 
XHE-l-027 C24H25N3Q3Si 431.559 1000 1000 1000 
XHE-l-030 C21H17N303 359 378 1000 1000 1000 1000 1000 
XHE-l-038 C23H19N30Si 381.502 132 1000 
/ 
J 
( /  
C,„H,,N,0 XHE-l-043 C20H11N30 309,321 31 95 272 81 1000 
\ 
\ P 
rr / < 
ir\ 
0 
CIJHUBFNJOJ XHE-l-046 C15H14BrN303 364 194 1000 1000 1000 1000 1000 
C„H.„N,0, XHE-l-048 C21H19N303 361 394 220 440 481 50 160 
0 <j*y 
A,X J 
y f\ 
C?JHJ-1N,0>SI XHE-l-050 C22H23N303Si 405.522 254 300 300 195 3000 
C,.H„N,0, XHE-l-051 C19H15N303 333.341 35 39 42 5 3 979 
-<Q 
0 
C„M, ,Bf/N,0, XHE-l-055b C17H11Br2N302 449.096 615 1000 1000 2213 268 1524 
f J 
o 
C;,H,»N>0 XHE-l-065 C24H19N30 365427 7.2 17 18 500 57 500 
0 
0 
Cj,HJtN303 XHE-I-066A(SS) C21H21N303 363.41 196.66 176.14 95.4 74 26 125.06 186.25 
c>ur 
O 
CJ,H?1NJO, XHE-I-066B(SR) C21H21N303 363.41 76.04 73.56 45.05 22.72 5342 51 32 
\/ 
S.-
/ 
w 
CJ.HJJN^OSI XHE-l-073 C21H19N30SI 357 481 62 155 217 1000 393 1000 
y 
w 
T~\=~ 
H 
C,9H„N,0 XHE-l-093 C19H13N30 299 326 2 7,1 89 1107 20 1162 
C„H,7N,O, XHE-l-096 C21H17N302 343.379 3079 1000 4636 1601 567 2712 
<7> 
00 
C24H27N303Si 433.575 10000 XHE-l-47 705 2502 2460 480 a 
XHE-ll-002 C19H21N3Q3 339 368 
396.26 4.7 4.4 20 1876 3531 
C20H18CIN3Q 351.829 1000 1897 144 
cn 
00 
T~ 
0 
C&-
C^H^O XHE-ll-011 C22H19N30 341 406 9 60 39 3233 90 1000 
. CM. 
XHE-H-012 C20H16BrN302 410.264 49 24 31 1042 14 2038 
\/_ 
/ 
W 
-N 
Cj,H?,N,OS( XHE-ll-014 C25H27N30SI 413.587 329 1098 1156 1000 2462 1000 
C:;HltN,0 XHE-ll-017 C22H19N30 341 406 3.3 10 7 258 17 294 
0> 
00 U> 
r j 
w 
CmH^NJO XHE-ll-019 C28H27N30 421.533 273 428 762 1000 1464 1000 p 
CKHISN30 XHE-ll-024 C20H19N30 317.384 0 09 0.18 0 32 14 024 11 
03-1031 XHE-ll-053 C22H17N302 355.389 287 45 96 1504 13 8 1000 
/=sN 
C,,H„N,Or XHE-ll-065 C17H13N502 319.317 1000 409 216 37 6.4 175 
<T> 
00 
i 
C,»HWN ,0. XHE-ll-070 C19H19N304 353.372 352 532 454 45% 55 1000 
0 
C„H,.N,0, XHE-II-073A (R ENRICHED) C18H19N303 325 362 5.9 11 10 15 1.18 140 
0 
rNvA 
CcH.^O, XHE-II-073B (S-ENRICHED) C18H19N303 325362 11 17 12 33 2.1 269 
CjA^c 
0 
CiiHjfNjOj XHE-ll-077 C23H27N303 393479 1363 1000 3403 3561 1000 1000 
cn oo Ln 
C20H19N3Q 317 384 1000 1000 1000 1000 1604 1000 
XHE-l!-087c C20H18BrN3Q 1000 1000 1000 1000 1000 396.28 1000 
C24H25N30 371.475 XHE-ll-098a 1000 1000 1000 1000 1000 1000 
C24H24BfN30 450.371 XHE-ll-098b 1000 1000 1000 1000 1000 1000 
cn 
00 cn 
XHE-I1-098C C24H24CIN3Q 405.92 1000 1000 1000 1000 1000 1000 
C15H15N303 XHE-lll-04 285.298 219 0.4 500 
XHE-lll-06a 340.174 
XHE-lll-06b C16H9BrCIN3Q 374.619 299 286 740 
cr» oo 
-N N-
XHE-III-06C C16H9Br2N30 419 07 210 319 
XHE-lll-12 C21H19N3QSi 357.481 240 1000 1000 181 536 
XHE-lll-13 C17H17N303 880 311.335 311 7.3 
XHE-lll-14 C18H11N30 285.299 
<x> 
00 
00 
C20H18FN3Q 335.375 XHE-lll-24 025 222 328 
XHE-lll-49 C15H14CIN303 319.743 4.2 38.7 85.1 5.5 
XHE-lll-54 C12H8CIN30 1071 1624 245 664 2048 1000 1158 1000 
1005 1642 1928 1000 1300 1000 
oo 
ID 
CuH.,N,OSt XHE-lll-67 C17H17N30Si 307.422 1000 1000 1000 1000 1000 1000 
0 
C„H„FN,0 XHE-lll-69 C12H8FN30 229 21 3433 1000 1000 1000 1000 1000 
P 
&• 
C, HSN |0 XHE-lll-70 C12H9N30 211.219 9975 2356 2484 711 500 1000 
/ 
r\ 
<y~ 
CnHsNiO XHE-lll-73 C14H9N30 235.241 1000 303 942 1000 492 1000 
C20H23N3Q4 XHE-lll-74 369.414 105 0.42 
05-1773 XHE-II-053-ACID C20H13N3Q2 5000 327.336 50 35 44 
C13H14N2Q3 XLI-? 246.262 
C33H26N606 XLI-093 602.596 2000 1000 1000 858 1550 
XLI-1? C10H8Br2N2Q2 347 991 CT> U5 
C18H12BrN3Q2 382 211 05-1724 XLI-12TC 
C12H11BrN2Q2 295 132 2078 5289 616 7 8382 05-1725 XU-13TC 
C19H19N304 05-1728 XLI-14TC 353.372 
05-1729 C17H13N303 XLI-15TC 307 303 
05-1730 C15H12BrN303 362.178 XLI-16TC 7664 3515 787.4 1831 CTi VO 
NJ 
05-1731 C19H20BrN3Q3 1066 120.6 XLI-17TC 418.284 224. 92 43 
05-1732 XLI-18TC C16H15N304 313308 
05-1733 C13H14N203 XLI-19TC 246 262 
XLI-2? C17H13BrN4 353.216 
^VA„ 
05-1727 C35H30N6Q6 XLI-210 630 649 661 2666 231 5.4 54.22 
cn 
00 
Cj?H ^BrN^O? 03-1026 XLi223 C22H20BrN302 C22H20BrN302 438.317 14 8.7 18 1000 10 2000 
C„H„N,0:Sl 03-1027 XLi224 C27H29N302Si C27H29N302Si 456.624 333 333 333 3000 333 2000 
<X^ 
C„H?lN,0, 03-1028 XLi225 C24H21N302 C24H21N302 383 442 333 225 174 3000 110 2000 
x L ^ i T " ^  $• 0 
C„H,tFsN,0,Si XLI-232 C23H21F6N303Si 529.507 
CjoH?ONJOSI XLI-250 (SHU-221) C20H20N20Si 332.471 1000 1000 339 1000 118 1000 
v\ 
C,.HnBrN, 03-1023 XU268 C17H13BrN4 C17H13BrN4 353.216 2.8145 0.6862 0.6243 
C;)HjjN,Sl 03-1024 XLi269 C22H22N4Si C23H23N3Si 369.534 221.8 154.2 15.51 
vv->00 
O 
C,»H„N. 03-1025 XU270 C19H14N4 C19H14N4 298.341 36.39 25.81 5.291 
.J 
CK 
03-1038 XLi275 C20H19N303 C20H19N303 349 383 35.61 
cn 10 tn 
348.622 XLI286 C16H1 IBrCINO 
349.61 XLI-286 C15H10BrCIN2Q 0.051 0.064 05-1715 0.118 0684 
XH296 332.786 
XLI-2TC C17H13BrN4 05-1711 353.216 1.673 3442 44 08 1.121 
XLI-3? C25H25N3Q2Si 427.57 
cn to cn 
o 
05-1712 XLI-317 C18H19N304 341 361 6024 24 05 4 562 0295 
0 
XLI-317 C18H19N304 341.361 
N 0 / 
~1' 
C j -• Hj | F 05-1710 XLI-332 C23H21 F6N303Si 529.507 1390 1507 3405 132.1 
Cj.H 
^4/ \_^-N 
f \ 
0 
,hsOj 03-1035 XLi337 C21H23N303 C21H23N303 365426 
C«H 
r(x 
iCIN, 03-1045 XL1338 C23H21CIN4 C23H21CIN4 388.893 380 189 692 5000 5000 <T> 
VD 
C23H22N4 03-1037 XLi339 C23H22N4 354 448 625 5000 5000 5000 5000 
03-1036 XLI340 C26H25N3Q2 C26H25N3Q2 411 496 
03-1042 XLi343 C20H19CIN2QSi C20H19CIN2QSi 366.916 1.375 17.71 150.5 
03-1040 Xli-347 C34H28N607 C34H28N6Q7 690.2 632 622 13 87 828.05 
05-1723 XLI-348 C20H19CIN2QSi 366.916 13.56 11.17 1.578 82.05 
cn U5 
00 
C,,H„C!N70 03-1043 XLi350 C17H11CIN20 C17H11CIN20 294.735 1.224 1.188 2 9 
rrf \y^ 1 ^\ CjT'" 
C„H„CINJOS> 03-1041 XLi351 C21H21CIN20Si C21H21CIN20Si 380 943 1.507 0.967 1.985 
jyp 
C,»HMCIN,O 03-1044 XLI352 C18H13CIN20 C18H13CIN20 308 762 1.56 0.991 1.957 
C 
iM/n/VVS L // o ^ 0 i , 
$ FTL 
1 0 c 
CJJHMP^OS 03-1039 XLi356 C33H34N606 C33H34N606 610.66 1851 5 4702.5 8545 100.5 5000 
Cj-i"7 
C,_H;.N,0. 03-1046 Xli366 C22H21N302 C22H21N302 359 421 1 (J) 
<D 
I / 
oCp 
0 
C,|H,SNJO 03-1047 XU368 C24H25N302 C18H18N20 278.348 
i ( y \  ° M K  
V"v\ 
•; | • 
/fX 
C,.H„N,O7 05-1721 XLI-374 C32H24N607 604.569 3795 2694 1864 76 14 
0 
CUHIJSRT^OJ 05-1717 XLI-379 C13H12BrN302 322.157 1037 482.4 357.5 36.13 
CV\ 
0 
C„H„CIN,0 05-1720 XLI-381 C15H12CIN30 285.728 619.9 285.6 3639 7051 
-J '̂V-V 
fV \ VA >. 
1 1 / 
' Y x  Y ' f )  
e 
05-1718 XLI-3B2 C29H28Br2N604 684.378 o o 
C39H46N6Q4Si2 718.991 05-1722 XLI-385 
05-1726 XLI-387 C33H30N6Q4 574629 5454 5000 5000 5000 5000 
XLI-4? C10H10N2Q2 190.199 
XLI-6TC 05-1716 C15H11N303 281,266 2371 1421 1840 1169 
• fJ 
 ̂ CHo 
C»H„BrfNjO, 05-1719 XLI-8TC C20H15BrFN302 428.254 21 52 11.01 2.155 4 059 
Vs-
iTY \ / 
* J" 
C,»H,,CIN, 03-0951 XLi-JY-DMH ANX3 C19H13CIN4 332.786 3.3 0 58 1.9 44 5000 
rri 
> JT 
C.,H,,CIN„Si 03-0950 XLi-JY-DMH-TMS C22H21N4SiCI) C22H21CIN4Si 404.967 35 63 99.13 69.7 5000 
0 
C„H„W, 05-1709 XLI-TC C13H14N203 246.262 8155 7528 1036 5089 
0 / 
CM 
03-1032 XliXHe-ll-048 C25H25N302Si C25H25N302Si 427.57 5000 5000 5000 5000 
. ^ 
rr^1 
C^H^CIN^O; XZ112 C20H16CIN302 365.813 
H 
YCT-5 C16H10N4 258.277 22 11.46 16 3 200 10000 
op-
CtflH,.,N, YCT-7A C16H10N4 258277 3 23.8 30.5 240 10000 
$ op 
C«iH,nN, YCT-7B C16H10N4 258.277 28 118 156 1000 10000 
0 
N̂ // 
o 
08-001 YT-5 C14H12BrN303 350 167 0.421 0.6034 36.06 1.695 
J3y( 
0 
CUM,,CIN,0» 08-004 YT-6 C14H12CIN303 305 716 15.31 87.8 6049 1 039 
0 
C„H,JNJOI 05-1770 YT-l-38 C18H15N303 321.33 945 9 326.8 245.9 4.07 
OH 
C„H14BrN,0 08-005 YT-II C18H14BrN30 368.227 6.932 0.8712 3518 5.119 
XT" 
o 
C.,H,vNjO. 08-009 YT-ll-76 C18H19N303 325.362 95.34 2.797 0 056 0 04 /\ i \ A* 
•^r5 0  ̂
0 0 
C^.Br^O. 07-007 YT-ll-791 C33H28Br2N606 764.42 1495 2681 527.4 144 
A/1/ ^ I :. 
: 1 A ,/vV\ 
•^V'O = 
CuH-^Br^O, 07-001 YT-ll-792 C34H30Br2N606 778447 7896 599 5 1698 83 18 
.<X5 W* 
0 
C^Bf^O, 07-002 YT-ll-793 C34H30Br2N606 778.447 1383 2881 782.6 128.9 
CH^Hu 
rvv w x ri 
XXfi C^X 
C^B^O, 07-011 YT-ll-794 C34H30Br2N804 774 461 4536 1262 4981 932 8 o Ln 
C16H16CIN3Q4 08-002 349.769 YT-ll-83 32.74 13 22 24 1 3 548 
C30H25N3Q5 507.537 YT-lll-1 
C31H26BrCIN606 07-009 YT-lll-10 693.932 1172 1915 282 9 1481 
C36H27CIN605 07-008 YT-lll-15 659 09 73.19 90.45 141.4 114 
O 
07-010 YT-lll-19 C34H36N804 620.701 5329 182.4 3817 3313 
08-008 YT-lll-23 C23H21N3Q2 371.432 23.65 19.87 1 105 
08-35 YT-lll-231 51.09 61.46 26.34 9.124 
08-003 YT-lll-25 C18H20CIN3Q4 377.822 2.531 5.786 5691 0 095 
08-17 YT-lll-271 C43H28F2N604 730.717 32 54 2 35 103 
08-28 YT-lll-272 295.9 14.98 10.77 103 3 
08-18 YT-lll-273 245.1 366 389 879.4 
08-14 YT-lll-28 130.7 80.03 82.9 192 
o 
Cj,H,„N40 08-006 YT-111-31 C21H16N40 340.378 36 39 67 85 129.7 7 59 
08-15 YT-lll-33 198 7 82 3 146 76.4 vj o 
00 
08-19 YT-lll-331 1199 665 759 1687 
08-20 YT-lll-332 5264 168 148 1365 
08-21 YT-lll-333 459.7 298.3 447.6 7182 
08-22 YT-lll-334 1930 1049 1102 3105 
08-23 YT-lll-341 370 196.5 203.7 673.3 
^sj 
o ID 
08-24 YT-lll-342 4283 68 95 836 135 7 
08-16 YT-lll-36 74.96 195 90.9 262.5 
r.,1HJ:FN,0. 08-33 YT-lll-38 C23H20FN302 389.422 1461 18.21 1463 3999 
08-36 YT-lll-39 161.5 336.3 412 224.4 >sj h-k o 
08-37 YT-lll-40 1454 2576 3543 112.6 
08-29 YT-lll-41 3052 745.7 510.8 416.8 
08-31 YT-IM-42 382.9 16.83 44.04 9.77 
08-32 YT-lll-44 37.83 9717 3739 24.04 
r>Wii 
.ly 
0 o 
CrtH2,C!jN,0, 07-003 YT-TC-1 C29H24CI2N606 623443 441 8 927,4 157.9 122.2 
. v^; TY-
«^V ./"YVX: 
\ 0 
0 
CjoH^CIjNgOj 07-004 YT-TC-2 C30H26CI2N606 637.47 839.1 1647 568.1 421 9 
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/ V ^ n/ X / A  1  
A/^, c V"\A 
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=A/y\ hc^ 
CvHMCt}N«Ok 07-005 YT-TC-3 C31H28CI2N606 651.497 141.4 11.43 118.1 29 22 
0 0 
f\X^\^Ws  
u' y 
•Ui OCl, 
!  '  ' \  
CxsHxOiHtOt 07-006 YT-TC-4 C30H26CI2N804 633.485 6291 3315 352.2 2881 
.̂ + 
o 
CirHuBrNjO, ZG-168 C17H18BrN303 392 247 11.2 107 92 0 47 9 4 
o— 
xir>; 
o 
ZG-208 C17H18IN303 439.248 9.7 112 10.9 0 38 4.6 
o—\ 
0 o 
C,,H,eN4Os ZG-213 C17H18N405 358.349 12.8 49 8 302 3 5 22 5 
ry& 
^xxV 
0 
ZG-224 C18H18N403S 370426 17.1 33 7 50 2.5 30,7 
0-4" . N / 1 
^' 
0 
C,?H1AN„O. ZG-234 C17H18N603 354 363 7.25 22.14 9.84 03 5.25 
CK+ 
MX 
0 
C,-H,„C IN ,0I ZG-63A C17H18CIN303 347.796 17.3 21.6 29.1 0 65 4 
?J 
0 
C„H,4CIN,O. ZG69A C15H14CIN303 319.743 6.8 16.3 9.2 0.85 54.6 
O J 
S& 
0 
C,KHMCIN,03 ZG-69a(Ro15-1310) C15H14CIN303 319.743 6.8 16.3 92 0.85 54.6 
O-—1 
lV<0 
CQ 
0 
C,.H„N3O, ZG-88 C17H19N303 313.351 
09-06 ZJW-ll-040 
) 
/ \= 
CJ-k. jjk 
^ *"" H 
ZK 93423 C22H20N204 376.405 4.1 4.2 6 4.5 1000 
X) 
= \̂ /̂ X 
- ~ J X J  
/h~̂  
C„H.,N,0 ZOLPIDEM C19H21N30 307,39 26.7 156 383 10000 10000 
05-1751 462.2 
vV 
0 
C„H„N,0 C18H14N20 274.317 763 42.1 47.4 6.8 3000 
YH 
cx X-> 
0 
CtoHK.NJO C20H16N20 300.354 965 345 590 150 1000 
cx 
yH 
Cr 
C»HT>FNJO C20H15FN20 318.344 73 31 53 19 1000 
VI M Cn 
xrf 
CiaMnSrN,0 C16H13BrN20 329.191 94 9.3 31 7.7 3000 
.̂ 0 
6 
C N..N.0 C17H13N30 275.305 320 310 350 265 3000 
C?lH;7NjOS» C21H22N20Si 346.498 94 73 203 63 3000 
Cov 
w 
CjnHuFNjO C20H15FN20 318.344 1000 1000 1000 1000 1000 
1 Or" 
C.^iH,,FNiO C20H15FN20 318 344 1000 1000 1000 1000 1000 
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Appendix VI. PDSP Activity Data 
The activity data at GABA and other receptors was carried out by Dr. Bryan Roth. 
The Roth Lab studies the structure and function of G-Protein coupled receptors (GPCRs). 
The Roth lab is the principal contractor for the NIMH Psychoactive Drug Screening 
Program which includes the PDSP K, database. The lab operates within the 
Pharmacology Department at the University of North Carolina at Chapel Hill. The 
database can be accessed online at https://kidbdev.med.unc.edu/pdsD/. 
PDSP Compound List Milwaukee Code # versus UNC Code Number for PDS 
UNC Roth Compound # Name MW 
401 BCCtC16H16N202 268.31 
402 3 EBC C13H12N20-HCI 248.5 
403 3 PBC C14H14N20-HCI 262.5 
404 RY-080 C17H15N303 309.32 
405 RV-024 C19H19N303 337.37 
406 Xhe 11-053 C22H17N302 335.39 
407 RY-023 C22H27N303Si 409.55 
408 RY-079 C20H23N303Si 381.5 
409 QH 11-066 C17H12N20 260.29 
410 CMD30 C15H11F3N202 308.26 
473 JY-HXE-053 C22H16FN302 (F.W. 373 373 
474 JY-032 C20H15BrFN302 428 
475 JYI-70 C19H13FN4 316 
477 XliHell-048 C25H25N302Si 427 
479 XIS270 C19H14N 298 
934 DMH-D-070 (C39H28N604Br2) 802 
935 DMH-D-048 (C49H46N604Si2) 838 
936 DMH-D-053 (C43H30N604i 694 
937 DM-ll-26 (C41H32N604Br2) 830 
939 DM-lll-97 (C45H34N604) 722 
940 DM-lll-93 (C40H30N605Br2) 832 
941 DM-lll-94 (C5QH48N605Si2} 868 
942 DM-lll-96 (C44H32N605) 724 
943 DM-ll-20 (C22H14N302F3) 408 
944 DM-ll-30 C20H13N302BrF3) 463 
945 DM-ll-33 (C20H13N302BrCI3) 511 
946 DM-ll-35 (C25H22N302SiF3) 481 
947 DM-lll-01 (C18H12N302Br) 381 
948 DM-ll-72 (C15H10N20BrCI) 348 
949 DM-ll-90 (C17H12N4BrCH 386 
950 XLi-JY-DMH-TMS C22H21N4SiCI) 404 
951 XLi-JY-DMH (C19H13N4CI) 332 
952 HzlllC20H16N3CI02 365.81 
953 Hzl20 C20H16N3I02 457.26 
954 Hzl41 C21H23N3Si 345.51 
955 Hzl46 C21H23N30Si 361.51 
956 Hzl50 C16H14N30Br 344.21 
957 Hzl47C18H15N30 289.33 
958 Hzl57 C19H19N30Si 333.46 
959 Hzl58 C20H21N30Si 347.49 
960 Hzl60 C17H13N30 275.3 
961 Hzl65 C24H24N402Si 428.56 
719 
CMPD # Name MW 
963 Hzl48 C18H15N3 273.33 
964 Hzl35 C16H14N3Br 328.21 
965 Hzl64 C19H15N402Br 411.25 
966 WYS1 C45H50N406 774.9 
967 WYS2C35H34N404 574.67 
968 WYS3C35H38N404 578.7 
969 WYS4 C48H56N408 816.98 
970 WYS5C37H42N404 606.25 
972 WYS7 C21H28N404Si 364.51 
973 WYS8C18H16N202 292.33 
974 WYS9 C16H15IN202 394.21 
975 WYS10 C14H9F3N202 294.23 
976 WYSll C15H11F3N203 324.25 
977 WYS12 C20H18N202S 350.44 
978 WYS13 C20H18N203 334.37 
979 WYS14 C34H29F3N404 614.61 
980 WYS15 C22H20N202 344.41 
981 WYS16 C18H22N202 298.38 
986 WYS21 C21H23IN204 494.32 
987 WYSC1 C16H16N202 268 
988 WYSC2 C15H11F3N202 308 
989 JYI-01(C19H20N303Br) 418 
990 JYI-02 (C24H29N303Si) 437 
991 JYI-03 (C21H21N303) 363 
992 JYI-04 (C21H23N303) 365 
993 JYI-06 (C23H23N304) 405 
994 JYI-19 (C23H23N303S) 421 
995 JYI-20 (C25H25N303) 415 
996 JYI-10 (C17H13N303F3Br) 444 
997 JYI-11 (C22H22N303F3Si) 462 
998 JYI-15 (C19H14N303F3) 389 
999 JYI-12 (C19H16N303F3) 390 
1001 JYI-13 (C21H16N304F3) 431 
1002 JYI-14 (C17H14N303F3 ) 365 
1003 JYI-21 (C23H17N303F3) 441 
1004 JYI-32 (C20H15N302BrF) 428 
1005 JYI-38 (C25H24N302FSi) 445 
1006 JYI-56 (C24H18N304F) 373 
1007 JYI-50 (C24H18N302SF) 469 
1008 JYI-49 (C20H12N302F4Br) 482 
1009 JYI-53 (C23H21N302F4Si) 475 
1010 JYI-59 (C22H13N302F4) 427 
1011 JYI-54 (C24H15N303F4) 469 
1012 JYI-60 (C17H11N20F) 278 
1013 JYI-64 (C17H12N4FBr) 371 
1014 JYI-70 (C19H13N4F) 316 
CMPD # Name MW 
1016 PS-l-27 C21H16N5BrO 434.3 
720 
1017 PS-1-28 C26H25N50Si 451.6 
1018 PS-1-26 C23H17N50 379.4 
1019 PS-1-34B C20H17N4BrO 409.3 
1020 PS-1-35 C23H22N50Br 464.4 
1021 PS-1-36 C28H31N50Si 481.7 
1022 PS-1-37 C25H23N50 409.5 
1023 XLi268 C17H13BrN4 353 
1024 XLi269 C22H22N4Si 370 
1025 XU270 C19H14N4 298.34 
1026 XLi223 C22H20BrN302 438.32 
1027 XLi224 C27H29N302Si 455.62 
1028 XU225 C24H21N302 383.44 
1029 CM-D45 C19H21N304 355.39 
1030 RY-024 C19H19N303 337.37 
1031 XHell-053 C22H17N302 355.39 
1032 XLiXHell-048 C25H25N302Si 427.57 
1033 RY-023 C22H27N303Si 409.55 
1034 RY-080 C17H15N303 309.32 
1035 XL 337C21H23N303 365.43 
1036 XL 340 C26H25N302 411.5 
1037 XL 339 C23H22N4 354.45 
1038 XL 275C20H19N303 349.38 
1039 XL 356 C33H34N606 610.66 
1040 XL 347 C34H28N607 632.62 
1041 XL 351 C21H21CIN20Si 380.94 
1042 XL 343 C20H19CIN20Si 366.92 
1043 XL 350 C17H11CIN20 294.73 
1044 XL 352 C18H13CIN20 308.76 
1045 XL 338 C23H21CIN4 388.89 
1048 JC184 C13H9BrN20S 321 
1049 JC207 C18H18N20SSi 338 
1050 JC208 C15H10N20S 266 
1051 JC209 C19H20N20SSi 352 
1052 JC222 C16H12N20S 280 
1055 JC221 C20H15N302S 361 
1684 RY069 388.38 
1685 PS-l-26 379.14 
1686 JC221 361.42 
1687 Hzl66 356.13 
1688 PS-l-28 451.18 
1689 Xli-JY-DMH 332.08 
1690 PS-l-37 425.22 
1691 PWZ-031A 296.15 
1692 XLI093 602.19 
1693 XLI356 610.66 
CMPD # Name MW 
1695 CM-D45 355.39 
1696 RY-059 345.35 
1697 PWZ-035A 305.76 
721 
1698 RY068 460.56 
1699 JY-l-70 316.11 
1709 RY-l-29 345.35 
3173 PWZ-029 291.73 
7828 SH-TR-CH3 312.37 
7829 SH-TS-CH3 312.37 
7944 JIE-1-12 361.43 
11461 TC-YJJG-24 316.74 
14413 MVL-VI-33 263.72 
14414 MVL-VI-34 263.72 
14460 MVL-Vl-52 269.3 
14567 TC-YJJG-26 250 
14575 TC-YJJG-24 0 
16067 OJ-MPP-1 269.1 
16068 YT-ll-76 325.36 
16069 HJ-l-040 341.4 
16070 ZJW-11-040 394.4 
16071 HZ-166 ACID 328.3 
16072 SH-l-75 355 
16073 YT-lll-40 411.43 
16074 YT-lll-41 409.48 
16075 XLI-210 630.65 
16076 YT-II-794 774.5 
16077 YT-ll-792 778.45 
16078 YT-ll-793 792.47 
16079 SR-ll-97 304.73 
16080 YT-lll-331 758.77 
16081 YT-lll-332 772.8 
16082 YT-lll-333 786.8 
16083 YT-lll-15 659.1 
16084 ZJW-11-065 358.4 
16085 ZJW-11-067 342.4 
16086 ZJW-11-061 355.4 
16087 ON-I-29A 305.71 
16088 XHE-ll-53 355.38 
16089 XLI-093 603 
16090 PWZ-029 291.73 
16091 BCCT 268.3 
16092 3 PBC 262.7 
16162 mlw-13 301.68 
16163 mlw-21 316.74 
16164 mlw-23 335.58 
16165 mlw-29 385.23 
CMPD # Name MW 
16167 mlw-35 380.03 
16168 mlw-36 312.23 
16169 mlw-38 346.13 
16170 mlw-58 272.68 
16171 mlw-59 286.71 
16172 
16173 
16174 
16175 
16176 
16177 
16178 
16179 
16180 
16181 
16182 
16183 
16184 
16185 
mlw-62 
mlw-64 
mlw-65 
mlw-69 
mlw-70 
mlw-88 
mlw-89 
mlw-103 
mlw-104 
mlw-111 
mlw-112 
mlw-113 
mlw-116 
mlw-117 
723 
CMPD PI Tier 5-HT1A 5-HT1B 5-HT1D 5-htle 5-HT2A 
473 Cook 
474 Cook 
475 Cook 
476 Cook i l 1 1 1 1  
477 Cook 2.205.00 
479 Cook >10000 
934 Cook I 
935 Cook 1 
936 Cook 1 
937 Cook 1 
939 Cook 1 
940 Cook 1 
941 Cook 1 
942 Cook 1 
943 Cook 1 
944 Cook 1 
Unless otherwise indicated (see Note), data represent Ki (nM) values obtained from non-linear regression 
of radioligand competition binding isotherms. Ki values are calculated from best fit IC50 values 
using the Cheng-Prusoff equation. 
Note: When the Hill coefficient {nH) is significantly different from -1 (assessed by F test), 
the IC5Q and nH are reported instead of the Ki. 
A * next to a value denotes ICso. 
To view the experiment error, source, species, concentration, etc, click on the result. 
Legend: Complete 
| 1 1 1 1 II 
CMPD PI Tier S-HT1A 5-HT1B S-HT1D S-htle 5-HT2A 
946 Cook 
947 Cook 
948 Cook 
949 Cook 
950 Cook 
951 Cook 
952 Cook 
953 Cook 
954 Cook 
955 Cook 
956 Cook 
957 Cook 
958 Cook 
959 Cook 
960 Cook 
961 Cook 
962 Cook 
963 Cook 
964 Cook 
965 Cook 
966 Cook 
967 Cook 
968 Cook 
969 Cook 
970 Cook 
972 Cook 
973 Cook 
974 Cook 
975 Cook 
976 Cook 
977 Cook 
CMPD PI Tier 5-HTlA 5-HT1B 5-HT1D 5-htle 5-HT2A 
979 Cook 
980 Cook 
981 Cook 
986 Cook 
987 Cook 
988 Cook 
989 Cook 
990 Cook 
991 Cook 
992 Cook 
993 Cook 
994 Cook 
995 Cook 
99S Cook 
997 Cook 
998 Cook 
999 Cook 
1001 Cook 
1002 Cook 
1003 Cook 
1004 Cook 
1005 Cook 
1006 Cook 
1007 Cook 
1008 Cook 
1009 Cook 
1010 Cook 
1011 Cook 
1012 Cook 
1013 Cook 
1014 Cook 
725 
CMPD Tier 5-HT1A 5-HT1B 5-HT1D 5-htle 5-HT2A 
1016 Cook 
1017 Cook 
1018 Cook 
1019 Cook 
1020 Cook 
1021 Cook 
1022 Cook 
1023 Cook 
1024 Cook 
1025 Cook 
1026 Cook 
1027 Cook 
1028 Cook 
1029 Cook 
1030 Cook 
1031 Cook 
1032 Cook 
1033 Cook 
1034 Cook 
1035 Cook 
1036 Cook 
1037 Cook 
1038 Cook 
1039 Cook 
1040 Cook 
1041 Cook 
1042 Cook 
1043 Cook 
1044 Cook 
1045 Cook 
1048 Cook 
1050 Cook 
1051 Cook 
1052 Cook 
1055 Cook 
1684 Cook 
1685 Cook 
1686 Cook 
1687 Cook 
1688 Cook 
1689 Cook 
1690 Cook 
1691 Cook 
1692 Cook 
1693 Cook 
1694 Cook 
1695 Cook 
1696 Cook 
1697 Cook 
1698 Cook 
1699 Cook 
1709 Cook 
3173 Cook 
7828 Cook 
7829 Cook 
7944 Cook 
11461 Cook 
14413 Cook 
Cook 
14460 Cook 
14567 Cook 
14575 Cook 
CMPO PI Tier 5-HT1A S-HT1B S-HT1D 5-htle S-HT2A 
16068 Cook 
16069 Cook 
16070 Cook 
16071 Cook 
16072 Cook 
16073 Cook 
16074 Cook 
16075 Cook 
16076 Cook 
16077 Cook 
16078 Cook 
16079 Cook 
16080 Cook 
16081 Cook 
16082 Cook 
16083 Cook 
16084 Cook 
16085 Cook 
16086 Cook 
16087 Cook 
16088 Cook 
16089 Cook 
16090 Cook 
16091 Cook 
16092 Cook 
16162 Cook 
16163 Cook 
16164 Cook 
16165 Cook 
16166 Cook 
16167 Cook 
16169 Cook 
16170 Cook 
16171 Cook 
16172 Cook 
16173 Cook 
16174 Cook 
16175 Cook 
16176 Cook 
16177 Cook 
16178 Cook 
16179 Cook 
16180 Cook 
16181 Cook 
16182 Cook 
16183 Cook 
16184 Cook 
16185 Cook 
S-HT3 5-HT4 5-ht5a 5-HT6 5-HT7 A1 5-HT2B CMPD 
CMPD 5-HT2B 5-HT2C 5-HT3 5-HT4 5-ht5a 5-HT6 5-HT7 A1 A2 A2A A2B A2B2 
946 
947 
948 
949 
950 
951 
952 
953 
954 
955 
956 
957 
958 
959 
960 
961 
962 
963 
964 
965 
966 
967 
968 
969 
970 
972 
973 
974 
975 
976 
977 
CMPO 5-HT2B 5-HT2C 5-HT3 S-HT4 5-ht5a 5-HT6 5-HT7 A1 A2 A2A A2B A2B2 
979 
980 
981 
986 
987 
988 
989 
990 
991 
992 
993 
994 
995 
996 
997 
998 
999 
1001 
1002 
1003 
1004 
1005 
1006 
1007 
1008 
1009 
1010 
1011 
1012 
1013 
1014 
5-HT7 S-HT6 5-HT2B CMPD 
1146l| 
14413 
14414 
14567 >: 
14575 
730 
CMPD 5-HT2B 5-HT2C 5-HT3 5-HT4 5-ht5a 5-HT6 5-HT7 A1 A2 A2A A2B A2B2 
16068 
16069 
16070 
16071 
16072 
16073 
16074 
16075 
16076 
16077 
16078 
16079 
16080 
16081 
16082 
16083 
16084 
16085 
16086 
16087 
16088 
16089 
16090 
16091 
16092 
16162 
16163 
16164 
16165 
16166 
16167 
16169 
16170 
16171 
16172 
16173 
16174 
16175 
16176 
16177 
16178 
16179 
16180 
16181 
16182 
16183 
16184 
16185 
731 
CMPD A2B4 A3B2 A3B4 A4B2 A4B2** A4B4 Alpha 1A AJphalD Alpha 2A Alpha 2B 
3.484.00 3.975.00 
4.242,00 3.408.00 
3.020.00 2.840.00 
476] 1 1 1 1 II 
1.764.00 1.878.00 3.296.00 
2.573.00 3.164.00 
934 
935 
936 
937 
939 
940 
941 
942 
943 
944 
CMPD A2B4 A3B2 A3B4 A4B2 A4B2** A484 Alpha 1A Alpha ID Alpha2A Alpha 2B 
946 
947 
948 
949 
950 
951 
952 
953 
954 
955 
956 
957 
958 
959 
960 
961 
962 
963 
964 
965 
966 
967 
968 
969 
970 
972 
973 
974 
975 
976 
977 
CMPD A2B4 A3B2 A3B4 A4B2 A4B2** A4B4 Alpha 1A AlphaXD Alpha 2A Alpha2B 
979 
980 
981 
986 
987 
988 
989 
990 
991 
992 
993 
994 
995 
996 
997 
998 
999 
1001 
1002 
1003 
1004 
1005 
1006 
1007 
1008 
1009 
1010 
1011 
1012 
1013 
1014 
>D i 
1016" 
1017~ 
1018 
1019' 
1020" 
102l" 
1022' 
1023' 
1024~ 
1025" 
1026' 
1027~ 
1028' 
1029 
1030' 
1031 
1032~ 
1033 
1034' 
1035' 
1036' 
1037" 
1038' 
1039' 
1040' 
1041 
1042' 
1043 
1044 
1045" 
1048" 
1050 
1051" 
1052' 
1055 
1684' 
1685' 
1686" 
1687 
1688" 
1689" 
1690' 
1691' 
1692' 
1693' 
1694" 
1695" 
1696" 
1697" 
1698" 
1699" 
1709" 
3173' 
7828' 
7829" 
7944' 
.1461' 
.4413" 
.4414 
.4460 
.4567" 
.45751 
Alpha 1A AiphaiD Alpha 2A Alpha 28 
734 
CMPD A2B4 A3B2 A3B4 A4B2 A4B2" A4B4 Alpha 1A AlphalD Alpha2A Alpha 2B 
16068 
16069 
16070 
16071 
16072 
16073 
16074 
16075 
16076 
16077 
16078 
16079 
16080 
16081 
16082 
16083 
16084 
16085 
16086 
16087 
16088 
16089 
16090 
16091 
16092 
16162 
16163 
16164 
16165 
16166 
16167 
16169 
16170 
16171 
16172 
16173 
16174 
16175 
16176 
16177 
16178 
16179 
16180 
16181 
16182 
16183 
16184 
16185 
D I 
473' 
474~ 
475~ 
476 
477' 
479' 
934" 
935" 
936' 
937" 
939~ 
940~ 
94l" 
942 
943 
944| 
ZI 
Alpha2C BZP Rat Brain Site Calcium Channel 
2.105.00 
1.597.00 
1.809.00 
D 
946' 
947~ 
948 
949' 
950" 
95l" 
952' 
953' 
954~ 
955' 
956" 
957~ 
958' 
959~ 
960 
961' 
962' 
963' 
964' 
965' 
966 
967' 
968' 
969 
970" 
972' 
973' 
974~ 
975~ 
976' 
977' 
P 
979' 
980' 
981 
986" 
987" 
988' 
989" 
990" 
99l" 
992" 
993" 
994" 
995' 
996' 
997' 
998' 
999' 
LOOl" 
1002" 
1003" 
1004" 
1005" 
[006' 
[007" 
.008 
1009" 
LOIO" 
LOll" 
1012" 
L013" 
L014| 
Alpha 2C AMPA* B2 Betal Beta 2 Beta3 BZP Rat Brain Site Calcium Channel 
Alpha2C AMPA* B2 Betal Beta2 Beta 3 B2P Rat Brain Site Calcium Channel 
Alpha2C Calcium Channel CMPD 
11461 
14413 
14414 
14460 
14567 2.646.00 
145751 9.660.00 
IPD 
16068 
16069' 
16070 
16071 
16072' 
16073 
16074" 
16075' 
16076' 
16077' 
16078' 
16079' 
16080 
16081 
16082 
16083' 
16084' 
16085 
16086' 
16087 
16088' 
16089' 
16090 
16091 
16092' 
16162 
16163 
16164' 
16165 
16166 
16167 
16169 
16170' 
16171 
16172 
16173 
16174' 
16175 
16176' 
16177' 
16178 
16179 
16180' 
16181 
16182 
16183 
16184' 
1618s| 
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Alpha 2C B2 Betal Beta2 Beta3 BZP Rat Brain Site Calcium Channel 
CMPO CB1 CBIH D1 D2 D3 D4 D5 OAT DOR EP1 EP2 EP3 
473 4.771,00 
474 •n 
475 
476 222 
All 1.745 00 1 3,500.00 1.400.00 1.400.00 1.62300 
479 
934 
935 
936 
937 
939 
940 
941 
942 
943 
944 
CMPD CB1 CBIH D1 D2 D3 D4 D5 DAT DOR EP1 EP2 EP3 
946 
947 
948 
949 
950 
951 
952 
953 
954 
955 
956 
957 
958 
959 
960 
961 
962 
963 
964 
965 
966 
967 
968 
969 
970 
972 
973 
974 
975 
976 
977 
CMPD CB1 CBIH D1 D2 D3 D4 D5 DAT DOR EP1 EP2 EP3 
979 
980 
981 
986 
987 
988 
989 
990 
991 
992 
993 
994 
995 
996 
997 
998 
999 
1001 
1002 
1003 
1004 
1005 
1006 
1007 
1008 
1009 
1010 
1011 
1012 
1013 
1014 
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CMPD 
11461 
14413 
14414 
14460 
14567 
14575 
1PP 
16068 
16069" 
16070" 
16071 
16072' 
16073' 
16074' 
16075' 
16076' 
16077* 
16078' 
16079' 
16080 
16081 
16082' 
16083' 
16084" 
16085' 
16086 
16087' 
16088' 
16089' 
16090' 
16091' 
16092' 
16162 
16163 
16164' 
16165' 
16166 
16167' 
16169' 
16170" 
16171' 
16172 
16173" 
16174' 
16175 
16176' 
16177' 
16178" 
16179" 
16180" 
16181" 
16182" 
16183" 
16184" 
161851 
742 
CB1 CB1H 02 D3 04 05 DAT DOR EP1 EP2 EP3 
D I 
473" 
474 
475 
476 
477 
479 
934~ 
935~ 
936' 
937" 
939~ 
940' 
941 
942' 
943' 
944| 
H 
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GABAA GABAa a3 GABAB 
D 
946 
947 
948 
949 
950' 
951' 
952 
953 
954" 
955 
956' 
957' 
958 
959' 
960' 
961' 
962' 
963' 
964' 
965' 
966' 
967' 
968 
969 
970' 
972~ 
973' 
974' 
975' 
976' 
977' 
D 
979 
980' 
981 
986 
987' 
988' 
989' 
990' 
99l' 
992 
993 
994' 
995" 
996" 
997" 
998" 
999" 
LOOl' 
[002" 
1003" 
[004" 
.005' 
-006 
[007" 
[Q08" 
.009" 
[010" 
[Oil 
.012" 
l013 ' 
.014" 
744 
GABAal GABAA GABAaa2 GABAa a3 GABAaa6 GABAB H2 
1.127.00 
14.5 
3.9 
09 
137 
J£. 
32.5 
51.1 
2.073.00 
481 
1.498.00 
271.6 
135.7 
2.432.00 
546.8 
m 
>10.C 
83.4 
30.5 
211 
47.2 
45.1 
GABAal GABAA GABAa a2 GABAa a3 GABAa a6 H2 
1.179.00 
47 
3.280.00 
21.1 
JJL 
m. 
M. 
288 
389 
99 
16 
111 
115.8 
21.9 
121.1 
J2l_ 
120 
L4 
117 
17 
_0J_ 
GABAaa2 GABAA GABAaa6 GABAB CMPD 
11461 
14413 
14414 
14567 
14575 
CMPD EP4 GABA al GABAA GABAa a2 GABAaa3 GABAa a6 GABAB HI H2 
16068 5 
16069 178 
16070 161 
16071 283 
16072 1.424.00 
16073 152 
16074 387 
16075 224 
16076 1,640.00 
16077 
16078 453 
16079 79 
16080 1.682.00 
16081 409 
16082 895 
16083 146 
16084 1.456.00 
16085 1.437.00 
16086 2.942.00 
16087 22Q 
16088 714 
16089 711 
16090 1.338.00 
16091 M 
16092 1.626.00 
16162 1.631.00 
16163 3.188.00 
16164 150 
16165 764 
16166 348 
16167 32£ 
16169 1.864.00 
16170 4,445.00 
16171 1.368.00 
16172 3.281.00 9,417.00 
16173 904 612 
16174 1.223.00 i
 
©
 
o
 
16175 4.970.00 1.684.00 
16176 8.816.00 1.460.00 
16177 1.590.00 1,141-90 
16178 1.171.00 1.853.00 
16179 3.781.00 383 
16180 3.615.00 8.578.00 
16181 2.232.00 9.732.00 
16182 1,111.00 >10,000 
16183 1.225.00 6.807.00 
16184 1.487.00 228 
16185 3.778.00 2.250.00 
Imidazoline 1 mGluR5_RatBrain CMPD 
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CMPO H3 H4 Imidazoline 1 KA KOR Ml M2 M3 M4 M5 mGluR5_RatBrain 
946 
947 
948 
949 
950 
951 
952 
953 
954 
955 
956 
957 
958 
959 
960 
961 
962 
963 
964 
965 
966 
967 
968 
969 
970 
972 
973 
974 
975 
976 
977 
CMPD H3 H4 imidazoline 1 KA KOR Ml M2 M3 M4 M5 mGluRS_RatBrain 
979 
980 
981 
986 
987 
988 
989 
990 
991 
992 
993 
994 
995 
996 
997 
998 
999 
1001 
1002 
1003 
1004 
1005 
1006 
1007 
1008 
1009 
1010 
1011 
1012 
1013 
1014 
Imidazoline 1 mGluR5_RatBrain CMPD 
>10.000 
11461 
14413 
14414 
14460] 
14567 
14575 
IPD I 
16068" 
16069' 
16070' 
16071" 
16072' 
16073' 
16074" 
16075" 
16076" 
16077" 
16078" 
16079" 
16080" 
16081' 
16082' 
16083 
16084' 
16085' 
16086' 
16087 
16088' 
16089' 
16090' 
16091' 
16092 
16162' 
16163" 
16164" 
16165" 
16166 
16167' 
16169" 
16170" 
16171" 
16172" 
16173' 
16174" 
16175" 
16176" 
16177" 
16178" 
16179" 
16180" 
16181" 
16182" 
16183" 
16184" 
161851 
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H3 H4 Imidazoline 1 KA KOR Ml M2 M3 M5 mGiuR5_RatBrain 
Oxytocin PKCalpha PKCbeta PKCdelta CMPD 
CMPD MOR NET NMDA NTS1 Oxytocin PBR PKCalpha PKCbeta PKCdelta 
946 
947 
948 
949 
950 
951 
952 
953 
954 
955 
956 
957 
958 
959 
960 
961 
962 
963 
964 
965 
966 
967 
968 
969 
970 
972 
973 
974 
975 
976 
977 
CMPD MOR NET NMOA NTS1 Oxytocin PBR PKCalpha PKCbeta PKCdelta 
979 
980 
981 
986 
987 
988 
989 
990 
991 
992 
993 
994 
995 
996 
997 
998 
999 
1001 
1002 
1003 
1004 
1005 
1006 
1007 
1008 
1009 
1010 
1011 
1012 
1013 
1014 
NTS1 Oxytocin PKCalpha PKCbeta PKCdelta CMPD 
11461 
14413 
14414 
14567 
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CMPD MOR NET NMDA NTS1 Oxytocin PBR PKCalpha PKCbeta PKCdelta 
16068 
16069 
16070 
lcn71 
16072 
16073 
16074 
16075 
16076 
16077 
16078 
16079 
16080 
16081 
16082 
16083 
16084 
16085 
16086 
16087 
16088 
16089 
16090 
16091 
16092 
16162 
16163 
16164 
16165 
16166 
16167 
16169 
16170 
16171 
16172 
16173 
16174 
16175 
16176 
16177 
16178 
16179 
16180 
16181 
16182 
16183 
16184 
16185 
D | 
473~ 
474 
475~ 
"477 
479~ 
934~ 
935' 
936' 
937~ 
939~ 
940 
941 
942 
943 
944[ 
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PKCepsiton PKCgamma Sigma X Sodium Channel VMAT2 Y2 
P 1 
946" 
947 
948 
OAO 
"950' 
95l' 
952~ 
953~ 
954~ 
955 
956' 
957~ 
958 
959' 
960 
961' 
962' 
963 
964' 
965' 
966' 
967' 
968 
969' 
970" 
972' 
973" 
974 
975" 
976" 
977' 
D " 
979" 
980' 
981' 
986' 
987 
988 
989 
990 
99l' 
992' 
993' 
994~ 
995 
996' 
997~ 
998' 
999" 
LOOl" 
L002' 
LQ03" 
L004" 
1005' 
L006' 
1007" 
.008 
[009 
LOIO" 
.Oil" 
.012" 
.013" 
.014| 
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PKCepsiion PKCgamma Sigma 1 Sodium Channel VIA V1B V2 VMAT1 VMAT2 Y2 
PKCepsiion PKCgamma Sigma 1 Sodium Channel VIA V1B V2 
Sodium Channel PKCepsilon PKCgamma 
11461 
14413 
14414 
14460 
14567 
14575 
IPD | 
16068' 
16069 
16070' 
16071 
16072' 
16073 
16074' 
16075" 
16076 
16077" 
16078 
16079' 
16080' 
16081' 
16082' 
16083' 
16084' 
16085' 
16086' 
16087' 
16088' 
16089' 
16090 
16091 
16092' 
16162' 
16163' 
16164' 
16165' 
16166' 
16167" 
16169 
16170' 
16171' 
16172 
16173 
16174' 
16175' 
16176 
16177' 
16178 
16179' 
16180' 
16181 
16182' 
16183' 
16184' 
16185| 
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PKCepsilon PKCgamma Sigma 1 Sodium Channel VIA V1B V2 VMATl VMAT2 Y2 
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Appendix VII. In Vitro Metabolic Stability of Selected Compounds Using Human 
Liver Microsomes 
O 
XHe-II-053 Acid 
Not metabolized by human liver microsomes 
at either of the concentrations tested (1 and 10 (iM) 
P 
LKH 
SR-II-54 
Not metabolized by human liver microsomes 
at either of the concentrations tested (1 and 10 |iM) 
HJ-I-40 
Not metabolized by human liver microsomes 
at either of the concentrations tested (1 and 10 |iM) 
EMJ-I-026 
Not metabolized by human liver microsomes 
at either of the concentrations tested (1 and 10 (iM) 
SH-053-2T-RCH3 
Not metabolized by human liver microsomes 
at either of the concentrations tested (1 and 10 jiM) 
HJ-I-037 
Not metabolized by human liver microsomes 
at either of the concentrations tested (1 and 10 |jM) 
ZJW-II-040 
Not melaboiized by human liver microsomes 
at either of the concentrations tested (1 and 10 jaM) 
HZ-166 
Showed only slight metabolism at 1 jiM and 10 fiM 
Only slight metabolism at 1 |iM and no metabolism at 10 
763 
ZJW-II-065 
Only slight metabolism at 1 and no metabolism at 10 |aM 
YT-III-15 
Showed significant metabolism at 1 (J.M but only slight metabolism at 10 |iM 
XHe-II-053 
Showed significant metabolism at both 1 and 10 |aM 
when incubated with human liver microsomes 
TMS 
HZ-166-TMS 
Showed significant metabolism at both 1 and 10 )iM 
when incubated with human liver microsomes 
JY-XHe-053 
Showed significant metabolism at both 1 and 10 
when incubated with human liver microsomes 
SH-053-2T-SCH3 
765 
Showed significant metabolism at both 1 and 10 (iM 
when incubated with human liver microsomes 
The metabolic stability of XHe-II-053(l), XHe-II-043 Acid(2), 
HZ-166(3), SR-II-54(4), HZ-166-TMS(5), HJ-I-40(6), EMJ-I-026(7), JY-XHe-053(8), 
SH-053-2'F-SCH3(9), SH-053-2'F-RCH3(10), YT-III-271(11), YT-III-15(12), HJ-I-
037(13), ZJW-II-065(14), and ZJW-II-040(15) using human liver microsomes was 
studied. The test articles were incubated at two concentrations (1 and 10 JIM) and 
aliquots (100 |il) were removed at various time points (0,15, 30 and 60 minutes), and 
analyzed by LC-MS/MS. 
The results for the metabolic stability of all 15 compounds using pooled human 
liver microsomes are summarized in Tables 1, 2 and 3. XHe-II-043 Acid(2), SR-II-54, 
HJ-I-40(6), EMJ-I-026(7), SH-053-2'F-RCH3(10), HJ-I-037(13), ZJW-II-040(15) were 
not metabolized by human liver microsomes at either of the concentrations tested (1 and 
10 (aM). HZ-166(3) showed slight metabolism at 1 |aM and 10 |iM. YT-III-271(11) and 
ZJW-II-065(14) showed slight metabolism at 1 (iM and no metabolism at 10 fiM. YT-
III-15(12) showed significant metabolism at 1 fiM but only slight metabolism at 10 (iM. 
XHe-II-053(l), HZ-166-TMS(5), JY-XHe-053(8), SH-053-2'F-SCH3(9) showed 
significant metabolism at both 1 and 10 (iM when incubated with human liver 
microsomes. 
When incubated with heat-inactivated human liver microsomes, there was no 
significant change in the % remaining of any of the 15 compounds after 60 minutes. This 
766 
suggests that the compounds are stable in the incubation conditions used in these 
experiments 
The results for the metabolic stability of midazolam using active and heat-
inactivated human liver microsomes are summarized in Table 4. Midazolam was 
consistently metabolized, indicating that the incubation conditions used were suitable for 
determining metabolic stability. 
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* auic -t 7. In vie™ metaboiic stability of XHE-II-053(1), XHE-II-043 acid(2), HZ-
166(3), SR-II-54 4), HZ-166-TMS(5) using human liver microsomes 
Mean % Remaining vs T = 0 min* 
Time, Human Liver Microsomes 
Test Article mm 1 mM" 10MM° 
XHe-ll-053(1) 
15 41.4 47.6 
30 11.1 13,9 
60 1.46 1.74 
XHe-ll-053(1) with 
Hlc Microsomes 
60 107 102 
15 108 95.6 
XHe-ll-043 Acid(2) 30 106 95.0 
60 111 95.0 
XHe-ll-043 Acid(2) with 
Hlc Microsomes 
60 106 97.4 
15 106 104 
HZ-166(3) 30 98.4 90.7 
60 80.4 76.3 
HZ-166(3) with 
Hlc Microsomes 
60 94.1 95.4 
15 102 91.4 
SR-ll-54(4) 30 94.7 86.1 
60 110 86.9 
SR-ll-54(4) with 
Hlc Microsomes 
60 97.4 88.7 
15 78.0 77.1 
HZ-166-TMS(5) 30 35.9 43.8 
60 7.8 13.8 
HZ-166-TMS(5) with 
Hlc Microsomes 
60 108 84.7 
" % remaining at T=0 is 100% 
b Samples were assayed in duplicate. 
* HI = Heat Inactivated 
768 
Table 48. In vitro metabolic stability of HJ-I-40(6), EMJ-I-026(7), JY-XHE-053(8), 
SH-053-2'F-SCH3(9V SH-053 2'F-RCH3(10) using human 
microsomes 
Mean % Remaining vs T = 0 min* 
Time, Human Liver Microsomes 
Test Article min 1 uM° 10 MM" 
15 109 104 
HJ-1-40(6) 30 126 106 
60 136 110 
HJ-l-40(6) with 
Hlc Microsomes 60 
110 110 
15 100 109 
EMJ-l-026(7) 30 107 108 
60 91.4 96.6 
EMJ-l-026(7) with 
Hi0 Microsomes 60 
137 119 
15 13.5 20.0 
JY-XHe-053(8) 30 2.13 3.60 
60 0.27 0.56 
JY-XHe-053(8) with 
Hlc Microsomes 60 
102 111 
15 6.18 11.7 
SH-053-2'F-SCH3(9) 30 0.85 1.72 
60 3.85" 0.20 
SH-053-2'F-SCH3(9) 
with 
HI0 Microsomes 
60 110 114 
15 86.7 97.9 
SH-053-2'F-RCH3(10) 30 86.7 105 
60 86.9 105 
SH-053-2'F-RCH3(10) 
with 
Hlc Microsomes 
60 115 117 
a % remaining at T=0 is 100% 
b Samples were assayed in duplicate. 
c HI = Heat Inactivated 
d Suspected contamination, if deleted value = 0.20 
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Table . In vitro metabolic stability of YT-III-271(11), YT-IH-i5(12), HJ-I-037(13), 
Test Article 
Time, 
min 
Mean % Remaining vs T = 0 min" 
Human Liver Microsomes 
1 mMd 10pM° 
YT-III-271(11) 
15 | 97.1 104 
30 83 5 102 
60 52.0 91.1 
YT-III-271 (11) with 
Hlc Microsomes 60 
117 97.0 
YT-III-15(12) 
15 87.3 107 
30 39.4 104 
60 5.2 82.8 
YT-lll-15(12) with 
Hlc Microsomes 60 
141 114 
HJ-I-037(13) 
15 97.7 96.8 
30 99.5 103 
60 92.7 103 
HJ-I-037(13) with 
Hlc Microsomes 60 117 108 
ZJW-II-065(14) 
15 984 111 
30 97.0 106 
60 82.5 95.6 
ZJW-II-065(14) with 
Hlc Microsomes 60 105 110 
ZJW-II-040(15) 
15 97.8 106 
30 98.7 99 3 
60 89.4 95.1 
ZJW-II-040(15) with 
Hlc Microsomes 60 
113 92.0 
* % remaining at T=0 is 100% 
b Samples were assayed in duplicate. 
c HI = Heat Inactivated 
Table 49. In vitro metabolic stability of Midazolam 
Test Article Time, min 
Mean % Remaining vs T = 0 min" 
Human Liver Microsomes 
10 mM° 
Midazolam 
15 36.9 ± 13 5 
30 18.7 ±7.3 
60 4.2 ±2.2 
Midazolam with 
Hlc Microsomes 
60 104± 1.2 
% remaining at T=0 is 100% 
Data from three experiments (samples were assayed in duplicate in each experiment). 
HI = Heat Inactivated 
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